id	sid	tid	token	lemma	pos
aji-165	1	1	_	_	PUNCT
aji-165	2	1	_	_	PUNCT
aji-165	3	1	_	_	PUNCT
aji-165	4	1	_	_	PUNCT
aji-165	5	1	_	_	PUNCT
aji-165	6	1	_	_	PUNCT
aji-165	7	1	_	_	PUNCT
aji-165	8	1	_	_	PUNCT
aji-165	9	1	_	_	PUNCT
aji-165	10	1	_	_	PUNCT
aji-165	11	1	_	_	PUNCT
aji-165	12	1	_	_	PUNCT
aji-165	13	1	_	_	PUNCT
aji-165	14	1	_	_	PUNCT
aji-165	15	1	_	_	PUNCT
aji-165	16	1	_	_	PUNCT
aji-165	17	1	_	_	PUNCT
aji-165	18	1	_	_	PUNCT
aji-165	19	1	_	_	PUNCT
aji-165	20	1	_	_	PUNCT
aji-165	21	1	_	_	PUNCT
aji-165	22	1	_	_	PUNCT
aji-165	23	1	_	_	PUNCT
aji-165	24	1	_	_	PUNCT
aji-165	25	1	_	_	PUNCT
aji-165	26	1	_	_	PUNCT
aji-165	27	1	_	_	PUNCT
aji-165	28	1	_	_	PUNCT
aji-165	29	1	_	_	PUNCT
aji-165	30	1	_	_	PUNCT
aji-165	31	1	_	_	PUNCT
aji-165	32	1	_	_	PUNCT
aji-165	33	1	_	_	PUNCT
aji-165	34	1	_	_	PUNCT
aji-165	35	1	_	_	PUNCT
aji-165	36	1	_	_	PUNCT
aji-165	37	1	_	_	PUNCT
aji-165	38	1	_	_	PUNCT
aji-165	39	1	_	_	PUNCT
aji-165	40	1	_	_	PUNCT
aji-165	41	1	_	_	PUNCT
aji-165	42	1	_	_	PUNCT
aji-165	43	1	_	_	PUNCT
aji-165	44	1	_	_	PUNCT
aji-165	45	1	_	_	PUNCT
aji-165	46	1	_	_	PUNCT
aji-165	47	1	_	_	PUNCT
aji-165	48	1	_	_	PUNCT
aji-165	49	1	_	_	PUNCT
aji-165	50	1	_	_	PUNCT
aji-165	51	1	_	_	PUNCT
aji-165	52	1	_	_	PUNCT
aji-165	53	1	_	_	PUNCT
aji-165	54	1	_	_	PUNCT
aji-165	55	1	_	_	PUNCT
aji-165	56	1	_	_	PUNCT
aji-165	57	1	_	_	PUNCT
aji-165	58	1	_	_	PUNCT
aji-165	59	1	_	_	PUNCT
aji-165	60	1	_	_	PUNCT
aji-165	61	1	_	_	PUNCT
aji-165	62	1	_	_	PUNCT
aji-165	63	1	_	_	PUNCT
aji-165	64	1	_	_	PUNCT
aji-165	65	1	_	_	PUNCT
aji-165	66	1	_	_	PUNCT
aji-165	67	1	_	_	PUNCT
aji-165	68	1	_	_	PUNCT
aji-165	69	1	_	_	PUNCT
aji-165	70	1	_	_	PUNCT
aji-165	71	1	_	_	PUNCT
aji-165	72	1	_	_	PUNCT
aji-165	73	1	_	_	PUNCT
aji-165	74	1	_	_	PUNCT
aji-165	75	1	_	_	PUNCT
aji-165	76	1	_	_	PUNCT
aji-165	77	1	_	_	PUNCT
aji-165	78	1	_	_	PUNCT
aji-165	79	1	_	_	PUNCT
aji-165	80	1	_	_	PUNCT
aji-165	81	1	_	_	PUNCT
aji-165	82	1	_	_	PUNCT
aji-165	83	1	_	_	PUNCT
aji-165	84	1	_	_	PUNCT
aji-165	85	1	_	_	PUNCT
aji-165	86	1	_	_	PUNCT
aji-165	87	1	_	_	PUNCT
aji-165	88	1	_	_	PUNCT
aji-165	89	1	_	_	PUNCT
aji-165	90	1	_	_	PUNCT
aji-165	91	1	_	_	PUNCT
aji-165	92	1	_	_	PUNCT
aji-165	93	1	_	_	PUNCT
aji-165	94	1	_	_	PUNCT
aji-165	95	1	_	_	PUNCT
aji-165	96	1	_	_	PUNCT
aji-165	97	1	_	_	PUNCT
aji-165	98	1	_	_	PUNCT
aji-165	99	1	_	_	PUNCT
aji-165	100	1	_	_	PUNCT
aji-165	101	1	_	_	PUNCT
aji-165	102	1	*	*	PUNCT
aji-165	102	2	corresponding	correspond	VERB
aji-165	102	3	author	author	NOUN
aji-165	102	4	:	:	PUNCT
aji-165	102	5	e	e	NOUN
aji-165	102	6	-	-	NOUN
aji-165	102	7	mail	mail	NOUN
aji-165	102	8	:	:	PUNCT
aji-165	102	9	nassarasma20@gmail.com	nassarasma20@gmail.com	NOUN
aji-165	102	10	;	;	PUNCT
aji-165	102	11	cite	cite	VERB
aji-165	102	12	as	as	ADP
aji-165	102	13	:	:	PUNCT
aji-165	102	14	nassar	nassar	PROPN
aji-165	102	15	,	,	PUNCT
aji-165	102	16	asma	asma	PROPN
aji-165	102	17	,	,	PUNCT
aji-165	102	18	amina	amina	PROPN
aji-165	102	19	alliouch	alliouch	PROPN
aji-165	102	20	-kerboua	-kerboua	PROPN
aji-165	102	21	,	,	PUNCT
aji-165	102	22	hacene	hacene	NOUN
aji-165	102	23	meriche	meriche	NOUN
aji-165	102	24	,	,	PUNCT
aji-165	102	25	nassima	nassima	PROPN
aji-165	102	26	sabiha	sabiha	PROPN
aji-165	102	27	gadiri	gadiri	NOUN
aji-165	102	28	,	,	PUNCT
aji-165	102	29	and	and	CCONJ
aji-165	102	30	frida	frida	PROPN
aji-165	102	31	chettab	chettab	PROPN
aji-165	102	32	.	.	PUNCT
aji-165	103	1	2025	2025	NUM
aji-165	103	2	.	.	PUNCT
aji-165	104	1	“	"	PUNCT
aji-165	104	2	clinical	clinical	ADJ
aji-165	104	3	profile	profile	NOUN
aji-165	104	4	and	and	CCONJ
aji-165	104	5	analysis	analysis	NOUN
aji-165	104	6	of	of	ADP
aji-165	104	7	biological	biological	ADJ
aji-165	104	8	markers	marker	NOUN
aji-165	104	9	(	(	PUNCT
aji-165	104	10	fecal	fecal	ADJ
aji-165	104	11	calprotectin	calprotectin	NOUN
aji-165	104	12	and	and	CCONJ
aji-165	104	13	crp	crp	NOUN
aji-165	104	14	)	)	PUNCT
aji-165	104	15	during	during	ADP
aji-165	104	16	relapse	relapse	NOUN
aji-165	104	17	of	of	ADP
aji-165	104	18	inflammatory	inflammatory	ADJ
aji-165	104	19	bowel	bowel	NOUN
aji-165	104	20	diseases	disease	NOUN
aji-165	104	21	in	in	ADP
aji-165	104	22	a	a	DET
aji-165	104	23	population	population	NOUN
aji-165	104	24	of	of	ADP
aji-165	104	25	adults	adult	NOUN
aji-165	104	26	”	"	PUNCT
aji-165	104	27	.	.	PUNCT
aji-165	105	1	asian	asian	ADJ
aji-165	105	2	journal	journal	NOUN
aji-165	105	3	of	of	ADP
aji-165	105	4	immunology	immunology	NOUN
aji-165	105	5	8	8	NUM
aji-165	105	6	(	(	PUNCT
aji-165	105	7	1):104	1):104	NOUN
aji-165	105	8	-	-	PUNCT
aji-165	105	9	19	19	NUM
aji-165	105	10	.	.	PUNCT
aji-165	106	1	https://doi.org/10.9734/aji/2025/v8i1165	https://doi.org/10.9734/aji/2025/v8i1165	PROPN
aji-165	106	2	.	.	PUNCT
aji-165	107	1	asian	asian	ADJ
aji-165	107	2	journal	journal	PROPN
aji-165	107	3	of	of	ADP
aji-165	107	4	immunology	immunology	NOUN
aji-165	107	5	volume	volume	NOUN
aji-165	107	6	8	8	NUM
aji-165	107	7	,	,	PUNCT
aji-165	107	8	issue	issue	NOUN
aji-165	107	9	1	1	NUM
aji-165	107	10	,	,	PUNCT
aji-165	107	11	page	page	NOUN
aji-165	107	12	104	104	NUM
aji-165	107	13	-	-	SYM
aji-165	107	14	119	119	NUM
aji-165	107	15	,	,	PUNCT
aji-165	107	16	2025	2025	NUM
aji-165	107	17	;	;	PUNCT
aji-165	107	18	article	article	NOUN
aji-165	107	19	no.aji.135189	no.aji.135189	ADJ
aji-165	107	20	clinical	clinical	ADJ
aji-165	107	21	profile	profile	NOUN
aji-165	107	22	and	and	CCONJ
aji-165	107	23	analysis	analysis	NOUN
aji-165	107	24	of	of	ADP
aji-165	107	25	biological	biological	ADJ
aji-165	107	26	markers	marker	NOUN
aji-165	107	27	(	(	PUNCT
aji-165	107	28	fecal	fecal	ADJ
aji-165	107	29	calprotectin	calprotectin	NOUN
aji-165	107	30	and	and	CCONJ
aji-165	107	31	crp	crp	NOUN
aji-165	107	32	)	)	PUNCT
aji-165	107	33	during	during	ADP
aji-165	107	34	relapse	relapse	NOUN
aji-165	107	35	of	of	ADP
aji-165	107	36	inflammatory	inflammatory	ADJ
aji-165	107	37	bowel	bowel	NOUN
aji-165	107	38	diseases	disease	NOUN
aji-165	107	39	in	in	ADP
aji-165	107	40	a	a	DET
aji-165	107	41	population	population	NOUN
aji-165	107	42	of	of	ADP
aji-165	107	43	adults	adult	NOUN
aji-165	107	44	asma	asma	PROPN
aji-165	107	45	nassar	nassar	PROPN
aji-165	107	46	a	a	PROPN
aji-165	107	47	*	*	PROPN
aji-165	107	48	,	,	PUNCT
aji-165	107	49	amina	amina	PROPN
aji-165	107	50	alliouch	alliouch	PROPN
aji-165	107	51	-kerboua	-kerboua	PROPN
aji-165	107	52	a	a	PRON
aji-165	107	53	,	,	PUNCT
aji-165	107	54	hacene	hacene	NOUN
aji-165	107	55	meriche	meriche	PROPN
aji-165	107	56	a	a	X
aji-165	107	57	,	,	PUNCT
aji-165	107	58	nassima	nassima	PROPN
aji-165	107	59	sabiha	sabiha	PROPN
aji-165	107	60	gadiri	gadiri	VERB
aji-165	107	61	a	a	PRON
aji-165	107	62	and	and	CCONJ
aji-165	107	63	frida	frida	PROPN
aji-165	107	64	chettab	chettab	PROPN
aji-165	107	65	b	b	PROPN
aji-165	107	66	a	a	DET
aji-165	107	67	department	department	NOUN
aji-165	107	68	of	of	ADP
aji-165	107	69	immunology	immunology	NOUN
aji-165	107	70	,	,	PUNCT
aji-165	107	71	clinique	clinique	NOUN
aji-165	107	72	saint	saint	PROPN
aji-165	107	73	therese	therese	PROPN
aji-165	107	74	uhc	uhc	PROPN
aji-165	107	75	,	,	PUNCT
aji-165	107	76	annaba	annaba	PROPN
aji-165	107	77	,	,	PUNCT
aji-165	107	78	algeria	algeria	PROPN
aji-165	107	79	.	.	PUNCT
aji-165	108	1	b	b	PROPN
aji-165	108	2	department	department	PROPN
aji-165	108	3	of	of	ADP
aji-165	108	4	gastroentero	gastroentero	NOUN
aji-165	108	5	-	-	PUNCT
aji-165	108	6	hepatology	hepatology	NOUN
aji-165	108	7	,	,	PUNCT
aji-165	108	8	hospital	hospital	NOUN
aji-165	108	9	ibn	ibn	PROPN
aji-165	108	10	sina	sina	PROPN
aji-165	108	11	uhc	uhc	PROPN
aji-165	108	12	,	,	PUNCT
aji-165	108	13	annaba	annaba	PROPN
aji-165	108	14	,	,	PUNCT
aji-165	108	15	algeria	algeria	PROPN
aji-165	108	16	.	.	PUNCT
aji-165	109	1	authors	author	NOUN
aji-165	109	2	’	'	PUNCT
aji-165	109	3	contributions	contribution	NOUN
aji-165	109	4	this	this	DET
aji-165	109	5	work	work	NOUN
aji-165	109	6	was	be	AUX
aji-165	109	7	carried	carry	VERB
aji-165	109	8	out	out	ADP
aji-165	109	9	in	in	ADP
aji-165	109	10	collaboration	collaboration	NOUN
aji-165	109	11	among	among	ADP
aji-165	109	12	all	all	DET
aji-165	109	13	authors	author	NOUN
aji-165	109	14	.	.	PUNCT
aji-165	110	1	all	all	DET
aji-165	110	2	authors	author	NOUN
aji-165	110	3	read	read	VERB
aji-165	110	4	and	and	CCONJ
aji-165	110	5	approved	approve	VERB
aji-165	110	6	the	the	DET
aji-165	110	7	final	final	ADJ
aji-165	110	8	manuscript	manuscript	NOUN
aji-165	110	9	.	.	PUNCT
aji-165	111	1	article	article	NOUN
aji-165	111	2	information	information	NOUN
aji-165	111	3	doi	doi	PROPN
aji-165	111	4	:	:	PUNCT
aji-165	111	5	https://doi.org/10.9734/aji/2025/v8i1165	https://doi.org/10.9734/aji/2025/v8i1165	VERB
aji-165	111	6	open	open	ADJ
aji-165	111	7	peer	peer	NOUN
aji-165	111	8	review	review	NOUN
aji-165	111	9	history	history	NOUN
aji-165	111	10	:	:	PUNCT
aji-165	111	11	this	this	DET
aji-165	111	12	journal	journal	NOUN
aji-165	111	13	follows	follow	VERB
aji-165	111	14	the	the	DET
aji-165	111	15	advanced	advance	VERB
aji-165	111	16	open	open	ADJ
aji-165	111	17	peer	peer	NOUN
aji-165	111	18	review	review	NOUN
aji-165	111	19	policy	policy	NOUN
aji-165	111	20	.	.	PUNCT
aji-165	112	1	identity	identity	NOUN
aji-165	112	2	of	of	ADP
aji-165	112	3	the	the	DET
aji-165	112	4	reviewers	reviewer	NOUN
aji-165	112	5	,	,	PUNCT
aji-165	112	6	editor(s	editor(s	NOUN
aji-165	112	7	)	)	PUNCT
aji-165	112	8	and	and	CCONJ
aji-165	112	9	additional	additional	ADJ
aji-165	112	10	reviewers	reviewer	NOUN
aji-165	112	11	,	,	PUNCT
aji-165	112	12	peer	peer	NOUN
aji-165	112	13	review	review	NOUN
aji-165	112	14	comments	comment	NOUN
aji-165	112	15	,	,	PUNCT
aji-165	112	16	different	different	ADJ
aji-165	112	17	versions	version	NOUN
aji-165	112	18	of	of	ADP
aji-165	112	19	the	the	DET
aji-165	112	20	manuscript	manuscript	NOUN
aji-165	112	21	,	,	PUNCT
aji-165	112	22	comments	comment	NOUN
aji-165	112	23	of	of	ADP
aji-165	112	24	the	the	DET
aji-165	112	25	editors	editor	NOUN
aji-165	112	26	,	,	PUNCT
aji-165	112	27	etc	etc	X
aji-165	112	28	are	be	AUX
aji-165	112	29	available	available	ADJ
aji-165	112	30	here	here	ADV
aji-165	112	31	:	:	PUNCT
aji-165	112	32	https://pr.sdiarticle5.com/review-history/135189	https://pr.sdiarticle5.com/review-history/135189	PROPN
aji-165	112	33	received	receive	VERB
aji-165	112	34	:	:	PUNCT
aji-165	112	35	26/02/2025	26/02/2025	NUM
aji-165	112	36	published	publish	VERB
aji-165	112	37	:	:	PUNCT
aji-165	112	38	05/05/2025	05/05/2025	NUM
aji-165	112	39	abstract	abstract	ADJ
aji-165	112	40	inflammatory	inflammatory	ADJ
aji-165	112	41	bowel	bowel	NOUN
aji-165	112	42	diseases	disease	NOUN
aji-165	112	43	(	(	PUNCT
aji-165	112	44	ibd	ibd	NOUN
aji-165	112	45	)	)	PUNCT
aji-165	112	46	are	be	AUX
aji-165	112	47	increasingly	increasingly	ADV
aji-165	112	48	common	common	ADJ
aji-165	112	49	pathologies	pathology	NOUN
aji-165	112	50	,	,	PUNCT
aji-165	112	51	affecting	affect	VERB
aji-165	112	52	both	both	DET
aji-165	112	53	adults	adult	NOUN
aji-165	112	54	and	and	CCONJ
aji-165	112	55	children	child	NOUN
aji-165	112	56	.	.	PUNCT
aji-165	113	1	this	this	DET
aji-165	113	2	study	study	NOUN
aji-165	113	3	investigates	investigate	VERB
aji-165	113	4	the	the	DET
aji-165	113	5	clinical	clinical	ADJ
aji-165	113	6	and	and	CCONJ
aji-165	113	7	epidemiological	epidemiological	ADJ
aji-165	113	8	characteristics	characteristic	NOUN
aji-165	113	9	of	of	ADP
aji-165	113	10	ibd	ibd	NOUN
aji-165	113	11	among	among	ADP
aji-165	113	12	patients	patient	NOUN
aji-165	113	13	at	at	ADP
aji-165	113	14	the	the	DET
aji-165	113	15	gastroentero	gastroentero	NOUN
aji-165	113	16	-	-	PUNCT
aji-165	113	17	hepatology	hepatology	PROPN
aji-165	113	18	department	department	PROPN
aji-165	113	19	of	of	ADP
aji-165	113	20	annaba	annaba	PROPN
aji-165	113	21	university	university	PROPN
aji-165	113	22	hospital	hospital	NOUN
aji-165	113	23	.	.	PUNCT
aji-165	114	1	conducted	conduct	VERB
aji-165	114	2	from	from	ADP
aji-165	114	3	original	original	ADJ
aji-165	114	4	research	research	NOUN
aji-165	114	5	article	article	NOUN
aji-165	114	6	https://doi.org/10.9734/aji/2025/v8i1165	https://doi.org/10.9734/aji/2025/v8i1165	PROPN
aji-165	114	7	https://pr.sdiarticle5.com/review-history/135189	https://pr.sdiarticle5.com/review-history/135189	PROPN
aji-165	114	8	nassar	nassar	PROPN
aji-165	114	9	et	et	PROPN
aji-165	114	10	al	al	PROPN
aji-165	114	11	.	.	PROPN
aji-165	114	12	;	;	PUNCT
aji-165	115	1	asian	asian	PROPN
aji-165	115	2	j.	j.	PROPN
aji-165	115	3	immunol	immunol	PROPN
aji-165	115	4	.	.	PROPN
aji-165	115	5	,	,	PUNCT
aji-165	115	6	vol	vol	NOUN
aji-165	115	7	.	.	PROPN
aji-165	115	8	8	8	NUM
aji-165	115	9	,	,	PUNCT
aji-165	115	10	no	no	INTJ
aji-165	115	11	.	.	NOUN
aji-165	115	12	1	1	NUM
aji-165	115	13	,	,	PUNCT
aji-165	115	14	pp	pp	ADJ
aji-165	115	15	.	.	PUNCT
aji-165	116	1	104	104	NUM
aji-165	116	2	-	-	SYM
aji-165	116	3	119	119	NUM
aji-165	116	4	,	,	PUNCT
aji-165	116	5	2025	2025	NUM
aji-165	116	6	;	;	PUNCT
aji-165	116	7	article	article	NOUN
aji-165	116	8	no.aji.135189	no.aji.135189	PROPN
aji-165	116	9	105	105	NUM
aji-165	116	10	february	february	NOUN
aji-165	116	11	2023	2023	NUM
aji-165	116	12	to	to	ADP
aji-165	116	13	september	september	PROPN
aji-165	116	14	2024	2024	NUM
aji-165	116	15	,	,	PUNCT
aji-165	116	16	the	the	DET
aji-165	116	17	prospective	prospective	ADJ
aji-165	116	18	descriptive	descriptive	ADJ
aji-165	116	19	analytical	analytical	ADJ
aji-165	116	20	study	study	NOUN
aji-165	116	21	included	include	VERB
aji-165	116	22	77	77	NUM
aji-165	116	23	patients	patient	NOUN
aji-165	116	24	diagnosed	diagnose	VERB
aji-165	116	25	with	with	ADP
aji-165	116	26	ibd	ibd	NOUN
aji-165	116	27	,	,	PUNCT
aji-165	116	28	focusing	focus	VERB
aji-165	116	29	on	on	ADP
aji-165	116	30	the	the	DET
aji-165	116	31	role	role	NOUN
aji-165	116	32	of	of	ADP
aji-165	116	33	biological	biological	ADJ
aji-165	116	34	markers	marker	NOUN
aji-165	116	35	,	,	PUNCT
aji-165	116	36	specifically	specifically	ADV
aji-165	116	37	c	c	NOUN
aji-165	116	38	-	-	PUNCT
aji-165	116	39	reactive	reactive	ADJ
aji-165	116	40	protein	protein	NOUN
aji-165	116	41	(	(	PUNCT
aji-165	116	42	crp	crp	NOUN
aji-165	116	43	)	)	PUNCT
aji-165	116	44	and	and	CCONJ
aji-165	116	45	fecal	fecal	ADJ
aji-165	116	46	calprotectin	calprotectin	NOUN
aji-165	116	47	(	(	PUNCT
aji-165	116	48	fc	fc	INTJ
aji-165	116	49	)	)	PUNCT
aji-165	116	50	,	,	PUNCT
aji-165	116	51	in	in	ADP
aji-165	116	52	non	non	ADJ
aji-165	116	53	-	-	ADJ
aji-165	116	54	invasive	invasive	ADJ
aji-165	116	55	disease	disease	NOUN
aji-165	116	56	assessment	assessment	NOUN
aji-165	116	57	.	.	PUNCT
aji-165	117	1	inclusion	inclusion	NOUN
aji-165	117	2	criteria	criterion	NOUN
aji-165	117	3	were	be	AUX
aji-165	117	4	based	base	VERB
aji-165	117	5	on	on	ADP
aji-165	117	6	clinical	clinical	ADJ
aji-165	117	7	,	,	PUNCT
aji-165	117	8	endoscopic	endoscopic	ADJ
aji-165	117	9	and	and	CCONJ
aji-165	117	10	histological	histological	ADJ
aji-165	117	11	assessments	assessment	NOUN
aji-165	117	12	.	.	PUNCT
aji-165	118	1	demographic	demographic	ADJ
aji-165	118	2	data	datum	NOUN
aji-165	118	3	,	,	PUNCT
aji-165	118	4	clinical	clinical	ADJ
aji-165	118	5	manifestations	manifestation	NOUN
aji-165	118	6	,	,	PUNCT
aji-165	118	7	crp	crp	PROPN
aji-165	118	8	and	and	CCONJ
aji-165	118	9	fc	fc	PROPN
aji-165	118	10	levels	level	NOUN
aji-165	118	11	were	be	AUX
aji-165	118	12	analyzed	analyze	VERB
aji-165	118	13	.	.	PUNCT
aji-165	119	1	among	among	ADP
aji-165	119	2	the	the	DET
aji-165	119	3	77	77	NUM
aji-165	119	4	patients	patient	NOUN
aji-165	119	5	,	,	PUNCT
aji-165	119	6	53	53	NUM
aji-165	119	7	patients	patient	NOUN
aji-165	119	8	or	or	CCONJ
aji-165	119	9	68.9	68.9	NUM
aji-165	119	10	%	%	NOUN
aji-165	119	11	had	have	VERB
aji-165	119	12	crohn	crohn	PROPN
aji-165	119	13	's	's	PART
aji-165	119	14	disease	disease	NOUN
aji-165	119	15	(	(	PUNCT
aji-165	119	16	cd	cd	PROPN
aji-165	119	17	)	)	PUNCT
aji-165	119	18	,	,	PUNCT
aji-165	119	19	while	while	SCONJ
aji-165	119	20	24	24	NUM
aji-165	119	21	patients	patient	NOUN
aji-165	119	22	or	or	CCONJ
aji-165	119	23	31.1	31.1	NUM
aji-165	119	24	%	%	NOUN
aji-165	119	25	suffered	suffer	VERB
aji-165	119	26	from	from	ADP
aji-165	119	27	ulcerative	ulcerative	ADJ
aji-165	119	28	colitis	colitis	NOUN
aji-165	119	29	(	(	PUNCT
aji-165	119	30	uc	uc	PROPN
aji-165	119	31	)	)	PUNCT
aji-165	119	32	.	.	PUNCT
aji-165	120	1	the	the	DET
aji-165	120	2	most	most	ADV
aji-165	120	3	prevalent	prevalent	ADJ
aji-165	120	4	symptoms	symptom	NOUN
aji-165	120	5	were	be	AUX
aji-165	120	6	abdominal	abdominal	ADJ
aji-165	120	7	pain	pain	NOUN
aji-165	120	8	and	and	CCONJ
aji-165	120	9	chronic	chronic	ADJ
aji-165	120	10	diarrhea	diarrhea	NOUN
aji-165	120	11	.	.	PUNCT
aji-165	121	1	among	among	ADP
aji-165	121	2	cd	cd	PROPN
aji-165	121	3	patients	patient	NOUN
aji-165	121	4	,	,	PUNCT
aji-165	121	5	ileal	ileal	ADJ
aji-165	121	6	involvement	involvement	NOUN
aji-165	121	7	was	be	AUX
aji-165	121	8	common	common	ADJ
aji-165	121	9	in	in	ADP
aji-165	121	10	21	21	NUM
aji-165	121	11	cases	case	NOUN
aji-165	121	12	(	(	PUNCT
aji-165	121	13	39.62	39.62	NUM
aji-165	121	14	%	%	NOUN
aji-165	121	15	)	)	PUNCT
aji-165	121	16	with	with	ADP
aji-165	121	17	25	25	NUM
aji-165	121	18	cases	case	NOUN
aji-165	121	19	(	(	PUNCT
aji-165	121	20	32,47	32,47	NUM
aji-165	121	21	%	%	NOUN
aji-165	121	22	)	)	PUNCT
aji-165	121	23	experiencing	experience	VERB
aji-165	121	24	complications	complication	NOUN
aji-165	121	25	the	the	DET
aji-165	121	26	study	study	NOUN
aji-165	121	27	found	find	VERB
aji-165	121	28	that	that	SCONJ
aji-165	121	29	34	34	NUM
aji-165	121	30	or	or	CCONJ
aji-165	121	31	46.57	46.57	NUM
aji-165	121	32	%	%	NOUN
aji-165	121	33	of	of	ADP
aji-165	121	34	patients	patient	NOUN
aji-165	121	35	had	have	VERB
aji-165	121	36	elevated	elevate	VERB
aji-165	121	37	crp	crp	NOUN
aji-165	121	38	levels	level	NOUN
aji-165	121	39	,	,	PUNCT
aji-165	121	40	with	with	ADP
aji-165	121	41	a	a	DET
aji-165	121	42	higher	high	ADJ
aji-165	121	43	prevalence	prevalence	NOUN
aji-165	121	44	in	in	ADP
aji-165	121	45	those	those	PRON
aji-165	121	46	with	with	ADP
aji-165	121	47	cd	cd	PROPN
aji-165	121	48	compared	compare	VERB
aji-165	121	49	to	to	ADP
aji-165	121	50	uc	uc	PROPN
aji-165	121	51	.	.	PUNCT
aji-165	122	1	a	a	DET
aji-165	122	2	statistically	statistically	ADV
aji-165	122	3	significant	significant	ADJ
aji-165	122	4	association	association	NOUN
aji-165	122	5	was	be	AUX
aji-165	122	6	observed	observe	VERB
aji-165	122	7	between	between	ADP
aji-165	122	8	crp	crp	PROPN
aji-165	122	9	levels	level	NOUN
aji-165	122	10	and	and	CCONJ
aji-165	122	11	ibd	ibd	PROPN
aji-165	122	12	type	type	NOUN
aji-165	122	13	.	.	PUNCT
aji-165	123	1	additionally	additionally	ADV
aji-165	123	2	,	,	PUNCT
aji-165	123	3	the	the	DET
aji-165	123	4	analysis	analysis	NOUN
aji-165	123	5	revealed	reveal	VERB
aji-165	123	6	that	that	SCONJ
aji-165	123	7	among	among	ADP
aji-165	123	8	patients	patient	NOUN
aji-165	123	9	experiencing	experience	VERB
aji-165	123	10	relapse	relapse	NOUN
aji-165	123	11	,	,	PUNCT
aji-165	123	12	20	20	NUM
aji-165	123	13	cases	case	NOUN
aji-165	123	14	or	or	CCONJ
aji-165	123	15	52.63	52.63	NUM
aji-165	123	16	%	%	NOUN
aji-165	123	17	had	have	VERB
aji-165	123	18	positive	positive	ADJ
aji-165	123	19	fc	fc	NOUN
aji-165	123	20	results	result	NOUN
aji-165	123	21	,	,	PUNCT
aji-165	123	22	compared	compare	VERB
aji-165	123	23	to	to	ADP
aji-165	123	24	14	14	NUM
aji-165	123	25	cases	case	NOUN
aji-165	123	26	or	or	CCONJ
aji-165	123	27	35.9	35.9	NUM
aji-165	123	28	%	%	NOUN
aji-165	123	29	in	in	ADP
aji-165	123	30	remission	remission	NOUN
aji-165	123	31	,	,	PUNCT
aji-165	123	32	indicating	indicate	VERB
aji-165	123	33	a	a	DET
aji-165	123	34	significant	significant	ADJ
aji-165	123	35	correlation	correlation	NOUN
aji-165	123	36	between	between	ADP
aji-165	123	37	relapse	relapse	NOUN
aji-165	123	38	status	status	NOUN
aji-165	123	39	and	and	CCONJ
aji-165	123	40	fc	fc	PROPN
aji-165	123	41	levels	level	NOUN
aji-165	123	42	(	(	PUNCT
aji-165	123	43	p=0.018	p=0.018	NOUN
aji-165	123	44	)	)	PUNCT
aji-165	123	45	.	.	PUNCT
aji-165	124	1	however	however	ADV
aji-165	124	2	,	,	PUNCT
aji-165	124	3	no	no	DET
aji-165	124	4	significant	significant	ADJ
aji-165	124	5	association	association	NOUN
aji-165	124	6	was	be	AUX
aji-165	124	7	found	find	VERB
aji-165	124	8	between	between	ADP
aji-165	124	9	relapse	relapse	NOUN
aji-165	124	10	status	status	NOUN
aji-165	124	11	and	and	CCONJ
aji-165	124	12	crp	crp	PROPN
aji-165	124	13	levels	level	NOUN
aji-165	124	14	,	,	PUNCT
aji-165	124	15	although	although	SCONJ
aji-165	124	16	a	a	DET
aji-165	124	17	significant	significant	ADJ
aji-165	124	18	difference	difference	NOUN
aji-165	124	19	in	in	ADP
aji-165	124	20	mean	mean	PROPN
aji-165	124	21	crp	crp	PROPN
aji-165	124	22	levels	level	NOUN
aji-165	124	23	between	between	ADP
aji-165	124	24	active	active	ADJ
aji-165	124	25	and	and	CCONJ
aji-165	124	26	remission	remission	NOUN
aji-165	124	27	states	state	NOUN
aji-165	124	28	in	in	ADP
aji-165	124	29	uc	uc	PROPN
aji-165	124	30	was	be	AUX
aji-165	124	31	noted	note	VERB
aji-165	124	32	(	(	PUNCT
aji-165	124	33	p=0.03	p=0.03	ADJ
aji-165	124	34	)	)	PUNCT
aji-165	124	35	.	.	PUNCT
aji-165	125	1	a	a	DET
aji-165	125	2	weak	weak	ADJ
aji-165	125	3	positive	positive	ADJ
aji-165	125	4	correlation	correlation	NOUN
aji-165	125	5	(	(	PUNCT
aji-165	125	6	r	r	NOUN
aji-165	125	7	=	=	NOUN
aji-165	125	8	0.12	0.12	NUM
aji-165	125	9	)	)	PUNCT
aji-165	125	10	between	between	ADP
aji-165	125	11	crp	crp	PROPN
aji-165	125	12	and	and	CCONJ
aji-165	125	13	fc	fc	VERB
aji-165	125	14	during	during	ADP
aji-165	125	15	active	active	ADJ
aji-165	125	16	phases	phase	NOUN
aji-165	125	17	was	be	AUX
aji-165	125	18	also	also	ADV
aji-165	125	19	identified	identify	VERB
aji-165	125	20	.	.	PUNCT
aji-165	126	1	the	the	DET
aji-165	126	2	findings	finding	NOUN
aji-165	126	3	underscore	underscore	VERB
aji-165	126	4	the	the	DET
aji-165	126	5	clinical	clinical	ADJ
aji-165	126	6	and	and	CCONJ
aji-165	126	7	epidemiological	epidemiological	ADJ
aji-165	126	8	profile	profile	NOUN
aji-165	126	9	of	of	ADP
aji-165	126	10	ibd	ibd	NOUN
aji-165	126	11	in	in	ADP
aji-165	126	12	this	this	DET
aji-165	126	13	population	population	NOUN
aji-165	126	14	,	,	PUNCT
aji-165	126	15	highlighting	highlight	VERB
aji-165	126	16	the	the	DET
aji-165	126	17	importance	importance	NOUN
aji-165	126	18	of	of	ADP
aji-165	126	19	fc	fc	PROPN
aji-165	126	20	as	as	ADP
aji-165	126	21	a	a	DET
aji-165	126	22	valuable	valuable	ADJ
aji-165	126	23	marker	marker	NOUN
aji-165	126	24	for	for	ADP
aji-165	126	25	monitoring	monitor	VERB
aji-165	126	26	disease	disease	NOUN
aji-165	126	27	activity	activity	NOUN
aji-165	126	28	and	and	CCONJ
aji-165	126	29	relapse	relapse	NOUN
aji-165	126	30	status	status	NOUN
aji-165	126	31	in	in	ADP
aji-165	126	32	ibd	ibd	PROPN
aji-165	126	33	patients	patient	NOUN
aji-165	126	34	.	.	PUNCT
aji-165	127	1	keywords	keyword	NOUN
aji-165	127	2	:	:	PUNCT
aji-165	127	3	fecal	fecal	ADJ
aji-165	127	4	calprotectin	calprotectin	NOUN
aji-165	127	5	;	;	PUNCT
aji-165	127	6	inflammatory	inflammatory	ADJ
aji-165	127	7	bowel	bowel	NOUN
aji-165	127	8	disease	disease	NOUN
aji-165	127	9	;	;	PUNCT
aji-165	127	10	crohn	crohn	PROPN
aji-165	127	11	's	's	PART
aji-165	127	12	disease	disease	NOUN
aji-165	127	13	;	;	PUNCT
aji-165	127	14	ulcerative	ulcerative	ADJ
aji-165	127	15	colitis	colitis	NOUN
aji-165	127	16	;	;	PUNCT
aji-165	127	17	creactive	creactive	ADJ
aji-165	127	18	protein	protein	NOUN
aji-165	127	19	.	.	PUNCT
aji-165	128	1	1	1	X
aji-165	128	2	.	.	X
aji-165	128	3	introduction	introduction	NOUN
aji-165	128	4	chronic	chronic	ADJ
aji-165	128	5	inflammatory	inflammatory	ADJ
aji-165	128	6	bowel	bowel	NOUN
aji-165	128	7	diseases	disease	NOUN
aji-165	128	8	(	(	PUNCT
aji-165	128	9	ibd	ibd	PROPN
aji-165	128	10	)	)	PUNCT
aji-165	128	11	,	,	PUNCT
aji-165	128	12	including	include	VERB
aji-165	128	13	crohn	crohn	PROPN
aji-165	128	14	's	's	PART
aji-165	128	15	disease	disease	NOUN
aji-165	128	16	(	(	PUNCT
aji-165	128	17	cd	cd	PROPN
aji-165	128	18	)	)	PUNCT
aji-165	128	19	and	and	CCONJ
aji-165	128	20	ulcerative	ulcerative	ADJ
aji-165	128	21	colitis	colitis	NOUN
aji-165	128	22	(	(	PUNCT
aji-165	128	23	uc	uc	PROPN
aji-165	128	24	)	)	PUNCT
aji-165	128	25	,	,	PUNCT
aji-165	128	26	are	be	AUX
aji-165	128	27	chronic	chronic	ADJ
aji-165	128	28	and	and	CCONJ
aji-165	128	29	progressive	progressive	ADJ
aji-165	128	30	pathologies	pathology	NOUN
aji-165	128	31	responsible	responsible	ADJ
aji-165	128	32	for	for	ADP
aji-165	128	33	irreversible	irreversible	ADJ
aji-165	128	34	destruction	destruction	NOUN
aji-165	128	35	of	of	ADP
aji-165	128	36	the	the	DET
aji-165	128	37	digestive	digestive	ADJ
aji-165	128	38	tract	tract	NOUN
aji-165	128	39	,	,	PUNCT
aji-165	128	40	leading	lead	VERB
aji-165	128	41	to	to	ADP
aji-165	128	42	significant	significant	ADJ
aji-165	128	43	alteration	alteration	NOUN
aji-165	128	44	in	in	ADP
aji-165	128	45	quality	quality	NOUN
aji-165	128	46	of	of	ADP
aji-165	128	47	life	life	NOUN
aji-165	128	48	.	.	PUNCT
aji-165	129	1	diagnosis	diagnosis	NOUN
aji-165	129	2	of	of	ADP
aji-165	129	3	ibd	ibd	PROPN
aji-165	129	4	is	be	AUX
aji-165	129	5	often	often	ADV
aji-165	129	6	difficult	difficult	ADJ
aji-165	129	7	in	in	ADP
aji-165	129	8	clinical	clinical	ADJ
aji-165	129	9	practice	practice	NOUN
aji-165	129	10	,	,	PUNCT
aji-165	129	11	due	due	ADP
aji-165	129	12	to	to	ADP
aji-165	129	13	pathognomonic	pathognomonic	ADJ
aji-165	129	14	symptoms	symptom	NOUN
aji-165	129	15	and	and	CCONJ
aji-165	129	16	considerable	considerable	ADJ
aji-165	129	17	overlap	overlap	NOUN
aji-165	129	18	with	with	ADP
aji-165	129	19	those	those	PRON
aji-165	129	20	of	of	ADP
aji-165	129	21	irritable	irritable	ADJ
aji-165	129	22	bowel	bowel	NOUN
aji-165	129	23	syndrome	syndrome	NOUN
aji-165	129	24	(	(	PUNCT
aji-165	129	25	ulcerative	ulcerative	ADJ
aji-165	129	26	colitis	colitis	NOUN
aji-165	129	27	pubmed	pubmed	PROPN
aji-165	129	28	,	,	PUNCT
aji-165	129	29	2024	2024	NUM
aji-165	129	30	;	;	PUNCT
aji-165	129	31	torres	torre	VERB
aji-165	129	32	et	et	PROPN
aji-165	129	33	al	al	PROPN
aji-165	129	34	.	.	PROPN
aji-165	129	35	,	,	PUNCT
aji-165	129	36	2017	2017	NUM
aji-165	129	37	)	)	PUNCT
aji-165	129	38	although	although	SCONJ
aji-165	129	39	endoscopy	endoscopy	NOUN
aji-165	129	40	has	have	AUX
aji-165	129	41	been	be	AUX
aji-165	129	42	the	the	DET
aji-165	129	43	mainstay	mainstay	NOUN
aji-165	129	44	of	of	ADP
aji-165	129	45	ibd	ibd	PROPN
aji-165	129	46	assessment	assessment	NOUN
aji-165	129	47	,	,	PUNCT
aji-165	129	48	the	the	DET
aji-165	129	49	feasibility	feasibility	NOUN
aji-165	129	50	of	of	ADP
aji-165	129	51	using	use	VERB
aji-165	129	52	ileo	ileo	NOUN
aji-165	129	53	colonoscopy	colonoscopy	NOUN
aji-165	129	54	repeatedly	repeatedly	ADV
aji-165	129	55	for	for	ADP
aji-165	129	56	long	long	ADJ
aji-165	129	57	-	-	PUNCT
aji-165	129	58	term	term	NOUN
aji-165	129	59	follow	follow	NOUN
aji-165	129	60	-	-	PUNCT
aji-165	129	61	up	up	NOUN
aji-165	129	62	is	be	AUX
aji-165	129	63	limited	limit	VERB
aji-165	129	64	by	by	ADP
aji-165	129	65	its	its	PRON
aji-165	129	66	availability	availability	NOUN
aji-165	129	67	,	,	PUNCT
aji-165	129	68	invasiveness	invasiveness	ADJ
aji-165	129	69	,	,	PUNCT
aji-165	129	70	patient	patient	ADJ
aji-165	129	71	tolerance	tolerance	NOUN
aji-165	129	72	and	and	CCONJ
aji-165	129	73	cost	cost	NOUN
aji-165	129	74	.	.	PUNCT
aji-165	130	1	there	there	PRON
aji-165	130	2	is	be	VERB
aji-165	130	3	therefore	therefore	ADV
aji-165	130	4	considerable	considerable	ADJ
aji-165	130	5	interest	interest	NOUN
aji-165	130	6	in	in	ADP
aji-165	130	7	using	use	VERB
aji-165	130	8	non	non	ADJ
aji-165	130	9	-	-	ADJ
aji-165	130	10	invasive	invasive	ADJ
aji-165	130	11	biomarkers	biomarker	NOUN
aji-165	130	12	to	to	PART
aji-165	130	13	monitor	monitor	VERB
aji-165	130	14	ibd	ibd	NOUN
aji-165	130	15	activity	activity	NOUN
aji-165	130	16	(	(	PUNCT
aji-165	130	17	ma	ma	PROPN
aji-165	130	18	et	et	PROPN
aji-165	130	19	al	al	PROPN
aji-165	130	20	.	.	PROPN
aji-165	130	21	,	,	PUNCT
aji-165	130	22	2019	2019	NUM
aji-165	130	23	)	)	PUNCT
aji-165	130	24	.	.	PUNCT
aji-165	131	1	fc	fc	PROPN
aji-165	131	2	,	,	PUNCT
aji-165	131	3	a	a	DET
aji-165	131	4	neutrophil	neutrophil	ADJ
aji-165	131	5	-	-	PUNCT
aji-165	131	6	derived	derive	VERB
aji-165	131	7	protein	protein	NOUN
aji-165	131	8	,	,	PUNCT
aji-165	131	9	is	be	AUX
aji-165	131	10	the	the	DET
aji-165	131	11	most	most	ADV
aji-165	131	12	sensitive	sensitive	ADJ
aji-165	131	13	biomarker	biomarker	NOUN
aji-165	131	14	of	of	ADP
aji-165	131	15	intestinal	intestinal	ADJ
aji-165	131	16	inflammation	inflammation	NOUN
aji-165	131	17	.	.	PUNCT
aji-165	132	1	fc	fc	PROPN
aji-165	132	2	levels	level	NOUN
aji-165	132	3	correlate	correlate	VERB
aji-165	132	4	well	well	ADV
aji-165	132	5	with	with	ADP
aji-165	132	6	endoscopic	endoscopic	ADJ
aji-165	132	7	scores	score	NOUN
aji-165	132	8	in	in	ADP
aji-165	132	9	cd	cd	PROPN
aji-165	132	10	and	and	CCONJ
aji-165	132	11	uc	uc	PROPN
aji-165	132	12	.	.	PROPN
aji-165	133	1	today	today	NOUN
aji-165	133	2	,	,	PUNCT
aji-165	133	3	fc	fc	PROPN
aji-165	133	4	is	be	AUX
aji-165	133	5	used	use	VERB
aji-165	133	6	in	in	ADP
aji-165	133	7	a	a	DET
aji-165	133	8	variety	variety	NOUN
aji-165	133	9	of	of	ADP
aji-165	133	10	clinical	clinical	ADJ
aji-165	133	11	settings	setting	NOUN
aji-165	133	12	,	,	PUNCT
aji-165	133	13	notably	notably	ADV
aji-165	133	14	for	for	ADP
aji-165	133	15	the	the	DET
aji-165	133	16	initial	initial	ADJ
aji-165	133	17	diagnosis	diagnosis	NOUN
aji-165	133	18	of	of	ADP
aji-165	133	19	ibd	ibd	PROPN
aji-165	133	20	(	(	PUNCT
aji-165	133	21	d’amico	d’amico	PROPN
aji-165	133	22	et	et	PROPN
aji-165	133	23	al	al	PROPN
aji-165	133	24	.	.	PROPN
aji-165	133	25	,	,	PUNCT
aji-165	133	26	2021).although	2021).although	PROPN
aji-165	133	27	fc	fc	PROPN
aji-165	133	28	and	and	CCONJ
aji-165	133	29	crp	crp	PROPN
aji-165	133	30	are	be	AUX
aji-165	133	31	the	the	DET
aji-165	133	32	most	most	ADV
aji-165	133	33	studied	study	VERB
aji-165	133	34	biomarkers	biomarker	NOUN
aji-165	133	35	in	in	ADP
aji-165	133	36	this	this	DET
aji-165	133	37	field	field	NOUN
aji-165	133	38	,	,	PUNCT
aji-165	133	39	there	there	PRON
aji-165	133	40	are	be	VERB
aji-165	133	41	concerns	concern	NOUN
aji-165	133	42	about	about	ADP
aji-165	133	43	the	the	DET
aji-165	133	44	sensitivity	sensitivity	NOUN
aji-165	133	45	and	and	CCONJ
aji-165	133	46	specificity	specificity	NOUN
aji-165	133	47	of	of	ADP
aji-165	133	48	crp	crp	PROPN
aji-165	133	49	in	in	ADP
aji-165	133	50	ibd	ibd	PROPN
aji-165	133	51	patients	patient	NOUN
aji-165	133	52	.	.	PUNCT
aji-165	134	1	moreover	moreover	ADV
aji-165	134	2	,	,	PUNCT
aji-165	134	3	patients	patient	NOUN
aji-165	134	4	often	often	ADV
aji-165	134	5	prefer	prefer	VERB
aji-165	134	6	blood	blood	NOUN
aji-165	134	7	tests	test	NOUN
aji-165	134	8	to	to	PART
aji-165	134	9	stool	stool	NOUN
aji-165	134	10	collection	collection	NOUN
aji-165	134	11	,	,	PUNCT
aji-165	134	12	which	which	PRON
aji-165	134	13	limits	limit	VERB
aji-165	134	14	the	the	DET
aji-165	134	15	acceptability	acceptability	NOUN
aji-165	134	16	of	of	ADP
aji-165	134	17	fc	fc	PROPN
aji-165	134	18	.	.	PUNCT
aji-165	135	1	finally	finally	ADV
aji-165	135	2	,	,	PUNCT
aji-165	135	3	the	the	DET
aji-165	135	4	optimal	optimal	ADJ
aji-165	135	5	thresholds	threshold	NOUN
aji-165	135	6	for	for	SCONJ
aji-165	135	7	fc	fc	PROPN
aji-165	135	8	to	to	PART
aji-165	135	9	predict	predict	VERB
aji-165	135	10	disease	disease	NOUN
aji-165	135	11	activity	activity	NOUN
aji-165	135	12	vary	vary	VERB
aji-165	135	13	according	accord	VERB
aji-165	135	14	to	to	ADP
aji-165	135	15	ibd	ibd	PROPN
aji-165	135	16	phenotype	phenotype	NOUN
aji-165	135	17	and	and	CCONJ
aji-165	135	18	the	the	DET
aji-165	135	19	tests	test	NOUN
aji-165	135	20	used	use	VERB
aji-165	135	21	(	(	PUNCT
aji-165	135	22	swaminathan	swaminathan	NOUN
aji-165	135	23	&	&	CCONJ
aji-165	135	24	day	day	PROPN
aji-165	135	25	,	,	PUNCT
aji-165	135	26	2024	2024	NUM
aji-165	135	27	)	)	PUNCT
aji-165	135	28	.	.	PUNCT
aji-165	136	1	our	our	PRON
aji-165	136	2	study	study	NOUN
aji-165	136	3	aims	aim	VERB
aji-165	136	4	to	to	PART
aji-165	136	5	assess	assess	VERB
aji-165	136	6	the	the	DET
aji-165	136	7	clinical	clinical	ADJ
aji-165	136	8	and	and	CCONJ
aji-165	136	9	epidemiological	epidemiological	ADJ
aji-165	136	10	profile	profile	NOUN
aji-165	136	11	of	of	ADP
aji-165	136	12	ibd	ibd	NOUN
aji-165	136	13	in	in	ADP
aji-165	136	14	adult	adult	NOUN
aji-165	136	15	population	population	NOUN
aji-165	136	16	.	.	PUNCT
aji-165	137	1	it	it	PRON
aji-165	137	2	also	also	ADV
aji-165	137	3	explores	explore	VERB
aji-165	137	4	the	the	DET
aji-165	137	5	correlation	correlation	NOUN
aji-165	137	6	between	between	ADP
aji-165	137	7	crp	crp	PROPN
aji-165	137	8	levels	level	NOUN
aji-165	137	9	and	and	CCONJ
aji-165	137	10	fc	fc	X
aji-165	137	11	in	in	ADP
aji-165	137	12	the	the	DET
aji-165	137	13	context	context	NOUN
aji-165	137	14	of	of	ADP
aji-165	137	15	ibd	ibd	PROPN
aji-165	137	16	,	,	PUNCT
aji-165	137	17	to	to	PART
aji-165	137	18	better	well	ADV
aji-165	137	19	understand	understand	VERB
aji-165	137	20	their	their	PRON
aji-165	137	21	usefulness	usefulness	NOUN
aji-165	137	22	as	as	ADP
aji-165	137	23	biological	biological	ADJ
aji-165	137	24	markers	marker	NOUN
aji-165	137	25	in	in	ADP
aji-165	137	26	monitoring	monitor	VERB
aji-165	137	27	intestinal	intestinal	ADJ
aji-165	137	28	inflammation	inflammation	NOUN
aji-165	137	29	.	.	PUNCT
aji-165	138	1	2	2	X
aji-165	138	2	.	.	X
aji-165	138	3	materials	material	NOUN
aji-165	138	4	and	and	CCONJ
aji-165	138	5	methods	method	NOUN
aji-165	138	6	the	the	DET
aji-165	138	7	present	present	ADJ
aji-165	138	8	study	study	NOUN
aji-165	138	9	was	be	AUX
aji-165	138	10	conducted	conduct	VERB
aji-165	138	11	in	in	ADP
aji-165	138	12	the	the	DET
aji-165	138	13	immunology	immunology	NOUN
aji-165	138	14	laboratory	laboratory	NOUN
aji-165	138	15	at	at	ADP
aji-165	138	16	annaba	annaba	PROPN
aji-165	138	17	university	university	PROPN
aji-165	138	18	hospital	hospital	NOUN
aji-165	138	19	,	,	PUNCT
aji-165	138	20	annaba	annaba	PROPN
aji-165	138	21	/	/	SYM
aji-165	138	22	algeria	algeria	PROPN
aji-165	138	23	,	,	PUNCT
aji-165	138	24	over	over	ADP
aji-165	138	25	a	a	DET
aji-165	138	26	period	period	NOUN
aji-165	138	27	of	of	ADP
aji-165	138	28	19	19	NUM
aji-165	138	29	months	month	NOUN
aji-165	138	30	,	,	PUNCT
aji-165	138	31	from	from	ADP
aji-165	138	32	february	february	PROPN
aji-165	138	33	9	9	NUM
aji-165	138	34	,	,	PUNCT
aji-165	138	35	2023	2023	NUM
aji-165	138	36	,	,	PUNCT
aji-165	138	37	to	to	ADP
aji-165	138	38	september	september	PROPN
aji-165	138	39	30	30	NUM
aji-165	138	40	,	,	PUNCT
aji-165	138	41	2024	2024	NUM
aji-165	138	42	.	.	PUNCT
aji-165	139	1	this	this	PRON
aji-165	139	2	is	be	AUX
aji-165	139	3	a	a	DET
aji-165	139	4	prospective	prospective	ADJ
aji-165	139	5	descriptiveanalytical	descriptiveanalytical	ADJ
aji-165	139	6	study	study	NOUN
aji-165	139	7	involving	involve	VERB
aji-165	139	8	a	a	DET
aji-165	139	9	sample	sample	NOUN
aji-165	139	10	of	of	ADP
aji-165	139	11	77	77	NUM
aji-165	139	12	adult	adult	NOUN
aji-165	139	13	patients	patient	NOUN
aji-165	139	14	referred	refer	VERB
aji-165	139	15	by	by	ADP
aji-165	139	16	the	the	DET
aji-165	139	17	gastroenterology	gastroenterology	NOUN
aji-165	139	18	and	and	CCONJ
aji-165	139	19	hepatology	hepatology	NOUN
aji-165	139	20	department	department	PROPN
aji-165	139	21	at	at	ADP
aji-165	139	22	annaba	annaba	PROPN
aji-165	139	23	university	university	PROPN
aji-165	139	24	hospital	hospital	NOUN
aji-165	139	25	.	.	PUNCT
aji-165	140	1	the	the	DET
aji-165	140	2	sample	sample	NOUN
aji-165	140	3	consisted	consist	VERB
aji-165	140	4	of	of	ADP
aji-165	140	5	29	29	NUM
aji-165	140	6	males	male	NOUN
aji-165	140	7	and	and	CCONJ
aji-165	140	8	48	48	NUM
aji-165	140	9	females	female	NOUN
aji-165	140	10	,	,	PUNCT
aji-165	140	11	with	with	ADP
aji-165	140	12	an	an	DET
aji-165	140	13	average	average	ADJ
aji-165	140	14	age	age	NOUN
aji-165	140	15	of	of	ADP
aji-165	140	16	39.7	39.7	NUM
aji-165	140	17	±	±	NUM
aji-165	140	18	17.47	17.47	NUM
aji-165	140	19	years	year	NOUN
aji-165	140	20	,	,	PUNCT
aji-165	140	21	a	a	DET
aji-165	140	22	median	median	ADJ
aji-165	140	23	age	age	NOUN
aji-165	140	24	of	of	ADP
aji-165	140	25	34	34	NUM
aji-165	140	26	years	year	NOUN
aji-165	140	27	,	,	PUNCT
aji-165	140	28	and	and	CCONJ
aji-165	140	29	a	a	DET
aji-165	140	30	mode	mode	NOUN
aji-165	140	31	of	of	ADP
aji-165	140	32	34	34	NUM
aji-165	140	33	years	year	NOUN
aji-165	140	34	.	.	PUNCT
aji-165	141	1	the	the	DET
aji-165	141	2	age	age	NOUN
aji-165	141	3	range	range	NOUN
aji-165	141	4	was	be	AUX
aji-165	141	5	from	from	ADP
aji-165	141	6	17	17	NUM
aji-165	141	7	to	to	PART
aji-165	141	8	82	82	NUM
aji-165	141	9	years	year	NOUN
aji-165	141	10	,	,	PUNCT
aji-165	141	11	resulting	result	VERB
aji-165	141	12	in	in	ADP
aji-165	141	13	a	a	DET
aji-165	141	14	male	male	NOUN
aji-165	141	15	-	-	PUNCT
aji-165	141	16	to	to	ADP
aji-165	141	17	-	-	PUNCT
aji-165	141	18	female	female	ADJ
aji-165	141	19	ratio	ratio	NOUN
aji-165	141	20	of	of	ADP
aji-165	141	21	0.6	0.6	NUM
aji-165	141	22	.	.	PUNCT
aji-165	142	1	inclusion	inclusion	NOUN
aji-165	142	2	criteria	criterion	NOUN
aji-165	142	3	patients	patient	NOUN
aji-165	142	4	included	include	VERB
aji-165	142	5	in	in	ADP
aji-165	142	6	our	our	PRON
aji-165	142	7	study	study	NOUN
aji-165	142	8	represent	represent	VERB
aji-165	142	9	those	those	PRON
aji-165	142	10	whose	whose	DET
aji-165	142	11	diagnosis	diagnosis	NOUN
aji-165	142	12	of	of	ADP
aji-165	142	13	ibd	ibd	PROPN
aji-165	142	14	(	(	PUNCT
aji-165	142	15	uc	uc	PROPN
aji-165	142	16	/	/	SYM
aji-165	142	17	cd	cd	PROPN
aji-165	142	18	)	)	PUNCT
aji-165	142	19	was	be	AUX
aji-165	142	20	confirmed	confirm	VERB
aji-165	142	21	nassar	nassar	PROPN
aji-165	142	22	et	et	PROPN
aji-165	142	23	al	al	PROPN
aji-165	142	24	.	.	PROPN
aji-165	142	25	;	;	PUNCT
aji-165	143	1	asian	asian	PROPN
aji-165	143	2	j.	j.	PROPN
aji-165	143	3	immunol	immunol	PROPN
aji-165	143	4	.	.	PROPN
aji-165	143	5	,	,	PUNCT
aji-165	143	6	vol	vol	NOUN
aji-165	143	7	.	.	PROPN
aji-165	143	8	8	8	NUM
aji-165	143	9	,	,	PUNCT
aji-165	143	10	no	no	INTJ
aji-165	143	11	.	.	NOUN
aji-165	143	12	1	1	NUM
aji-165	143	13	,	,	PUNCT
aji-165	143	14	pp	pp	ADJ
aji-165	143	15	.	.	PUNCT
aji-165	144	1	104	104	NUM
aji-165	144	2	-	-	SYM
aji-165	144	3	119	119	NUM
aji-165	144	4	,	,	PUNCT
aji-165	144	5	2025	2025	NUM
aji-165	144	6	;	;	PUNCT
aji-165	144	7	article	article	NOUN
aji-165	144	8	no.aji.135189	no.aji.135189	NOUN
aji-165	144	9	106	106	NUM
aji-165	144	10	on	on	ADP
aji-165	144	11	the	the	DET
aji-165	144	12	basis	basis	NOUN
aji-165	144	13	of	of	ADP
aji-165	144	14	clinical	clinical	ADJ
aji-165	144	15	,	,	PUNCT
aji-165	144	16	endoscopic	endoscopic	ADJ
aji-165	144	17	,	,	PUNCT
aji-165	144	18	and	and	CCONJ
aji-165	144	19	histological	histological	ADJ
aji-165	144	20	criteria	criterion	NOUN
aji-165	144	21	(	(	PUNCT
aji-165	144	22	montreal	montreal	PROPN
aji-165	144	23	classifications	classification	NOUN
aji-165	144	24	)	)	PUNCT
aji-165	144	25	and	and	CCONJ
aji-165	144	26	referred	refer	VERB
aji-165	144	27	to	to	ADP
aji-165	144	28	the	the	DET
aji-165	144	29	immunology	immunology	NOUN
aji-165	144	30	laboratory	laboratory	NOUN
aji-165	144	31	for	for	ADP
aji-165	144	32	immunological	immunological	ADJ
aji-165	144	33	work	work	NOUN
aji-165	144	34	-	-	PUNCT
aji-165	144	35	up	up	NOUN
aji-165	144	36	:	:	PUNCT
aji-165	144	37	determination	determination	NOUN
aji-165	144	38	of	of	ADP
aji-165	144	39	fc	fc	PROPN
aji-165	144	40	and	and	CCONJ
aji-165	144	41	crp	crp	PROPN
aji-165	144	42	.	.	PUNCT
aji-165	145	1	exclusion	exclusion	NOUN
aji-165	145	2	criteria	criterion	NOUN
aji-165	145	3	patients	patient	NOUN
aji-165	145	4	whose	whose	DET
aji-165	145	5	diagnosis	diagnosis	NOUN
aji-165	145	6	of	of	ADP
aji-165	145	7	ibd	ibd	NOUN
aji-165	145	8	has	have	AUX
aji-165	145	9	not	not	PART
aji-165	145	10	been	be	AUX
aji-165	145	11	confirmed	confirm	VERB
aji-165	145	12	(	(	PUNCT
aji-165	145	13	still	still	ADV
aji-165	145	14	under	under	ADP
aji-165	145	15	investigation	investigation	NOUN
aji-165	145	16	)	)	PUNCT
aji-165	145	17	.	.	PUNCT
aji-165	146	1	patients	patient	NOUN
aji-165	146	2	with	with	ADP
aji-165	146	3	incomplete	incomplete	ADJ
aji-165	146	4	or	or	CCONJ
aji-165	146	5	unusable	unusable	ADJ
aji-165	146	6	clinical	clinical	ADJ
aji-165	146	7	records	record	NOUN
aji-165	146	8	.	.	PUNCT
aji-165	147	1	patients	patient	NOUN
aji-165	147	2	diagnosed	diagnose	VERB
aji-165	147	3	with	with	ADP
aji-165	147	4	indeterminate	indeterminate	ADJ
aji-165	147	5	colitis	colitis	NOUN
aji-165	147	6	.	.	PUNCT
aji-165	148	1	77	77	NUM
aji-165	148	2	patients	patient	NOUN
aji-165	148	3	met	meet	VERB
aji-165	148	4	the	the	DET
aji-165	148	5	criteria	criterion	NOUN
aji-165	148	6	and	and	CCONJ
aji-165	148	7	consented	consent	VERB
aji-165	148	8	to	to	PART
aji-165	148	9	participate	participate	VERB
aji-165	148	10	in	in	ADP
aji-165	148	11	the	the	DET
aji-165	148	12	study	study	NOUN
aji-165	148	13	2.1	2.1	NUM
aji-165	148	14	the	the	DET
aji-165	148	15	included	include	VERB
aji-165	148	16	immunological	immunological	ADJ
aji-165	148	17	analysis	analysis	NOUN
aji-165	148	18	techniques	technique	NOUN
aji-165	148	19	included	include	VERB
aji-165	148	20	among	among	ADP
aji-165	148	21	the	the	DET
aji-165	148	22	immunological	immunological	ADJ
aji-165	148	23	analysis	analysis	NOUN
aji-165	148	24	techniques	technique	NOUN
aji-165	148	25	were	be	AUX
aji-165	148	26	:	:	PUNCT
aji-165	148	27	–	–	PUNCT
aji-165	148	28	determination	determination	NOUN
aji-165	148	29	of	of	ADP
aji-165	148	30	the	the	DET
aji-165	148	31	fc	fc	PROPN
aji-165	148	32	using	use	VERB
aji-165	148	33	the	the	DET
aji-165	148	34	sandwich	sandwich	NOUN
aji-165	148	35	elisa	elisa	NOUN
aji-165	148	36	technique	technique	NOUN
aji-165	148	37	(	(	PUNCT
aji-165	148	38	enzyme	enzyme	NOUN
aji-165	148	39	-	-	PUNCT
aji-165	148	40	linked	link	VERB
aji-165	148	41	immunosorbent	immunosorbent	NOUN
aji-165	148	42	assay	assay	ADV
aji-165	148	43	from	from	ADP
aji-165	148	44	inova	inova	PROPN
aji-165	148	45	diagnostics	diagnostic	NOUN
aji-165	148	46	)	)	PUNCT
aji-165	148	47	on	on	ADP
aji-165	148	48	stool	stool	NOUN
aji-165	148	49	samples	sample	NOUN
aji-165	148	50	–	–	PUNCT
aji-165	148	51	determination	determination	NOUN
aji-165	148	52	of	of	ADP
aji-165	148	53	crp	crp	PROPN
aji-165	148	54	by	by	ADP
aji-165	148	55	fai	fai	X
aji-165	148	56	(	(	PUNCT
aji-165	148	57	fluorescence	fluorescence	PROPN
aji-165	148	58	immunoassay	immunoassay	PROPN
aji-165	148	59	)	)	PUNCT
aji-165	148	60	on	on	ADP
aji-165	148	61	a	a	DET
aji-165	148	62	serum	serum	NOUN
aji-165	148	63	samples	sample	NOUN
aji-165	148	64	.	.	PUNCT
aji-165	149	1	2.2	2.2	NUM
aji-165	149	2	data	datum	NOUN
aji-165	149	3	collection	collection	NOUN
aji-165	149	4	and	and	CCONJ
aji-165	149	5	statistical	statistical	ADJ
aji-165	149	6	analysis	analysis	NOUN
aji-165	149	7	statistical	statistical	ADJ
aji-165	149	8	analyses	analysis	NOUN
aji-165	149	9	were	be	AUX
aji-165	149	10	conducted	conduct	VERB
aji-165	149	11	using	use	VERB
aji-165	149	12	spss	spss	PROPN
aji-165	149	13	software	software	NOUN
aji-165	149	14	.	.	PUNCT
aji-165	150	1	the	the	DET
aji-165	150	2	following	follow	VERB
aji-165	150	3	statistical	statistical	ADJ
aji-165	150	4	tests	test	NOUN
aji-165	150	5	were	be	AUX
aji-165	150	6	employed	employ	VERB
aji-165	150	7	to	to	PART
aji-165	150	8	compare	compare	VERB
aji-165	150	9	the	the	DET
aji-165	150	10	different	different	ADJ
aji-165	150	11	subgroups	subgroup	NOUN
aji-165	150	12	:	:	PUNCT
aji-165	150	13	✓	✓	ADJ
aji-165	150	14	chi	chi	ADJ
aji-165	150	15	-	-	PUNCT
aji-165	150	16	square	square	ADJ
aji-165	150	17	test	test	NOUN
aji-165	150	18	:	:	PUNCT
aji-165	150	19	used	use	VERB
aji-165	150	20	for	for	ADP
aji-165	150	21	comparing	compare	VERB
aji-165	150	22	qualitative	qualitative	ADJ
aji-165	150	23	variables	variable	NOUN
aji-165	150	24	.	.	PUNCT
aji-165	151	1	✓	✓	ADJ
aji-165	151	2	student	student	NOUN
aji-165	151	3	's	's	PART
aji-165	151	4	t	t	NOUN
aji-165	151	5	-	-	PUNCT
aji-165	151	6	test	test	NOUN
aji-165	151	7	and	and	CCONJ
aji-165	151	8	analysis	analysis	NOUN
aji-165	151	9	of	of	ADP
aji-165	151	10	variance	variance	NOUN
aji-165	151	11	(	(	PUNCT
aji-165	151	12	anova	anova	PROPN
aji-165	151	13	):	):	PUNCT
aji-165	151	14	utilized	utilize	VERB
aji-165	151	15	for	for	ADP
aji-165	151	16	comparing	compare	VERB
aji-165	151	17	means	mean	NOUN
aji-165	151	18	across	across	ADP
aji-165	151	19	groups	group	NOUN
aji-165	151	20	.	.	PUNCT
aji-165	152	1	✓	✓	ADJ
aji-165	152	2	spearman	spearman	NOUN
aji-165	152	3	's	's	PART
aji-165	152	4	rank	rank	NOUN
aji-165	152	5	correlation	correlation	NOUN
aji-165	152	6	:	:	PUNCT
aji-165	152	7	applied	apply	VERB
aji-165	152	8	to	to	PART
aji-165	152	9	assess	assess	VERB
aji-165	152	10	the	the	DET
aji-165	152	11	correlation	correlation	NOUN
aji-165	152	12	between	between	ADP
aji-165	152	13	fc	fc	PROPN
aji-165	152	14	levels	level	NOUN
aji-165	152	15	and	and	CCONJ
aji-165	152	16	crp	crp	PROPN
aji-165	152	17	levels	level	NOUN
aji-165	152	18	.	.	PUNCT
aji-165	153	1	a	a	DET
aji-165	153	2	significance	significance	NOUN
aji-165	153	3	level	level	NOUN
aji-165	153	4	of	of	ADP
aji-165	153	5	0.05	0.05	NUM
aji-165	153	6	was	be	AUX
aji-165	153	7	established	establish	VERB
aji-165	153	8	for	for	ADP
aji-165	153	9	all	all	DET
aji-165	153	10	analyses	analysis	NOUN
aji-165	153	11	.	.	PUNCT
aji-165	154	1	3	3	X
aji-165	154	2	.	.	NOUN
aji-165	154	3	results	result	VERB
aji-165	154	4	3.1	3.1	NUM
aji-165	154	5	study	study	NOUN
aji-165	154	6	population	population	NOUN
aji-165	154	7	description	description	NOUN
aji-165	154	8	the	the	DET
aji-165	154	9	study	study	NOUN
aji-165	154	10	population	population	NOUN
aji-165	154	11	consisted	consist	VERB
aji-165	154	12	of	of	ADP
aji-165	154	13	77	77	NUM
aji-165	154	14	patients	patient	NOUN
aji-165	154	15	referred	refer	VERB
aji-165	154	16	by	by	ADP
aji-165	154	17	the	the	DET
aji-165	154	18	gastroenterology	gastroenterology	NOUN
aji-165	154	19	department	department	NOUN
aji-165	154	20	.	.	PUNCT
aji-165	155	1	among	among	ADP
aji-165	155	2	the	the	DET
aji-165	155	3	included	include	VERB
aji-165	155	4	patients	patient	NOUN
aji-165	155	5	,	,	PUNCT
aji-165	155	6	53	53	NUM
aji-165	155	7	(	(	PUNCT
aji-165	155	8	68.9	68.9	NUM
aji-165	155	9	%	%	NOUN
aji-165	155	10	)	)	PUNCT
aji-165	155	11	were	be	AUX
aji-165	155	12	diagnosed	diagnose	VERB
aji-165	155	13	with	with	ADP
aji-165	155	14	crohn	crohn	PROPN
aji-165	155	15	's	's	PART
aji-165	155	16	disease	disease	NOUN
aji-165	155	17	(	(	PUNCT
aji-165	155	18	cd	cd	PROPN
aji-165	155	19	)	)	PUNCT
aji-165	155	20	and	and	CCONJ
aji-165	155	21	24	24	NUM
aji-165	155	22	(	(	PUNCT
aji-165	155	23	31.1	31.1	NUM
aji-165	155	24	%	%	NOUN
aji-165	155	25	)	)	PUNCT
aji-165	155	26	with	with	ADP
aji-165	155	27	ulcerative	ulcerative	ADJ
aji-165	155	28	colitis	colitis	NOUN
aji-165	155	29	(	(	PUNCT
aji-165	155	30	uc	uc	PROPN
aji-165	155	31	)	)	PUNCT
aji-165	155	32	.	.	PUNCT
aji-165	156	1	specifically	specifically	ADV
aji-165	156	2	,	,	PUNCT
aji-165	156	3	cd	cd	PROPN
aji-165	156	4	was	be	AUX
aji-165	156	5	identified	identify	VERB
aji-165	156	6	in	in	ADP
aji-165	156	7	20	20	NUM
aji-165	156	8	men	man	NOUN
aji-165	156	9	(	(	PUNCT
aji-165	156	10	25.97	25.97	NUM
aji-165	156	11	%	%	NOUN
aji-165	156	12	of	of	ADP
aji-165	156	13	cases	case	NOUN
aji-165	156	14	)	)	PUNCT
aji-165	156	15	and	and	CCONJ
aji-165	156	16	33	33	NUM
aji-165	156	17	women	woman	NOUN
aji-165	156	18	(	(	PUNCT
aji-165	156	19	42.85	42.85	NUM
aji-165	156	20	%	%	NOUN
aji-165	156	21	of	of	ADP
aji-165	156	22	cases	case	NOUN
aji-165	156	23	)	)	PUNCT
aji-165	156	24	,	,	PUNCT
aji-165	156	25	resulting	result	VERB
aji-165	156	26	in	in	ADP
aji-165	156	27	a	a	DET
aji-165	156	28	male	male	NOUN
aji-165	156	29	-	-	PUNCT
aji-165	156	30	to	to	ADP
aji-165	156	31	-	-	PUNCT
aji-165	156	32	female	female	ADJ
aji-165	156	33	ratio	ratio	NOUN
aji-165	156	34	of	of	ADP
aji-165	156	35	0.6	0.6	NUM
aji-165	156	36	.	.	PUNCT
aji-165	157	1	uc	uc	PROPN
aji-165	157	2	was	be	AUX
aji-165	157	3	diagnosed	diagnose	VERB
aji-165	157	4	in	in	ADP
aji-165	157	5	15	15	NUM
aji-165	157	6	women	woman	NOUN
aji-165	157	7	(	(	PUNCT
aji-165	157	8	19.48	19.48	NUM
aji-165	157	9	%	%	NOUN
aji-165	157	10	of	of	ADP
aji-165	157	11	patients	patient	NOUN
aji-165	157	12	)	)	PUNCT
aji-165	157	13	and	and	CCONJ
aji-165	157	14	11	11	NUM
aji-165	157	15	men	man	NOUN
aji-165	157	16	(	(	PUNCT
aji-165	157	17	11.68	11.68	NUM
aji-165	157	18	%	%	NOUN
aji-165	157	19	of	of	ADP
aji-165	157	20	patients	patient	NOUN
aji-165	157	21	)	)	PUNCT
aji-165	157	22	,	,	PUNCT
aji-165	157	23	yielding	yield	VERB
aji-165	157	24	a	a	DET
aji-165	157	25	male	male	NOUN
aji-165	157	26	-	-	PUNCT
aji-165	157	27	to	to	ADP
aji-165	157	28	-	-	PUNCT
aji-165	157	29	female	female	ADJ
aji-165	157	30	ratio	ratio	NOUN
aji-165	157	31	of	of	ADP
aji-165	157	32	0.73	0.73	NUM
aji-165	157	33	.	.	PUNCT
aji-165	158	1	no	no	DET
aji-165	158	2	significant	significant	ADJ
aji-165	158	3	association	association	NOUN
aji-165	158	4	was	be	AUX
aji-165	158	5	found	find	VERB
aji-165	158	6	between	between	ADP
aji-165	158	7	gender	gender	NOUN
aji-165	158	8	and	and	CCONJ
aji-165	158	9	type	type	NOUN
aji-165	158	10	of	of	ADP
aji-165	158	11	ibd	ibd	PROPN
aji-165	158	12	(	(	PUNCT
aji-165	158	13	uc	uc	NOUN
aji-165	158	14	or	or	CCONJ
aji-165	158	15	cd	cd	PROPN
aji-165	158	16	)	)	PUNCT
aji-165	158	17	.	.	PUNCT
aji-165	159	1	in	in	ADP
aji-165	159	2	our	our	PRON
aji-165	159	3	cohort	cohort	NOUN
aji-165	159	4	of	of	ADP
aji-165	159	5	cd	cd	PROPN
aji-165	159	6	cases	case	NOUN
aji-165	159	7	,	,	PUNCT
aji-165	159	8	ileal	ileal	ADJ
aji-165	159	9	localization	localization	NOUN
aji-165	159	10	was	be	AUX
aji-165	159	11	the	the	DET
aji-165	159	12	most	most	ADV
aji-165	159	13	prevalent	prevalent	ADJ
aji-165	159	14	,	,	PUNCT
aji-165	159	15	accounting	account	VERB
aji-165	159	16	for	for	ADP
aji-165	159	17	21	21	NUM
aji-165	159	18	cases	case	NOUN
aji-165	159	19	(	(	PUNCT
aji-165	159	20	39.62	39.62	NUM
aji-165	159	21	%	%	NOUN
aji-165	159	22	)	)	PUNCT
aji-165	159	23	,	,	PUNCT
aji-165	159	24	followed	follow	VERB
aji-165	159	25	by	by	ADP
aji-165	159	26	colonic	colonic	ADJ
aji-165	159	27	localization	localization	NOUN
aji-165	159	28	,	,	PUNCT
aji-165	159	29	which	which	PRON
aji-165	159	30	involved	involve	VERB
aji-165	159	31	14	14	NUM
aji-165	159	32	patients	patient	NOUN
aji-165	159	33	(	(	PUNCT
aji-165	159	34	23.81	23.81	NUM
aji-165	159	35	%	%	NOUN
aji-165	159	36	)	)	PUNCT
aji-165	159	37	.	.	PUNCT
aji-165	160	1	additionally	additionally	ADV
aji-165	160	2	,	,	PUNCT
aji-165	160	3	5	5	NUM
aji-165	160	4	patients	patient	NOUN
aji-165	160	5	(	(	PUNCT
aji-165	160	6	5.3	5.3	NUM
aji-165	160	7	%	%	NOUN
aji-165	160	8	of	of	ADP
aji-165	160	9	the	the	DET
aji-165	160	10	cohort	cohort	NOUN
aji-165	160	11	)	)	PUNCT
aji-165	160	12	were	be	AUX
aji-165	160	13	active	active	ADJ
aji-165	160	14	smokers	smoker	NOUN
aji-165	160	15	.	.	PUNCT
aji-165	161	1	regarding	regard	VERB
aji-165	161	2	disease	disease	NOUN
aji-165	161	3	activity	activity	NOUN
aji-165	161	4	,	,	PUNCT
aji-165	161	5	38	38	NUM
aji-165	161	6	patients	patient	NOUN
aji-165	161	7	(	(	PUNCT
aji-165	161	8	49.35	49.35	NUM
aji-165	161	9	%	%	NOUN
aji-165	161	10	)	)	PUNCT
aji-165	161	11	were	be	AUX
aji-165	161	12	in	in	ADP
aji-165	161	13	the	the	DET
aji-165	161	14	relapse	relapse	NOUN
aji-165	161	15	phase	phase	NOUN
aji-165	161	16	,	,	PUNCT
aji-165	161	17	including	include	VERB
aji-165	161	18	24	24	NUM
aji-165	161	19	with	with	ADP
aji-165	161	20	cd	cd	PROPN
aji-165	161	21	;	;	PUNCT
aji-165	161	22	however	however	ADV
aji-165	161	23	,	,	PUNCT
aji-165	161	24	no	no	DET
aji-165	161	25	statistically	statistically	ADV
aji-165	161	26	significant	significant	ADJ
aji-165	161	27	association	association	NOUN
aji-165	161	28	was	be	AUX
aji-165	161	29	observed	observe	VERB
aji-165	161	30	.	.	PUNCT
aji-165	162	1	in	in	ADP
aji-165	162	2	terms	term	NOUN
aji-165	162	3	of	of	ADP
aji-165	162	4	treatment	treatment	NOUN
aji-165	162	5	,	,	PUNCT
aji-165	162	6	15	15	NUM
aji-165	162	7	(	(	PUNCT
aji-165	162	8	19	19	NUM
aji-165	162	9	,	,	PUNCT
aji-165	162	10	5	5	NUM
aji-165	162	11	%	%	NOUN
aji-165	162	12	)	)	PUNCT
aji-165	162	13	of	of	ADP
aji-165	162	14	patients	patient	NOUN
aji-165	162	15	received	receive	VERB
aji-165	162	16	anti	anti	ADJ
aji-165	162	17	-	-	ADJ
aji-165	162	18	tnf	tnf	ADJ
aji-165	162	19	therapy	therapy	NOUN
aji-165	162	20	,	,	PUNCT
aji-165	162	21	12	12	NUM
aji-165	162	22	(	(	PUNCT
aji-165	162	23	15	15	NUM
aji-165	162	24	,	,	PUNCT
aji-165	162	25	6	6	NUM
aji-165	162	26	%	%	NOUN
aji-165	162	27	)	)	PUNCT
aji-165	162	28	were	be	AUX
aji-165	162	29	on	on	ADP
aji-165	162	30	a	a	DET
aji-165	162	31	combination	combination	NOUN
aji-165	162	32	of	of	ADP
aji-165	162	33	therapies	therapy	NOUN
aji-165	162	34	,	,	PUNCT
aji-165	162	35	11	11	NUM
aji-165	162	36	(	(	PUNCT
aji-165	162	37	14.3	14.3	NUM
aji-165	162	38	%	%	NOUN
aji-165	162	39	)	)	PUNCT
aji-165	162	40	were	be	AUX
aji-165	162	41	treated	treat	VERB
aji-165	162	42	with	with	ADP
aji-165	162	43	corticosteroids	corticosteroid	NOUN
aji-165	162	44	,	,	PUNCT
aji-165	162	45	while	while	SCONJ
aji-165	162	46	8	8	NUM
aji-165	162	47	(	(	PUNCT
aji-165	162	48	10.4	10.4	NUM
aji-165	162	49	%	%	NOUN
aji-165	162	50	)	)	PUNCT
aji-165	162	51	received	receive	VERB
aji-165	162	52	immunosuppressants	immunosuppressant	NOUN
aji-165	162	53	and	and	CCONJ
aji-165	162	54	6	6	NUM
aji-165	162	55	(	(	PUNCT
aji-165	162	56	7.8	7.8	NUM
aji-165	162	57	%	%	NOUN
aji-165	162	58	)	)	PUNCT
aji-165	162	59	were	be	AUX
aji-165	162	60	treated	treat	VERB
aji-165	162	61	with	with	ADP
aji-165	162	62	salicylates	salicylate	NOUN
aji-165	162	63	.	.	PUNCT
aji-165	163	1	(	(	PUNCT
aji-165	163	2	table	table	NOUN
aji-165	163	3	1	1	NUM
aji-165	163	4	)	)	PUNCT
aji-165	163	5	complications	complication	NOUN
aji-165	163	6	of	of	ADP
aji-165	163	7	ibd	ibd	PROPN
aji-165	163	8	:	:	PUNCT
aji-165	163	9	the	the	DET
aji-165	163	10	results	result	NOUN
aji-165	163	11	suggest	suggest	VERB
aji-165	163	12	that	that	SCONJ
aji-165	163	13	the	the	DET
aji-165	163	14	obstructive	obstructive	ADJ
aji-165	163	15	tableau	tableau	PROPN
aji-165	163	16	is	be	AUX
aji-165	163	17	more	more	ADV
aji-165	163	18	frequent	frequent	ADJ
aji-165	163	19	in	in	ADP
aji-165	163	20	patients	patient	NOUN
aji-165	163	21	with	with	ADP
aji-165	163	22	cd	cd	PROPN
aji-165	163	23	,	,	PUNCT
aji-165	163	24	with	with	ADP
aji-165	163	25	a	a	DET
aji-165	163	26	statistically	statistically	ADV
aji-165	163	27	significant	significant	ADJ
aji-165	163	28	difference	difference	NOUN
aji-165	163	29	(	(	PUNCT
aji-165	163	30	p	p	NOUN
aji-165	163	31	=	=	NOUN
aji-165	163	32	0.04	0.04	NUM
aji-165	163	33	)	)	PUNCT
aji-165	163	34	.	.	PUNCT
aji-165	164	1	there	there	PRON
aji-165	164	2	is	be	VERB
aji-165	164	3	a	a	DET
aji-165	164	4	trend	trend	NOUN
aji-165	164	5	towards	towards	ADP
aji-165	164	6	a	a	DET
aji-165	164	7	difference	difference	NOUN
aji-165	164	8	for	for	ADP
aji-165	164	9	fistulas	fistula	NOUN
aji-165	164	10	,	,	PUNCT
aji-165	164	11	although	although	SCONJ
aji-165	164	12	not	not	PART
aji-165	164	13	significant	significant	ADJ
aji-165	164	14	(	(	PUNCT
aji-165	164	15	p	p	X
aji-165	164	16	=	=	NOUN
aji-165	164	17	0.07	0.07	NUM
aji-165	164	18	)	)	PUNCT
aji-165	164	19	.	.	PUNCT
aji-165	165	1	other	other	ADJ
aji-165	165	2	complications	complication	NOUN
aji-165	165	3	(	(	PUNCT
aji-165	165	4	stenosis	stenosis	NOUN
aji-165	165	5	,	,	PUNCT
aji-165	165	6	abdominal	abdominal	ADJ
aji-165	165	7	mass	mass	NOUN
aji-165	165	8	)	)	PUNCT
aji-165	165	9	show	show	VERB
aji-165	165	10	no	no	DET
aji-165	165	11	significant	significant	ADJ
aji-165	165	12	differences	difference	NOUN
aji-165	165	13	between	between	ADP
aji-165	165	14	cd	cd	PROPN
aji-165	165	15	and	and	CCONJ
aji-165	165	16	uc	uc	PROPN
aji-165	165	17	patients	patient	NOUN
aji-165	165	18	(	(	PUNCT
aji-165	165	19	fig	fig	NOUN
aji-165	165	20	.	.	PUNCT
aji-165	165	21	1	1	NUM
aji-165	165	22	)	)	PUNCT
aji-165	165	23	.	.	PUNCT
aji-165	166	1	digestive	digestive	ADJ
aji-165	166	2	manifestations	manifestation	NOUN
aji-165	166	3	:	:	PUNCT
aji-165	166	4	digestive	digestive	ADJ
aji-165	166	5	manifestations	manifestation	NOUN
aji-165	166	6	were	be	AUX
aji-165	166	7	dominated	dominate	VERB
aji-165	166	8	by	by	ADP
aji-165	166	9	abdominal	abdominal	ADJ
aji-165	166	10	pain	pain	NOUN
aji-165	166	11	in	in	ADP
aji-165	166	12	55	55	NUM
aji-165	166	13	cases	case	NOUN
aji-165	166	14	(	(	PUNCT
aji-165	166	15	71.43	71.43	NUM
aji-165	166	16	%	%	NOUN
aji-165	166	17	)	)	PUNCT
aji-165	166	18	,	,	PUNCT
aji-165	166	19	followed	follow	VERB
aji-165	166	20	by	by	ADP
aji-165	166	21	chronic	chronic	ADJ
aji-165	166	22	diarrhea	diarrhea	NOUN
aji-165	166	23	in	in	ADP
aji-165	166	24	50	50	NUM
aji-165	166	25	cases	case	NOUN
aji-165	166	26	(	(	PUNCT
aji-165	166	27	64.93	64.93	NUM
aji-165	166	28	%	%	NOUN
aji-165	166	29	)	)	PUNCT
aji-165	166	30	,	,	PUNCT
aji-165	166	31	rectal	rectal	ADJ
aji-165	166	32	bleeding	bleeding	NOUN
aji-165	166	33	in	in	ADP
aji-165	166	34	15	15	NUM
aji-165	166	35	cases	case	NOUN
aji-165	166	36	or	or	CCONJ
aji-165	166	37	19.48	19.48	NUM
aji-165	166	38	%	%	NOUN
aji-165	166	39	(	(	PUNCT
aji-165	166	40	14.28	14.28	NUM
aji-165	166	41	of	of	ADP
aji-165	166	42	cases	case	NOUN
aji-165	166	43	with	with	ADP
aji-165	166	44	uc	uc	PROPN
aji-165	166	45	)	)	PUNCT
aji-165	166	46	,	,	PUNCT
aji-165	166	47	purulent	purulent	ADJ
aji-165	166	48	diarrhea	diarrhea	NOUN
aji-165	166	49	and	and	CCONJ
aji-165	166	50	false	false	ADJ
aji-165	166	51	needs	need	NOUN
aji-165	166	52	in	in	ADP
aji-165	166	53	7	7	NUM
aji-165	166	54	cases	case	NOUN
aji-165	166	55	(	(	PUNCT
aji-165	166	56	9.09	9.09	NUM
aji-165	166	57	%	%	NOUN
aji-165	166	58	)	)	PUNCT
aji-165	166	59	and	and	CCONJ
aji-165	166	60	constipation	constipation	NOUN
aji-165	166	61	in	in	ADP
aji-165	166	62	3	3	NUM
aji-165	166	63	cases	case	NOUN
aji-165	166	64	(	(	PUNCT
aji-165	166	65	3.9	3.9	NUM
aji-165	166	66	%	%	NOUN
aji-165	166	67	)	)	PUNCT
aji-165	166	68	.	.	PUNCT
aji-165	167	1	rectal	rectal	ADJ
aji-165	167	2	bleeding	bleeding	NOUN
aji-165	167	3	is	be	AUX
aji-165	167	4	significantly	significantly	ADV
aji-165	167	5	more	more	ADV
aji-165	167	6	frequent	frequent	ADJ
aji-165	167	7	in	in	ADP
aji-165	167	8	uc	uc	PROPN
aji-165	167	9	patients	patient	NOUN
aji-165	167	10	(	(	PUNCT
aji-165	167	11	p	p	X
aji-165	167	12	<	<	X
aji-165	167	13	0.0001	0.0001	NUM
aji-165	167	14	)	)	PUNCT
aji-165	167	15	,	,	PUNCT
aji-165	167	16	consistent	consistent	ADJ
aji-165	167	17	with	with	ADP
aji-165	167	18	this	this	DET
aji-165	167	19	disease	disease	NOUN
aji-165	167	20	.	.	PUNCT
aji-165	168	1	other	other	ADJ
aji-165	168	2	symptoms	symptom	NOUN
aji-165	168	3	(	(	PUNCT
aji-165	168	4	abdominal	abdominal	ADJ
aji-165	168	5	pain	pain	NOUN
aji-165	168	6	,	,	PUNCT
aji-165	168	7	chronic	chronic	ADJ
aji-165	168	8	diarrhea	diarrhea	NOUN
aji-165	168	9	,	,	PUNCT
aji-165	168	10	false	false	ADJ
aji-165	168	11	needs	need	NOUN
aji-165	168	12	,	,	PUNCT
aji-165	168	13	purulent	purulent	ADJ
aji-165	168	14	diarrhea	diarrhea	NOUN
aji-165	168	15	,	,	PUNCT
aji-165	168	16	and	and	CCONJ
aji-165	168	17	constipation	constipation	NOUN
aji-165	168	18	)	)	PUNCT
aji-165	168	19	showed	show	VERB
aji-165	168	20	no	no	DET
aji-165	168	21	significant	significant	ADJ
aji-165	168	22	differences	difference	NOUN
aji-165	168	23	between	between	ADP
aji-165	168	24	cd	cd	PROPN
aji-165	168	25	and	and	CCONJ
aji-165	168	26	uc	uc	ADJ
aji-165	168	27	patients	patient	NOUN
aji-165	168	28	.	.	PUNCT
aji-165	169	1	(	(	PUNCT
aji-165	169	2	table	table	NOUN
aji-165	169	3	2	2	NUM
aji-165	169	4	)	)	PUNCT
aji-165	169	5	nassar	nassar	PROPN
aji-165	169	6	et	et	PROPN
aji-165	169	7	al	al	PROPN
aji-165	169	8	.	.	PROPN
aji-165	169	9	;	;	PUNCT
aji-165	169	10	asian	asian	PROPN
aji-165	169	11	j.	j.	PROPN
aji-165	169	12	immunol	immunol	PROPN
aji-165	169	13	.	.	PROPN
aji-165	169	14	,	,	PUNCT
aji-165	169	15	vol	vol	NOUN
aji-165	169	16	.	.	PROPN
aji-165	169	17	8	8	NUM
aji-165	169	18	,	,	PUNCT
aji-165	169	19	no	no	INTJ
aji-165	169	20	.	.	NOUN
aji-165	169	21	1	1	NUM
aji-165	169	22	,	,	PUNCT
aji-165	169	23	pp	pp	ADJ
aji-165	169	24	.	.	PUNCT
aji-165	170	1	104	104	NUM
aji-165	170	2	-	-	SYM
aji-165	170	3	119	119	NUM
aji-165	170	4	,	,	PUNCT
aji-165	170	5	2025	2025	NUM
aji-165	170	6	;	;	PUNCT
aji-165	170	7	article	article	NOUN
aji-165	170	8	no.aji.135189	no.aji.135189	NOUN
aji-165	170	9	107	107	NUM
aji-165	170	10	extra	extra	ADJ
aji-165	170	11	-	-	ADJ
aji-165	170	12	digestive	digestive	ADJ
aji-165	170	13	manifestations	manifestation	NOUN
aji-165	170	14	:	:	PUNCT
aji-165	170	15	none	none	NOUN
aji-165	170	16	of	of	ADP
aji-165	170	17	the	the	DET
aji-165	170	18	extra	extra	ADJ
aji-165	170	19	-	-	ADJ
aji-165	170	20	intestinal	intestinal	ADJ
aji-165	170	21	manifestations	manifestation	NOUN
aji-165	170	22	evaluated	evaluate	VERB
aji-165	170	23	(	(	PUNCT
aji-165	170	24	peripheral	peripheral	ADJ
aji-165	170	25	arthritis	arthritis	NOUN
aji-165	170	26	,	,	PUNCT
aji-165	170	27	axial	axial	ADJ
aji-165	170	28	rheumatism	rheumatism	NOUN
aji-165	170	29	,	,	PUNCT
aji-165	170	30	uveitis	uveitis	NOUN
aji-165	170	31	,	,	PUNCT
aji-165	170	32	erythema	erythema	ADJ
aji-165	170	33	nodosum	nodosum	NOUN
aji-165	170	34	,	,	PUNCT
aji-165	170	35	oral	oral	ADJ
aji-165	170	36	ulcerations	ulceration	NOUN
aji-165	170	37	,	,	PUNCT
aji-165	170	38	steatosis	steatosis	NOUN
aji-165	170	39	)	)	PUNCT
aji-165	170	40	showed	show	VERB
aji-165	170	41	any	any	DET
aji-165	170	42	statistically	statistically	ADV
aji-165	170	43	significant	significant	ADJ
aji-165	170	44	difference	difference	NOUN
aji-165	170	45	between	between	ADP
aji-165	170	46	uc	uc	PROPN
aji-165	170	47	and	and	CCONJ
aji-165	170	48	cd	cd	PROPN
aji-165	170	49	patients	patient	NOUN
aji-165	170	50	.	.	PUNCT
aji-165	171	1	(	(	PUNCT
aji-165	171	2	table	table	NOUN
aji-165	171	3	3	3	NUM
aji-165	171	4	)	)	PUNCT
aji-165	171	5	table	table	NOUN
aji-165	171	6	1	1	NUM
aji-165	171	7	.	.	PUNCT
aji-165	171	8	description	description	NOUN
aji-165	171	9	of	of	ADP
aji-165	171	10	study	study	NOUN
aji-165	171	11	population	population	NOUN
aji-165	171	12	sample	sample	NOUN
aji-165	171	13	size	size	NOUN
aji-165	171	14	percentage	percentage	NOUN
aji-165	171	15	pearson	pearson	PROPN
aji-165	171	16	chisquare	chisquare	PROPN
aji-165	171	17	test	test	NOUN
aji-165	171	18	type	type	NOUN
aji-165	171	19	of	of	ADP
aji-165	171	20	ibd	ibd	PROPN
aji-165	171	21	cd	cd	PROPN
aji-165	171	22	uc	uc	PROPN
aji-165	171	23	53	53	NUM
aji-165	171	24	24	24	NUM
aji-165	171	25	68,9	68,9	NUM
aji-165	171	26	%	%	NOUN
aji-165	171	27	31,1	31,1	NOUN
aji-165	171	28	%	%	NOUN
aji-165	171	29	ibd	ibd	NOUN
aji-165	171	30	by	by	ADP
aji-165	171	31	gender	gender	PROPN
aji-165	171	32	cd	cd	PROPN
aji-165	171	33	man	man	NOUN
aji-165	171	34	woman	woman	NOUN
aji-165	171	35	uc	uc	INTJ
aji-165	171	36	man	man	NOUN
aji-165	171	37	woman	woman	NOUN
aji-165	171	38	20	20	NUM
aji-165	171	39	33	33	NUM
aji-165	171	40	9	9	NUM
aji-165	171	41	15	15	NUM
aji-165	171	42	25,97	25,97	NUM
aji-165	171	43	%	%	NOUN
aji-165	171	44	42,85	42,85	NUM
aji-165	171	45	%	%	NOUN
aji-165	171	46	11,68	11,68	NUM
aji-165	171	47	%	%	NOUN
aji-165	171	48	19,48	19,48	NUM
aji-165	171	49	%	%	NOUN
aji-165	171	50	p=0,98	p=0,98	NOUN
aji-165	171	51	localization	localization	NOUN
aji-165	171	52	(	(	PUNCT
aji-165	171	53	cd	cd	NOUN
aji-165	171	54	)	)	PUNCT
aji-165	171	55	ileal	ileal	ADJ
aji-165	171	56	ileocolic	ileocolic	NOUN
aji-165	171	57	colonic	colonic	VERB
aji-165	171	58	21	21	NUM
aji-165	171	59	13	13	NUM
aji-165	171	60	14	14	NUM
aji-165	171	61	39,62	39,62	NUM
aji-165	171	62	%	%	NOUN
aji-165	171	63	24,52	24,52	NUM
aji-165	171	64	%	%	NOUN
aji-165	171	65	26,41	26,41	NUM
aji-165	171	66	%	%	NOUN
aji-165	171	67	smoking	smoking	NOUN
aji-165	171	68	factor	factor	NOUN
aji-165	171	69	smoker	smoker	VERB
aji-165	171	70	5	5	NUM
aji-165	171	71	5,3	5,3	NUM
aji-165	171	72	%	%	NOUN
aji-165	171	73	ibd	ibd	NOUN
aji-165	171	74	in	in	ADP
aji-165	171	75	relapse	relapse	NOUN
aji-165	171	76	phase	phase	NOUN
aji-165	171	77	cd	cd	PROPN
aji-165	171	78	uc	uc	PROPN
aji-165	171	79	24	24	NUM
aji-165	171	80	14	14	NUM
aji-165	171	81	31,17	31,17	NUM
aji-165	171	82	%	%	NOUN
aji-165	171	83	18,18	18,18	NUM
aji-165	171	84	%	%	NOUN
aji-165	171	85	p=0,28	p=0,28	PROPN
aji-165	171	86	treatments	treatment	VERB
aji-165	171	87	corticosteroids	corticosteroid	NOUN
aji-165	171	88	immunosuppressants	immunosuppressant	NOUN
aji-165	171	89	anti	anti	ADJ
aji-165	171	90	-	-	ADJ
aji-165	171	91	tnf	tnf	ADJ
aji-165	171	92	aminosalicylates	aminosalicylate	NOUN
aji-165	171	93	(	(	PUNCT
aji-165	171	94	5	5	NUM
aji-165	171	95	-	-	PUNCT
aji-165	171	96	asa	asa	NOUN
aji-165	171	97	)	)	PUNCT
aji-165	171	98	combination	combination	NOUN
aji-165	171	99	therapy	therapy	NOUN
aji-165	171	100	11	11	NUM
aji-165	171	101	8	8	NUM
aji-165	171	102	15	15	NUM
aji-165	171	103	6	6	NUM
aji-165	171	104	12	12	NUM
aji-165	171	105	14,3	14,3	NUM
aji-165	171	106	%	%	NOUN
aji-165	171	107	10,4	10,4	NUM
aji-165	171	108	%	%	NOUN
aji-165	171	109	19,5	19,5	NUM
aji-165	171	110	%	%	NOUN
aji-165	171	111	7,8	7,8	NUM
aji-165	171	112	%	%	NOUN
aji-165	171	113	15,6	15,6	NUM
aji-165	171	114	%	%	NOUN
aji-165	171	115	fig	fig	NOUN
aji-165	171	116	.	.	PUNCT
aji-165	172	1	1	1	X
aji-165	172	2	.	.	X
aji-165	172	3	ibd	ibd	NOUN
aji-165	172	4	population	population	NOUN
aji-165	172	5	distribution	distribution	NOUN
aji-165	172	6	based	base	VERB
aji-165	172	7	on	on	ADP
aji-165	172	8	complications	complication	NOUN
aji-165	172	9	table	table	NOUN
aji-165	172	10	2	2	NUM
aji-165	172	11	.	.	PUNCT
aji-165	173	1	ibd	ibd	NOUN
aji-165	173	2	cases	case	NOUN
aji-165	173	3	distribution	distribution	NOUN
aji-165	173	4	based	base	VERB
aji-165	173	5	on	on	ADP
aji-165	173	6	digestive	digestive	ADJ
aji-165	173	7	symptoms	symptom	NOUN
aji-165	173	8	abdominal	abdominal	ADJ
aji-165	173	9	pain	pain	NOUN
aji-165	173	10	chronic	chronic	ADJ
aji-165	173	11	diarrhea	diarrhea	NOUN
aji-165	173	12	rectal	rectal	ADJ
aji-165	173	13	bleeding	bleed	VERB
aji-165	173	14	false	false	ADJ
aji-165	173	15	needs	need	NOUN
aji-165	173	16	purulent	purulent	ADJ
aji-165	173	17	diarrhea	diarrhea	NOUN
aji-165	173	18	constipation	constipation	NOUN
aji-165	173	19	cd	cd	PROPN
aji-165	173	20	40	40	NUM
aji-165	173	21	(	(	PUNCT
aji-165	173	22	51	51	NUM
aji-165	173	23	,	,	PUNCT
aji-165	173	24	9	9	NUM
aji-165	173	25	%	%	NOUN
aji-165	173	26	)	)	PUNCT
aji-165	174	1	35(45	35(45	NUM
aji-165	174	2	,	,	PUNCT
aji-165	174	3	45	45	NUM
aji-165	174	4	%	%	NOUN
aji-165	174	5	)	)	PUNCT
aji-165	174	6	4(5	4(5	PROPN
aji-165	174	7	,	,	PUNCT
aji-165	174	8	19	19	NUM
aji-165	174	9	%	%	NOUN
aji-165	174	10	)	)	PUNCT
aji-165	175	1	6(7,79	6(7,79	NUM
aji-165	175	2	%	%	NOUN
aji-165	175	3	)	)	PUNCT
aji-165	175	4	5(6,49	5(6,49	NUM
aji-165	175	5	%	%	NOUN
aji-165	175	6	)	)	PUNCT
aji-165	175	7	1(1,3	1(1,3	NUM
aji-165	175	8	%	%	NOUN
aji-165	175	9	)	)	PUNCT
aji-165	176	1	uc	uc	PROPN
aji-165	176	2	15(19,5	15(19,5	NUM
aji-165	176	3	%	%	NOUN
aji-165	176	4	)	)	PUNCT
aji-165	176	5	15(19,5	15(19,5	NUM
aji-165	176	6	%	%	NOUN
aji-165	176	7	)	)	PUNCT
aji-165	176	8	11(14,28	11(14,28	NUM
aji-165	176	9	%	%	NOUN
aji-165	176	10	)	)	PUNCT
aji-165	176	11	1(1,3	1(1,3	NUM
aji-165	176	12	%	%	NOUN
aji-165	176	13	)	)	PUNCT
aji-165	177	1	2(2,6	2(2,6	NUM
aji-165	177	2	%	%	NOUN
aji-165	177	3	)	)	PUNCT
aji-165	178	1	2(2,6	2(2,6	NUM
aji-165	178	2	%	%	NOUN
aji-165	178	3	)	)	PUNCT
aji-165	178	4	total	total	NOUN
aji-165	178	5	55	55	NUM
aji-165	178	6	50	50	NUM
aji-165	178	7	15	15	NUM
aji-165	178	8	7	7	NUM
aji-165	178	9	7	7	NUM
aji-165	178	10	3	3	NUM
aji-165	178	11	%	%	NOUN
aji-165	178	12	71,43	71,43	ADJ
aji-165	178	13	64,93	64,93	NUM
aji-165	178	14	19,48	19,48	NUM
aji-165	178	15	9,09	9,09	NUM
aji-165	178	16	9,09	9,09	NUM
aji-165	178	17	3,9	3,9	NUM
aji-165	178	18	p	p	NOUN
aji-165	178	19	0,24	0,24	X
aji-165	179	1	0,76	0,76	X
aji-165	180	1	<	<	X
aji-165	180	2	0,0001	0,0001	X
aji-165	180	3	0,30	0,30	NUM
aji-165	180	4	0,87	0,87	PUNCT
aji-165	181	1	0,17	0,17	NOUN
aji-165	181	2	0	0	NUM
aji-165	181	3	5	5	NUM
aji-165	181	4	10	10	NUM
aji-165	181	5	15	15	NUM
aji-165	181	6	stenosis	stenosis	NOUN
aji-165	181	7	fistula	fistula	NOUN
aji-165	181	8	abdominal	abdominal	ADJ
aji-165	181	9	mass	mass	NOUN
aji-165	181	10	obstructive	obstructive	ADJ
aji-165	181	11	tableau	tableau	PROPN
aji-165	181	12	uc	uc	INTJ
aji-165	181	13	cd	cd	PROPN
aji-165	181	14	p=0.04	p=0.04	PROPN
aji-165	181	15	nassar	nassar	PROPN
aji-165	181	16	et	et	PROPN
aji-165	181	17	al	al	PROPN
aji-165	181	18	.	.	PROPN
aji-165	181	19	;	;	PUNCT
aji-165	181	20	asian	asian	PROPN
aji-165	181	21	j.	j.	PROPN
aji-165	181	22	immunol	immunol	PROPN
aji-165	181	23	.	.	PROPN
aji-165	181	24	,	,	PUNCT
aji-165	181	25	vol	vol	NOUN
aji-165	181	26	.	.	PROPN
aji-165	181	27	8	8	NUM
aji-165	181	28	,	,	PUNCT
aji-165	181	29	no	no	INTJ
aji-165	181	30	.	.	NOUN
aji-165	181	31	1	1	NUM
aji-165	181	32	,	,	PUNCT
aji-165	181	33	pp	pp	ADJ
aji-165	181	34	.	.	PUNCT
aji-165	182	1	104	104	NUM
aji-165	182	2	-	-	SYM
aji-165	182	3	119	119	NUM
aji-165	182	4	,	,	PUNCT
aji-165	182	5	2025	2025	NUM
aji-165	182	6	;	;	PUNCT
aji-165	182	7	article	article	NOUN
aji-165	182	8	no.aji.135189	no.aji.135189	NOUN
aji-165	182	9	108	108	NUM
aji-165	182	10	table	table	NOUN
aji-165	182	11	3	3	NUM
aji-165	182	12	.	.	PUNCT
aji-165	183	1	population	population	NOUN
aji-165	183	2	distribution	distribution	NOUN
aji-165	183	3	based	base	VERB
aji-165	183	4	on	on	ADP
aji-165	183	5	extra	extra	ADJ
aji-165	183	6	-	-	ADJ
aji-165	183	7	digestive	digestive	ADJ
aji-165	183	8	symptoms	symptom	NOUN
aji-165	183	9	peripheral	peripheral	ADJ
aji-165	183	10	arthritis	arthritis	NOUN
aji-165	183	11	axial	axial	ADJ
aji-165	183	12	rheumatism	rheumatism	NOUN
aji-165	183	13	uveitis	uveitis	NOUN
aji-165	183	14	erythema	erythema	VERB
aji-165	183	15	nodosum	nodosum	ADJ
aji-165	183	16	oral	oral	ADJ
aji-165	183	17	ulcerations	ulceration	NOUN
aji-165	183	18	steatosis	steatosis	NOUN
aji-165	183	19	uc	uc	NOUN
aji-165	183	20	3(3,9	3(3,9	NUM
aji-165	183	21	%	%	NOUN
aji-165	183	22	)	)	PUNCT
aji-165	184	1	2(2,6	2(2,6	NUM
aji-165	184	2	%	%	NOUN
aji-165	184	3	)	)	PUNCT
aji-165	185	1	2(2,6	2(2,6	NUM
aji-165	185	2	%	%	NOUN
aji-165	185	3	)	)	PUNCT
aji-165	185	4	0	0	NUM
aji-165	186	1	4(5,2	4(5,2	NUM
aji-165	186	2	%	%	NOUN
aji-165	186	3	)	)	PUNCT
aji-165	186	4	0	0	NUM
aji-165	187	1	cd	cd	PROPN
aji-165	187	2	20(25,97	20(25,97	NUM
aji-165	187	3	%	%	NOUN
aji-165	187	4	)	)	PUNCT
aji-165	188	1	7(9,09	7(9,09	NUM
aji-165	188	2	%	%	NOUN
aji-165	188	3	)	)	PUNCT
aji-165	188	4	6(7,8	6(7,8	NUM
aji-165	188	5	%	%	NOUN
aji-165	188	6	)	)	PUNCT
aji-165	189	1	3(3,9	3(3,9	NUM
aji-165	189	2	%	%	NOUN
aji-165	189	3	)	)	PUNCT
aji-165	189	4	12(15,6	12(15,6	NUM
aji-165	189	5	%	%	NOUN
aji-165	189	6	)	)	PUNCT
aji-165	189	7	3(3,9	3(3,9	NUM
aji-165	189	8	%	%	NOUN
aji-165	189	9	)	)	PUNCT
aji-165	189	10	total	total	NOUN
aji-165	189	11	23	23	NUM
aji-165	189	12	9	9	NUM
aji-165	189	13	8	8	NUM
aji-165	189	14	3	3	NUM
aji-165	189	15	16	16	NUM
aji-165	189	16	3	3	NUM
aji-165	189	17	%	%	NOUN
aji-165	189	18	29,87	29,87	NUM
aji-165	189	19	11,69	11,69	NUM
aji-165	189	20	10,39	10,39	NUM
aji-165	189	21	3,9	3,9	NUM
aji-165	189	22	20,78	20,78	NOUN
aji-165	189	23	3,9	3,9	NUM
aji-165	189	24	p	p	NOUN
aji-165	189	25	0,25	0,25	NUM
aji-165	189	26	0,53	0,53	NOUN
aji-165	189	27	0,69	0,69	PUNCT
aji-165	189	28	0,23	0,23	NOUN
aji-165	189	29	0,54	0,54	NUM
aji-165	190	1	0,23	0,23	NOUN
aji-165	190	2	3.2	3.2	NUM
aji-165	190	3	fc	fc	PROPN
aji-165	190	4	and	and	CCONJ
aji-165	190	5	crp	crp	PROPN
aji-165	190	6	assay	assay	PROPN
aji-165	190	7	results	result	VERB
aji-165	190	8	3.2.1	3.2.1	NUM
aji-165	190	9	population	population	NOUN
aji-165	190	10	distribution	distribution	NOUN
aji-165	190	11	based	base	VERB
aji-165	190	12	on	on	ADP
aji-165	190	13	fc	fc	PROPN
aji-165	190	14	findings	finding	NOUN
aji-165	190	15	among	among	ADP
aji-165	190	16	the	the	DET
aji-165	190	17	77	77	NUM
aji-165	190	18	patients	patient	NOUN
aji-165	190	19	,	,	PUNCT
aji-165	190	20	34	34	NUM
aji-165	190	21	(	(	PUNCT
aji-165	190	22	44.2	44.2	NUM
aji-165	190	23	%	%	NOUN
aji-165	190	24	)	)	PUNCT
aji-165	190	25	were	be	AUX
aji-165	190	26	fc	fc	PROPN
aji-165	190	27	positive	positive	ADJ
aji-165	190	28	,	,	PUNCT
aji-165	190	29	36	36	NUM
aji-165	190	30	(	(	PUNCT
aji-165	190	31	46.8	46.8	NUM
aji-165	190	32	%	%	NOUN
aji-165	190	33	)	)	PUNCT
aji-165	190	34	were	be	AUX
aji-165	190	35	fc	fc	X
aji-165	190	36	negative	negative	ADJ
aji-165	190	37	and	and	CCONJ
aji-165	190	38	7	7	NUM
aji-165	190	39	(	(	PUNCT
aji-165	190	40	9.1	9.1	NUM
aji-165	190	41	%	%	NOUN
aji-165	190	42	)	)	PUNCT
aji-165	190	43	were	be	AUX
aji-165	190	44	fc	fc	PROPN
aji-165	190	45	equivocal	equivocal	ADJ
aji-165	190	46	(	(	PUNCT
aji-165	190	47	table	table	NOUN
aji-165	190	48	4	4	NUM
aji-165	190	49	)	)	PUNCT
aji-165	190	50	.	.	PUNCT
aji-165	191	1	3.2.2	3.2.2	NUM
aji-165	191	2	fc	fc	PROPN
aji-165	191	3	results	result	NOUN
aji-165	191	4	in	in	ADP
aji-165	191	5	relapse	relapse	NOUN
aji-165	191	6	/	/	SYM
aji-165	191	7	non	non	ADJ
aji-165	191	8	-	-	ADJ
aji-165	191	9	relapse	relapse	ADJ
aji-165	191	10	status	status	NOUN
aji-165	191	11	the	the	DET
aji-165	191	12	results	result	NOUN
aji-165	191	13	show	show	VERB
aji-165	191	14	a	a	DET
aji-165	191	15	significant	significant	ADJ
aji-165	191	16	difference	difference	NOUN
aji-165	191	17	between	between	ADP
aji-165	191	18	relapsing	relapse	VERB
aji-165	191	19	and	and	CCONJ
aji-165	191	20	non	non	ADJ
aji-165	191	21	-	-	ADJ
aji-165	191	22	relapsing	relapsing	ADJ
aji-165	191	23	patients	patient	NOUN
aji-165	191	24	in	in	ADP
aji-165	191	25	terms	term	NOUN
aji-165	191	26	of	of	ADP
aji-165	191	27	fc	fc	PROPN
aji-165	191	28	.	.	PUNCT
aji-165	192	1	patients	patient	NOUN
aji-165	192	2	in	in	ADP
aji-165	192	3	relapse	relapse	NOUN
aji-165	192	4	had	have	VERB
aji-165	192	5	a	a	DET
aji-165	192	6	higher	high	ADJ
aji-165	192	7	proportion	proportion	NOUN
aji-165	192	8	of	of	ADP
aji-165	192	9	positive	positive	ADJ
aji-165	192	10	fc	fc	NOUN
aji-165	192	11	(	(	PUNCT
aji-165	192	12	20	20	NUM
aji-165	192	13	patients	patient	NOUN
aji-165	192	14	or	or	CCONJ
aji-165	192	15	52.63	52.63	NUM
aji-165	192	16	%	%	NOUN
aji-165	192	17	)	)	PUNCT
aji-165	192	18	compared	compare	VERB
aji-165	192	19	with	with	ADP
aji-165	192	20	patients	patient	NOUN
aji-165	192	21	not	not	PART
aji-165	192	22	in	in	ADP
aji-165	192	23	relapse	relapse	NOUN
aji-165	192	24	(	(	PUNCT
aji-165	192	25	14	14	NUM
aji-165	192	26	patients	patient	NOUN
aji-165	192	27	or	or	CCONJ
aji-165	192	28	35.9	35.9	NUM
aji-165	192	29	%	%	NOUN
aji-165	192	30	)	)	PUNCT
aji-165	192	31	,	,	PUNCT
aji-165	192	32	and	and	CCONJ
aji-165	192	33	none	none	NOUN
aji-165	192	34	of	of	ADP
aji-165	192	35	the	the	DET
aji-165	192	36	patients	patient	NOUN
aji-165	192	37	in	in	ADP
aji-165	192	38	relapse	relapse	NOUN
aji-165	192	39	had	have	VERB
aji-165	192	40	an	an	DET
aji-165	192	41	equivocal	equivocal	ADJ
aji-165	192	42	fc	fc	NOUN
aji-165	192	43	.	.	PUNCT
aji-165	193	1	this	this	DET
aji-165	193	2	difference	difference	NOUN
aji-165	193	3	is	be	AUX
aji-165	193	4	confirmed	confirm	VERB
aji-165	193	5	by	by	ADP
aji-165	193	6	a	a	DET
aji-165	193	7	p	p	NOUN
aji-165	193	8	-	-	PUNCT
aji-165	193	9	value	value	NOUN
aji-165	193	10	of	of	ADP
aji-165	193	11	0.018	0.018	NUM
aji-165	193	12	,	,	PUNCT
aji-165	193	13	indicating	indicate	VERB
aji-165	193	14	a	a	DET
aji-165	193	15	significant	significant	ADJ
aji-165	193	16	association	association	NOUN
aji-165	193	17	between	between	ADP
aji-165	193	18	relapse	relapse	NOUN
aji-165	193	19	status	status	NOUN
aji-165	193	20	and	and	CCONJ
aji-165	193	21	fc	fc	INTJ
aji-165	193	22	.	.	PUNCT
aji-165	194	1	(	(	PUNCT
aji-165	194	2	table	table	NOUN
aji-165	194	3	5	5	NUM
aji-165	194	4	)	)	PUNCT
aji-165	194	5	3.2.3	3.2.3	NUM
aji-165	194	6	fc	fc	PROPN
aji-165	194	7	results	result	NOUN
aji-165	194	8	according	accord	VERB
aji-165	194	9	to	to	ADP
aji-165	194	10	ibd	ibd	NOUN
aji-165	194	11	the	the	DET
aji-165	194	12	results	result	NOUN
aji-165	194	13	indicate	indicate	VERB
aji-165	194	14	that	that	SCONJ
aji-165	194	15	,	,	PUNCT
aji-165	194	16	although	although	SCONJ
aji-165	194	17	there	there	PRON
aji-165	194	18	are	be	VERB
aji-165	194	19	differences	difference	NOUN
aji-165	194	20	in	in	ADP
aji-165	194	21	fc	fc	PROPN
aji-165	194	22	between	between	ADP
aji-165	194	23	the	the	DET
aji-165	194	24	relapse	relapse	NOUN
aji-165	194	25	and	and	CCONJ
aji-165	194	26	remission	remission	NOUN
aji-165	194	27	phases	phase	NOUN
aji-165	194	28	,	,	PUNCT
aji-165	194	29	these	these	DET
aji-165	194	30	differences	difference	NOUN
aji-165	194	31	are	be	AUX
aji-165	194	32	not	not	PART
aji-165	194	33	statistically	statistically	ADV
aji-165	194	34	significant	significant	ADJ
aji-165	194	35	,	,	PUNCT
aji-165	194	36	with	with	ADP
aji-165	194	37	a	a	DET
aji-165	194	38	p	p	NOUN
aji-165	194	39	-	-	PUNCT
aji-165	194	40	value	value	NOUN
aji-165	194	41	of	of	ADP
aji-165	194	42	0.10	0.10	NUM
aji-165	194	43	for	for	ADP
aji-165	194	44	both	both	PRON
aji-165	194	45	cd	cd	PROPN
aji-165	194	46	and	and	CCONJ
aji-165	194	47	uc	uc	ADJ
aji-165	194	48	patients	patient	NOUN
aji-165	194	49	.	.	PUNCT
aji-165	195	1	(	(	PUNCT
aji-165	195	2	table	table	NOUN
aji-165	195	3	6	6	NUM
aji-165	195	4	)	)	PUNCT
aji-165	195	5	the	the	DET
aji-165	195	6	comparison	comparison	NOUN
aji-165	195	7	between	between	ADP
aji-165	195	8	uc	uc	PROPN
aji-165	195	9	and	and	CCONJ
aji-165	195	10	cd	cd	PROPN
aji-165	195	11	during	during	ADP
aji-165	195	12	the	the	DET
aji-165	195	13	relapse	relapse	NOUN
aji-165	195	14	phases	phase	NOUN
aji-165	195	15	yielded	yield	VERB
aji-165	195	16	a	a	DET
aji-165	195	17	p	p	NOUN
aji-165	195	18	-	-	PUNCT
aji-165	195	19	value	value	NOUN
aji-165	195	20	of	of	ADP
aji-165	195	21	0.27	0.27	NUM
aji-165	195	22	,	,	PUNCT
aji-165	195	23	also	also	ADV
aji-165	195	24	non	non	ADJ
aji-165	195	25	-	-	ADJ
aji-165	195	26	significant	significant	ADJ
aji-165	195	27	.	.	PUNCT
aji-165	196	1	(	(	PUNCT
aji-165	196	2	table	table	NOUN
aji-165	196	3	7	7	NUM
aji-165	196	4	)	)	PUNCT
aji-165	196	5	.	.	PUNCT
aji-165	197	1	table	table	NOUN
aji-165	197	2	4	4	NUM
aji-165	197	3	.	.	PUNCT
aji-165	198	1	population	population	NOUN
aji-165	198	2	distribution	distribution	NOUN
aji-165	198	3	based	base	VERB
aji-165	198	4	on	on	ADP
aji-165	198	5	fc	fc	PROPN
aji-165	198	6	findings	finding	VERB
aji-165	198	7	positive	positive	ADJ
aji-165	198	8	fc	fc	PROPN
aji-165	198	9	negative	negative	PROPN
aji-165	198	10	fc	fc	PROPN
aji-165	198	11	equivocal	equivocal	PROPN
aji-165	198	12	fc	fc	PROPN
aji-165	198	13	total	total	ADJ
aji-165	198	14	number	number	NOUN
aji-165	198	15	of	of	ADP
aji-165	198	16	patients	patient	NOUN
aji-165	198	17	34	34	NUM
aji-165	198	18	36	36	NUM
aji-165	198	19	7	7	NUM
aji-165	198	20	77	77	NUM
aji-165	198	21	%	%	NOUN
aji-165	199	1	44,2	44,2	NUM
aji-165	200	1	46,8	46,8	NOUN
aji-165	200	2	9,1	9,1	NUM
aji-165	200	3	100	100	NUM
aji-165	200	4	table	table	NOUN
aji-165	200	5	5	5	NUM
aji-165	200	6	.	.	PUNCT
aji-165	200	7	fc	fc	PROPN
aji-165	200	8	results	result	VERB
aji-165	200	9	in	in	ADP
aji-165	200	10	relapse	relapse	NOUN
aji-165	200	11	/	/	SYM
aji-165	200	12	non	non	ADJ
aji-165	200	13	-	-	ADJ
aji-165	200	14	relapse	relapse	ADJ
aji-165	200	15	status	status	NOUN
aji-165	200	16	positive	positive	ADJ
aji-165	200	17	fc	fc	PROPN
aji-165	200	18	negative	negative	PROPN
aji-165	200	19	fc	fc	PROPN
aji-165	200	20	equivocal	equivocal	PROPN
aji-165	200	21	fc	fc	PROPN
aji-165	200	22	relapse	relapse	PROPN
aji-165	200	23	20(52,63	20(52,63	NUM
aji-165	200	24	%	%	NOUN
aji-165	200	25	)	)	PUNCT
aji-165	201	1	18(47,37	18(47,37	NUM
aji-165	201	2	%	%	NOUN
aji-165	201	3	)	)	PUNCT
aji-165	201	4	0	0	PUNCT
aji-165	202	1	nonrelapse	nonrelapse	ADJ
aji-165	202	2	14(35,9	14(35,9	NUM
aji-165	202	3	%	%	NOUN
aji-165	202	4	)	)	PUNCT
aji-165	202	5	18(46,15	18(46,15	NUM
aji-165	202	6	%	%	NOUN
aji-165	202	7	)	)	PUNCT
aji-165	202	8	7(17,9	7(17,9	NOUN
aji-165	202	9	%	%	NOUN
aji-165	202	10	)	)	PUNCT
aji-165	202	11	total	total	ADJ
aji-165	202	12	34(44	34(44	PROPN
aji-165	202	13	,	,	PUNCT
aji-165	202	14	2	2	NUM
aji-165	202	15	%	%	NOUN
aji-165	202	16	)	)	PUNCT
aji-165	203	1	36(46	36(46	NOUN
aji-165	203	2	,	,	PUNCT
aji-165	203	3	8	8	NUM
aji-165	203	4	%	%	NOUN
aji-165	203	5	)	)	PUNCT
aji-165	203	6	7(9	7(9	NUM
aji-165	203	7	,	,	PUNCT
aji-165	203	8	1	1	NUM
aji-165	203	9	%	%	NOUN
aji-165	203	10	)	)	PUNCT
aji-165	203	11	pearson	pearson	PROPN
aji-165	203	12	chi	chi	PROPN
aji-165	203	13	-	-	PUNCT
aji-165	203	14	square	square	ADJ
aji-165	203	15	test	test	NOUN
aji-165	203	16	p=	p=	NOUN
aji-165	203	17	0,018	0,018	NUM
aji-165	203	18	table	table	NOUN
aji-165	203	19	6	6	NUM
aji-165	203	20	.	.	PUNCT
aji-165	203	21	fc	fc	PROPN
aji-165	203	22	results	result	NOUN
aji-165	203	23	according	accord	VERB
aji-165	203	24	to	to	ADP
aji-165	203	25	the	the	DET
aji-165	203	26	type	type	NOUN
aji-165	203	27	of	of	ADP
aji-165	203	28	ibd	ibd	NOUN
aji-165	203	29	and	and	CCONJ
aji-165	203	30	active	active	ADJ
aji-165	203	31	/	/	SYM
aji-165	203	32	inactive	inactive	ADJ
aji-165	203	33	status	status	NOUN
aji-165	203	34	positive	positive	ADJ
aji-165	203	35	fc	fc	PROPN
aji-165	203	36	negative	negative	PROPN
aji-165	203	37	fc	fc	PROPN
aji-165	203	38	equivocal	equivocal	PROPN
aji-165	203	39	fc	fc	PROPN
aji-165	203	40	pearson	pearson	PROPN
aji-165	203	41	chi	chi	PROPN
aji-165	203	42	-	-	PUNCT
aji-165	203	43	square	square	PROPN
aji-165	203	44	test	test	NOUN
aji-165	203	45	cd	cd	PROPN
aji-165	203	46	(	(	PUNCT
aji-165	203	47	relapse	relapse	NOUN
aji-165	203	48	)	)	PUNCT
aji-165	203	49	24	24	NUM
aji-165	203	50	cases	case	NOUN
aji-165	203	51	11(45,83	11(45,83	NUM
aji-165	203	52	%	%	NOUN
aji-165	203	53	)	)	PUNCT
aji-165	203	54	13(54,17	13(54,17	NUM
aji-165	203	55	%	%	NOUN
aji-165	203	56	)	)	PUNCT
aji-165	203	57	0	0	NUM
aji-165	204	1	p=0,10	p=0,10	PROPN
aji-165	204	2	cd	cd	NOUN
aji-165	204	3	(	(	PUNCT
aji-165	204	4	non	non	X
aji-165	204	5	-relapse	-relapse	NOUN
aji-165	204	6	)	)	PUNCT
aji-165	204	7	29cases	29cases	NUM
aji-165	204	8	11(37,93	11(37,93	NUM
aji-165	204	9	%	%	NOUN
aji-165	204	10	)	)	PUNCT
aji-165	204	11	13(44,83	13(44,83	NUM
aji-165	204	12	%	%	NOUN
aji-165	204	13	)	)	PUNCT
aji-165	204	14	5(17,24	5(17,24	NUM
aji-165	204	15	%	%	NOUN
aji-165	204	16	)	)	PUNCT
aji-165	204	17	uc(relapse	uc(relapse	NOUN
aji-165	204	18	)	)	PUNCT
aji-165	204	19	14	14	NUM
aji-165	204	20	cases	case	NOUN
aji-165	204	21	9(64,29	9(64,29	NUM
aji-165	204	22	%	%	NOUN
aji-165	204	23	)	)	PUNCT
aji-165	205	1	5(35,71	5(35,71	NUM
aji-165	205	2	%	%	NOUN
aji-165	205	3	)	)	PUNCT
aji-165	205	4	0	0	NUM
aji-165	206	1	p=0,10	p=0,10	NOUN
aji-165	206	2	uc	uc	NOUN
aji-165	206	3	(	(	PUNCT
aji-165	206	4	non	non	X
aji-165	206	5	-relapse	-relapse	NOUN
aji-165	206	6	)	)	PUNCT
aji-165	206	7	10	10	NUM
aji-165	206	8	cases	case	NOUN
aji-165	206	9	3(30	3(30	NUM
aji-165	206	10	%	%	NOUN
aji-165	206	11	)	)	PUNCT
aji-165	206	12	5(50	5(50	NUM
aji-165	206	13	%	%	NOUN
aji-165	206	14	)	)	PUNCT
aji-165	206	15	2(20	2(20	NUM
aji-165	206	16	%	%	NOUN
aji-165	206	17	)	)	PUNCT
aji-165	206	18	total	total	NOUN
aji-165	206	19	(	(	PUNCT
aji-165	206	20	77	77	NUM
aji-165	206	21	)	)	PUNCT
aji-165	206	22	34(44,2	34(44,2	NUM
aji-165	206	23	%	%	NOUN
aji-165	206	24	)	)	PUNCT
aji-165	207	1	36(46,8	36(46,8	NUM
aji-165	207	2	%	%	NOUN
aji-165	207	3	)	)	PUNCT
aji-165	208	1	7(9,1	7(9,1	NUM
aji-165	208	2	%	%	NOUN
aji-165	208	3	)	)	PUNCT
aji-165	208	4	nassar	nassar	PROPN
aji-165	208	5	et	et	PROPN
aji-165	208	6	al	al	PROPN
aji-165	208	7	.	.	PROPN
aji-165	208	8	;	;	PUNCT
aji-165	208	9	asian	asian	PROPN
aji-165	208	10	j.	j.	PROPN
aji-165	208	11	immunol	immunol	PROPN
aji-165	208	12	.	.	PROPN
aji-165	208	13	,	,	PUNCT
aji-165	208	14	vol	vol	NOUN
aji-165	208	15	.	.	PROPN
aji-165	208	16	8	8	NUM
aji-165	208	17	,	,	PUNCT
aji-165	208	18	no	no	INTJ
aji-165	208	19	.	.	NOUN
aji-165	208	20	1	1	NUM
aji-165	208	21	,	,	PUNCT
aji-165	208	22	pp	pp	ADJ
aji-165	208	23	.	.	PUNCT
aji-165	209	1	104	104	NUM
aji-165	209	2	-	-	SYM
aji-165	209	3	119	119	NUM
aji-165	209	4	,	,	PUNCT
aji-165	209	5	2025	2025	NUM
aji-165	209	6	;	;	PUNCT
aji-165	209	7	article	article	NOUN
aji-165	209	8	no.aji.135189	no.aji.135189	VERB
aji-165	209	9	109	109	NUM
aji-165	209	10	table	table	NOUN
aji-165	209	11	7	7	NUM
aji-165	209	12	.	.	PUNCT
aji-165	209	13	comparison	comparison	NOUN
aji-165	209	14	of	of	ADP
aji-165	209	15	fc	fc	PROPN
aji-165	209	16	results	result	NOUN
aji-165	209	17	between	between	ADP
aji-165	209	18	uc	uc	PROPN
aji-165	209	19	and	and	CCONJ
aji-165	209	20	cd	cd	PROPN
aji-165	209	21	during	during	ADP
aji-165	209	22	relapse	relapse	NOUN
aji-165	209	23	phase	phase	NOUN
aji-165	209	24	positive	positive	ADJ
aji-165	209	25	fc	fc	PROPN
aji-165	209	26	negative	negative	PROPN
aji-165	209	27	fc	fc	PROPN
aji-165	209	28	equivocal	equivocal	PROPN
aji-165	209	29	fc	fc	PROPN
aji-165	209	30	pearson	pearson	PROPN
aji-165	209	31	chi	chi	PROPN
aji-165	209	32	-	-	PUNCT
aji-165	209	33	square	square	PROPN
aji-165	209	34	test	test	NOUN
aji-165	209	35	cd	cd	PROPN
aji-165	209	36	(	(	PUNCT
aji-165	209	37	relapse	relapse	NOUN
aji-165	209	38	)	)	PUNCT
aji-165	209	39	24	24	NUM
aji-165	209	40	cases	case	NOUN
aji-165	209	41	11(45,83	11(45,83	NUM
aji-165	209	42	%	%	NOUN
aji-165	209	43	)	)	PUNCT
aji-165	209	44	13(45,17	13(45,17	NUM
aji-165	209	45	%	%	NOUN
aji-165	209	46	)	)	PUNCT
aji-165	209	47	0	0	NUM
aji-165	210	1	p=0,27	p=0,27	NOUN
aji-165	210	2	uc	uc	NOUN
aji-165	210	3	(	(	PUNCT
aji-165	210	4	relapse	relapse	NOUN
aji-165	210	5	)	)	PUNCT
aji-165	210	6	14	14	NUM
aji-165	210	7	cases	case	NOUN
aji-165	210	8	9(64,29	9(64,29	NUM
aji-165	210	9	%	%	NOUN
aji-165	210	10	)	)	PUNCT
aji-165	210	11	5(35,71	5(35,71	NUM
aji-165	210	12	%	%	NOUN
aji-165	210	13	)	)	PUNCT
aji-165	210	14	0	0	NUM
aji-165	210	15	total	total	NOUN
aji-165	210	16	(	(	PUNCT
aji-165	210	17	38	38	NUM
aji-165	210	18	)	)	PUNCT
aji-165	210	19	20(52,63	20(52,63	NUM
aji-165	210	20	%	%	NOUN
aji-165	210	21	)	)	PUNCT
aji-165	210	22	18(47,37	18(47,37	NUM
aji-165	210	23	%	%	NOUN
aji-165	210	24	)	)	PUNCT
aji-165	210	25	0	0	NUM
aji-165	211	1	3.2.4	3.2.4	NUM
aji-165	211	2	distribution	distribution	NOUN
aji-165	211	3	of	of	ADP
aji-165	211	4	the	the	DET
aji-165	211	5	population	population	NOUN
aji-165	211	6	according	accord	VERB
aji-165	211	7	to	to	ADP
aji-165	211	8	crp	crp	PROPN
aji-165	211	9	levels	level	NOUN
aji-165	211	10	in	in	ADP
aji-165	211	11	our	our	PRON
aji-165	211	12	study	study	NOUN
aji-165	211	13	,	,	PUNCT
aji-165	211	14	34	34	NUM
aji-165	211	15	patients	patient	NOUN
aji-165	211	16	(	(	PUNCT
aji-165	211	17	46.57	46.57	NUM
aji-165	211	18	%	%	NOUN
aji-165	211	19	)	)	PUNCT
aji-165	211	20	had	have	VERB
aji-165	211	21	a	a	DET
aji-165	211	22	crp	crp	NOUN
aji-165	211	23	level	level	NOUN
aji-165	211	24	of	of	ADP
aji-165	211	25	≥	≥	NUM
aji-165	211	26	6	6	NUM
aji-165	211	27	mg	mg	PROPN
aji-165	211	28	/	/	SYM
aji-165	211	29	l	l	NOUN
aji-165	211	30	,	,	PUNCT
aji-165	211	31	while	while	SCONJ
aji-165	211	32	39	39	NUM
aji-165	211	33	patients	patient	NOUN
aji-165	211	34	(	(	PUNCT
aji-165	211	35	53.42	53.42	NUM
aji-165	211	36	%	%	NOUN
aji-165	211	37	)	)	PUNCT
aji-165	211	38	had	have	VERB
aji-165	211	39	a	a	DET
aji-165	211	40	crp	crp	NOUN
aji-165	211	41	level	level	NOUN
aji-165	211	42	of	of	ADP
aji-165	211	43	<	<	X
aji-165	211	44	6	6	NUM
aji-165	211	45	mg	mg	PROPN
aji-165	211	46	/	/	SYM
aji-165	211	47	l.	l.	PROPN
aji-165	211	48	patients	patient	NOUN
aji-165	211	49	with	with	ADP
aji-165	211	50	cd	cd	PROPN
aji-165	211	51	had	have	VERB
aji-165	211	52	a	a	DET
aji-165	211	53	higher	high	ADJ
aji-165	211	54	proportion	proportion	NOUN
aji-165	211	55	of	of	ADP
aji-165	211	56	positive	positive	ADJ
aji-165	211	57	crp	crp	NOUN
aji-165	211	58	compared	compare	VERB
aji-165	211	59	to	to	ADP
aji-165	211	60	patients	patient	NOUN
aji-165	211	61	with	with	ADP
aji-165	211	62	uc	uc	PROPN
aji-165	211	63	.	.	PUNCT
aji-165	212	1	the	the	DET
aji-165	212	2	fisher	fisher	PROPN
aji-165	212	3	's	's	PART
aji-165	212	4	exact	exact	ADJ
aji-165	212	5	test	test	NOUN
aji-165	212	6	showed	show	VERB
aji-165	212	7	a	a	DET
aji-165	212	8	statistically	statistically	ADV
aji-165	212	9	significant	significant	ADJ
aji-165	212	10	association	association	NOUN
aji-165	212	11	(	(	PUNCT
aji-165	212	12	p=0.007	p=0.007	X
aji-165	212	13	)	)	PUNCT
aji-165	212	14	between	between	ADP
aji-165	212	15	crp	crp	PROPN
aji-165	212	16	levels	level	NOUN
aji-165	212	17	and	and	CCONJ
aji-165	212	18	the	the	DET
aji-165	212	19	type	type	NOUN
aji-165	212	20	of	of	ADP
aji-165	212	21	ibd	ibd	PROPN
aji-165	212	22	(	(	PUNCT
aji-165	212	23	fig	fig	NOUN
aji-165	212	24	.	.	PUNCT
aji-165	213	1	2	2	NUM
aji-165	213	2	)	)	PUNCT
aji-165	213	3	.	.	PUNCT
aji-165	214	1	3.2.5	3.2.5	NUM
aji-165	214	2	crp	crp	NOUN
aji-165	214	3	results	result	VERB
aji-165	214	4	according	accord	VERB
aji-165	214	5	to	to	ADP
aji-165	214	6	active	active	ADJ
aji-165	214	7	/	/	SYM
aji-165	214	8	inactive	inactive	ADJ
aji-165	214	9	disease	disease	NOUN
aji-165	214	10	status	status	NOUN
aji-165	214	11	the	the	DET
aji-165	214	12	results	result	NOUN
aji-165	214	13	suggest	suggest	VERB
aji-165	214	14	that	that	SCONJ
aji-165	214	15	there	there	PRON
aji-165	214	16	is	be	VERB
aji-165	214	17	no	no	DET
aji-165	214	18	significant	significant	ADJ
aji-165	214	19	link	link	NOUN
aji-165	214	20	between	between	ADP
aji-165	214	21	disease	disease	NOUN
aji-165	214	22	status	status	NOUN
aji-165	214	23	(	(	PUNCT
aji-165	214	24	active	active	ADJ
aji-165	214	25	or	or	CCONJ
aji-165	214	26	inactive	inactive	ADJ
aji-165	214	27	)	)	PUNCT
aji-165	214	28	and	and	CCONJ
aji-165	214	29	crp	crp	PROPN
aji-165	214	30	levels	level	NOUN
aji-165	214	31	(	(	PUNCT
aji-165	214	32	<	<	X
aji-165	214	33	6	6	NUM
aji-165	214	34	and	and	CCONJ
aji-165	214	35	≥6	≥6	NUM
aji-165	214	36	)	)	PUNCT
aji-165	214	37	,	,	PUNCT
aji-165	214	38	according	accord	VERB
aji-165	214	39	to	to	ADP
aji-165	214	40	fisher	fisher	PROPN
aji-165	214	41	's	's	PART
aji-165	214	42	exact	exact	ADJ
aji-165	214	43	test	test	NOUN
aji-165	214	44	(	(	PUNCT
aji-165	214	45	p	p	NOUN
aji-165	214	46	=	=	NOUN
aji-165	214	47	0.48	0.48	NUM
aji-165	214	48	)	)	PUNCT
aji-165	214	49	.	.	PUNCT
aji-165	215	1	(	(	PUNCT
aji-165	215	2	table	table	NOUN
aji-165	215	3	8)	8)	NUM
aji-165	215	4	3.2.6	3.2.6	NUM
aji-165	215	5	crp	crp	NOUN
aji-165	215	6	results	result	NOUN
aji-165	215	7	according	accord	VERB
aji-165	215	8	to	to	ADP
aji-165	215	9	the	the	DET
aji-165	215	10	type	type	NOUN
aji-165	215	11	of	of	ADP
aji-165	215	12	ibd	ibd	NOUN
aji-165	215	13	in	in	ADP
aji-165	215	14	patients	patient	NOUN
aji-165	215	15	with	with	ADP
aji-165	215	16	cd	cd	PROPN
aji-165	215	17	,	,	PUNCT
aji-165	215	18	no	no	DET
aji-165	215	19	significant	significant	ADJ
aji-165	215	20	difference	difference	NOUN
aji-165	215	21	in	in	ADP
aji-165	215	22	crp	crp	PROPN
aji-165	215	23	levels	level	NOUN
aji-165	215	24	was	be	AUX
aji-165	215	25	observed	observe	VERB
aji-165	215	26	between	between	ADP
aji-165	215	27	the	the	DET
aji-165	215	28	active	active	ADJ
aji-165	215	29	and	and	CCONJ
aji-165	215	30	remission	remission	NOUN
aji-165	215	31	phases	phase	NOUN
aji-165	215	32	(	(	PUNCT
aji-165	215	33	p	p	NOUN
aji-165	215	34	=	=	NOUN
aji-165	215	35	0.80	0.80	NUM
aji-165	215	36	)	)	PUNCT
aji-165	215	37	.	.	PUNCT
aji-165	216	1	for	for	ADP
aji-165	216	2	uc	uc	PROPN
aji-165	216	3	,	,	PUNCT
aji-165	216	4	there	there	PRON
aji-165	216	5	is	be	VERB
aji-165	216	6	a	a	DET
aji-165	216	7	trend	trend	NOUN
aji-165	216	8	toward	toward	ADP
aji-165	216	9	a	a	DET
aji-165	216	10	difference	difference	NOUN
aji-165	216	11	,	,	PUNCT
aji-165	216	12	but	but	CCONJ
aji-165	216	13	it	it	PRON
aji-165	216	14	is	be	AUX
aji-165	216	15	not	not	PART
aji-165	216	16	statistically	statistically	ADV
aji-165	216	17	significant	significant	ADJ
aji-165	216	18	(	(	PUNCT
aji-165	216	19	p	p	X
aji-165	216	20	=	=	NOUN
aji-165	216	21	0.08	0.08	NUM
aji-165	216	22	)	)	PUNCT
aji-165	216	23	.	.	PUNCT
aji-165	217	1	(	(	PUNCT
aji-165	217	2	table	table	NOUN
aji-165	217	3	9	9	NUM
aji-165	217	4	)	)	PUNCT
aji-165	217	5	the	the	DET
aji-165	217	6	comparison	comparison	NOUN
aji-165	217	7	between	between	ADP
aji-165	217	8	patients	patient	NOUN
aji-165	217	9	with	with	ADP
aji-165	217	10	active	active	ADJ
aji-165	217	11	cd	cd	NOUN
aji-165	217	12	and	and	CCONJ
aji-165	217	13	those	those	PRON
aji-165	217	14	with	with	ADP
aji-165	217	15	active	active	ADJ
aji-165	217	16	ulcerative	ulcerative	ADJ
aji-165	217	17	colitis	colitis	NOUN
aji-165	217	18	uc	uc	PROPN
aji-165	217	19	also	also	ADV
aji-165	217	20	yields	yield	VERB
aji-165	217	21	a	a	DET
aji-165	217	22	non	non	ADJ
aji-165	217	23	-	-	ADJ
aji-165	217	24	significant	significant	ADJ
aji-165	217	25	result	result	NOUN
aji-165	217	26	(	(	PUNCT
aji-165	217	27	p	p	X
aji-165	217	28	=	=	NOUN
aji-165	217	29	0.17	0.17	NUM
aji-165	217	30	)	)	PUNCT
aji-165	217	31	.	.	PUNCT
aji-165	218	1	(	(	PUNCT
aji-165	218	2	table	table	NOUN
aji-165	218	3	10	10	NUM
aji-165	218	4	)	)	PUNCT
aji-165	218	5	.	.	PUNCT
aji-165	219	1	fig	fig	NOUN
aji-165	219	2	.	.	PUNCT
aji-165	220	1	2	2	X
aji-165	220	2	.	.	X
aji-165	220	3	distribution	distribution	NOUN
aji-165	220	4	of	of	ADP
aji-165	220	5	the	the	DET
aji-165	220	6	population	population	NOUN
aji-165	220	7	according	accord	VERB
aji-165	220	8	to	to	ADP
aji-165	220	9	crp	crp	PROPN
aji-165	220	10	levels	level	NOUN
aji-165	220	11	table	table	VERB
aji-165	220	12	8	8	NUM
aji-165	220	13	.	.	PUNCT
aji-165	221	1	crp	crp	PROPN
aji-165	221	2	results	result	VERB
aji-165	221	3	according	accord	VERB
aji-165	221	4	to	to	ADP
aji-165	221	5	active	active	ADJ
aji-165	221	6	/	/	SYM
aji-165	221	7	inactive	inactive	ADJ
aji-165	221	8	disease	disease	NOUN
aji-165	221	9	status	status	NOUN
aji-165	221	10	crp	crp	PROPN
aji-165	221	11	<	<	X
aji-165	221	12	6	6	NUM
aji-165	221	13	mg	mg	PROPN
aji-165	221	14	/	/	SYM
aji-165	221	15	l	l	NOUN
aji-165	221	16	crp≥	crp≥	PROPN
aji-165	221	17	6mg	6mg	ADJ
aji-165	221	18	/	/	SYM
aji-165	221	19	l	l	NOUN
aji-165	221	20	fisher	fisher	NOUN
aji-165	221	21	's	's	PART
aji-165	221	22	exact	exact	ADJ
aji-165	221	23	test	test	NOUN
aji-165	221	24	relapse	relapse	NOUN
aji-165	221	25	37	37	NUM
aji-165	221	26	cases	case	NOUN
aji-165	221	27	18	18	NUM
aji-165	221	28	(	(	PUNCT
aji-165	221	29	48,65	48,65	NOUN
aji-165	221	30	%	%	NOUN
aji-165	221	31	)	)	PUNCT
aji-165	221	32	19	19	NUM
aji-165	221	33	(	(	PUNCT
aji-165	221	34	51,35	51,35	NUM
aji-165	221	35	%	%	NOUN
aji-165	221	36	)	)	PUNCT
aji-165	222	1	p=0,48	p=0,48	PRON
aji-165	222	2	non	non	X
aji-165	222	3	–	–	PUNCT
aji-165	222	4	relapse	relapse	VERB
aji-165	222	5	36	36	NUM
aji-165	222	6	cases	case	NOUN
aji-165	222	7	21	21	NUM
aji-165	222	8	(	(	PUNCT
aji-165	222	9	58,33	58,33	NUM
aji-165	222	10	%	%	NOUN
aji-165	222	11	)	)	PUNCT
aji-165	222	12	15	15	NUM
aji-165	222	13	(	(	PUNCT
aji-165	222	14	41,67	41,67	NOUN
aji-165	222	15	%	%	NOUN
aji-165	222	16	)	)	PUNCT
aji-165	222	17	total	total	NOUN
aji-165	222	18	(	(	PUNCT
aji-165	222	19	73	73	NUM
aji-165	222	20	)	)	PUNCT
aji-165	222	21	39	39	NUM
aji-165	222	22	(	(	PUNCT
aji-165	222	23	53,42	53,42	NUM
aji-165	222	24	%	%	NOUN
aji-165	222	25	)	)	PUNCT
aji-165	222	26	34	34	NUM
aji-165	222	27	(	(	PUNCT
aji-165	222	28	46,57	46,57	NOUN
aji-165	222	29	%	%	NOUN
aji-165	222	30	)	)	PUNCT
aji-165	222	31	table	table	NOUN
aji-165	222	32	9	9	NUM
aji-165	222	33	.	.	PUNCT
aji-165	222	34	crp	crp	PROPN
aji-165	222	35	results	result	VERB
aji-165	222	36	according	accord	VERB
aji-165	222	37	to	to	ADP
aji-165	222	38	the	the	DET
aji-165	222	39	type	type	NOUN
aji-165	222	40	of	of	ADP
aji-165	222	41	ibd	ibd	PROPN
aji-165	222	42	crp	crp	PROPN
aji-165	222	43	<	<	NOUN
aji-165	222	44	6mg	6mg	ADJ
aji-165	222	45	/	/	SYM
aji-165	222	46	l	l	NOUN
aji-165	222	47	crp≥6mg	crp≥6mg	NOUN
aji-165	222	48	/	/	SYM
aji-165	222	49	l	l	NOUN
aji-165	222	50	pearson	pearson	PROPN
aji-165	222	51	chi	chi	PROPN
aji-165	222	52	-	-	PUNCT
aji-165	222	53	square	square	PROPN
aji-165	222	54	test	test	NOUN
aji-165	222	55	cd	cd	PROPN
aji-165	222	56	(	(	PUNCT
aji-165	222	57	relapse	relapse	NOUN
aji-165	222	58	)	)	PUNCT
aji-165	222	59	24	24	NUM
aji-165	222	60	cases	case	NOUN
aji-165	222	61	14(58,33	14(58,33	NUM
aji-165	222	62	%	%	NOUN
aji-165	222	63	)	)	PUNCT
aji-165	222	64	10(41,67	10(41,67	NUM
aji-165	222	65	%	%	NOUN
aji-165	222	66	)	)	PUNCT
aji-165	223	1	p=	p=	PROPN
aji-165	223	2	0,80	0,80	NUM
aji-165	223	3	cd	cd	PROPN
aji-165	223	4	(	(	PUNCT
aji-165	223	5	non	non	ADJ
aji-165	223	6	-	-	NOUN
aji-165	223	7	relapse	relapse	ADJ
aji-165	223	8	)	)	PUNCT
aji-165	223	9	29	29	NUM
aji-165	223	10	cases	case	NOUN
aji-165	223	11	16(55,17	16(55,17	NUM
aji-165	223	12	%	%	NOUN
aji-165	223	13	)	)	PUNCT
aji-165	223	14	13(44,83	13(44,83	NUM
aji-165	223	15	%	%	NOUN
aji-165	223	16	)	)	PUNCT
aji-165	223	17	uc	uc	INTJ
aji-165	223	18	(	(	PUNCT
aji-165	223	19	relapse	relapse	NOUN
aji-165	223	20	)	)	PUNCT
aji-165	223	21	13	13	NUM
aji-165	223	22	cases	case	NOUN
aji-165	223	23	4(30,77	4(30,77	NUM
aji-165	223	24	%	%	NOUN
aji-165	223	25	)	)	PUNCT
aji-165	224	1	9(69,23	9(69,23	NUM
aji-165	224	2	%	%	NOUN
aji-165	224	3	)	)	PUNCT
aji-165	225	1	p=0,08	p=0,08	NOUN
aji-165	225	2	uc	uc	NOUN
aji-165	225	3	(	(	PUNCT
aji-165	225	4	on	on	ADP
aji-165	225	5	-	-	PUNCT
aji-165	225	6	relapse	relapse	NOUN
aji-165	225	7	)	)	PUNCT
aji-165	225	8	7	7	NUM
aji-165	225	9	cases	case	NOUN
aji-165	225	10	5(71,42	5(71,42	NUM
aji-165	225	11	%	%	NOUN
aji-165	225	12	)	)	PUNCT
aji-165	225	13	2(28,6	2(28,6	NUM
aji-165	225	14	%	%	NOUN
aji-165	225	15	)	)	PUNCT
aji-165	225	16	total	total	NOUN
aji-165	225	17	(	(	PUNCT
aji-165	225	18	73	73	NUM
aji-165	225	19	)	)	PUNCT
aji-165	225	20	39	39	NUM
aji-165	225	21	(	(	PUNCT
aji-165	225	22	53,42	53,42	NUM
aji-165	225	23	%	%	NOUN
aji-165	225	24	)	)	PUNCT
aji-165	225	25	34(46,57	34(46,57	NUM
aji-165	225	26	%	%	NOUN
aji-165	225	27	)	)	PUNCT
aji-165	225	28	0	0	NUM
aji-165	225	29	10	10	NUM
aji-165	225	30	20	20	NUM
aji-165	225	31	30	30	NUM
aji-165	225	32	cd	cd	NOUN
aji-165	225	33	uc	uc	PROPN
aji-165	225	34	<	<	X
aji-165	225	35	6	6	NUM
aji-165	225	36	30	30	NUM
aji-165	225	37	9	9	NUM
aji-165	225	38	6≥	6≥	NUM
aji-165	225	39	23	23	NUM
aji-165	225	40	11	11	NUM
aji-165	225	41	30	30	NUM
aji-165	225	42	9	9	NUM
aji-165	225	43	23	23	NUM
aji-165	225	44	11	11	NUM
aji-165	225	45	<	<	X
aji-165	225	46	6	6	NUM
aji-165	225	47	6≥	6≥	NUM
aji-165	225	48	p=0,007	p=0,007	ADP
aji-165	225	49	nassar	nassar	PROPN
aji-165	225	50	et	et	PROPN
aji-165	225	51	al	al	PROPN
aji-165	225	52	.	.	PROPN
aji-165	225	53	;	;	PUNCT
aji-165	225	54	asian	asian	PROPN
aji-165	225	55	j.	j.	PROPN
aji-165	225	56	immunol	immunol	PROPN
aji-165	225	57	.	.	PROPN
aji-165	225	58	,	,	PUNCT
aji-165	225	59	vol	vol	NOUN
aji-165	225	60	.	.	PROPN
aji-165	225	61	8	8	NUM
aji-165	225	62	,	,	PUNCT
aji-165	225	63	no	no	INTJ
aji-165	225	64	.	.	NOUN
aji-165	225	65	1	1	NUM
aji-165	225	66	,	,	PUNCT
aji-165	225	67	pp	pp	ADJ
aji-165	225	68	.	.	PUNCT
aji-165	226	1	104	104	NUM
aji-165	226	2	-	-	SYM
aji-165	226	3	119	119	NUM
aji-165	226	4	,	,	PUNCT
aji-165	226	5	2025	2025	NUM
aji-165	226	6	;	;	PUNCT
aji-165	226	7	article	article	NOUN
aji-165	226	8	no.aji.135189	no.aji.135189	VERB
aji-165	226	9	110	110	NUM
aji-165	226	10	table	table	NOUN
aji-165	226	11	10	10	NUM
aji-165	226	12	.	.	PUNCT
aji-165	227	1	comparison	comparison	NOUN
aji-165	227	2	of	of	ADP
aji-165	227	3	crp	crp	PROPN
aji-165	227	4	results	result	NOUN
aji-165	227	5	between	between	ADP
aji-165	227	6	cd	cd	PROPN
aji-165	227	7	and	and	CCONJ
aji-165	227	8	uc	uc	PROPN
aji-165	227	9	in	in	ADP
aji-165	227	10	active	active	ADJ
aji-165	227	11	phase	phase	NOUN
aji-165	227	12	crp	crp	NOUN
aji-165	227	13	<	<	NOUN
aji-165	227	14	6mg	6mg	ADJ
aji-165	227	15	/	/	SYM
aji-165	227	16	l	l	NOUN
aji-165	227	17	crp≥6mg	crp≥6mg	NOUN
aji-165	227	18	/	/	SYM
aji-165	227	19	l	l	NOUN
aji-165	227	20	pearson	pearson	PROPN
aji-165	227	21	chi	chi	PROPN
aji-165	227	22	-	-	PUNCT
aji-165	227	23	square	square	PROPN
aji-165	227	24	test	test	NOUN
aji-165	227	25	cd	cd	PROPN
aji-165	227	26	(	(	PUNCT
aji-165	227	27	relapse	relapse	NOUN
aji-165	227	28	)	)	PUNCT
aji-165	227	29	24	24	NUM
aji-165	227	30	cases	case	NOUN
aji-165	227	31	14(58,33	14(58,33	NUM
aji-165	227	32	%	%	NOUN
aji-165	227	33	)	)	PUNCT
aji-165	227	34	10(41,67	10(41,67	NUM
aji-165	227	35	%	%	NOUN
aji-165	227	36	)	)	PUNCT
aji-165	227	37	p=	p=	NOUN
aji-165	228	1	0,17	0,17	ADJ
aji-165	228	2	uc	uc	PROPN
aji-165	228	3	(	(	PUNCT
aji-165	228	4	relapse	relapse	NOUN
aji-165	228	5	)	)	PUNCT
aji-165	228	6	13	13	NUM
aji-165	228	7	cases	case	NOUN
aji-165	228	8	4(30,77	4(30,77	NUM
aji-165	228	9	%	%	NOUN
aji-165	228	10	)	)	PUNCT
aji-165	229	1	9(69,23	9(69,23	NUM
aji-165	229	2	%	%	NOUN
aji-165	229	3	)	)	PUNCT
aji-165	229	4	total	total	NOUN
aji-165	229	5	(	(	PUNCT
aji-165	229	6	37	37	NUM
aji-165	229	7	)	)	PUNCT
aji-165	229	8	18(48,65	18(48,65	NUM
aji-165	229	9	%	%	NOUN
aji-165	229	10	)	)	PUNCT
aji-165	229	11	19(51,35	19(51,35	NUM
aji-165	229	12	%	%	NOUN
aji-165	229	13	)	)	PUNCT
aji-165	229	14	3.2.7	3.2.7	NUM
aji-165	229	15	crp	crp	PROPN
aji-165	229	16	/fc	/fc	PROPN
aji-165	229	17	results	result	NOUN
aji-165	229	18	according	accord	VERB
aji-165	229	19	to	to	ADP
aji-165	229	20	different	different	ADJ
aji-165	229	21	locations	location	NOUN
aji-165	229	22	in	in	ADP
aji-165	229	23	crohn	crohn	PROPN
aji-165	229	24	's	's	PART
aji-165	229	25	disease	disease	NOUN
aji-165	229	26	there	there	PRON
aji-165	229	27	is	be	VERB
aji-165	229	28	no	no	DET
aji-165	229	29	statistically	statistically	ADV
aji-165	229	30	significant	significant	ADJ
aji-165	229	31	difference	difference	NOUN
aji-165	229	32	between	between	ADP
aji-165	229	33	fc	fc	PROPN
aji-165	229	34	results	result	NOUN
aji-165	229	35	and	and	CCONJ
aji-165	229	36	the	the	DET
aji-165	229	37	different	different	ADJ
aji-165	229	38	localization	localization	NOUN
aji-165	229	39	in	in	ADP
aji-165	229	40	cd	cd	PROPN
aji-165	229	41	(	(	PUNCT
aji-165	229	42	table	table	NOUN
aji-165	229	43	11	11	NUM
aji-165	229	44	)	)	PUNCT
aji-165	229	45	.	.	PUNCT
aji-165	230	1	the	the	DET
aji-165	230	2	results	result	NOUN
aji-165	230	3	indicate	indicate	VERB
aji-165	230	4	that	that	SCONJ
aji-165	230	5	there	there	PRON
aji-165	230	6	is	be	VERB
aji-165	230	7	no	no	DET
aji-165	230	8	statistically	statistically	ADV
aji-165	230	9	significant	significant	ADJ
aji-165	230	10	difference	difference	NOUN
aji-165	230	11	in	in	ADP
aji-165	230	12	crp	crp	PROPN
aji-165	230	13	levels	level	NOUN
aji-165	230	14	(	(	PUNCT
aji-165	230	15	≥	≥	NUM
aji-165	230	16	6	6	NUM
aji-165	230	17	or	or	CCONJ
aji-165	230	18	<	<	X
aji-165	230	19	6	6	NUM
aji-165	230	20	)	)	PUNCT
aji-165	230	21	for	for	ADP
aji-165	230	22	ileal	ileal	ADJ
aji-165	230	23	and	and	CCONJ
aji-165	230	24	ileocolonic	ileocolonic	ADJ
aji-165	230	25	locations	location	NOUN
aji-165	230	26	.	.	PUNCT
aji-165	231	1	however	however	ADV
aji-165	231	2	,	,	PUNCT
aji-165	231	3	there	there	PRON
aji-165	231	4	is	be	VERB
aji-165	231	5	a	a	DET
aji-165	231	6	suggestive	suggestive	ADJ
aji-165	231	7	trend	trend	NOUN
aji-165	231	8	in	in	ADP
aji-165	231	9	the	the	DET
aji-165	231	10	colonic	colonic	ADJ
aji-165	231	11	location	location	NOUN
aji-165	231	12	with	with	ADP
aji-165	231	13	a	a	DET
aji-165	231	14	p	p	NOUN
aji-165	231	15	-	-	PUNCT
aji-165	231	16	value	value	NOUN
aji-165	231	17	of	of	ADP
aji-165	231	18	0.06	0.06	NUM
aji-165	231	19	(	(	PUNCT
aji-165	231	20	table	table	NOUN
aji-165	231	21	12	12	NUM
aji-165	231	22	)	)	PUNCT
aji-165	231	23	.	.	PUNCT
aji-165	232	1	3.3	3.3	NUM
aji-165	232	2	comparison	comparison	NOUN
aji-165	232	3	of	of	ADP
aji-165	232	4	the	the	DET
aji-165	232	5	average	average	ADJ
aji-165	232	6	rate	rate	NOUN
aji-165	232	7	of	of	ADP
aji-165	232	8	fc	fc	PROPN
aji-165	232	9	and	and	CCONJ
aji-165	232	10	crp	crp	PROPN
aji-165	232	11	3.3.1	3.3.1	NUM
aji-165	232	12	comparison	comparison	NOUN
aji-165	232	13	of	of	ADP
aji-165	232	14	the	the	DET
aji-165	232	15	average	average	ADJ
aji-165	232	16	rate	rate	NOUN
aji-165	232	17	of	of	ADP
aji-165	232	18	fc	fc	PROPN
aji-165	232	19	between	between	ADP
aji-165	232	20	cd	cd	PROPN
aji-165	232	21	and	and	CCONJ
aji-165	232	22	uc	uc	PROPN
aji-165	232	23	during	during	ADP
aji-165	232	24	flare	flare	NOUN
aji-165	232	25	-	-	PUNCT
aji-165	232	26	up	up	ADP
aji-165	232	27	the	the	DET
aji-165	232	28	average	average	ADJ
aji-165	232	29	rate	rate	NOUN
aji-165	232	30	of	of	ADP
aji-165	232	31	fc	fc	PROPN
aji-165	232	32	is	be	AUX
aji-165	232	33	higher	high	ADJ
aji-165	232	34	during	during	ADP
aji-165	232	35	uc	uc	PROPN
aji-165	232	36	than	than	ADP
aji-165	232	37	in	in	ADP
aji-165	232	38	cd	cd	PROPN
aji-165	232	39	,	,	PUNCT
aji-165	232	40	however	however	ADV
aji-165	232	41	these	these	DET
aji-165	232	42	results	result	NOUN
aji-165	232	43	do	do	AUX
aji-165	232	44	not	not	PART
aji-165	232	45	establish	establish	VERB
aji-165	232	46	a	a	DET
aji-165	232	47	significant	significant	ADJ
aji-165	232	48	distinction	distinction	NOUN
aji-165	232	49	between	between	ADP
aji-165	232	50	uc	uc	PROPN
aji-165	232	51	and	and	CCONJ
aji-165	232	52	cd	cd	PROPN
aji-165	232	53	in	in	ADP
aji-165	232	54	terms	term	NOUN
aji-165	232	55	of	of	ADP
aji-165	232	56	fc	fc	PROPN
aji-165	232	57	(	(	PUNCT
aji-165	232	58	p=0.09	p=0.09	PROPN
aji-165	232	59	)	)	PUNCT
aji-165	232	60	.	.	PUNCT
aji-165	233	1	(	(	PUNCT
aji-165	233	2	table	table	NOUN
aji-165	233	3	13	13	NUM
aji-165	233	4	)	)	PUNCT
aji-165	233	5	3.3.2	3.3.2	NUM
aji-165	233	6	comparison	comparison	NOUN
aji-165	233	7	of	of	ADP
aji-165	233	8	the	the	DET
aji-165	233	9	mean	mean	ADJ
aji-165	233	10	fc	fc	PROPN
aji-165	233	11	levels	level	NOUN
aji-165	233	12	between	between	ADP
aji-165	233	13	active	active	ADJ
aji-165	233	14	and	and	CCONJ
aji-165	233	15	remission	remission	NOUN
aji-165	233	16	states	state	NOUN
aji-165	233	17	in	in	ADP
aji-165	233	18	uc	uc	PROPN
aji-165	233	19	the	the	DET
aji-165	233	20	mean	mean	ADJ
aji-165	233	21	fc	fc	PROPN
aji-165	233	22	levels	level	NOUN
aji-165	233	23	are	be	AUX
aji-165	233	24	higher	high	ADJ
aji-165	233	25	in	in	ADP
aji-165	233	26	patients	patient	NOUN
aji-165	233	27	in	in	ADP
aji-165	233	28	the	the	DET
aji-165	233	29	'	'	PUNCT
aji-165	233	30	active	active	ADJ
aji-165	233	31	'	'	PUNCT
aji-165	233	32	state	state	NOUN
aji-165	233	33	(	(	PUNCT
aji-165	233	34	531	531	NUM
aji-165	233	35	mg	mg	NUM
aji-165	233	36	/	/	SYM
aji-165	233	37	l	l	NOUN
aji-165	233	38	)	)	PUNCT
aji-165	233	39	compared	compare	VERB
aji-165	233	40	to	to	ADP
aji-165	233	41	those	those	PRON
aji-165	233	42	in	in	ADP
aji-165	233	43	'	'	PUNCT
aji-165	233	44	remission	remission	NOUN
aji-165	233	45	'	'	PUNCT
aji-165	233	46	(	(	PUNCT
aji-165	233	47	412.6	412.6	NUM
aji-165	233	48	mg	mg	PROPN
aji-165	233	49	/	/	SYM
aji-165	233	50	l	l	NOUN
aji-165	233	51	)	)	PUNCT
aji-165	233	52	.	.	PUNCT
aji-165	234	1	however	however	ADV
aji-165	234	2	,	,	PUNCT
aji-165	234	3	the	the	DET
aji-165	234	4	standard	standard	ADJ
aji-165	234	5	deviations	deviation	NOUN
aji-165	234	6	are	be	AUX
aji-165	234	7	very	very	ADV
aji-165	234	8	high	high	ADJ
aji-165	234	9	in	in	ADP
aji-165	234	10	both	both	DET
aji-165	234	11	groups	group	NOUN
aji-165	234	12	(	(	PUNCT
aji-165	234	13	751.71	751.71	NUM
aji-165	234	14	for	for	ADP
aji-165	234	15	patients	patient	NOUN
aji-165	234	16	in	in	ADP
aji-165	234	17	the	the	DET
aji-165	234	18	active	active	ADJ
aji-165	234	19	state	state	NOUN
aji-165	234	20	and	and	CCONJ
aji-165	234	21	879.82	879.82	NUM
aji-165	234	22	for	for	ADP
aji-165	234	23	those	those	PRON
aji-165	234	24	in	in	ADP
aji-165	234	25	remission	remission	NOUN
aji-165	234	26	)	)	PUNCT
aji-165	234	27	,	,	PUNCT
aji-165	234	28	suggesting	suggest	VERB
aji-165	234	29	a	a	DET
aji-165	234	30	large	large	ADJ
aji-165	234	31	variability	variability	NOUN
aji-165	234	32	in	in	ADP
aji-165	234	33	individual	individual	ADJ
aji-165	234	34	values	value	NOUN
aji-165	234	35	.	.	PUNCT
aji-165	235	1	this	this	PRON
aji-165	235	2	could	could	AUX
aji-165	235	3	indicate	indicate	VERB
aji-165	235	4	a	a	DET
aji-165	235	5	heterogeneous	heterogeneous	ADJ
aji-165	235	6	distribution	distribution	NOUN
aji-165	235	7	of	of	ADP
aji-165	235	8	fc	fc	PROPN
aji-165	235	9	levels	level	NOUN
aji-165	235	10	within	within	ADP
aji-165	235	11	each	each	DET
aji-165	235	12	group	group	NOUN
aji-165	235	13	.	.	PUNCT
aji-165	236	1	despite	despite	SCONJ
aji-165	236	2	this	this	DET
aji-165	236	3	difference	difference	NOUN
aji-165	236	4	in	in	ADP
aji-165	236	5	means	mean	NOUN
aji-165	236	6	,	,	PUNCT
aji-165	236	7	the	the	DET
aji-165	236	8	comparison	comparison	NOUN
aji-165	236	9	between	between	ADP
aji-165	236	10	the	the	DET
aji-165	236	11	two	two	NUM
aji-165	236	12	groups	group	NOUN
aji-165	236	13	does	do	AUX
aji-165	236	14	not	not	PART
aji-165	236	15	reveal	reveal	VERB
aji-165	236	16	a	a	DET
aji-165	236	17	statistically	statistically	ADV
aji-165	236	18	significant	significant	ADJ
aji-165	236	19	difference	difference	NOUN
aji-165	236	20	(	(	PUNCT
aji-165	236	21	p=0	p=0	PROPN
aji-165	236	22	,	,	PUNCT
aji-165	236	23	73	73	NUM
aji-165	236	24	)	)	PUNCT
aji-165	236	25	(	(	PUNCT
aji-165	236	26	table	table	NOUN
aji-165	236	27	14	14	NUM
aji-165	236	28	)	)	PUNCT
aji-165	236	29	.	.	PUNCT
aji-165	237	1	table	table	NOUN
aji-165	237	2	11	11	NUM
aji-165	237	3	.	.	PUNCT
aji-165	238	1	fc	fc	PROPN
aji-165	238	2	results	result	NOUN
aji-165	238	3	according	accord	VERB
aji-165	238	4	to	to	ADP
aji-165	238	5	different	different	ADJ
aji-165	238	6	locations	location	NOUN
aji-165	238	7	in	in	ADP
aji-165	238	8	crohn	crohn	PROPN
aji-165	238	9	's	's	PART
aji-165	238	10	disease	disease	NOUN
aji-165	238	11	ileal	ileal	NOUN
aji-165	238	12	localization	localization	NOUN
aji-165	238	13	ileocolic	ileocolic	ADJ
aji-165	238	14	localization	localization	NOUN
aji-165	238	15	colonic	colonic	NOUN
aji-165	238	16	localization	localization	NOUN
aji-165	238	17	positive	positive	ADJ
aji-165	238	18	fc	fc	NOUN
aji-165	238	19	10(47,62	10(47,62	NUM
aji-165	238	20	%	%	NOUN
aji-165	238	21	)	)	PUNCT
aji-165	238	22	3(23,1	3(23,1	NUM
aji-165	238	23	)	)	PUNCT
aji-165	238	24	7(50	7(50	NUM
aji-165	238	25	%	%	NOUN
aji-165	238	26	)	)	PUNCT
aji-165	238	27	negative	negative	ADJ
aji-165	238	28	fc	fc	PROPN
aji-165	238	29	10(47,62	10(47,62	NUM
aji-165	238	30	%	%	NOUN
aji-165	238	31	)	)	PUNCT
aji-165	238	32	8(61,54	8(61,54	NUM
aji-165	238	33	%	%	NOUN
aji-165	238	34	)	)	PUNCT
aji-165	239	1	6(42,86	6(42,86	NUM
aji-165	239	2	%	%	NOUN
aji-165	239	3	)	)	PUNCT
aji-165	239	4	equivocal	equivocal	ADJ
aji-165	239	5	fc	fc	PROPN
aji-165	240	1	1(4,8	1(4,8	NUM
aji-165	240	2	%	%	NOUN
aji-165	240	3	)	)	PUNCT
aji-165	240	4	2(15,38	2(15,38	NUM
aji-165	240	5	%	%	NOUN
aji-165	240	6	)	)	PUNCT
aji-165	240	7	1	1	NUM
aji-165	240	8	(	(	PUNCT
aji-165	240	9	7,14	7,14	NUM
aji-165	240	10	%	%	NOUN
aji-165	240	11	)	)	PUNCT
aji-165	240	12	p	p	NOUN
aji-165	240	13	value	value	NOUN
aji-165	240	14	0,56	0,56	NOUN
aji-165	240	15	0,27	0,27	NUM
aji-165	241	1	0,74	0,74	NUM
aji-165	241	2	table	table	NOUN
aji-165	241	3	12	12	NUM
aji-165	241	4	.	.	PUNCT
aji-165	242	1	crp	crp	PROPN
aji-165	242	2	results	result	VERB
aji-165	242	3	according	accord	VERB
aji-165	242	4	to	to	ADP
aji-165	242	5	different	different	ADJ
aji-165	242	6	locations	location	NOUN
aji-165	242	7	in	in	ADP
aji-165	242	8	crohn	crohn	PROPN
aji-165	242	9	's	's	PART
aji-165	242	10	disease	disease	NOUN
aji-165	242	11	ileal	ileal	NOUN
aji-165	242	12	localization	localization	NOUN
aji-165	242	13	ileocolic	ileocolic	ADJ
aji-165	242	14	localization	localization	NOUN
aji-165	242	15	colonic	colonic	NOUN
aji-165	242	16	localization	localization	NOUN
aji-165	242	17	crp≥6	crp≥6	X
aji-165	242	18	mg	mg	NOUN
aji-165	242	19	/	/	SYM
aji-165	242	20	l	l	NOUN
aji-165	242	21	8(38,1	8(38,1	NUM
aji-165	242	22	%	%	NOUN
aji-165	242	23	)	)	PUNCT
aji-165	242	24	5(38,46	5(38,46	NUM
aji-165	242	25	%	%	NOUN
aji-165	242	26	)	)	PUNCT
aji-165	243	1	9(64,29	9(64,29	NUM
aji-165	243	2	%	%	NOUN
aji-165	243	3	)	)	PUNCT
aji-165	243	4	crp	crp	PROPN
aji-165	244	1	<	<	X
aji-165	244	2	6	6	NUM
aji-165	244	3	mg	mg	NUM
aji-165	244	4	/	/	SYM
aji-165	244	5	l	l	NOUN
aji-165	244	6	13(61,9	13(61,9	NUM
aji-165	244	7	%	%	NOUN
aji-165	244	8	)	)	PUNCT
aji-165	244	9	8(61,54	8(61,54	NUM
aji-165	244	10	%	%	NOUN
aji-165	244	11	)	)	PUNCT
aji-165	244	12	5(35,71	5(35,71	NUM
aji-165	244	13	%	%	NOUN
aji-165	244	14	)	)	PUNCT
aji-165	244	15	p	p	NOUN
aji-165	244	16	value	value	NOUN
aji-165	244	17	0,58	0,58	NUM
aji-165	244	18	0,67	0,67	PUNCT
aji-165	245	1	0,06	0,06	PROPN
aji-165	245	2	table	table	NOUN
aji-165	245	3	13	13	NUM
aji-165	245	4	.	.	PUNCT
aji-165	246	1	comparison	comparison	NOUN
aji-165	246	2	of	of	ADP
aji-165	246	3	the	the	DET
aji-165	246	4	average	average	ADJ
aji-165	246	5	rate	rate	NOUN
aji-165	246	6	of	of	ADP
aji-165	246	7	fc	fc	PROPN
aji-165	246	8	between	between	ADP
aji-165	246	9	cd	cd	PROPN
aji-165	246	10	and	and	CCONJ
aji-165	246	11	uc	uc	PROPN
aji-165	246	12	during	during	ADP
aji-165	246	13	flare	flare	NOUN
aji-165	246	14	-	-	PUNCT
aji-165	246	15	up	up	ADP
aji-165	246	16	ibd	ibd	PROPN
aji-165	246	17	n	n	PRON
aji-165	246	18	mean	mean	VERB
aji-165	246	19	(	(	PUNCT
aji-165	246	20	mg	mg	PROPN
aji-165	246	21	/	/	SYM
aji-165	246	22	kg	kg	NOUN
aji-165	246	23	)	)	PUNCT
aji-165	246	24	standard	standard	ADJ
aji-165	246	25	deviation	deviation	NOUN
aji-165	246	26	fc	fc	PROPN
aji-165	246	27	uc	uc	PROPN
aji-165	246	28	14	14	NUM
aji-165	246	29	531,11	531,11	NOUN
aji-165	246	30	780,1	780,1	NUM
aji-165	246	31	cd	cd	PROPN
aji-165	246	32	24	24	NUM
aji-165	246	33	249,88	249,88	NOUN
aji-165	246	34	326,24	326,24	NUM
aji-165	246	35	student	student	NOUN
aji-165	246	36	's	's	PART
aji-165	246	37	t	t	NOUN
aji-165	246	38	-	-	PUNCT
aji-165	246	39	test	test	NOUN
aji-165	246	40	p=0,09	p=0,09	PROPN
aji-165	246	41	table	table	NOUN
aji-165	246	42	14	14	NUM
aji-165	246	43	.	.	PUNCT
aji-165	247	1	comparison	comparison	NOUN
aji-165	247	2	of	of	ADP
aji-165	247	3	the	the	DET
aji-165	247	4	mean	mean	ADJ
aji-165	247	5	fc	fc	PROPN
aji-165	247	6	levels	level	NOUN
aji-165	247	7	between	between	ADP
aji-165	247	8	active	active	ADJ
aji-165	247	9	and	and	CCONJ
aji-165	247	10	remission	remission	NOUN
aji-165	247	11	states	state	NOUN
aji-165	247	12	in	in	ADP
aji-165	247	13	uc	uc	PROPN
aji-165	247	14	clinical	clinical	ADJ
aji-165	247	15	status	status	NOUN
aji-165	247	16	n	n	ADV
aji-165	247	17	mean	mean	VERB
aji-165	247	18	(	(	PUNCT
aji-165	247	19	mg	mg	PROPN
aji-165	247	20	/	/	SYM
aji-165	247	21	kg	kg	NOUN
aji-165	247	22	)	)	PUNCT
aji-165	247	23	standard	standard	ADJ
aji-165	247	24	deviation	deviation	NOUN
aji-165	247	25	fc	fc	INTJ
aji-165	247	26	in	in	ADP
aji-165	247	27	a	a	DET
aji-165	247	28	flare	flare	NOUN
aji-165	247	29	-	-	PUNCT
aji-165	247	30	up	up	NOUN
aji-165	247	31	14	14	NUM
aji-165	247	32	531	531	NUM
aji-165	247	33	751,71	751,71	NOUN
aji-165	247	34	in	in	ADP
aji-165	247	35	remission	remission	NOUN
aji-165	247	36	10	10	NUM
aji-165	247	37	412,6	412,6	PROPN
aji-165	247	38	879,82	879,82	PROPN
aji-165	247	39	student	student	NOUN
aji-165	247	40	's	's	PART
aji-165	247	41	t	t	NOUN
aji-165	247	42	-	-	PUNCT
aji-165	247	43	test	test	NOUN
aji-165	247	44	p=0,73	p=0,73	NOUN
aji-165	247	45	nassar	nassar	PROPN
aji-165	247	46	et	et	PROPN
aji-165	247	47	al	al	PROPN
aji-165	247	48	.	.	PROPN
aji-165	247	49	;	;	PUNCT
aji-165	248	1	asian	asian	PROPN
aji-165	248	2	j.	j.	PROPN
aji-165	248	3	immunol	immunol	PROPN
aji-165	248	4	.	.	PROPN
aji-165	248	5	,	,	PUNCT
aji-165	248	6	vol	vol	NOUN
aji-165	248	7	.	.	PROPN
aji-165	248	8	8	8	NUM
aji-165	248	9	,	,	PUNCT
aji-165	248	10	no	no	INTJ
aji-165	248	11	.	.	NOUN
aji-165	248	12	1	1	NUM
aji-165	248	13	,	,	PUNCT
aji-165	248	14	pp	pp	ADJ
aji-165	248	15	.	.	PUNCT
aji-165	249	1	104	104	NUM
aji-165	249	2	-	-	SYM
aji-165	249	3	119	119	NUM
aji-165	249	4	,	,	PUNCT
aji-165	249	5	2025	2025	NUM
aji-165	249	6	;	;	PUNCT
aji-165	249	7	article	article	NOUN
aji-165	249	8	no.aji.135189	no.aji.135189	NOUN
aji-165	249	9	111	111	NUM
aji-165	249	10	3.3.3	3.3.3	NUM
aji-165	249	11	comparison	comparison	NOUN
aji-165	249	12	of	of	ADP
aji-165	249	13	the	the	DET
aji-165	249	14	mean	mean	ADJ
aji-165	249	15	fc	fc	PROPN
aji-165	249	16	levels	level	NOUN
aji-165	249	17	between	between	ADP
aji-165	249	18	active	active	ADJ
aji-165	249	19	and	and	CCONJ
aji-165	249	20	remission	remission	NOUN
aji-165	249	21	states	state	NOUN
aji-165	249	22	in	in	ADP
aji-165	249	23	cd	cd	PROPN
aji-165	249	24	the	the	DET
aji-165	249	25	mean	mean	PROPN
aji-165	249	26	fc	fc	PROPN
aji-165	249	27	levels	level	NOUN
aji-165	249	28	are	be	AUX
aji-165	249	29	very	very	ADV
aji-165	249	30	close	close	ADJ
aji-165	249	31	between	between	ADP
aji-165	249	32	the	the	DET
aji-165	249	33	two	two	NUM
aji-165	249	34	groups	group	NOUN
aji-165	249	35	:	:	PUNCT
aji-165	249	36	250	250	NUM
aji-165	249	37	mg	mg	NUM
aji-165	249	38	/	/	SYM
aji-165	249	39	l	l	NOUN
aji-165	249	40	during	during	ADP
aji-165	249	41	the	the	DET
aji-165	249	42	active	active	ADJ
aji-165	249	43	phase	phase	NOUN
aji-165	249	44	and	and	CCONJ
aji-165	249	45	258	258	NUM
aji-165	249	46	mg	mg	PROPN
aji-165	249	47	/	/	SYM
aji-165	249	48	l	l	NOUN
aji-165	249	49	in	in	ADP
aji-165	249	50	remission	remission	NOUN
aji-165	249	51	.	.	PUNCT
aji-165	250	1	however	however	ADV
aji-165	250	2	,	,	PUNCT
aji-165	250	3	the	the	DET
aji-165	250	4	standard	standard	ADJ
aji-165	250	5	deviations	deviation	NOUN
aji-165	250	6	reveal	reveal	VERB
aji-165	250	7	greater	great	ADJ
aji-165	250	8	variability	variability	NOUN
aji-165	250	9	in	in	ADP
aji-165	250	10	the	the	DET
aji-165	250	11	remission	remission	NOUN
aji-165	250	12	group	group	NOUN
aji-165	250	13	(	(	PUNCT
aji-165	250	14	555.53	555.53	NUM
aji-165	250	15	)	)	PUNCT
aji-165	250	16	compared	compare	VERB
aji-165	250	17	to	to	ADP
aji-165	250	18	the	the	DET
aji-165	250	19	active	active	ADJ
aji-165	250	20	group	group	NOUN
aji-165	250	21	(	(	PUNCT
aji-165	250	22	320	320	NUM
aji-165	250	23	)	)	PUNCT
aji-165	250	24	,	,	PUNCT
aji-165	250	25	indicating	indicate	VERB
aji-165	250	26	that	that	SCONJ
aji-165	250	27	the	the	DET
aji-165	250	28	fc	fc	PROPN
aji-165	250	29	values	value	NOUN
aji-165	250	30	are	be	AUX
aji-165	250	31	more	more	ADV
aji-165	250	32	dispersed	disperse	VERB
aji-165	250	33	among	among	ADP
aji-165	250	34	patients	patient	NOUN
aji-165	250	35	in	in	ADP
aji-165	250	36	remission	remission	NOUN
aji-165	250	37	.	.	PUNCT
aji-165	251	1	the	the	DET
aji-165	251	2	student	student	NOUN
aji-165	251	3	's	's	PART
aji-165	251	4	t	t	PROPN
aji-165	251	5	-	-	PUNCT
aji-165	251	6	test	test	NOUN
aji-165	251	7	indicates	indicate	VERB
aji-165	251	8	that	that	SCONJ
aji-165	251	9	there	there	PRON
aji-165	251	10	is	be	VERB
aji-165	251	11	no	no	DET
aji-165	251	12	statistically	statistically	ADV
aji-165	251	13	significant	significant	ADJ
aji-165	251	14	difference	difference	NOUN
aji-165	251	15	between	between	ADP
aji-165	251	16	the	the	DET
aji-165	251	17	mean	mean	ADJ
aji-165	251	18	fc	fc	PROPN
aji-165	251	19	levels	level	NOUN
aji-165	251	20	based	base	VERB
aji-165	251	21	on	on	ADP
aji-165	251	22	clinical	clinical	ADJ
aji-165	251	23	status	status	NOUN
aji-165	251	24	(	(	PUNCT
aji-165	251	25	p=0	p=0	PROPN
aji-165	251	26	,	,	PUNCT
aji-165	251	27	95	95	NUM
aji-165	251	28	)	)	PUNCT
aji-165	251	29	.	.	PUNCT
aji-165	252	1	(	(	PUNCT
aji-165	252	2	table	table	NOUN
aji-165	252	3	15	15	NUM
aji-165	252	4	)	)	PUNCT
aji-165	252	5	3.3.4	3.3.4	NUM
aji-165	252	6	comparison	comparison	NOUN
aji-165	252	7	of	of	ADP
aji-165	252	8	the	the	DET
aji-165	252	9	mean	mean	ADJ
aji-165	252	10	crp	crp	PROPN
aji-165	252	11	levels	level	NOUN
aji-165	252	12	between	between	ADP
aji-165	252	13	cd	cd	PROPN
aji-165	252	14	and	and	CCONJ
aji-165	252	15	uc	uc	PROPN
aji-165	252	16	during	during	ADP
aji-165	252	17	the	the	DET
aji-165	252	18	active	active	ADJ
aji-165	252	19	phase	phase	NOUN
aji-165	252	20	the	the	DET
aji-165	252	21	student	student	NOUN
aji-165	252	22	's	's	PART
aji-165	252	23	t	t	PROPN
aji-165	252	24	-	-	PUNCT
aji-165	252	25	test	test	NOUN
aji-165	252	26	yielded	yield	VERB
aji-165	252	27	a	a	DET
aji-165	252	28	p	p	NOUN
aji-165	252	29	-	-	PUNCT
aji-165	252	30	value	value	NOUN
aji-165	252	31	of	of	ADP
aji-165	252	32	0.88	0.88	NUM
aji-165	252	33	,	,	PUNCT
aji-165	252	34	indicating	indicate	VERB
aji-165	252	35	that	that	SCONJ
aji-165	252	36	the	the	DET
aji-165	252	37	difference	difference	NOUN
aji-165	252	38	between	between	ADP
aji-165	252	39	the	the	DET
aji-165	252	40	mean	mean	ADJ
aji-165	252	41	crp	crp	PROPN
aji-165	252	42	levels	level	NOUN
aji-165	252	43	of	of	ADP
aji-165	252	44	the	the	DET
aji-165	252	45	two	two	NUM
aji-165	252	46	groups	group	NOUN
aji-165	252	47	is	be	AUX
aji-165	252	48	not	not	PART
aji-165	252	49	statistically	statistically	ADV
aji-165	252	50	significant	significant	ADJ
aji-165	252	51	.	.	PUNCT
aji-165	253	1	(	(	PUNCT
aji-165	253	2	table	table	NOUN
aji-165	253	3	16	16	NUM
aji-165	253	4	)	)	PUNCT
aji-165	253	5	3.3.5	3.3.5	NUM
aji-165	253	6	comparison	comparison	NOUN
aji-165	253	7	of	of	ADP
aji-165	253	8	the	the	DET
aji-165	253	9	mean	mean	ADJ
aji-165	253	10	crp	crp	PROPN
aji-165	253	11	levels	level	NOUN
aji-165	253	12	between	between	ADP
aji-165	253	13	active	active	ADJ
aji-165	253	14	and	and	CCONJ
aji-165	253	15	remission	remission	NOUN
aji-165	253	16	states	state	NOUN
aji-165	253	17	in	in	ADP
aji-165	253	18	uc	uc	PROPN
aji-165	253	19	the	the	DET
aji-165	253	20	difference	difference	NOUN
aji-165	253	21	between	between	ADP
aji-165	253	22	the	the	DET
aji-165	253	23	mean	mean	PROPN
aji-165	253	24	crp	crp	PROPN
aji-165	253	25	levels	level	NOUN
aji-165	253	26	in	in	ADP
aji-165	253	27	the	the	DET
aji-165	253	28	two	two	NUM
aji-165	253	29	clinical	clinical	ADJ
aji-165	253	30	states	state	NOUN
aji-165	253	31	is	be	AUX
aji-165	253	32	statistically	statistically	ADV
aji-165	253	33	significant	significant	ADJ
aji-165	253	34	(	(	PUNCT
aji-165	253	35	p=0.03	p=0.03	ADJ
aji-165	253	36	)	)	PUNCT
aji-165	253	37	.	.	PUNCT
aji-165	254	1	(	(	PUNCT
aji-165	254	2	table	table	NOUN
aji-165	254	3	17	17	NUM
aji-165	254	4	)	)	PUNCT
aji-165	254	5	3.3.6	3.3.6	NUM
aji-165	254	6	comparison	comparison	NOUN
aji-165	254	7	of	of	ADP
aji-165	254	8	the	the	DET
aji-165	254	9	mean	mean	ADJ
aji-165	254	10	crp	crp	PROPN
aji-165	254	11	levels	level	NOUN
aji-165	254	12	between	between	ADP
aji-165	254	13	active	active	ADJ
aji-165	254	14	and	and	CCONJ
aji-165	254	15	remission	remission	NOUN
aji-165	254	16	states	state	NOUN
aji-165	254	17	in	in	ADP
aji-165	254	18	cd	cd	NOUN
aji-165	254	19	patients	patient	NOUN
aji-165	254	20	in	in	ADP
aji-165	254	21	the	the	DET
aji-165	254	22	"	"	PUNCT
aji-165	254	23	active	active	ADJ
aji-165	254	24	"	"	PUNCT
aji-165	254	25	state	state	NOUN
aji-165	254	26	have	have	VERB
aji-165	254	27	a	a	DET
aji-165	254	28	slightly	slightly	ADV
aji-165	254	29	higher	high	ADJ
aji-165	254	30	mean	mean	NOUN
aji-165	254	31	crp	crp	NOUN
aji-165	254	32	level	level	NOUN
aji-165	254	33	(	(	PUNCT
aji-165	254	34	19.62	19.62	NUM
aji-165	254	35	mg	mg	PROPN
aji-165	254	36	/	/	SYM
aji-165	254	37	l	l	NOUN
aji-165	254	38	)	)	PUNCT
aji-165	254	39	compared	compare	VERB
aji-165	254	40	to	to	ADP
aji-165	254	41	those	those	PRON
aji-165	254	42	"	"	PUNCT
aji-165	254	43	in	in	ADP
aji-165	254	44	remission	remission	NOUN
aji-165	254	45	"	"	PUNCT
aji-165	254	46	(	(	PUNCT
aji-165	254	47	12.06	12.06	NUM
aji-165	254	48	mg	mg	NUM
aji-165	254	49	/	/	SYM
aji-165	254	50	l	l	NOUN
aji-165	254	51	)	)	PUNCT
aji-165	254	52	.	.	PUNCT
aji-165	255	1	however	however	ADV
aji-165	255	2	,	,	PUNCT
aji-165	255	3	the	the	DET
aji-165	255	4	student	student	NOUN
aji-165	255	5	's	's	PART
aji-165	255	6	t	t	NOUN
aji-165	255	7	-	-	PUNCT
aji-165	255	8	test	test	NOUN
aji-165	255	9	(	(	PUNCT
aji-165	255	10	p	p	X
aji-165	255	11	=	=	NOUN
aji-165	255	12	0.37	0.37	NUM
aji-165	255	13	)	)	PUNCT
aji-165	255	14	indicates	indicate	VERB
aji-165	255	15	that	that	SCONJ
aji-165	255	16	this	this	DET
aji-165	255	17	difference	difference	NOUN
aji-165	255	18	is	be	AUX
aji-165	255	19	not	not	PART
aji-165	255	20	statistically	statistically	ADV
aji-165	255	21	significant	significant	ADJ
aji-165	255	22	.	.	PUNCT
aji-165	256	1	(	(	PUNCT
aji-165	256	2	table	table	NOUN
aji-165	256	3	18	18	NUM
aji-165	256	4	)	)	PUNCT
aji-165	256	5	3.3.7	3.3.7	NUM
aji-165	256	6	comparison	comparison	NOUN
aji-165	256	7	of	of	ADP
aji-165	256	8	the	the	DET
aji-165	256	9	mean	mean	ADJ
aji-165	256	10	fc	fc	PROPN
aji-165	256	11	levels	level	NOUN
aji-165	256	12	according	accord	VERB
aji-165	256	13	to	to	ADP
aji-165	256	14	disease	disease	NOUN
aji-165	256	15	location	location	NOUN
aji-165	256	16	in	in	ADP
aji-165	256	17	cd	cd	PROPN
aji-165	256	18	although	although	SCONJ
aji-165	256	19	there	there	PRON
aji-165	256	20	are	be	VERB
aji-165	256	21	differences	difference	NOUN
aji-165	256	22	in	in	ADP
aji-165	256	23	the	the	DET
aji-165	256	24	mean	mean	ADJ
aji-165	256	25	fecal	fecal	ADJ
aji-165	256	26	calprotectin	calprotectin	NOUN
aji-165	256	27	(	(	PUNCT
aji-165	256	28	fc	fc	X
aji-165	256	29	)	)	PUNCT
aji-165	256	30	levels	level	NOUN
aji-165	256	31	based	base	VERB
aji-165	256	32	on	on	ADP
aji-165	256	33	the	the	DET
aji-165	256	34	location	location	NOUN
aji-165	256	35	of	of	ADP
aji-165	256	36	the	the	DET
aji-165	256	37	disease	disease	NOUN
aji-165	256	38	(	(	PUNCT
aji-165	256	39	ileal	ileal	ADJ
aji-165	256	40	,	,	PUNCT
aji-165	256	41	ileocolonic	ileocolonic	ADJ
aji-165	256	42	,	,	PUNCT
aji-165	256	43	colonic	colonic	NOUN
aji-165	256	44	)	)	PUNCT
aji-165	256	45	,	,	PUNCT
aji-165	256	46	these	these	DET
aji-165	256	47	differences	difference	NOUN
aji-165	256	48	are	be	AUX
aji-165	256	49	not	not	PART
aji-165	256	50	statistically	statistically	ADV
aji-165	256	51	significant	significant	ADJ
aji-165	256	52	(	(	PUNCT
aji-165	256	53	p=0	p=0	PROPN
aji-165	256	54	,	,	PUNCT
aji-165	256	55	53	53	NUM
aji-165	256	56	)	)	PUNCT
aji-165	256	57	.	.	PUNCT
aji-165	257	1	(	(	PUNCT
aji-165	257	2	table	table	NOUN
aji-165	257	3	19	19	NUM
aji-165	257	4	)	)	PUNCT
aji-165	257	5	table	table	NOUN
aji-165	257	6	15	15	NUM
aji-165	257	7	.	.	PUNCT
aji-165	258	1	comparison	comparison	NOUN
aji-165	258	2	of	of	ADP
aji-165	258	3	the	the	DET
aji-165	258	4	mean	mean	ADJ
aji-165	258	5	fc	fc	PROPN
aji-165	258	6	levels	level	NOUN
aji-165	258	7	between	between	ADP
aji-165	258	8	active	active	ADJ
aji-165	258	9	and	and	CCONJ
aji-165	258	10	remission	remission	NOUN
aji-165	258	11	states	state	NOUN
aji-165	258	12	in	in	ADP
aji-165	258	13	cd	cd	PROPN
aji-165	258	14	clinical	clinical	ADJ
aji-165	258	15	status	status	NOUN
aji-165	258	16	n	n	ADV
aji-165	258	17	mean	mean	VERB
aji-165	258	18	(	(	PUNCT
aji-165	258	19	mg	mg	PROPN
aji-165	258	20	/	/	SYM
aji-165	258	21	kg	kg	NOUN
aji-165	258	22	)	)	PUNCT
aji-165	258	23	standard	standard	ADJ
aji-165	258	24	deviation	deviation	NOUN
aji-165	258	25	fc	fc	INTJ
aji-165	258	26	in	in	ADP
aji-165	258	27	a	a	DET
aji-165	258	28	flare	flare	NOUN
aji-165	258	29	-	-	PUNCT
aji-165	258	30	up	up	NOUN
aji-165	258	31	24	24	NUM
aji-165	258	32	250	250	NUM
aji-165	258	33	320	320	NUM
aji-165	258	34	in	in	ADP
aji-165	258	35	remission	remission	NOUN
aji-165	258	36	29	29	NUM
aji-165	258	37	258	258	NUM
aji-165	258	38	555,53	555,53	NUM
aji-165	258	39	student	student	NOUN
aji-165	258	40	's	's	PART
aji-165	258	41	t	t	NOUN
aji-165	258	42	test	test	NOUN
aji-165	258	43	p=0,95	p=0,95	PROPN
aji-165	258	44	table	table	NOUN
aji-165	258	45	16	16	NUM
aji-165	258	46	.	.	PUNCT
aji-165	259	1	comparison	comparison	NOUN
aji-165	259	2	of	of	ADP
aji-165	259	3	the	the	DET
aji-165	259	4	mean	mean	ADJ
aji-165	259	5	crp	crp	PROPN
aji-165	259	6	levels	level	NOUN
aji-165	259	7	between	between	ADP
aji-165	259	8	cd	cd	PROPN
aji-165	259	9	and	and	CCONJ
aji-165	259	10	uc	uc	PROPN
aji-165	259	11	during	during	ADP
aji-165	259	12	the	the	DET
aji-165	259	13	active	active	ADJ
aji-165	259	14	phase	phase	NOUN
aji-165	259	15	ibd	ibd	NOUN
aji-165	259	16	n	n	PRON
aji-165	259	17	mean	mean	VERB
aji-165	259	18	(	(	PUNCT
aji-165	259	19	mg	mg	PROPN
aji-165	259	20	/	/	SYM
aji-165	259	21	l	l	NOUN
aji-165	259	22	)	)	PUNCT
aji-165	259	23	standard	standard	ADJ
aji-165	259	24	deviation	deviation	NOUN
aji-165	259	25	crp	crp	PROPN
aji-165	259	26	uc	uc	PROPN
aji-165	259	27	14	14	NUM
aji-165	259	28	18,12	18,12	PROPN
aji-165	259	29	15,76	15,76	PROPN
aji-165	259	30	cd	cd	NOUN
aji-165	259	31	24	24	NUM
aji-165	259	32	19,7	19,7	PROPN
aji-165	259	33	38,88	38,88	NUM
aji-165	259	34	student	student	NOUN
aji-165	259	35	's	's	PART
aji-165	259	36	t	t	PROPN
aji-165	259	37	-	-	PUNCT
aji-165	259	38	test	test	NOUN
aji-165	259	39	p=0,88	p=0,88	PROPN
aji-165	259	40	table	table	NOUN
aji-165	259	41	17	17	NUM
aji-165	259	42	.	.	PUNCT
aji-165	260	1	comparison	comparison	NOUN
aji-165	260	2	of	of	ADP
aji-165	260	3	the	the	DET
aji-165	260	4	mean	mean	ADJ
aji-165	260	5	crp	crp	PROPN
aji-165	260	6	levels	level	NOUN
aji-165	260	7	between	between	ADP
aji-165	260	8	active	active	ADJ
aji-165	260	9	and	and	CCONJ
aji-165	260	10	remission	remission	NOUN
aji-165	260	11	states	state	NOUN
aji-165	260	12	in	in	ADP
aji-165	260	13	uc	uc	PROPN
aji-165	260	14	clinical	clinical	ADJ
aji-165	260	15	status	status	NOUN
aji-165	260	16	n	n	ADV
aji-165	260	17	mean	mean	VERB
aji-165	260	18	(	(	PUNCT
aji-165	260	19	mg	mg	PROPN
aji-165	260	20	/	/	SYM
aji-165	260	21	l	l	NOUN
aji-165	260	22	)	)	PUNCT
aji-165	260	23	standard	standard	ADJ
aji-165	260	24	deviation	deviation	NOUN
aji-165	260	25	crp	crp	NOUN
aji-165	260	26	in	in	ADP
aji-165	260	27	a	a	DET
aji-165	260	28	flare	flare	NOUN
aji-165	260	29	-	-	PUNCT
aji-165	260	30	up	up	NOUN
aji-165	260	31	13	13	NUM
aji-165	260	32	17,73	17,73	NUM
aji-165	260	33	15,54	15,54	NUM
aji-165	260	34	in	in	ADP
aji-165	260	35	remission	remission	NOUN
aji-165	260	36	7	7	NUM
aji-165	260	37	6,84	6,84	NUM
aji-165	260	38	5,76	5,76	NUM
aji-165	260	39	student	student	NOUN
aji-165	260	40	's	's	PART
aji-165	260	41	t	t	NOUN
aji-165	260	42	-	-	PUNCT
aji-165	260	43	test	test	NOUN
aji-165	260	44	p=0,03	p=0,03	PROPN
aji-165	260	45	table	table	NOUN
aji-165	260	46	18	18	NUM
aji-165	260	47	.	.	PUNCT
aji-165	261	1	comparison	comparison	NOUN
aji-165	261	2	of	of	ADP
aji-165	261	3	the	the	DET
aji-165	261	4	mean	mean	ADJ
aji-165	261	5	crp	crp	PROPN
aji-165	261	6	levels	level	NOUN
aji-165	261	7	between	between	ADP
aji-165	261	8	active	active	ADJ
aji-165	261	9	and	and	CCONJ
aji-165	261	10	remission	remission	NOUN
aji-165	261	11	states	state	NOUN
aji-165	261	12	in	in	ADP
aji-165	261	13	cd	cd	PROPN
aji-165	261	14	clinical	clinical	ADJ
aji-165	261	15	status	status	NOUN
aji-165	262	1	n	n	ADV
aji-165	262	2	mean	mean	VERB
aji-165	262	3	(	(	PUNCT
aji-165	262	4	mg	mg	PROPN
aji-165	262	5	/	/	SYM
aji-165	262	6	l	l	NOUN
aji-165	262	7	)	)	PUNCT
aji-165	262	8	standard	standard	ADJ
aji-165	262	9	deviation	deviation	NOUN
aji-165	262	10	crp	crp	NOUN
aji-165	262	11	in	in	ADP
aji-165	262	12	a	a	DET
aji-165	262	13	flare	flare	NOUN
aji-165	262	14	-	-	PUNCT
aji-165	262	15	up	up	NOUN
aji-165	262	16	24	24	NUM
aji-165	262	17	19,62	19,62	NUM
aji-165	262	18	38,12	38,12	NUM
aji-165	262	19	in	in	ADP
aji-165	262	20	remission	remission	NOUN
aji-165	262	21	29	29	NUM
aji-165	262	22	12.06	12.06	NUM
aji-165	262	23	14,63	14,63	NUM
aji-165	262	24	student	student	NOUN
aji-165	262	25	's	's	PART
aji-165	262	26	t	t	PROPN
aji-165	262	27	-	-	PUNCT
aji-165	262	28	test	test	NOUN
aji-165	262	29	p=0,37	p=0,37	PROPN
aji-165	262	30	nassar	nassar	PROPN
aji-165	262	31	et	et	PROPN
aji-165	262	32	al	al	PROPN
aji-165	262	33	.	.	PROPN
aji-165	262	34	;	;	PUNCT
aji-165	262	35	asian	asian	PROPN
aji-165	262	36	j.	j.	PROPN
aji-165	262	37	immunol	immunol	PROPN
aji-165	262	38	.	.	PROPN
aji-165	262	39	,	,	PUNCT
aji-165	262	40	vol	vol	NOUN
aji-165	262	41	.	.	PROPN
aji-165	262	42	8	8	NUM
aji-165	262	43	,	,	PUNCT
aji-165	262	44	no	no	INTJ
aji-165	262	45	.	.	NOUN
aji-165	262	46	1	1	NUM
aji-165	262	47	,	,	PUNCT
aji-165	262	48	pp	pp	ADJ
aji-165	262	49	.	.	PUNCT
aji-165	263	1	104	104	NUM
aji-165	263	2	-	-	SYM
aji-165	263	3	119	119	NUM
aji-165	263	4	,	,	PUNCT
aji-165	263	5	2025	2025	NUM
aji-165	263	6	;	;	PUNCT
aji-165	263	7	article	article	NOUN
aji-165	263	8	no.aji.135189	no.aji.135189	VERB
aji-165	263	9	112	112	NUM
aji-165	263	10	table	table	NOUN
aji-165	263	11	19	19	NUM
aji-165	263	12	.	.	PUNCT
aji-165	263	13	comparison	comparison	NOUN
aji-165	263	14	of	of	ADP
aji-165	263	15	the	the	DET
aji-165	263	16	mean	mean	ADJ
aji-165	263	17	fc	fc	PROPN
aji-165	263	18	levels	level	NOUN
aji-165	263	19	among	among	ADP
aji-165	263	20	different	different	ADJ
aji-165	263	21	locations	location	NOUN
aji-165	263	22	in	in	ADP
aji-165	263	23	cd	cd	PROPN
aji-165	263	24	ileal	ileal	NOUN
aji-165	263	25	localization	localization	NOUN
aji-165	263	26	ileocolic	ileocolic	ADJ
aji-165	263	27	localization	localization	NOUN
aji-165	263	28	colonic	colonic	NOUN
aji-165	263	29	localization	localization	NOUN
aji-165	263	30	mean	mean	VERB
aji-165	263	31	fc	fc	PROPN
aji-165	263	32	rate	rate	NOUN
aji-165	263	33	(	(	PUNCT
aji-165	263	34	mg	mg	PROPN
aji-165	263	35	/	/	SYM
aji-165	263	36	kg	kg	NOUN
aji-165	263	37	)	)	PUNCT
aji-165	263	38	269,13	269,13	NUM
aji-165	263	39	127,40	127,40	NUM
aji-165	263	40	403,21	403,21	NUM
aji-165	263	41	standard	standard	ADJ
aji-165	263	42	deviation	deviation	NOUN
aji-165	263	43	325,9	325,9	NOUN
aji-165	263	44	146,84	146,84	NUM
aji-165	263	45	843,10	843,10	PROPN
aji-165	263	46	anova	anova	PROPN
aji-165	263	47	test	test	NOUN
aji-165	263	48	p=	p=	PROPN
aji-165	263	49	0,53	0,53	NOUN
aji-165	263	50	table	table	NOUN
aji-165	263	51	20	20	NUM
aji-165	263	52	.	.	PUNCT
aji-165	264	1	comparison	comparison	NOUN
aji-165	264	2	of	of	ADP
aji-165	264	3	the	the	DET
aji-165	264	4	mean	mean	ADJ
aji-165	264	5	crp	crp	PROPN
aji-165	264	6	levels	level	NOUN
aji-165	264	7	among	among	ADP
aji-165	264	8	different	different	ADJ
aji-165	264	9	locations	location	NOUN
aji-165	264	10	in	in	ADP
aji-165	264	11	cd	cd	PROPN
aji-165	264	12	ileal	ileal	NOUN
aji-165	264	13	localization	localization	NOUN
aji-165	264	14	ileocolic	ileocolic	ADJ
aji-165	264	15	localization	localization	NOUN
aji-165	264	16	colonic	colonic	NOUN
aji-165	264	17	localization	localization	NOUN
aji-165	264	18	mean	mean	VERB
aji-165	264	19	crp	crp	PROPN
aji-165	264	20	rate	rate	NOUN
aji-165	264	21	(	(	PUNCT
aji-165	264	22	mg	mg	PROPN
aji-165	264	23	/	/	SYM
aji-165	264	24	l	l	NOUN
aji-165	264	25	)	)	PUNCT
aji-165	264	26	7,99	7,99	PROPN
aji-165	265	1	13,44	13,44	NUM
aji-165	265	2	20,67	20,67	NUM
aji-165	265	3	standard	standard	ADJ
aji-165	265	4	deviation	deviation	NOUN
aji-165	265	5	11,1	11,1	NUM
aji-165	265	6	13,15	13,15	NUM
aji-165	265	7	23,82	23,82	PROPN
aji-165	265	8	anova	anova	PROPN
aji-165	265	9	test	test	NOUN
aji-165	265	10	p=0,38	p=0,38	PROPN
aji-165	265	11	3.3.8	3.3.8	NUM
aji-165	265	12	comparison	comparison	NOUN
aji-165	265	13	of	of	ADP
aji-165	265	14	the	the	DET
aji-165	265	15	mean	mean	ADJ
aji-165	265	16	crp	crp	PROPN
aji-165	265	17	levels	level	NOUN
aji-165	265	18	according	accord	VERB
aji-165	265	19	to	to	ADP
aji-165	265	20	disease	disease	NOUN
aji-165	265	21	location	location	NOUN
aji-165	265	22	in	in	ADP
aji-165	265	23	cd	cd	PROPN
aji-165	265	24	although	although	SCONJ
aji-165	265	25	there	there	PRON
aji-165	265	26	are	be	VERB
aji-165	265	27	differences	difference	NOUN
aji-165	265	28	in	in	ADP
aji-165	265	29	the	the	DET
aji-165	265	30	mean	mean	ADJ
aji-165	265	31	crp	crp	PROPN
aji-165	265	32	levels	level	NOUN
aji-165	265	33	based	base	VERB
aji-165	265	34	on	on	ADP
aji-165	265	35	the	the	DET
aji-165	265	36	location	location	NOUN
aji-165	265	37	of	of	ADP
aji-165	265	38	the	the	DET
aji-165	265	39	disease	disease	NOUN
aji-165	265	40	(	(	PUNCT
aji-165	265	41	ileal	ileal	ADJ
aji-165	265	42	,	,	PUNCT
aji-165	265	43	ileocolonic	ileocolonic	ADJ
aji-165	265	44	,	,	PUNCT
aji-165	265	45	colonic	colonic	NOUN
aji-165	265	46	)	)	PUNCT
aji-165	265	47	,	,	PUNCT
aji-165	265	48	these	these	DET
aji-165	265	49	differences	difference	NOUN
aji-165	265	50	are	be	AUX
aji-165	265	51	not	not	PART
aji-165	265	52	statistically	statistically	ADV
aji-165	265	53	significant	significant	ADJ
aji-165	265	54	(	(	PUNCT
aji-165	265	55	p=0	p=0	PROPN
aji-165	265	56	,	,	PUNCT
aji-165	265	57	38	38	NUM
aji-165	265	58	)	)	PUNCT
aji-165	265	59	.	.	PUNCT
aji-165	266	1	(	(	PUNCT
aji-165	266	2	table	table	NOUN
aji-165	266	3	20	20	NUM
aji-165	266	4	)	)	PUNCT
aji-165	266	5	3.4	3.4	NUM
aji-165	266	6	correlation	correlation	NOUN
aji-165	266	7	test	test	NOUN
aji-165	266	8	between	between	ADP
aji-165	266	9	fc	fc	PROPN
aji-165	266	10	and	and	CCONJ
aji-165	266	11	crp	crp	PROPN
aji-165	266	12	during	during	ADP
aji-165	266	13	the	the	DET
aji-165	266	14	active	active	ADJ
aji-165	266	15	phase	phase	NOUN
aji-165	266	16	the	the	DET
aji-165	266	17	correlation	correlation	NOUN
aji-165	266	18	between	between	ADP
aji-165	266	19	crp	crp	PROPN
aji-165	266	20	and	and	CCONJ
aji-165	266	21	fc	fc	PROPN
aji-165	266	22	is	be	AUX
aji-165	266	23	weak	weak	ADJ
aji-165	266	24	and	and	CCONJ
aji-165	266	25	positive	positive	ADJ
aji-165	266	26	(	(	PUNCT
aji-165	266	27	r	r	NOUN
aji-165	266	28	=	=	NOUN
aji-165	266	29	0.12	0.12	NUM
aji-165	266	30	)	)	PUNCT
aji-165	266	31	.	.	PUNCT
aji-165	267	1	this	this	PRON
aji-165	267	2	means	mean	VERB
aji-165	267	3	that	that	SCONJ
aji-165	267	4	as	as	ADP
aji-165	267	5	the	the	DET
aji-165	267	6	fc	fc	PROPN
aji-165	267	7	variable	variable	NOUN
aji-165	267	8	increases	increase	NOUN
aji-165	267	9	,	,	PUNCT
aji-165	267	10	crp	crp	PROPN
aji-165	267	11	tends	tend	VERB
aji-165	267	12	to	to	PART
aji-165	267	13	increase	increase	VERB
aji-165	267	14	as	as	ADV
aji-165	267	15	well	well	ADV
aji-165	267	16	,	,	PUNCT
aji-165	267	17	but	but	CCONJ
aji-165	267	18	only	only	ADV
aji-165	267	19	very	very	ADV
aji-165	267	20	slightly	slightly	ADV
aji-165	267	21	.	.	PUNCT
aji-165	268	1	however	however	ADV
aji-165	268	2	,	,	PUNCT
aji-165	268	3	since	since	SCONJ
aji-165	268	4	p	p	NOUN
aji-165	268	5	=	=	NOUN
aji-165	268	6	0.48	0.48	NUM
aji-165	268	7	,	,	PUNCT
aji-165	268	8	this	this	DET
aji-165	268	9	correlation	correlation	NOUN
aji-165	268	10	is	be	AUX
aji-165	268	11	not	not	PART
aji-165	268	12	statistically	statistically	ADV
aji-165	268	13	significant	significant	ADJ
aji-165	268	14	.	.	PUNCT
aji-165	269	1	in	in	ADP
aji-165	269	2	practical	practical	ADJ
aji-165	269	3	terms	term	NOUN
aji-165	269	4	,	,	PUNCT
aji-165	269	5	this	this	PRON
aji-165	269	6	indicates	indicate	VERB
aji-165	269	7	that	that	SCONJ
aji-165	269	8	crp	crp	PROPN
aji-165	269	9	and	and	CCONJ
aji-165	269	10	fc	fc	PROPN
aji-165	269	11	should	should	AUX
aji-165	269	12	be	be	AUX
aji-165	269	13	used	use	VERB
aji-165	269	14	complementarily	complementarily	ADV
aji-165	269	15	and	and	CCONJ
aji-165	269	16	not	not	PART
aji-165	269	17	interchangeably	interchangeably	ADV
aji-165	269	18	to	to	PART
aji-165	269	19	assess	assess	VERB
aji-165	269	20	inflammation	inflammation	NOUN
aji-165	269	21	in	in	ADP
aji-165	269	22	adult	adult	NOUN
aji-165	269	23	patients	patient	NOUN
aji-165	269	24	with	with	ADP
aji-165	269	25	inflammatory	inflammatory	ADJ
aji-165	269	26	bowel	bowel	NOUN
aji-165	269	27	disease	disease	NOUN
aji-165	269	28	(	(	PUNCT
aji-165	269	29	ibd	ibd	PROPN
aji-165	269	30	)	)	PUNCT
aji-165	269	31	.	.	PUNCT
aji-165	270	1	a	a	DET
aji-165	270	2	low	low	ADJ
aji-165	270	3	crp	crp	NOUN
aji-165	270	4	does	do	AUX
aji-165	270	5	not	not	PART
aji-165	270	6	necessarily	necessarily	ADV
aji-165	270	7	indicate	indicate	VERB
aji-165	270	8	low	low	ADJ
aji-165	270	9	intestinal	intestinal	ADJ
aji-165	270	10	inflammation	inflammation	NOUN
aji-165	270	11	,	,	PUNCT
aji-165	270	12	highlighting	highlight	VERB
aji-165	270	13	the	the	DET
aji-165	270	14	importance	importance	NOUN
aji-165	270	15	of	of	ADP
aji-165	270	16	measuring	measure	VERB
aji-165	270	17	fc	fc	PROPN
aji-165	270	18	for	for	ADP
aji-165	270	19	an	an	DET
aji-165	270	20	accurate	accurate	ADJ
aji-165	270	21	evaluation	evaluation	NOUN
aji-165	270	22	.	.	PUNCT
aji-165	271	1	(	(	PUNCT
aji-165	271	2	fig	fig	NOUN
aji-165	271	3	.	.	PUNCT
aji-165	272	1	3	3	NUM
aji-165	272	2	)	)	PUNCT
aji-165	272	3	.	.	PUNCT
aji-165	273	1	fig	fig	NOUN
aji-165	273	2	.	.	PUNCT
aji-165	274	1	3	3	X
aji-165	274	2	.	.	X
aji-165	274	3	scatter	scatter	NOUN
aji-165	274	4	plot	plot	NOUN
aji-165	274	5	of	of	ADP
aji-165	274	6	correlation	correlation	NOUN
aji-165	274	7	between	between	ADP
aji-165	274	8	fc	fc	PROPN
aji-165	274	9	and	and	CCONJ
aji-165	274	10	crp	crp	PROPN
aji-165	274	11	during	during	ADP
aji-165	274	12	the	the	DET
aji-165	274	13	active	active	ADJ
aji-165	274	14	phase	phase	NOUN
aji-165	274	15	spearman	spearman	NOUN
aji-165	274	16	correlation	correlation	NOUN
aji-165	274	17	test	test	NOUN
aji-165	274	18	p=	p=	NOUN
aji-165	274	19	0,48	0,48	NUM
aji-165	274	20	r=0,12	r=0,12	VERB
aji-165	274	21	nassar	nassar	PROPN
aji-165	274	22	et	et	PROPN
aji-165	274	23	al	al	PROPN
aji-165	274	24	.	.	PROPN
aji-165	274	25	;	;	PUNCT
aji-165	274	26	asian	asian	PROPN
aji-165	274	27	j.	j.	PROPN
aji-165	274	28	immunol	immunol	PROPN
aji-165	274	29	.	.	PROPN
aji-165	274	30	,	,	PUNCT
aji-165	274	31	vol	vol	NOUN
aji-165	274	32	.	.	PROPN
aji-165	274	33	8	8	NUM
aji-165	274	34	,	,	PUNCT
aji-165	274	35	no	no	INTJ
aji-165	274	36	.	.	NOUN
aji-165	274	37	1	1	NUM
aji-165	274	38	,	,	PUNCT
aji-165	274	39	pp	pp	ADJ
aji-165	274	40	.	.	PUNCT
aji-165	275	1	104	104	NUM
aji-165	275	2	-	-	SYM
aji-165	275	3	119	119	NUM
aji-165	275	4	,	,	PUNCT
aji-165	275	5	2025	2025	NUM
aji-165	275	6	;	;	PUNCT
aji-165	275	7	article	article	NOUN
aji-165	275	8	no.aji.135189	no.aji.135189	ADJ
aji-165	275	9	113	113	NUM
aji-165	275	10	4	4	NUM
aji-165	275	11	.	.	PUNCT
aji-165	276	1	discussion	discussion	NOUN
aji-165	276	2	4.1	4.1	NUM
aji-165	276	3	description	description	NOUN
aji-165	276	4	of	of	ADP
aji-165	276	5	the	the	DET
aji-165	276	6	studied	study	VERB
aji-165	276	7	population	population	NOUN
aji-165	276	8	inflammatory	inflammatory	ADJ
aji-165	276	9	bowel	bowel	NOUN
aji-165	276	10	diseases	disease	NOUN
aji-165	276	11	(	(	PUNCT
aji-165	276	12	ibd	ibd	NOUN
aji-165	276	13	)	)	PUNCT
aji-165	276	14	do	do	AUX
aji-165	276	15	not	not	PART
aji-165	276	16	appear	appear	VERB
aji-165	276	17	to	to	PART
aji-165	276	18	have	have	VERB
aji-165	276	19	a	a	DET
aji-165	276	20	gender	gender	NOUN
aji-165	276	21	preference	preference	NOUN
aji-165	276	22	(	(	PUNCT
aji-165	276	23	cosnes	cosne	NOUN
aji-165	276	24	et	et	NOUN
aji-165	276	25	al	al	PROPN
aji-165	276	26	.	.	PROPN
aji-165	276	27	,	,	PUNCT
aji-165	276	28	2011	2011	NUM
aji-165	276	29	)	)	PUNCT
aji-165	276	30	.	.	PUNCT
aji-165	277	1	however	however	ADV
aji-165	277	2	,	,	PUNCT
aji-165	277	3	according	accord	VERB
aji-165	277	4	to	to	ADP
aji-165	277	5	delmondes	delmonde	NOUN
aji-165	277	6	lm	lm	PROPN
aji-165	277	7	and	and	CCONJ
aji-165	277	8	al	al	PROPN
aji-165	277	9	.	.	PROPN
aji-165	277	10	,	,	PUNCT
aji-165	277	11	a	a	DET
aji-165	277	12	general	general	ADJ
aji-165	277	13	female	female	ADJ
aji-165	277	14	predominance	predominance	NOUN
aji-165	277	15	has	have	AUX
aji-165	277	16	been	be	AUX
aji-165	277	17	observed	observe	VERB
aji-165	277	18	in	in	ADP
aji-165	277	19	ibd	ibd	NOUN
aji-165	277	20	cases	case	NOUN
aji-165	277	21	,	,	PUNCT
aji-165	277	22	with	with	ADP
aji-165	277	23	a	a	DET
aji-165	277	24	male	male	NOUN
aji-165	277	25	-	-	PUNCT
aji-165	277	26	tofemale	tofemale	NOUN
aji-165	277	27	ratio	ratio	NOUN
aji-165	277	28	of	of	ADP
aji-165	277	29	0.641	0.641	NUM
aji-165	277	30	(	(	PUNCT
aji-165	277	31	lm	lm	INTJ
aji-165	277	32	et	et	PROPN
aji-165	277	33	al	al	PROPN
aji-165	277	34	.	.	PROPN
aji-165	277	35	,	,	PUNCT
aji-165	277	36	2015	2015	NUM
aji-165	277	37	)	)	PUNCT
aji-165	277	38	.	.	PUNCT
aji-165	278	1	a	a	DET
aji-165	278	2	cohort	cohort	NOUN
aji-165	278	3	study	study	NOUN
aji-165	278	4	conducted	conduct	VERB
aji-165	278	5	in	in	ADP
aji-165	278	6	canada	canada	PROPN
aji-165	278	7	in	in	ADP
aji-165	278	8	2017	2017	NUM
aji-165	278	9	involving	involve	VERB
aji-165	278	10	45567	45567	NUM
aji-165	278	11	patients	patient	NOUN
aji-165	278	12	showed	show	VERB
aji-165	278	13	similar	similar	ADJ
aji-165	278	14	results	result	NOUN
aji-165	278	15	.	.	PUNCT
aji-165	279	1	lima	lima	NOUN
aji-165	279	2	martins	martin	NOUN
aji-165	279	3	and	and	CCONJ
aji-165	279	4	al	al	PROPN
aji-165	279	5	.	.	PROPN
aji-165	279	6	also	also	ADV
aji-165	279	7	reported	report	VERB
aji-165	279	8	this	this	DET
aji-165	279	9	finding	finding	NOUN
aji-165	279	10	in	in	ADP
aji-165	279	11	their	their	PRON
aji-165	279	12	study	study	NOUN
aji-165	279	13	in	in	ADP
aji-165	279	14	2018	2018	NUM
aji-165	279	15	(	(	PUNCT
aji-165	279	16	benchimol	benchimol	NOUN
aji-165	279	17	et	et	PROPN
aji-165	279	18	al	al	PROPN
aji-165	279	19	.	.	PROPN
aji-165	279	20	,	,	PUNCT
aji-165	279	21	2017	2017	NUM
aji-165	279	22	;	;	PUNCT
aji-165	279	23	lm	lm	INTJ
aji-165	279	24	et	et	PROPN
aji-165	279	25	al	al	PROPN
aji-165	279	26	.	.	PROPN
aji-165	279	27	,	,	PUNCT
aji-165	279	28	2018	2018	NUM
aji-165	279	29	)	)	PUNCT
aji-165	279	30	.	.	PUNCT
aji-165	280	1	conversely	conversely	ADV
aji-165	280	2	,	,	PUNCT
aji-165	280	3	a	a	DET
aji-165	280	4	study	study	NOUN
aji-165	280	5	by	by	ADP
aji-165	280	6	wang	wang	PROPN
aji-165	280	7	zz	zz	PROPN
aji-165	280	8	and	and	CCONJ
aji-165	280	9	al	al	PROPN
aji-165	280	10	.	.	PROPN
aji-165	281	1	in	in	ADP
aji-165	281	2	2017	2017	NUM
aji-165	281	3	highlighted	highlight	VERB
aji-165	281	4	a	a	DET
aji-165	281	5	male	male	ADJ
aji-165	281	6	predominance	predominance	NOUN
aji-165	281	7	in	in	ADP
aji-165	281	8	ibd	ibd	PROPN
aji-165	281	9	cases	case	NOUN
aji-165	281	10	(	(	PUNCT
aji-165	281	11	jm	jm	PROPN
aji-165	281	12	et	et	PROPN
aji-165	281	13	al	al	PROPN
aji-165	281	14	.	.	PROPN
aji-165	281	15	,	,	PUNCT
aji-165	281	16	2018	2018	NUM
aji-165	281	17	)	)	PUNCT
aji-165	281	18	.	.	PUNCT
aji-165	282	1	in	in	ADP
aji-165	282	2	a	a	DET
aji-165	282	3	german	german	ADJ
aji-165	282	4	study	study	NOUN
aji-165	282	5	,	,	PUNCT
aji-165	282	6	the	the	DET
aji-165	282	7	peak	peak	NOUN
aji-165	282	8	incidence	incidence	NOUN
aji-165	282	9	for	for	ADP
aji-165	282	10	both	both	DET
aji-165	282	11	crohn	crohn	NOUN
aji-165	282	12	's	's	PART
aji-165	282	13	disease	disease	NOUN
aji-165	282	14	(	(	PUNCT
aji-165	282	15	cd	cd	PROPN
aji-165	282	16	)	)	PUNCT
aji-165	282	17	and	and	CCONJ
aji-165	282	18	ulcerative	ulcerative	ADJ
aji-165	282	19	colitis	colitis	NOUN
aji-165	282	20	(	(	PUNCT
aji-165	282	21	uc	uc	PROPN
aji-165	282	22	)	)	PUNCT
aji-165	282	23	was	be	AUX
aji-165	282	24	observed	observe	VERB
aji-165	282	25	in	in	ADP
aji-165	282	26	patients	patient	NOUN
aji-165	282	27	aged	age	VERB
aji-165	282	28	30	30	NUM
aji-165	282	29	years	year	NOUN
aji-165	282	30	or	or	CCONJ
aji-165	282	31	younger	young	ADJ
aji-165	282	32	(	(	PUNCT
aji-165	282	33	kostev	kostev	NOUN
aji-165	282	34	et	et	PROPN
aji-165	282	35	al	al	PROPN
aji-165	282	36	.	.	PROPN
aji-165	282	37	,	,	PUNCT
aji-165	282	38	2018	2018	NUM
aji-165	282	39	)	)	PUNCT
aji-165	282	40	.	.	PUNCT
aji-165	283	1	the	the	DET
aji-165	283	2	average	average	ADJ
aji-165	283	3	age	age	NOUN
aji-165	283	4	in	in	ADP
aji-165	283	5	the	the	DET
aji-165	283	6	oranian	oranian	NOUN
aji-165	283	7	study	study	NOUN
aji-165	283	8	was	be	AUX
aji-165	283	9	reported	report	VERB
aji-165	283	10	as	as	ADP
aji-165	283	11	31.2	31.2	NUM
aji-165	283	12	±	±	NUM
aji-165	283	13	3.4	3.4	NUM
aji-165	283	14	years	year	NOUN
aji-165	283	15	(	(	PUNCT
aji-165	283	16	masson	masson	PROPN
aji-165	283	17	,	,	PUNCT
aji-165	283	18	2024	2024	NUM
aji-165	283	19	)	)	PUNCT
aji-165	283	20	.	.	PUNCT
aji-165	284	1	in	in	ADP
aji-165	284	2	a	a	DET
aji-165	284	3	study	study	NOUN
aji-165	284	4	by	by	ADP
aji-165	284	5	huguet	huguet	PROPN
aji-165	284	6	j	j	PROPN
aji-165	284	7	and	and	CCONJ
aji-165	284	8	al	al	PROPN
aji-165	284	9	.	.	PROPN
aji-165	284	10	in	in	ADP
aji-165	284	11	2018	2018	NUM
aji-165	284	12	,	,	PUNCT
aji-165	284	13	nearly	nearly	ADV
aji-165	284	14	69	69	NUM
aji-165	284	15	%	%	NOUN
aji-165	284	16	of	of	ADP
aji-165	284	17	patients	patient	NOUN
aji-165	284	18	were	be	AUX
aji-165	284	19	over	over	ADV
aji-165	284	20	60	60	NUM
aji-165	284	21	years	year	NOUN
aji-165	284	22	old	old	ADJ
aji-165	284	23	(	(	PUNCT
aji-165	284	24	jm	jm	PROPN
aji-165	284	25	et	et	PROPN
aji-165	284	26	al	al	PROPN
aji-165	284	27	.	.	PROPN
aji-165	284	28	,	,	PUNCT
aji-165	284	29	2018	2018	NUM
aji-165	284	30	)	)	PUNCT
aji-165	284	31	.	.	PUNCT
aji-165	285	1	in	in	ADP
aji-165	285	2	our	our	PRON
aji-165	285	3	series	series	NOUN
aji-165	285	4	,	,	PUNCT
aji-165	285	5	the	the	DET
aji-165	285	6	mean	mean	ADJ
aji-165	285	7	age	age	NOUN
aji-165	285	8	was	be	AUX
aji-165	285	9	39.7	39.7	NUM
aji-165	285	10	years	year	NOUN
aji-165	285	11	±	±	NUM
aji-165	285	12	17.47	17.47	NUM
aji-165	285	13	years	year	NOUN
aji-165	285	14	.	.	PUNCT
aji-165	286	1	in	in	ADP
aji-165	286	2	a	a	DET
aji-165	286	3	moroccan	moroccan	ADJ
aji-165	286	4	study	study	NOUN
aji-165	286	5	,	,	PUNCT
aji-165	286	6	cd	cd	PROPN
aji-165	286	7	accounted	account	VERB
aji-165	286	8	for	for	ADP
aji-165	286	9	46.67	46.67	NUM
aji-165	286	10	%	%	NOUN
aji-165	286	11	of	of	ADP
aji-165	286	12	cases	case	NOUN
aji-165	286	13	(	(	PUNCT
aji-165	286	14	ibd	ibd	PROPN
aji-165	286	15	,	,	PUNCT
aji-165	286	16	n.d	n.d	PROPN
aji-165	286	17	.	.	PROPN
aji-165	286	18	)	)	PUNCT
aji-165	286	19	.	.	PUNCT
aji-165	287	1	in	in	ADP
aji-165	287	2	our	our	PRON
aji-165	287	3	series	series	NOUN
aji-165	287	4	,	,	PUNCT
aji-165	287	5	we	we	PRON
aji-165	287	6	noted	note	VERB
aji-165	287	7	a	a	DET
aji-165	287	8	clear	clear	ADJ
aji-165	287	9	predominance	predominance	NOUN
aji-165	287	10	of	of	ADP
aji-165	287	11	cd	cd	PROPN
aji-165	287	12	,	,	PUNCT
aji-165	287	13	comprising	comprise	VERB
aji-165	287	14	68.9	68.9	NUM
aji-165	287	15	%	%	NOUN
aji-165	287	16	of	of	ADP
aji-165	287	17	cases	case	NOUN
aji-165	287	18	.	.	PUNCT
aji-165	288	1	cd	cd	PROPN
aji-165	288	2	can	can	AUX
aji-165	288	3	affect	affect	VERB
aji-165	288	4	any	any	DET
aji-165	288	5	part	part	NOUN
aji-165	288	6	of	of	ADP
aji-165	288	7	the	the	DET
aji-165	288	8	gastrointestinal	gastrointestinal	ADJ
aji-165	288	9	tract	tract	NOUN
aji-165	288	10	but	but	CCONJ
aji-165	288	11	shows	show	VERB
aji-165	288	12	a	a	DET
aji-165	288	13	preference	preference	NOUN
aji-165	288	14	for	for	ADP
aji-165	288	15	the	the	DET
aji-165	288	16	ileocecal	ileocecal	ADJ
aji-165	288	17	region	region	NOUN
aji-165	288	18	.	.	PUNCT
aji-165	289	1	the	the	DET
aji-165	289	2	montreal	montreal	PROPN
aji-165	289	3	classification	classification	NOUN
aji-165	289	4	is	be	AUX
aji-165	289	5	widely	widely	ADV
aji-165	289	6	used	use	VERB
aji-165	289	7	by	by	ADP
aji-165	289	8	gastroenterologists	gastroenterologist	NOUN
aji-165	289	9	for	for	ADP
aji-165	289	10	lesion	lesion	NOUN
aji-165	289	11	topography	topography	NOUN
aji-165	289	12	(	(	PUNCT
aji-165	289	13	satsangi	satsangi	PROPN
aji-165	289	14	et	et	PROPN
aji-165	289	15	al	al	PROPN
aji-165	289	16	.	.	PROPN
aji-165	289	17	,	,	PUNCT
aji-165	289	18	2006	2006	NUM
aji-165	289	19	)	)	PUNCT
aji-165	289	20	.	.	PUNCT
aji-165	290	1	according	accord	VERB
aji-165	290	2	to	to	ADP
aji-165	290	3	literature	literature	NOUN
aji-165	290	4	data	data	PROPN
aji-165	290	5	,	,	PUNCT
aji-165	290	6	the	the	DET
aji-165	290	7	small	small	ADJ
aji-165	290	8	intestine	intestine	NOUN
aji-165	290	9	and	and	CCONJ
aji-165	290	10	colon	colon	NOUN
aji-165	290	11	are	be	AUX
aji-165	290	12	preferred	preferred	ADJ
aji-165	290	13	sites	site	NOUN
aji-165	290	14	for	for	ADP
aji-165	290	15	cd	cd	PROPN
aji-165	290	16	.	.	PUNCT
aji-165	291	1	in	in	ADP
aji-165	291	2	our	our	PRON
aji-165	291	3	case	case	NOUN
aji-165	291	4	series	series	NOUN
aji-165	291	5	of	of	ADP
aji-165	291	6	cd	cd	PROPN
aji-165	291	7	,	,	PUNCT
aji-165	291	8	ileal	ileal	ADJ
aji-165	291	9	localization	localization	NOUN
aji-165	291	10	was	be	AUX
aji-165	291	11	the	the	DET
aji-165	291	12	most	most	ADV
aji-165	291	13	common	common	ADJ
aji-165	291	14	,	,	PUNCT
aji-165	291	15	representing	represent	VERB
aji-165	291	16	39.62	39.62	NUM
aji-165	291	17	%	%	NOUN
aji-165	291	18	of	of	ADP
aji-165	291	19	cases	case	NOUN
aji-165	291	20	,	,	PUNCT
aji-165	291	21	followed	follow	VERB
aji-165	291	22	by	by	ADP
aji-165	291	23	colonic	colonic	ADJ
aji-165	291	24	localization	localization	NOUN
aji-165	291	25	at	at	ADP
aji-165	291	26	26.41	26.41	NUM
aji-165	291	27	%	%	NOUN
aji-165	291	28	.	.	PUNCT
aji-165	292	1	the	the	DET
aji-165	292	2	observed	observed	ADJ
aji-165	292	3	differences	difference	NOUN
aji-165	292	4	may	may	AUX
aji-165	292	5	be	be	AUX
aji-165	292	6	linked	link	VERB
aji-165	292	7	to	to	ADP
aji-165	292	8	geographical	geographical	ADJ
aji-165	292	9	,	,	PUNCT
aji-165	292	10	environmental	environmental	ADJ
aji-165	292	11	,	,	PUNCT
aji-165	292	12	or	or	CCONJ
aji-165	292	13	genetic	genetic	ADJ
aji-165	292	14	factors	factor	NOUN
aji-165	292	15	influencing	influence	VERB
aji-165	292	16	the	the	DET
aji-165	292	17	presentation	presentation	NOUN
aji-165	292	18	of	of	ADP
aji-165	292	19	ibd	ibd	PROPN
aji-165	292	20	.	.	PUNCT
aji-165	293	1	fistulas	fistula	NOUN
aji-165	293	2	are	be	AUX
aji-165	293	3	among	among	ADP
aji-165	293	4	the	the	DET
aji-165	293	5	most	most	ADV
aji-165	293	6	frequently	frequently	ADV
aji-165	293	7	encountered	encounter	VERB
aji-165	293	8	complications	complication	NOUN
aji-165	293	9	in	in	ADP
aji-165	293	10	cd	cd	PROPN
aji-165	293	11	(	(	PUNCT
aji-165	293	12	management	management	NOUN
aji-165	293	13	of	of	ADP
aji-165	293	14	acute	acute	ADJ
aji-165	293	15	ano	ano	ADJ
aji-165	293	16	-	-	ADJ
aji-165	293	17	perineal	perineal	ADJ
aji-165	293	18	crohn	crohn	NOUN
aji-165	293	19	’s	’s	PART
aji-165	293	20	disease	disease	NOUN
aji-165	293	21	,	,	PUNCT
aji-165	293	22	2024	2024	NUM
aji-165	293	23	)	)	PUNCT
aji-165	293	24	.	.	PUNCT
aji-165	294	1	our	our	PRON
aji-165	294	2	results	result	NOUN
aji-165	294	3	suggest	suggest	VERB
aji-165	294	4	that	that	SCONJ
aji-165	294	5	obstructive	obstructive	ADJ
aji-165	294	6	presentations	presentation	NOUN
aji-165	294	7	are	be	AUX
aji-165	294	8	more	more	ADV
aji-165	294	9	common	common	ADJ
aji-165	294	10	in	in	ADP
aji-165	294	11	patients	patient	NOUN
aji-165	294	12	with	with	ADP
aji-165	294	13	cd	cd	PROPN
aji-165	294	14	,	,	PUNCT
aji-165	294	15	with	with	ADP
aji-165	294	16	a	a	DET
aji-165	294	17	statistically	statistically	ADV
aji-165	294	18	significant	significant	ADJ
aji-165	294	19	difference	difference	NOUN
aji-165	294	20	(	(	PUNCT
aji-165	294	21	p=	p=	NOUN
aji-165	294	22	0.04	0.04	NUM
aji-165	294	23	)	)	PUNCT
aji-165	294	24	.	.	PUNCT
aji-165	295	1	this	this	DET
aji-165	295	2	discrepancy	discrepancy	NOUN
aji-165	295	3	with	with	ADP
aji-165	295	4	existing	exist	VERB
aji-165	295	5	literature	literature	NOUN
aji-165	295	6	may	may	AUX
aji-165	295	7	arise	arise	VERB
aji-165	295	8	from	from	ADP
aji-165	295	9	geographical	geographical	ADJ
aji-165	295	10	variations	variation	NOUN
aji-165	295	11	,	,	PUNCT
aji-165	295	12	access	access	NOUN
aji-165	295	13	to	to	ADP
aji-165	295	14	care	care	NOUN
aji-165	295	15	,	,	PUNCT
aji-165	295	16	or	or	CCONJ
aji-165	295	17	differences	difference	NOUN
aji-165	295	18	in	in	ADP
aji-165	295	19	follow	follow	NOUN
aji-165	295	20	-	-	PUNCT
aji-165	295	21	up	up	NOUN
aji-165	295	22	and	and	CCONJ
aji-165	295	23	treatment	treatment	NOUN
aji-165	295	24	practices	practice	NOUN
aji-165	295	25	.	.	PUNCT
aji-165	296	1	a	a	DET
aji-165	296	2	dutch	dutch	ADJ
aji-165	296	3	population	population	NOUN
aji-165	296	4	study	study	NOUN
aji-165	296	5	by	by	ADP
aji-165	296	6	smids	smid	NOUN
aji-165	296	7	c	c	PROPN
aji-165	296	8	and	and	CCONJ
aji-165	296	9	al	al	PROPN
aji-165	296	10	.	.	PROPN
aji-165	296	11	found	find	VERB
aji-165	296	12	that	that	SCONJ
aji-165	296	13	44	44	NUM
aji-165	296	14	%	%	NOUN
aji-165	296	15	of	of	ADP
aji-165	296	16	patients	patient	NOUN
aji-165	296	17	with	with	ADP
aji-165	296	18	cd	cd	PROPN
aji-165	296	19	smoked	smoke	VERB
aji-165	296	20	,	,	PUNCT
aji-165	296	21	compared	compare	VERB
aji-165	296	22	to	to	ADP
aji-165	296	23	20	20	NUM
aji-165	296	24	%	%	NOUN
aji-165	296	25	with	with	ADP
aji-165	296	26	crohn	crohn	PROPN
aji-165	296	27	's	's	PART
aji-165	296	28	disease	disease	NOUN
aji-165	296	29	indeterminate	indeterminate	NOUN
aji-165	296	30	(	(	PUNCT
aji-165	296	31	cdi	cdi	PROPN
aji-165	296	32	)	)	PUNCT
aji-165	296	33	and	and	CCONJ
aji-165	296	34	7	7	NUM
aji-165	296	35	%	%	NOUN
aji-165	296	36	with	with	ADP
aji-165	296	37	uc	uc	PROPN
aji-165	296	38	(	(	PUNCT
aji-165	296	39	smids	smid	NOUN
aji-165	296	40	et	et	PROPN
aji-165	296	41	al	al	PROPN
aji-165	296	42	.	.	PROPN
aji-165	296	43	,	,	PUNCT
aji-165	296	44	2017	2017	NUM
aji-165	296	45	)	)	PUNCT
aji-165	296	46	.	.	PUNCT
aji-165	297	1	among	among	ADP
aji-165	297	2	our	our	PRON
aji-165	297	3	patients	patient	NOUN
aji-165	297	4	,	,	PUNCT
aji-165	297	5	5.3	5.3	NUM
aji-165	297	6	%	%	NOUN
aji-165	297	7	were	be	AUX
aji-165	297	8	smokers	smoker	NOUN
aji-165	297	9	,	,	PUNCT
aji-165	297	10	all	all	PRON
aji-165	297	11	diagnosed	diagnose	VERB
aji-165	297	12	with	with	ADP
aji-165	297	13	cd	cd	PROPN
aji-165	297	14	.	.	PUNCT
aji-165	298	1	our	our	PRON
aji-165	298	2	findings	finding	NOUN
aji-165	298	3	do	do	AUX
aji-165	298	4	not	not	PART
aji-165	298	5	align	align	VERB
aji-165	298	6	with	with	ADP
aji-165	298	7	the	the	DET
aji-165	298	8	literature	literature	NOUN
aji-165	298	9	and	and	CCONJ
aji-165	298	10	may	may	AUX
aji-165	298	11	be	be	AUX
aji-165	298	12	biased	bias	VERB
aji-165	298	13	due	due	ADP
aji-165	298	14	to	to	ADP
aji-165	298	15	our	our	PRON
aji-165	298	16	small	small	ADJ
aji-165	298	17	sample	sample	NOUN
aji-165	298	18	size	size	NOUN
aji-165	298	19	;	;	PUNCT
aji-165	298	20	however	however	ADV
aji-165	298	21	,	,	PUNCT
aji-165	298	22	smoking	smoking	NOUN
aji-165	298	23	appears	appear	VERB
aji-165	298	24	more	more	ADV
aji-165	298	25	prevalent	prevalent	ADJ
aji-165	298	26	in	in	ADP
aji-165	298	27	cd	cd	NOUN
aji-165	298	28	cases	case	NOUN
aji-165	298	29	than	than	ADP
aji-165	298	30	in	in	ADP
aji-165	298	31	uc	uc	PROPN
aji-165	298	32	.	.	PUNCT
aji-165	299	1	according	accord	VERB
aji-165	299	2	to	to	ADP
aji-165	299	3	research	research	NOUN
aji-165	299	4	by	by	ADP
aji-165	299	5	casellas	casellas	PROPN
aji-165	299	6	f	f	PROPN
aji-165	299	7	and	and	CCONJ
aji-165	299	8	al	al	PROPN
aji-165	299	9	.	.	PROPN
aji-165	299	10	,	,	PUNCT
aji-165	299	11	studying	study	VERB
aji-165	299	12	disease	disease	NOUN
aji-165	299	13	activity	activity	NOUN
aji-165	299	14	among	among	ADP
aji-165	299	15	a	a	DET
aji-165	299	16	population	population	NOUN
aji-165	299	17	of	of	ADP
aji-165	299	18	117	117	NUM
aji-165	299	19	ibd	ibd	NOUN
aji-165	299	20	patients	patient	NOUN
aji-165	299	21	,	,	PUNCT
aji-165	299	22	among	among	ADP
aji-165	299	23	those	those	PRON
aji-165	299	24	with	with	ADP
aji-165	299	25	cd	cd	PROPN
aji-165	299	26	,	,	PUNCT
aji-165	299	27	six	six	NUM
aji-165	299	28	subjects	subject	NOUN
aji-165	299	29	experienced	experience	VERB
aji-165	299	30	at	at	ADP
aji-165	299	31	least	least	ADV
aji-165	299	32	one	one	NUM
aji-165	299	33	relapse	relapse	NOUN
aji-165	299	34	compared	compare	VERB
aji-165	299	35	to	to	ADP
aji-165	299	36	58	58	NUM
aji-165	299	37	who	who	PRON
aji-165	299	38	were	be	AUX
aji-165	299	39	in	in	ADP
aji-165	299	40	remission	remission	NOUN
aji-165	299	41	.	.	PUNCT
aji-165	300	1	for	for	ADP
aji-165	300	2	uc	uc	PROPN
aji-165	300	3	cases	case	NOUN
aji-165	300	4	,	,	PUNCT
aji-165	300	5	four	four	NUM
aji-165	300	6	patients	patient	NOUN
aji-165	300	7	had	have	VERB
aji-165	300	8	relapses	relapse	NOUN
aji-165	300	9	while	while	SCONJ
aji-165	300	10	49	49	NUM
aji-165	300	11	showed	show	VERB
aji-165	300	12	no	no	DET
aji-165	300	13	disease	disease	NOUN
aji-165	300	14	activity	activity	NOUN
aji-165	300	15	(	(	PUNCT
aji-165	300	16	nahon	nahon	PROPN
aji-165	300	17	et	et	PROPN
aji-165	300	18	al	al	PROPN
aji-165	300	19	.	.	PROPN
aji-165	300	20	,	,	PUNCT
aji-165	300	21	2018	2018	NUM
aji-165	300	22	)	)	PUNCT
aji-165	300	23	.	.	PUNCT
aji-165	301	1	in	in	ADP
aji-165	301	2	our	our	PRON
aji-165	301	3	series	series	NOUN
aji-165	301	4	,	,	PUNCT
aji-165	301	5	38	38	NUM
aji-165	301	6	patients	patient	NOUN
aji-165	301	7	(	(	PUNCT
aji-165	301	8	49.35	49.35	NUM
aji-165	301	9	%	%	NOUN
aji-165	301	10	)	)	PUNCT
aji-165	301	11	were	be	AUX
aji-165	301	12	experiencing	experience	VERB
aji-165	301	13	flare	flare	NOUN
aji-165	301	14	-	-	PUNCT
aji-165	301	15	ups	up	NOUN
aji-165	301	16	,	,	PUNCT
aji-165	301	17	with	with	ADP
aji-165	301	18	31.17	31.17	NUM
aji-165	301	19	%	%	NOUN
aji-165	301	20	having	have	VERB
aji-165	301	21	cd	cd	PROPN
aji-165	301	22	.	.	PUNCT
aji-165	302	1	the	the	DET
aji-165	302	2	increase	increase	NOUN
aji-165	302	3	in	in	ADP
aji-165	302	4	flare	flare	NOUN
aji-165	302	5	-	-	PUNCT
aji-165	302	6	ups	up	NOUN
aji-165	302	7	within	within	ADP
aji-165	302	8	our	our	PRON
aji-165	302	9	series	series	NOUN
aji-165	302	10	may	may	AUX
aji-165	302	11	be	be	AUX
aji-165	302	12	attributed	attribute	VERB
aji-165	302	13	to	to	ADP
aji-165	302	14	the	the	DET
aji-165	302	15	small	small	ADJ
aji-165	302	16	sample	sample	NOUN
aji-165	302	17	size	size	NOUN
aji-165	302	18	.	.	PUNCT
aji-165	303	1	a	a	DET
aji-165	303	2	moroccan	moroccan	ADJ
aji-165	303	3	study	study	NOUN
aji-165	303	4	reported	report	VERB
aji-165	303	5	abdominal	abdominal	ADJ
aji-165	303	6	pain	pain	NOUN
aji-165	303	7	in	in	ADP
aji-165	303	8	20	20	NUM
aji-165	303	9	patients	patient	NOUN
aji-165	303	10	with	with	ADP
aji-165	303	11	cd	cd	PROPN
aji-165	303	12	(	(	PUNCT
aji-165	303	13	33.3	33.3	NUM
aji-165	303	14	%	%	NOUN
aji-165	303	15	)	)	PUNCT
aji-165	303	16	and	and	CCONJ
aji-165	303	17	in	in	ADP
aji-165	303	18	14	14	NUM
aji-165	303	19	patients	patient	NOUN
aji-165	303	20	with	with	ADP
aji-165	303	21	uc	uc	PROPN
aji-165	303	22	(	(	PUNCT
aji-165	303	23	23.3	23.3	NUM
aji-165	303	24	%	%	NOUN
aji-165	303	25	)	)	PUNCT
aji-165	303	26	.	.	PUNCT
aji-165	304	1	false	false	ADJ
aji-165	304	2	needs	need	NOUN
aji-165	304	3	were	be	AUX
aji-165	304	4	reported	report	VERB
aji-165	304	5	in	in	ADP
aji-165	304	6	32	32	NUM
aji-165	304	7	patients	patient	NOUN
aji-165	304	8	(	(	PUNCT
aji-165	304	9	53.3	53.3	NUM
aji-165	304	10	%	%	NOUN
aji-165	304	11	)	)	PUNCT
aji-165	304	12	,	,	PUNCT
aji-165	304	13	including	include	VERB
aji-165	304	14	ten	ten	NUM
aji-165	304	15	with	with	ADP
aji-165	304	16	cd	cd	PROPN
aji-165	304	17	(	(	PUNCT
aji-165	304	18	16.67	16.67	NUM
aji-165	304	19	%	%	NOUN
aji-165	304	20	)	)	PUNCT
aji-165	304	21	and	and	CCONJ
aji-165	304	22	twenty	twenty	NUM
aji-165	304	23	-	-	PUNCT
aji-165	304	24	one	one	NUM
aji-165	304	25	with	with	ADP
aji-165	304	26	uc	uc	PROPN
aji-165	304	27	(	(	PUNCT
aji-165	304	28	35	35	NUM
aji-165	304	29	%	%	NOUN
aji-165	304	30	)	)	PUNCT
aji-165	304	31	.	.	PUNCT
aji-165	305	1	rectal	rectal	ADJ
aji-165	305	2	bleeding	bleeding	NOUN
aji-165	305	3	was	be	AUX
aji-165	305	4	noted	note	VERB
aji-165	305	5	in	in	ADP
aji-165	305	6	25	25	NUM
aji-165	305	7	%	%	NOUN
aji-165	305	8	of	of	ADP
aji-165	305	9	patients	patient	NOUN
aji-165	305	10	with	with	ADP
aji-165	305	11	uc	uc	PROPN
aji-165	305	12	(	(	PUNCT
aji-165	305	13	ibd	ibd	PROPN
aji-165	305	14	,	,	PUNCT
aji-165	305	15	n.d	n.d	PROPN
aji-165	305	16	.	.	PROPN
aji-165	305	17	)	)	PUNCT
aji-165	305	18	.	.	PUNCT
aji-165	306	1	in	in	ADP
aji-165	306	2	our	our	PRON
aji-165	306	3	series	series	NOUN
aji-165	306	4	,	,	PUNCT
aji-165	306	5	digestive	digestive	ADJ
aji-165	306	6	manifestations	manifestation	NOUN
aji-165	306	7	were	be	AUX
aji-165	306	8	dominated	dominate	VERB
aji-165	306	9	by	by	ADP
aji-165	306	10	abdominal	abdominal	ADJ
aji-165	306	11	pain	pain	NOUN
aji-165	306	12	in	in	ADP
aji-165	306	13	51.95	51.95	NUM
aji-165	306	14	%	%	NOUN
aji-165	306	15	of	of	ADP
aji-165	306	16	patients	patient	NOUN
aji-165	306	17	with	with	ADP
aji-165	306	18	cd	cd	PROPN
aji-165	306	19	and	and	CCONJ
aji-165	306	20	in	in	ADP
aji-165	306	21	19.48	19.48	NUM
aji-165	306	22	%	%	NOUN
aji-165	306	23	of	of	ADP
aji-165	306	24	those	those	PRON
aji-165	306	25	with	with	ADP
aji-165	306	26	uc	uc	PROPN
aji-165	306	27	.	.	PROPN
aji-165	306	28	chronic	chronic	ADJ
aji-165	306	29	diarrhea	diarrhea	NOUN
aji-165	306	30	was	be	AUX
aji-165	306	31	present	present	ADJ
aji-165	306	32	in	in	ADP
aji-165	306	33	45.45	45.45	NUM
aji-165	306	34	%	%	NOUN
aji-165	306	35	of	of	ADP
aji-165	306	36	cd	cd	NOUN
aji-165	306	37	cases	case	NOUN
aji-165	306	38	and	and	CCONJ
aji-165	306	39	in	in	ADP
aji-165	306	40	19.48	19.48	NUM
aji-165	306	41	%	%	NOUN
aji-165	306	42	of	of	ADP
aji-165	306	43	uc	uc	PROPN
aji-165	306	44	cases	case	NOUN
aji-165	306	45	;	;	PUNCT
aji-165	306	46	rectal	rectal	ADJ
aji-165	306	47	bleeding	bleeding	NOUN
aji-165	306	48	occurred	occur	VERB
aji-165	306	49	in	in	ADP
aji-165	306	50	19.48	19.48	NUM
aji-165	306	51	%	%	NOUN
aji-165	306	52	of	of	ADP
aji-165	306	53	cases	case	NOUN
aji-165	306	54	(	(	PUNCT
aji-165	306	55	14.28	14.28	NUM
aji-165	306	56	%	%	NOUN
aji-165	306	57	with	with	ADP
aji-165	306	58	uc	uc	PROPN
aji-165	306	59	)	)	PUNCT
aji-165	306	60	,	,	PUNCT
aji-165	306	61	and	and	CCONJ
aji-165	306	62	false	false	ADJ
aji-165	306	63	needs	need	NOUN
aji-165	306	64	were	be	AUX
aji-165	306	65	reported	report	VERB
aji-165	306	66	in	in	ADP
aji-165	306	67	9.09	9.09	NUM
aji-165	306	68	%	%	NOUN
aji-165	306	69	of	of	ADP
aji-165	306	70	cases	case	NOUN
aji-165	306	71	(	(	PUNCT
aji-165	306	72	7.79	7.79	NUM
aji-165	306	73	%	%	NOUN
aji-165	306	74	with	with	ADP
aji-165	306	75	cd	cd	PROPN
aji-165	306	76	)	)	PUNCT
aji-165	306	77	.	.	PUNCT
aji-165	307	1	these	these	DET
aji-165	307	2	results	result	NOUN
aji-165	307	3	are	be	AUX
aji-165	307	4	consistent	consistent	ADJ
aji-165	307	5	with	with	ADP
aji-165	307	6	literature	literature	NOUN
aji-165	307	7	data	datum	NOUN
aji-165	307	8	.	.	PUNCT
aji-165	308	1	an	an	DET
aji-165	308	2	iranian	iranian	ADJ
aji-165	308	3	study	study	NOUN
aji-165	308	4	conducted	conduct	VERB
aji-165	308	5	by	by	ADP
aji-165	308	6	zobeiri	zobeiri	PROPN
aji-165	308	7	m	m	PROPN
aji-165	308	8	and	and	CCONJ
aji-165	308	9	al	al	PROPN
aji-165	308	10	.	.	PROPN
aji-165	308	11	highlighted	highlight	VERB
aji-165	308	12	that	that	SCONJ
aji-165	308	13	extra	extra	ADJ
aji-165	308	14	-	-	ADJ
aji-165	308	15	digestive	digestive	ADJ
aji-165	308	16	symptoms	symptom	NOUN
aji-165	308	17	were	be	AUX
aji-165	308	18	marked	mark	VERB
aji-165	308	19	by	by	ADP
aji-165	308	20	musculoskeletal	musculoskeletal	ADJ
aji-165	308	21	signs	sign	NOUN
aji-165	308	22	(	(	PUNCT
aji-165	308	23	51.9	51.9	NUM
aji-165	308	24	%	%	NOUN
aji-165	308	25	)	)	PUNCT
aji-165	308	26	,	,	PUNCT
aji-165	308	27	followed	follow	VERB
aji-165	308	28	by	by	ADP
aji-165	308	29	ocular	ocular	ADJ
aji-165	308	30	signs	sign	NOUN
aji-165	308	31	(	(	PUNCT
aji-165	308	32	27.9	27.9	NUM
aji-165	308	33	%	%	NOUN
aji-165	308	34	)	)	PUNCT
aji-165	308	35	,	,	PUNCT
aji-165	308	36	and	and	CCONJ
aji-165	308	37	skin	skin	NOUN
aji-165	308	38	signs	sign	NOUN
aji-165	308	39	(	(	PUNCT
aji-165	308	40	22.7	22.7	NUM
aji-165	308	41	%	%	NOUN
aji-165	308	42	)	)	PUNCT
aji-165	308	43	(	(	PUNCT
aji-165	308	44	gao	gao	PROPN
aji-165	308	45	et	et	PROPN
aji-165	308	46	al	al	PROPN
aji-165	308	47	.	.	PROPN
aji-165	308	48	,	,	PUNCT
aji-165	308	49	2017	2017	NUM
aji-165	308	50	)	)	PUNCT
aji-165	308	51	.	.	PUNCT
aji-165	309	1	in	in	ADP
aji-165	309	2	our	our	PRON
aji-165	309	3	study	study	NOUN
aji-165	309	4	,	,	PUNCT
aji-165	309	5	articular	articular	ADJ
aji-165	309	6	signs	sign	NOUN
aji-165	309	7	were	be	AUX
aji-165	309	8	present	present	ADJ
aji-165	309	9	in	in	ADP
aji-165	309	10	41.55	41.55	NUM
aji-165	309	11	%	%	NOUN
aji-165	309	12	of	of	ADP
aji-165	309	13	patients	patient	NOUN
aji-165	309	14	;	;	PUNCT
aji-165	309	15	ocular	ocular	ADJ
aji-165	309	16	manifestations	manifestation	NOUN
aji-165	309	17	occurred	occur	VERB
aji-165	309	18	in	in	ADP
aji-165	309	19	10.4	10.4	NUM
aji-165	309	20	%	%	NOUN
aji-165	309	21	,	,	PUNCT
aji-165	309	22	and	and	CCONJ
aji-165	309	23	skin	skin	NOUN
aji-165	309	24	signs	sign	NOUN
aji-165	309	25	were	be	AUX
aji-165	309	26	seen	see	VERB
aji-165	309	27	in	in	ADP
aji-165	309	28	nassar	nassar	PROPN
aji-165	309	29	et	et	PROPN
aji-165	309	30	al	al	PROPN
aji-165	309	31	.	.	PROPN
aji-165	309	32	;	;	PUNCT
aji-165	310	1	asian	asian	PROPN
aji-165	310	2	j.	j.	PROPN
aji-165	310	3	immunol	immunol	PROPN
aji-165	310	4	.	.	PROPN
aji-165	310	5	,	,	PUNCT
aji-165	310	6	vol	vol	NOUN
aji-165	310	7	.	.	PROPN
aji-165	310	8	8	8	NUM
aji-165	310	9	,	,	PUNCT
aji-165	310	10	no	no	INTJ
aji-165	310	11	.	.	NOUN
aji-165	310	12	1	1	NUM
aji-165	310	13	,	,	PUNCT
aji-165	310	14	pp	pp	ADJ
aji-165	310	15	.	.	PUNCT
aji-165	311	1	104	104	NUM
aji-165	311	2	-	-	SYM
aji-165	311	3	119	119	NUM
aji-165	311	4	,	,	PUNCT
aji-165	311	5	2025	2025	NUM
aji-165	311	6	;	;	PUNCT
aji-165	311	7	article	article	NOUN
aji-165	311	8	no.aji.135189	no.aji.135189	VERB
aji-165	311	9	114	114	NUM
aji-165	311	10	3.9	3.9	NUM
aji-165	311	11	%	%	NOUN
aji-165	311	12	.	.	PUNCT
aji-165	312	1	our	our	PRON
aji-165	312	2	results	result	NOUN
aji-165	312	3	align	align	VERB
aji-165	312	4	well	well	ADV
aji-165	312	5	with	with	ADP
aji-165	312	6	those	those	PRON
aji-165	312	7	reported	report	VERB
aji-165	312	8	in	in	ADP
aji-165	312	9	other	other	ADJ
aji-165	312	10	studies	study	NOUN
aji-165	312	11	.	.	PUNCT
aji-165	313	1	4.2	4.2	NUM
aji-165	313	2	results	result	NOUN
aji-165	313	3	of	of	ADP
aji-165	313	4	fc	fc	PROPN
aji-165	313	5	and	and	CCONJ
aji-165	313	6	crp	crp	PROPN
aji-165	313	7	testing	testing	NOUN
aji-165	313	8	in	in	ADP
aji-165	313	9	a	a	DET
aji-165	313	10	chinese	chinese	ADJ
aji-165	313	11	study	study	NOUN
aji-165	313	12	,	,	PUNCT
aji-165	313	13	crp	crp	PROPN
aji-165	313	14	levels	level	NOUN
aji-165	313	15	were	be	AUX
aji-165	313	16	found	find	VERB
aji-165	313	17	to	to	PART
aji-165	313	18	be	be	AUX
aji-165	313	19	higher	high	ADJ
aji-165	313	20	among	among	ADP
aji-165	313	21	patients	patient	NOUN
aji-165	313	22	with	with	ADP
aji-165	313	23	cd	cd	PROPN
aji-165	313	24	(	(	PUNCT
aji-165	313	25	wang	wang	PROPN
aji-165	313	26	et	et	PROPN
aji-165	313	27	al	al	PROPN
aji-165	313	28	.	.	PROPN
aji-165	313	29	,	,	PUNCT
aji-165	313	30	2013	2013	NUM
aji-165	313	31	)	)	PUNCT
aji-165	313	32	.	.	PUNCT
aji-165	314	1	in	in	ADP
aji-165	314	2	our	our	PRON
aji-165	314	3	series	series	NOUN
aji-165	314	4	,	,	PUNCT
aji-165	314	5	34	34	NUM
aji-165	314	6	patients	patient	NOUN
aji-165	314	7	(	(	PUNCT
aji-165	314	8	46.57	46.57	NUM
aji-165	314	9	%	%	NOUN
aji-165	314	10	)	)	PUNCT
aji-165	314	11	had	have	VERB
aji-165	314	12	crp	crp	PROPN
aji-165	314	13	levels	level	NOUN
aji-165	314	14	≥6	≥6	ADP
aji-165	314	15	mg	mg	X
aji-165	314	16	/	/	SYM
aji-165	314	17	l	l	NOUN
aji-165	314	18	(	(	PUNCT
aji-165	314	19	with	with	ADP
aji-165	314	20	29.87	29.87	NUM
aji-165	314	21	%	%	NOUN
aji-165	314	22	having	have	VERB
aji-165	314	23	cd	cd	PROPN
aji-165	314	24	)	)	PUNCT
aji-165	314	25	.	.	PUNCT
aji-165	315	1	our	our	PRON
aji-165	315	2	findings	finding	NOUN
aji-165	315	3	are	be	AUX
aji-165	315	4	consistent	consistent	ADJ
aji-165	315	5	with	with	ADP
aji-165	315	6	existing	exist	VERB
aji-165	315	7	literature	literature	NOUN
aji-165	315	8	.	.	PUNCT
aji-165	316	1	schoepfer	schoepfer	NOUN
aji-165	316	2	and	and	CCONJ
aji-165	316	3	al	al	PROPN
aji-165	316	4	.	.	PROPN
aji-165	316	5	reported	report	VERB
aji-165	316	6	a	a	DET
aji-165	316	7	higher	high	ADJ
aji-165	316	8	correlation	correlation	NOUN
aji-165	316	9	between	between	ADP
aji-165	316	10	the	the	DET
aji-165	316	11	endoscopic	endoscopic	ADJ
aji-165	316	12	activity	activity	NOUN
aji-165	316	13	of	of	ADP
aji-165	316	14	uc	uc	PROPN
aji-165	316	15	and	and	CCONJ
aji-165	316	16	fc	fc	PROPN
aji-165	316	17	levels	level	NOUN
aji-165	316	18	(	(	PUNCT
aji-165	316	19	r	r	NOUN
aji-165	316	20	=	=	NOUN
aji-165	316	21	0.8	0.8	NUM
aji-165	316	22	)	)	PUNCT
aji-165	316	23	compared	compare	VERB
aji-165	316	24	to	to	ADP
aji-165	316	25	crp	crp	PROPN
aji-165	316	26	(	(	PUNCT
aji-165	316	27	r	r	NOUN
aji-165	316	28	=	=	SYM
aji-165	316	29	0.5	0.5	NUM
aji-165	316	30	)	)	PUNCT
aji-165	316	31	(	(	PUNCT
aji-165	316	32	schoepfer	schoepfer	VERB
aji-165	316	33	et	et	PROPN
aji-165	316	34	al	al	PROPN
aji-165	316	35	.	.	PROPN
aji-165	316	36	,	,	PUNCT
aji-165	316	37	2024	2024	NUM
aji-165	316	38	)	)	PUNCT
aji-165	316	39	.	.	PUNCT
aji-165	317	1	a	a	DET
aji-165	317	2	study	study	NOUN
aji-165	317	3	conducted	conduct	VERB
aji-165	317	4	at	at	ADP
aji-165	317	5	the	the	DET
aji-165	317	6	gastroenterology	gastroenterology	NOUN
aji-165	317	7	clinic	clinic	NOUN
aji-165	317	8	of	of	ADP
aji-165	317	9	rsud	rsud	PROPN
aji-165	317	10	dr	dr	PROPN
aji-165	317	11	.	.	PROPN
aji-165	317	12	soetomo	soetomo	PROPN
aji-165	317	13	hospital	hospital	PROPN
aji-165	317	14	in	in	ADP
aji-165	317	15	surabaya	surabaya	PROPN
aji-165	317	16	from	from	ADP
aji-165	317	17	march	march	PROPN
aji-165	317	18	to	to	ADP
aji-165	317	19	august	august	PROPN
aji-165	317	20	2020	2020	NUM
aji-165	317	21	included	include	VERB
aji-165	317	22	30	30	NUM
aji-165	317	23	participants	participant	NOUN
aji-165	317	24	with	with	ADP
aji-165	317	25	uc	uc	PROPN
aji-165	317	26	.	.	PUNCT
aji-165	318	1	this	this	DET
aji-165	318	2	crosssectional	crosssectional	ADJ
aji-165	318	3	analytical	analytical	ADJ
aji-165	318	4	study	study	NOUN
aji-165	318	5	aimed	aim	VERB
aji-165	318	6	to	to	PART
aji-165	318	7	evaluate	evaluate	VERB
aji-165	318	8	colitis	colitis	NOUN
aji-165	318	9	activity	activity	NOUN
aji-165	318	10	through	through	ADP
aji-165	318	11	crp	crp	PROPN
aji-165	318	12	and	and	CCONJ
aji-165	318	13	fc	fc	PROPN
aji-165	318	14	measurements	measurement	NOUN
aji-165	318	15	.	.	PUNCT
aji-165	319	1	during	during	ADP
aji-165	319	2	flare	flare	NOUN
aji-165	319	3	-	-	PUNCT
aji-165	319	4	ups	up	NOUN
aji-165	319	5	,	,	PUNCT
aji-165	319	6	fc	fc	PROPN
aji-165	319	7	was	be	AUX
aji-165	319	8	positive	positive	ADJ
aji-165	319	9	in	in	ADP
aji-165	319	10	20	20	NUM
aji-165	319	11	patients	patient	NOUN
aji-165	319	12	(	(	PUNCT
aji-165	319	13	67	67	NUM
aji-165	319	14	%	%	NOUN
aji-165	319	15	)	)	PUNCT
aji-165	319	16	,	,	PUNCT
aji-165	319	17	while	while	SCONJ
aji-165	319	18	crp	crp	PROPN
aji-165	319	19	was	be	AUX
aji-165	319	20	positive	positive	ADJ
aji-165	319	21	in	in	ADP
aji-165	319	22	13	13	NUM
aji-165	319	23	patients	patient	NOUN
aji-165	319	24	(	(	PUNCT
aji-165	319	25	43	43	NUM
aji-165	319	26	%	%	NOUN
aji-165	319	27	)	)	PUNCT
aji-165	319	28	.	.	PUNCT
aji-165	320	1	a	a	DET
aji-165	320	2	significant	significant	ADJ
aji-165	320	3	relationship	relationship	NOUN
aji-165	320	4	was	be	AUX
aji-165	320	5	observed	observe	VERB
aji-165	320	6	between	between	ADP
aji-165	320	7	fc	fc	PROPN
aji-165	320	8	and	and	CCONJ
aji-165	320	9	crp	crp	PROPN
aji-165	320	10	,	,	PUNCT
aji-165	320	11	with	with	ADP
aji-165	320	12	a	a	DET
aji-165	320	13	correlation	correlation	NOUN
aji-165	320	14	coefficient	coefficient	NOUN
aji-165	320	15	(	(	PUNCT
aji-165	320	16	r	r	NOUN
aji-165	320	17	)	)	PUNCT
aji-165	320	18	of	of	ADP
aji-165	320	19	0.57	0.57	NUM
aji-165	320	20	(	(	PUNCT
aji-165	320	21	p	p	X
aji-165	320	22	=	=	NOUN
aji-165	320	23	0.01	0.01	NUM
aji-165	320	24	)	)	PUNCT
aji-165	320	25	(	(	PUNCT
aji-165	320	26	anindita	anindita	VERB
aji-165	320	27	et	et	PROPN
aji-165	320	28	al	al	PROPN
aji-165	320	29	.	.	PROPN
aji-165	320	30	,	,	PUNCT
aji-165	320	31	2023	2023	NUM
aji-165	320	32	)	)	PUNCT
aji-165	320	33	.	.	PUNCT
aji-165	321	1	in	in	ADP
aji-165	321	2	our	our	PRON
aji-165	321	3	study	study	NOUN
aji-165	321	4	,	,	PUNCT
aji-165	321	5	patients	patient	NOUN
aji-165	321	6	in	in	ADP
aji-165	321	7	flare	flare	PROPN
aji-165	321	8	had	have	VERB
aji-165	321	9	a	a	DET
aji-165	321	10	higher	high	ADJ
aji-165	321	11	proportion	proportion	NOUN
aji-165	321	12	of	of	ADP
aji-165	321	13	positive	positive	ADJ
aji-165	321	14	fc	fc	NOUN
aji-165	321	15	(	(	PUNCT
aji-165	321	16	52.63	52.63	NUM
aji-165	321	17	%	%	NOUN
aji-165	321	18	)	)	PUNCT
aji-165	321	19	compared	compare	VERB
aji-165	321	20	to	to	ADP
aji-165	321	21	patients	patient	NOUN
aji-165	321	22	in	in	ADP
aji-165	321	23	remission	remission	NOUN
aji-165	321	24	(	(	PUNCT
aji-165	321	25	35.9	35.9	NUM
aji-165	321	26	%	%	NOUN
aji-165	321	27	)	)	PUNCT
aji-165	321	28	,	,	PUNCT
aji-165	321	29	and	and	CCONJ
aji-165	321	30	none	none	NOUN
aji-165	321	31	of	of	ADP
aji-165	321	32	the	the	DET
aji-165	321	33	patients	patient	NOUN
aji-165	321	34	in	in	ADP
aji-165	321	35	flare	flare	PROPN
aji-165	321	36	had	have	VERB
aji-165	321	37	equivocal	equivocal	ADJ
aji-165	321	38	fc	fc	PROPN
aji-165	321	39	results	result	NOUN
aji-165	321	40	.	.	PUNCT
aji-165	322	1	this	this	DET
aji-165	322	2	difference	difference	NOUN
aji-165	322	3	was	be	AUX
aji-165	322	4	confirmed	confirm	VERB
aji-165	322	5	by	by	ADP
aji-165	322	6	a	a	DET
aji-165	322	7	p	p	NOUN
aji-165	322	8	-	-	PUNCT
aji-165	322	9	value	value	NOUN
aji-165	322	10	of	of	ADP
aji-165	322	11	0.018	0.018	NUM
aji-165	322	12	,	,	PUNCT
aji-165	322	13	indicating	indicate	VERB
aji-165	322	14	a	a	DET
aji-165	322	15	significant	significant	ADJ
aji-165	322	16	association	association	NOUN
aji-165	322	17	between	between	ADP
aji-165	322	18	flare	flare	NOUN
aji-165	322	19	status	status	NOUN
aji-165	322	20	and	and	CCONJ
aji-165	322	21	fc	fc	PROPN
aji-165	322	22	levels	level	NOUN
aji-165	322	23	.	.	PUNCT
aji-165	323	1	our	our	PRON
aji-165	323	2	results	result	NOUN
aji-165	323	3	suggest	suggest	VERB
aji-165	323	4	that	that	SCONJ
aji-165	323	5	although	although	SCONJ
aji-165	323	6	there	there	PRON
aji-165	323	7	are	be	VERB
aji-165	323	8	differences	difference	NOUN
aji-165	323	9	in	in	ADP
aji-165	323	10	fc	fc	PROPN
aji-165	323	11	between	between	ADP
aji-165	323	12	flare	flare	NOUN
aji-165	323	13	and	and	CCONJ
aji-165	323	14	remission	remission	NOUN
aji-165	323	15	phases	phase	NOUN
aji-165	323	16	,	,	PUNCT
aji-165	323	17	these	these	PRON
aji-165	323	18	are	be	AUX
aji-165	323	19	not	not	PART
aji-165	323	20	statistically	statistically	ADV
aji-165	323	21	significant	significant	ADJ
aji-165	323	22	with	with	ADP
aji-165	323	23	a	a	DET
aji-165	323	24	p	p	NOUN
aji-165	323	25	-	-	PUNCT
aji-165	323	26	value	value	NOUN
aji-165	323	27	of	of	ADP
aji-165	323	28	0.1	0.1	NUM
aji-165	323	29	for	for	ADP
aji-165	323	30	patients	patient	NOUN
aji-165	323	31	with	with	ADP
aji-165	323	32	cd	cd	PROPN
aji-165	323	33	and	and	CCONJ
aji-165	323	34	uc	uc	PROPN
aji-165	323	35	.	.	PUNCT
aji-165	324	1	furthermore	furthermore	ADV
aji-165	324	2	,	,	PUNCT
aji-165	324	3	the	the	DET
aji-165	324	4	comparison	comparison	NOUN
aji-165	324	5	between	between	ADP
aji-165	324	6	cd	cd	PROPN
aji-165	324	7	and	and	CCONJ
aji-165	324	8	uc	uc	PROPN
aji-165	324	9	during	during	ADP
aji-165	324	10	flare	flare	NOUN
aji-165	324	11	phases	phase	NOUN
aji-165	324	12	yielded	yield	VERB
aji-165	324	13	a	a	DET
aji-165	324	14	p	p	NOUN
aji-165	324	15	-	-	PUNCT
aji-165	324	16	value	value	NOUN
aji-165	324	17	of	of	ADP
aji-165	324	18	0.27	0.27	NUM
aji-165	324	19	,	,	PUNCT
aji-165	324	20	which	which	PRON
aji-165	324	21	is	be	AUX
aji-165	324	22	also	also	ADV
aji-165	324	23	not	not	PART
aji-165	324	24	significant	significant	ADJ
aji-165	324	25	.	.	PUNCT
aji-165	325	1	this	this	PRON
aji-165	325	2	supports	support	VERB
aji-165	325	3	the	the	DET
aji-165	325	4	notion	notion	NOUN
aji-165	325	5	that	that	SCONJ
aji-165	325	6	fc	fc	PROPN
aji-165	325	7	is	be	AUX
aji-165	325	8	a	a	DET
aji-165	325	9	good	good	ADJ
aji-165	325	10	biomarker	biomarker	NOUN
aji-165	325	11	for	for	ADP
aji-165	325	12	inflammation	inflammation	NOUN
aji-165	325	13	in	in	ADP
aji-165	325	14	the	the	DET
aji-165	325	15	context	context	NOUN
aji-165	325	16	of	of	ADP
aji-165	325	17	inflammatory	inflammatory	ADJ
aji-165	325	18	bowel	bowel	NOUN
aji-165	325	19	diseases	disease	NOUN
aji-165	325	20	(	(	PUNCT
aji-165	325	21	ibd	ibd	PROPN
aji-165	325	22	)	)	PUNCT
aji-165	325	23	,	,	PUNCT
aji-165	325	24	consistent	consistent	ADJ
aji-165	325	25	with	with	ADP
aji-165	325	26	previous	previous	ADJ
aji-165	325	27	studies	study	NOUN
aji-165	325	28	.	.	PUNCT
aji-165	326	1	a	a	DET
aji-165	326	2	study	study	NOUN
aji-165	326	3	conducted	conduct	VERB
aji-165	326	4	between	between	ADP
aji-165	326	5	2018	2018	NUM
aji-165	326	6	and	and	CCONJ
aji-165	326	7	2019	2019	NUM
aji-165	326	8	involving	involve	VERB
aji-165	326	9	49	49	NUM
aji-165	326	10	patients	patient	NOUN
aji-165	326	11	with	with	ADP
aji-165	326	12	cd	cd	PROPN
aji-165	326	13	and	and	CCONJ
aji-165	326	14	31	31	NUM
aji-165	326	15	healthy	healthy	ADJ
aji-165	326	16	controls	control	NOUN
aji-165	326	17	recruited	recruit	VERB
aji-165	326	18	from	from	ADP
aji-165	326	19	the	the	DET
aji-165	326	20	gastroenterology	gastroenterology	NOUN
aji-165	326	21	and	and	CCONJ
aji-165	326	22	hepatology	hepatology	NOUN
aji-165	326	23	department	department	PROPN
aji-165	326	24	at	at	ADP
aji-165	326	25	the	the	DET
aji-165	326	26	university	university	NOUN
aji-165	326	27	hospital	hospital	NOUN
aji-165	326	28	in	in	ADP
aji-165	326	29	krakow	krakow	PROPN
aji-165	326	30	,	,	PUNCT
aji-165	326	31	poland	poland	PROPN
aji-165	326	32	,	,	PUNCT
aji-165	326	33	found	find	VERB
aji-165	326	34	significantly	significantly	ADV
aji-165	326	35	higher	high	ADJ
aji-165	326	36	serum	serum	PROPN
aji-165	326	37	crp	crp	PROPN
aji-165	326	38	levels	level	NOUN
aji-165	326	39	in	in	ADP
aji-165	326	40	the	the	DET
aji-165	326	41	cd	cd	PROPN
aji-165	326	42	group	group	NOUN
aji-165	326	43	compared	compare	VERB
aji-165	326	44	to	to	ADP
aji-165	326	45	the	the	DET
aji-165	326	46	control	control	NOUN
aji-165	326	47	group	group	NOUN
aji-165	326	48	.	.	PUNCT
aji-165	327	1	additionally	additionally	ADV
aji-165	327	2	,	,	PUNCT
aji-165	327	3	in	in	ADP
aji-165	327	4	patients	patient	NOUN
aji-165	327	5	with	with	ADP
aji-165	327	6	cd	cd	PROPN
aji-165	327	7	,	,	PUNCT
aji-165	327	8	serum	serum	PROPN
aji-165	327	9	crp	crp	PROPN
aji-165	327	10	concentrations	concentration	NOUN
aji-165	327	11	were	be	AUX
aji-165	327	12	markedly	markedly	ADV
aji-165	327	13	higher	high	ADJ
aji-165	327	14	during	during	ADP
aji-165	327	15	active	active	ADJ
aji-165	327	16	disease	disease	NOUN
aji-165	327	17	than	than	ADP
aji-165	327	18	during	during	ADP
aji-165	327	19	inactive	inactive	ADJ
aji-165	327	20	disease	disease	NOUN
aji-165	327	21	(	(	PUNCT
aji-165	327	22	słowińska	słowińska	NOUN
aji-165	327	23	-	-	PUNCT
aji-165	327	24	solnica	solnica	NOUN
aji-165	327	25	et	et	PROPN
aji-165	327	26	al	al	PROPN
aji-165	327	27	.	.	PROPN
aji-165	327	28	,	,	PUNCT
aji-165	327	29	2021	2021	NUM
aji-165	327	30	)	)	PUNCT
aji-165	327	31	.	.	PUNCT
aji-165	328	1	a	a	DET
aji-165	328	2	study	study	NOUN
aji-165	328	3	conducted	conduct	VERB
aji-165	328	4	in	in	ADP
aji-165	328	5	2006	2006	NUM
aji-165	328	6	in	in	ADP
aji-165	328	7	italy	italy	PROPN
aji-165	328	8	,	,	PUNCT
aji-165	328	9	in	in	ADP
aji-165	328	10	76	76	NUM
aji-165	328	11	ibd	ibd	NOUN
aji-165	328	12	patients	patient	NOUN
aji-165	328	13	(	(	PUNCT
aji-165	328	14	29	29	NUM
aji-165	328	15	cd	cd	NOUN
aji-165	328	16	and	and	CCONJ
aji-165	328	17	47	47	NUM
aji-165	328	18	uc	uc	ADJ
aji-165	328	19	)	)	PUNCT
aji-165	328	20	fecal	fecal	ADJ
aji-165	328	21	calprotectin	calprotectin	NOUN
aji-165	328	22	has	have	AUX
aji-165	328	23	been	be	AUX
aji-165	328	24	evaluated	evaluate	VERB
aji-165	328	25	by	by	ADP
aji-165	328	26	a	a	DET
aji-165	328	27	commercial	commercial	ADJ
aji-165	328	28	elisa	elisa	PROPN
aji-165	328	29	kit	kit	PROPN
aji-165	328	30	.	.	PUNCT
aji-165	329	1	results	result	NOUN
aji-165	329	2	demonstrate	demonstrate	VERB
aji-165	329	3	that	that	SCONJ
aji-165	329	4	levels	level	NOUN
aji-165	329	5	of	of	ADP
aji-165	329	6	this	this	DET
aji-165	329	7	protein	protein	NOUN
aji-165	329	8	in	in	ADP
aji-165	329	9	the	the	DET
aji-165	329	10	stool	stool	NOUN
aji-165	329	11	are	be	AUX
aji-165	329	12	significantly	significantly	ADV
aji-165	329	13	more	more	ADV
aji-165	329	14	elevated	elevated	ADJ
aji-165	329	15	in	in	ADP
aji-165	329	16	active	active	ADJ
aji-165	329	17	cd	cd	NOUN
aji-165	329	18	and	and	CCONJ
aji-165	329	19	uc	uc	ADJ
aji-165	329	20	patients	patient	NOUN
aji-165	329	21	than	than	ADP
aji-165	329	22	in	in	ADP
aji-165	329	23	normal	normal	ADJ
aji-165	329	24	volunteers	volunteer	NOUN
aji-165	329	25	.	.	PUNCT
aji-165	330	1	moreover	moreover	ADV
aji-165	330	2	,	,	PUNCT
aji-165	330	3	in	in	ADP
aji-165	330	4	cd	cd	PROPN
aji-165	330	5	patients	patient	NOUN
aji-165	330	6	levels	level	NOUN
aji-165	330	7	of	of	ADP
aji-165	330	8	calprotectin	calprotectin	NOUN
aji-165	330	9	are	be	AUX
aji-165	330	10	higher	high	ADJ
aji-165	330	11	than	than	ADP
aji-165	330	12	in	in	ADP
aji-165	330	13	uc	uc	PROPN
aji-165	330	14	(	(	PUNCT
aji-165	330	15	amati	amati	PROPN
aji-165	330	16	et	et	PROPN
aji-165	330	17	al	al	PROPN
aji-165	330	18	.	.	PROPN
aji-165	330	19	,	,	PUNCT
aji-165	330	20	2006	2006	NUM
aji-165	330	21	)	)	PUNCT
aji-165	330	22	.	.	PUNCT
aji-165	331	1	our	our	PRON
aji-165	331	2	results	result	NOUN
aji-165	331	3	reveal	reveal	VERB
aji-165	331	4	no	no	DET
aji-165	331	5	significant	significant	ADJ
aji-165	331	6	link	link	NOUN
aji-165	331	7	between	between	ADP
aji-165	331	8	flare	flare	NOUN
aji-165	331	9	status	status	NOUN
aji-165	331	10	(	(	PUNCT
aji-165	331	11	flare	flare	NOUN
aji-165	331	12	or	or	CCONJ
aji-165	331	13	non	non	ADJ
aji-165	331	14	-	-	ADJ
aji-165	331	15	flare	flare	ADJ
aji-165	331	16	)	)	PUNCT
aji-165	331	17	and	and	CCONJ
aji-165	331	18	crp	crp	PROPN
aji-165	331	19	levels	level	NOUN
aji-165	331	20	(	(	PUNCT
aji-165	331	21	<	<	X
aji-165	331	22	6	6	NUM
aji-165	331	23	and	and	CCONJ
aji-165	331	24	≥6	≥6	NUM
aji-165	331	25	)	)	PUNCT
aji-165	331	26	(	(	PUNCT
aji-165	331	27	p	p	X
aji-165	331	28	=	=	NOUN
aji-165	331	29	0.48	0.48	NUM
aji-165	331	30	)	)	PUNCT
aji-165	331	31	.	.	PUNCT
aji-165	332	1	in	in	ADP
aji-165	332	2	cd	cd	PROPN
aji-165	332	3	patients	patient	NOUN
aji-165	332	4	,	,	PUNCT
aji-165	332	5	no	no	DET
aji-165	332	6	significant	significant	ADJ
aji-165	332	7	difference	difference	NOUN
aji-165	332	8	in	in	ADP
aji-165	332	9	crp	crp	PROPN
aji-165	332	10	was	be	AUX
aji-165	332	11	observed	observe	VERB
aji-165	332	12	between	between	ADP
aji-165	332	13	flare	flare	NOUN
aji-165	332	14	and	and	CCONJ
aji-165	332	15	remission	remission	NOUN
aji-165	332	16	phases	phase	NOUN
aji-165	332	17	(	(	PUNCT
aji-165	332	18	p	p	NOUN
aji-165	332	19	=	=	NOUN
aji-165	332	20	0.8	0.8	NUM
aji-165	332	21	)	)	PUNCT
aji-165	332	22	.	.	PUNCT
aji-165	333	1	for	for	ADP
aji-165	333	2	uc	uc	PROPN
aji-165	333	3	,	,	PUNCT
aji-165	333	4	a	a	DET
aji-165	333	5	trend	trend	NOUN
aji-165	333	6	towards	towards	ADP
aji-165	333	7	a	a	DET
aji-165	333	8	difference	difference	NOUN
aji-165	333	9	was	be	AUX
aji-165	333	10	noted	note	VERB
aji-165	333	11	,	,	PUNCT
aji-165	333	12	although	although	SCONJ
aji-165	333	13	it	it	PRON
aji-165	333	14	was	be	AUX
aji-165	333	15	not	not	PART
aji-165	333	16	statistically	statistically	ADV
aji-165	333	17	significant	significant	ADJ
aji-165	333	18	(	(	PUNCT
aji-165	333	19	p	p	X
aji-165	333	20	=	=	NOUN
aji-165	333	21	0.08	0.08	NUM
aji-165	333	22	)	)	PUNCT
aji-165	333	23	.	.	PUNCT
aji-165	334	1	differences	difference	NOUN
aji-165	334	2	in	in	ADP
aji-165	334	3	disease	disease	NOUN
aji-165	334	4	location	location	NOUN
aji-165	334	5	in	in	ADP
aji-165	334	6	cd	cd	PROPN
aji-165	334	7	may	may	AUX
aji-165	334	8	account	account	VERB
aji-165	334	9	for	for	ADP
aji-165	334	10	some	some	PRON
aji-165	334	11	of	of	ADP
aji-165	334	12	the	the	DET
aji-165	334	13	inter	inter	ADJ
aji-165	334	14	-	-	ADJ
aji-165	334	15	individual	individual	ADJ
aji-165	334	16	variation	variation	NOUN
aji-165	334	17	in	in	ADP
aji-165	334	18	fc	fc	PROPN
aji-165	334	19	.	.	PUNCT
aji-165	335	1	however	however	ADV
aji-165	335	2	,	,	PUNCT
aji-165	335	3	fc	fc	PROPN
aji-165	335	4	and	and	CCONJ
aji-165	335	5	other	other	ADJ
aji-165	335	6	stool	stool	NOUN
aji-165	335	7	biomarkers	biomarker	NOUN
aji-165	335	8	have	have	AUX
aji-165	335	9	been	be	AUX
aji-165	335	10	found	find	VERB
aji-165	335	11	to	to	PART
aji-165	335	12	have	have	VERB
aji-165	335	13	low	low	ADJ
aji-165	335	14	sensitivity	sensitivity	NOUN
aji-165	335	15	in	in	ADP
aji-165	335	16	detecting	detect	VERB
aji-165	335	17	isolated	isolate	VERB
aji-165	335	18	small	small	ADJ
aji-165	335	19	bowel	bowel	NOUN
aji-165	335	20	involvement	involvement	NOUN
aji-165	335	21	seen	see	VERB
aji-165	335	22	on	on	ADP
aji-165	335	23	wireless	wireless	ADJ
aji-165	335	24	capsule	capsule	NOUN
aji-165	335	25	endoscopy	endoscopy	NOUN
aji-165	335	26	(	(	PUNCT
aji-165	335	27	sands	sand	NOUN
aji-165	335	28	,	,	PUNCT
aji-165	335	29	2015	2015	NUM
aji-165	335	30	)	)	PUNCT
aji-165	335	31	.	.	PUNCT
aji-165	336	1	gecse	gecse	PROPN
aji-165	336	2	and	and	CCONJ
aji-165	336	3	al	al	PROPN
aji-165	336	4	.	.	PROPN
aji-165	336	5	demonstrated	demonstrate	VERB
aji-165	336	6	that	that	SCONJ
aji-165	336	7	patients	patient	NOUN
aji-165	336	8	with	with	ADP
aji-165	336	9	large	large	ADJ
aji-165	336	10	ulcerations	ulceration	NOUN
aji-165	336	11	(	(	PUNCT
aji-165	336	12	>	>	SYM
aji-165	336	13	5	5	NUM
aji-165	336	14	mm	mm	NOUN
aji-165	336	15	)	)	PUNCT
aji-165	336	16	in	in	ADP
aji-165	336	17	the	the	DET
aji-165	336	18	ileum	ileum	NOUN
aji-165	336	19	had	have	VERB
aji-165	336	20	significantly	significantly	ADV
aji-165	336	21	lower	low	ADJ
aji-165	336	22	fc	fc	PROPN
aji-165	336	23	concentrations	concentration	NOUN
aji-165	336	24	compared	compare	VERB
aji-165	336	25	to	to	ADP
aji-165	336	26	those	those	PRON
aji-165	336	27	with	with	ADP
aji-165	336	28	ileocolonic	ileocolonic	ADJ
aji-165	336	29	or	or	CCONJ
aji-165	336	30	colonic	colonic	ADJ
aji-165	336	31	disease	disease	NOUN
aji-165	336	32	(	(	PUNCT
aji-165	336	33	297	297	NUM
aji-165	336	34	vs.	vs.	ADP
aji-165	336	35	1,523	1,523	NUM
aji-165	336	36	μg	μg	PROPN
aji-165	336	37	/	/	SYM
aji-165	336	38	g	g	PROPN
aji-165	336	39	,	,	PUNCT
aji-165	336	40	p	p	X
aji-165	336	41	<	<	X
aji-165	336	42	0.0001	0.0001	NUM
aji-165	336	43	)	)	PUNCT
aji-165	336	44	.	.	PUNCT
aji-165	337	1	a	a	DET
aji-165	337	2	study	study	NOUN
aji-165	337	3	involving	involve	VERB
aji-165	337	4	120	120	NUM
aji-165	337	5	patients	patient	NOUN
aji-165	337	6	with	with	ADP
aji-165	337	7	cd	cd	PROPN
aji-165	337	8	examined	examine	VERB
aji-165	337	9	disease	disease	NOUN
aji-165	337	10	activity	activity	NOUN
aji-165	337	11	using	use	VERB
aji-165	337	12	biological	biological	ADJ
aji-165	337	13	markers	marker	NOUN
aji-165	337	14	as	as	ADV
aji-165	337	15	well	well	ADV
aji-165	337	16	as	as	ADP
aji-165	337	17	endoscopic	endoscopic	ADJ
aji-165	337	18	and	and	CCONJ
aji-165	337	19	radiographic	radiographic	ADJ
aji-165	337	20	methods	method	NOUN
aji-165	337	21	.	.	PUNCT
aji-165	338	1	fc	fc	PROPN
aji-165	338	2	concentration	concentration	NOUN
aji-165	338	3	was	be	AUX
aji-165	338	4	measured	measure	VERB
aji-165	338	5	in	in	ADP
aji-165	338	6	stool	stool	NOUN
aji-165	338	7	samples	sample	NOUN
aji-165	338	8	.	.	PUNCT
aji-165	339	1	among	among	ADP
aji-165	339	2	these	these	DET
aji-165	339	3	patients	patient	NOUN
aji-165	339	4	,	,	PUNCT
aji-165	339	5	45	45	NUM
aji-165	339	6	%	%	NOUN
aji-165	339	7	had	have	VERB
aji-165	339	8	ileocolonic	ileocolonic	ADJ
aji-165	339	9	cd	cd	NOUN
aji-165	339	10	,	,	PUNCT
aji-165	339	11	36.5	36.5	NUM
aji-165	339	12	%	%	NOUN
aji-165	339	13	had	have	VERB
aji-165	339	14	small	small	ADJ
aji-165	339	15	bowel	bowel	NOUN
aji-165	339	16	cd	cd	PROPN
aji-165	339	17	,	,	PUNCT
aji-165	339	18	and	and	CCONJ
aji-165	339	19	18.5	18.5	NUM
aji-165	339	20	%	%	NOUN
aji-165	339	21	had	have	VERB
aji-165	339	22	colonic	colonic	ADJ
aji-165	339	23	cd	cd	NOUN
aji-165	339	24	.	.	PUNCT
aji-165	340	1	in	in	ADP
aji-165	340	2	small	small	ADJ
aji-165	340	3	bowel	bowel	NOUN
aji-165	340	4	cd	cd	NOUN
aji-165	340	5	patients	patient	NOUN
aji-165	340	6	,	,	PUNCT
aji-165	340	7	fc	fc	PROPN
aji-165	340	8	was	be	AUX
aji-165	340	9	significantly	significantly	ADV
aji-165	340	10	correlated	correlate	VERB
aji-165	340	11	with	with	ADP
aji-165	340	12	crp	crp	PROPN
aji-165	340	13	(	(	PUNCT
aji-165	340	14	p	p	X
aji-165	340	15	=	=	NOUN
aji-165	340	16	0.03	0.03	NUM
aji-165	340	17	)	)	PUNCT
aji-165	340	18	,	,	PUNCT
aji-165	340	19	endoscopic	endoscopic	ADJ
aji-165	340	20	activity	activity	NOUN
aji-165	340	21	(	(	PUNCT
aji-165	340	22	p	p	X
aji-165	340	23	<	<	X
aji-165	340	24	0.0001	0.0001	NUM
aji-165	340	25	)	)	PUNCT
aji-165	340	26	,	,	PUNCT
aji-165	340	27	and	and	CCONJ
aji-165	340	28	radiographic	radiographic	ADJ
aji-165	340	29	assessment	assessment	NOUN
aji-165	340	30	(	(	PUNCT
aji-165	340	31	p	p	X
aji-165	340	32	=	=	NOUN
aji-165	340	33	0.03	0.03	NUM
aji-165	340	34	)	)	PUNCT
aji-165	340	35	.	.	PUNCT
aji-165	341	1	similarly	similarly	ADV
aji-165	341	2	,	,	PUNCT
aji-165	341	3	in	in	ADP
aji-165	341	4	colonic	colonic	ADJ
aji-165	341	5	cd	cd	NOUN
aji-165	341	6	patients	patient	NOUN
aji-165	341	7	,	,	PUNCT
aji-165	341	8	fc	fc	PROPN
aji-165	341	9	correlated	correlate	VERB
aji-165	341	10	with	with	ADP
aji-165	341	11	crp	crp	PROPN
aji-165	341	12	(	(	PUNCT
aji-165	341	13	p	p	X
aji-165	341	14	=	=	PROPN
aji-165	341	15	0.0009	0.0009	NUM
aji-165	341	16	)	)	PUNCT
aji-165	341	17	and	and	CCONJ
aji-165	341	18	endoscopic	endoscopic	ADJ
aji-165	341	19	activity	activity	NOUN
aji-165	341	20	(	(	PUNCT
aji-165	341	21	p	p	NOUN
aji-165	341	22	=	=	NOUN
aji-165	341	23	0.0002	0.0002	NUM
aji-165	341	24	)	)	PUNCT
aji-165	341	25	.	.	PUNCT
aji-165	342	1	however	however	ADV
aji-165	342	2	,	,	PUNCT
aji-165	342	3	among	among	ADP
aji-165	342	4	small	small	ADJ
aji-165	342	5	bowel	bowel	NOUN
aji-165	342	6	cd	cd	NOUN
aji-165	342	7	patients	patient	NOUN
aji-165	342	8	,	,	PUNCT
aji-165	342	9	the	the	DET
aji-165	342	10	crohn	crohn	NOUN
aji-165	342	11	's	's	PART
aji-165	342	12	disease	disease	NOUN
aji-165	342	13	activity	activity	NOUN
aji-165	342	14	index	index	NOUN
aji-165	342	15	(	(	PUNCT
aji-165	342	16	cdai	cdai	NOUN
aji-165	342	17	)	)	PUNCT
aji-165	342	18	and	and	CCONJ
aji-165	342	19	inflammatory	inflammatory	ADJ
aji-165	342	20	markers	marker	NOUN
aji-165	342	21	were	be	AUX
aji-165	342	22	not	not	PART
aji-165	342	23	correlated	correlate	VERB
aji-165	342	24	with	with	ADP
aji-165	342	25	endoscopic	endoscopic	ADJ
aji-165	342	26	and	and	CCONJ
aji-165	342	27	radiographic	radiographic	ADJ
aji-165	342	28	evaluations	evaluation	NOUN
aji-165	342	29	.	.	PUNCT
aji-165	343	1	for	for	ADP
aji-165	343	2	ileocolonic	ileocolonic	ADJ
aji-165	343	3	cd	cd	NOUN
aji-165	343	4	patients	patient	NOUN
aji-165	343	5	,	,	PUNCT
aji-165	343	6	fc	fc	PROPN
aji-165	343	7	showed	show	VERB
aji-165	343	8	a	a	DET
aji-165	343	9	significant	significant	ADJ
aji-165	343	10	correlation	correlation	NOUN
aji-165	343	11	with	with	ADP
aji-165	343	12	endoscopy	endoscopy	NOUN
aji-165	343	13	(	(	PUNCT
aji-165	343	14	p=0.006	p=0.006	NOUN
aji-165	343	15	)	)	PUNCT
aji-165	343	16	,	,	PUNCT
aji-165	343	17	radiographic	radiographic	ADJ
aji-165	343	18	assessment	assessment	NOUN
aji-165	343	19	(	(	PUNCT
aji-165	343	20	p	p	X
aji-165	343	21	=	=	NOUN
aji-165	343	22	0.04	0.04	NUM
aji-165	343	23	)	)	PUNCT
aji-165	343	24	,	,	PUNCT
aji-165	343	25	cdai	cdai	X
aji-165	343	26	(	(	PUNCT
aji-165	343	27	p	p	X
aji-165	343	28	=	=	NOUN
aji-165	343	29	0.0006	0.0006	NUM
aji-165	343	30	)	)	PUNCT
aji-165	343	31	,	,	PUNCT
aji-165	343	32	as	as	ADV
aji-165	343	33	well	well	ADV
aji-165	343	34	as	as	ADP
aji-165	343	35	most	most	ADJ
aji-165	343	36	biological	biological	ADJ
aji-165	343	37	markers	marker	NOUN
aji-165	343	38	.	.	PUNCT
aji-165	344	1	the	the	DET
aji-165	344	2	concentration	concentration	NOUN
aji-165	344	3	of	of	ADP
aji-165	344	4	fc	fc	PROPN
aji-165	344	5	reflects	reflect	VERB
aji-165	344	6	inflammatory	inflammatory	ADJ
aji-165	344	7	activity	activity	NOUN
aji-165	344	8	more	more	ADV
aji-165	344	9	accurately	accurately	ADV
aji-165	344	10	in	in	ADP
aji-165	344	11	patients	patient	NOUN
aji-165	344	12	with	with	ADP
aji-165	344	13	lesions	lesion	NOUN
aji-165	344	14	in	in	ADP
aji-165	344	15	both	both	CCONJ
aji-165	344	16	nassar	nassar	PROPN
aji-165	344	17	et	et	PROPN
aji-165	344	18	al	al	PROPN
aji-165	344	19	.	.	PROPN
aji-165	344	20	;	;	PUNCT
aji-165	345	1	asian	asian	PROPN
aji-165	345	2	j.	j.	PROPN
aji-165	345	3	immunol	immunol	PROPN
aji-165	345	4	.	.	PROPN
aji-165	345	5	,	,	PUNCT
aji-165	345	6	vol	vol	NOUN
aji-165	345	7	.	.	PROPN
aji-165	345	8	8	8	NUM
aji-165	345	9	,	,	PUNCT
aji-165	345	10	no	no	INTJ
aji-165	345	11	.	.	NOUN
aji-165	345	12	1	1	NUM
aji-165	345	13	,	,	PUNCT
aji-165	345	14	pp	pp	ADJ
aji-165	345	15	.	.	PUNCT
aji-165	346	1	104	104	NUM
aji-165	346	2	-	-	SYM
aji-165	346	3	119	119	NUM
aji-165	346	4	,	,	PUNCT
aji-165	346	5	2025	2025	NUM
aji-165	346	6	;	;	PUNCT
aji-165	346	7	article	article	NOUN
aji-165	346	8	no.aji.135189	no.aji.135189	NOUN
aji-165	346	9	115	115	NUM
aji-165	346	10	the	the	DET
aji-165	346	11	small	small	ADJ
aji-165	346	12	intestine	intestine	NOUN
aji-165	346	13	and	and	CCONJ
aji-165	346	14	colon	colon	NOUN
aji-165	346	15	compared	compare	VERB
aji-165	346	16	to	to	ADP
aji-165	346	17	those	those	PRON
aji-165	346	18	with	with	ADP
aji-165	346	19	isolated	isolated	ADJ
aji-165	346	20	small	small	ADJ
aji-165	346	21	bowel	bowel	NOUN
aji-165	346	22	disease	disease	NOUN
aji-165	346	23	(	(	PUNCT
aji-165	346	24	sands	sand	NOUN
aji-165	346	25	,	,	PUNCT
aji-165	346	26	2015	2015	NUM
aji-165	346	27	)	)	PUNCT
aji-165	346	28	.	.	PUNCT
aji-165	347	1	a	a	DET
aji-165	347	2	study	study	NOUN
aji-165	347	3	involving	involve	VERB
aji-165	347	4	273	273	NUM
aji-165	347	5	cd	cd	NOUN
aji-165	347	6	patients	patient	NOUN
aji-165	347	7	,	,	PUNCT
aji-165	347	8	including	include	VERB
aji-165	347	9	41	41	NUM
aji-165	347	10	with	with	ADP
aji-165	347	11	ileal	ileal	ADJ
aji-165	347	12	disease	disease	NOUN
aji-165	347	13	and	and	CCONJ
aji-165	347	14	189	189	NUM
aji-165	347	15	with	with	ADP
aji-165	347	16	ileocolonic	ileocolonic	ADJ
aji-165	347	17	disease	disease	NOUN
aji-165	347	18	,	,	PUNCT
aji-165	347	19	showed	show	VERB
aji-165	347	20	that	that	SCONJ
aji-165	347	21	fc	fc	PROPN
aji-165	347	22	was	be	AUX
aji-165	347	23	significantly	significantly	ADV
aji-165	347	24	correlated	correlate	VERB
aji-165	347	25	with	with	ADP
aji-165	347	26	cdai	cdai	NOUN
aji-165	347	27	;	;	PUNCT
aji-165	347	28	correlation	correlation	NOUN
aji-165	347	29	coefficients	coefficient	NOUN
aji-165	347	30	were	be	AUX
aji-165	347	31	0.711	0.711	NUM
aji-165	347	32	for	for	ADP
aji-165	347	33	ileal	ileal	ADJ
aji-165	347	34	disease	disease	NOUN
aji-165	347	35	patients	patient	NOUN
aji-165	347	36	and	and	CCONJ
aji-165	347	37	0.687	0.687	NUM
aji-165	347	38	for	for	ADP
aji-165	347	39	ileocolonic	ileocolonic	ADJ
aji-165	347	40	disease	disease	NOUN
aji-165	347	41	patients	patient	NOUN
aji-165	347	42	(	(	PUNCT
aji-165	347	43	gecse	gecse	PROPN
aji-165	347	44	et	et	PROPN
aji-165	347	45	al	al	PROPN
aji-165	347	46	.	.	PROPN
aji-165	347	47	,	,	PUNCT
aji-165	347	48	2015	2015	NUM
aji-165	347	49	)	)	PUNCT
aji-165	347	50	.	.	PUNCT
aji-165	348	1	in	in	ADP
aji-165	348	2	our	our	PRON
aji-165	348	3	study	study	NOUN
aji-165	348	4	,	,	PUNCT
aji-165	348	5	although	although	SCONJ
aji-165	348	6	there	there	PRON
aji-165	348	7	are	be	VERB
aji-165	348	8	differences	difference	NOUN
aji-165	348	9	in	in	ADP
aji-165	348	10	average	average	ADJ
aji-165	348	11	fc	fc	PROPN
aji-165	348	12	levels	level	NOUN
aji-165	348	13	based	base	VERB
aji-165	348	14	on	on	ADP
aji-165	348	15	disease	disease	NOUN
aji-165	348	16	location	location	NOUN
aji-165	348	17	(	(	PUNCT
aji-165	348	18	ileal	ileal	ADJ
aji-165	348	19	,	,	PUNCT
aji-165	348	20	ileocolonic	ileocolonic	ADJ
aji-165	348	21	,	,	PUNCT
aji-165	348	22	colonic	colonic	NOUN
aji-165	348	23	)	)	PUNCT
aji-165	348	24	,	,	PUNCT
aji-165	348	25	these	these	DET
aji-165	348	26	differences	difference	NOUN
aji-165	348	27	are	be	AUX
aji-165	348	28	not	not	PART
aji-165	348	29	statistically	statistically	ADV
aji-165	348	30	significant	significant	ADJ
aji-165	348	31	,	,	PUNCT
aji-165	348	32	possibly	possibly	ADV
aji-165	348	33	due	due	ADP
aji-165	348	34	to	to	ADP
aji-165	348	35	sample	sample	NOUN
aji-165	348	36	size	size	NOUN
aji-165	348	37	or	or	CCONJ
aji-165	348	38	individual	individual	ADJ
aji-165	348	39	variations	variation	NOUN
aji-165	348	40	.	.	PUNCT
aji-165	349	1	according	accord	VERB
aji-165	349	2	to	to	ADP
aji-165	349	3	a	a	DET
aji-165	349	4	study	study	NOUN
aji-165	349	5	including	include	VERB
aji-165	349	6	88	88	NUM
aji-165	349	7	patients	patient	NOUN
aji-165	349	8	with	with	ADP
aji-165	349	9	an	an	DET
aji-165	349	10	average	average	ADJ
aji-165	349	11	age	age	NOUN
aji-165	349	12	of	of	ADP
aji-165	349	13	34±10.8	34±10.8	PROPN
aji-165	349	14	years	year	NOUN
aji-165	349	15	,	,	PUNCT
aji-165	349	16	twelve	twelve	NUM
aji-165	349	17	(	(	PUNCT
aji-165	349	18	13.6	13.6	NUM
aji-165	349	19	%	%	NOUN
aji-165	349	20	)	)	PUNCT
aji-165	349	21	had	have	VERB
aji-165	349	22	negative	negative	ADJ
aji-165	349	23	crp	crp	NOUN
aji-165	349	24	results	result	NOUN
aji-165	349	25	.	.	PUNCT
aji-165	350	1	while	while	SCONJ
aji-165	350	2	location	location	NOUN
aji-165	350	3	did	do	AUX
aji-165	350	4	not	not	PART
aji-165	350	5	serve	serve	VERB
aji-165	350	6	as	as	ADP
aji-165	350	7	a	a	DET
aji-165	350	8	significant	significant	ADJ
aji-165	350	9	predictor	predictor	NOUN
aji-165	350	10	,	,	PUNCT
aji-165	350	11	all	all	DET
aji-165	350	12	patients	patient	NOUN
aji-165	350	13	with	with	ADP
aji-165	350	14	negative	negative	ADJ
aji-165	350	15	crp	crp	PROPN
aji-165	350	16	had	have	VERB
aji-165	350	17	ileal	ileal	ADJ
aji-165	350	18	involvement	involvement	NOUN
aji-165	350	19	(	(	PUNCT
aji-165	350	20	stawczykeder	stawczykeder	PROPN
aji-165	350	21	et	et	PROPN
aji-165	350	22	al	al	PROPN
aji-165	350	23	.	.	PROPN
aji-165	350	24	,	,	PUNCT
aji-165	350	25	2015	2015	NUM
aji-165	350	26	)	)	PUNCT
aji-165	350	27	.	.	PUNCT
aji-165	351	1	in	in	ADP
aji-165	351	2	our	our	PRON
aji-165	351	3	study	study	NOUN
aji-165	351	4	,	,	PUNCT
aji-165	351	5	results	result	NOUN
aji-165	351	6	indicate	indicate	VERB
aji-165	351	7	no	no	DET
aji-165	351	8	statistically	statistically	ADV
aji-165	351	9	significant	significant	ADJ
aji-165	351	10	difference	difference	NOUN
aji-165	351	11	between	between	ADP
aji-165	351	12	crp	crp	PROPN
aji-165	351	13	levels	level	NOUN
aji-165	351	14	(	(	PUNCT
aji-165	351	15	≥6	≥6	NUM
aji-165	351	16	or	or	CCONJ
aji-165	351	17	<	<	X
aji-165	351	18	6	6	NUM
aji-165	351	19	)	)	PUNCT
aji-165	351	20	for	for	ADP
aji-165	351	21	ileal	ileal	ADJ
aji-165	351	22	and	and	CCONJ
aji-165	351	23	ileocolonic	ileocolonic	ADJ
aji-165	351	24	locations	location	NOUN
aji-165	351	25	;	;	PUNCT
aji-165	351	26	however	however	ADV
aji-165	351	27	,	,	PUNCT
aji-165	351	28	there	there	PRON
aji-165	351	29	is	be	VERB
aji-165	351	30	a	a	DET
aji-165	351	31	suggestive	suggestive	ADJ
aji-165	351	32	trend	trend	NOUN
aji-165	351	33	for	for	ADP
aji-165	351	34	colonic	colonic	ADJ
aji-165	351	35	location	location	NOUN
aji-165	351	36	with	with	ADP
aji-165	351	37	a	a	DET
aji-165	351	38	p	p	NOUN
aji-165	351	39	-	-	PUNCT
aji-165	351	40	value	value	NOUN
aji-165	351	41	of	of	ADP
aji-165	351	42	0.06	0.06	NUM
aji-165	351	43	.	.	PUNCT
aji-165	352	1	there	there	PRON
aji-165	352	2	is	be	VERB
aji-165	352	3	an	an	DET
aji-165	352	4	emphasis	emphasis	NOUN
aji-165	352	5	on	on	ADP
aji-165	352	6	the	the	DET
aji-165	352	7	similarity	similarity	NOUN
aji-165	352	8	regarding	regard	VERB
aji-165	352	9	the	the	DET
aji-165	352	10	absence	absence	NOUN
aji-165	352	11	of	of	ADP
aji-165	352	12	significant	significant	ADJ
aji-165	352	13	predictors	predictor	NOUN
aji-165	352	14	related	relate	VERB
aji-165	352	15	to	to	ADP
aji-165	352	16	location	location	NOUN
aji-165	352	17	,	,	PUNCT
aji-165	352	18	suggesting	suggest	VERB
aji-165	352	19	that	that	SCONJ
aji-165	352	20	despite	despite	SCONJ
aji-165	352	21	variations	variation	NOUN
aji-165	352	22	across	across	ADP
aji-165	352	23	studies	study	NOUN
aji-165	352	24	,	,	PUNCT
aji-165	352	25	there	there	PRON
aji-165	352	26	is	be	VERB
aji-165	352	27	a	a	DET
aji-165	352	28	general	general	ADJ
aji-165	352	29	trend	trend	NOUN
aji-165	352	30	indicating	indicate	VERB
aji-165	352	31	that	that	SCONJ
aji-165	352	32	ileal	ileal	ADJ
aji-165	352	33	location	location	NOUN
aji-165	352	34	does	do	AUX
aji-165	352	35	not	not	PART
aji-165	352	36	appear	appear	VERB
aji-165	352	37	to	to	PART
aji-165	352	38	be	be	AUX
aji-165	352	39	strongly	strongly	ADV
aji-165	352	40	correlated	correlate	VERB
aji-165	352	41	with	with	ADP
aji-165	352	42	crp	crp	PROPN
aji-165	352	43	levels	level	NOUN
aji-165	352	44	.	.	PUNCT
aji-165	353	1	4.3	4.3	NUM
aji-165	353	2	comparison	comparison	NOUN
aji-165	353	3	between	between	ADP
aji-165	353	4	the	the	DET
aji-165	353	5	average	average	ADJ
aji-165	353	6	levels	level	NOUN
aji-165	353	7	of	of	ADP
aji-165	353	8	fc	fc	PROPN
aji-165	353	9	/	/	SYM
aji-165	353	10	crp	crp	PROPN
aji-165	353	11	in	in	ADP
aji-165	353	12	a	a	DET
aji-165	353	13	prospective	prospective	ADJ
aji-165	353	14	study	study	NOUN
aji-165	353	15	involving	involve	VERB
aji-165	353	16	patients	patient	NOUN
aji-165	353	17	recruited	recruit	VERB
aji-165	353	18	from	from	ADP
aji-165	353	19	the	the	DET
aji-165	353	20	inflammatory	inflammatory	ADJ
aji-165	353	21	bowel	bowel	NOUN
aji-165	353	22	disease	disease	NOUN
aji-165	353	23	unit	unit	NOUN
aji-165	353	24	at	at	ADP
aji-165	353	25	the	the	DET
aji-165	353	26	university	university	NOUN
aji-165	353	27	hospital	hospital	NOUN
aji-165	353	28	of	of	ADP
aji-165	353	29	saint	saint	PROPN
aji-165	353	30	etienne	etienne	PROPN
aji-165	353	31	between	between	ADP
aji-165	353	32	june	june	PROPN
aji-165	353	33	2017	2017	NUM
aji-165	353	34	and	and	CCONJ
aji-165	353	35	june	june	PROPN
aji-165	353	36	2018	2018	NUM
aji-165	353	37	,	,	PUNCT
aji-165	353	38	patients	patient	NOUN
aji-165	353	39	were	be	AUX
aji-165	353	40	followed	follow	VERB
aji-165	353	41	for	for	ADP
aji-165	353	42	12	12	NUM
aji-165	353	43	months	month	NOUN
aji-165	353	44	or	or	CCONJ
aji-165	353	45	until	until	ADP
aji-165	353	46	relapse	relapse	NOUN
aji-165	353	47	.	.	PUNCT
aji-165	354	1	the	the	DET
aji-165	354	2	measurement	measurement	NOUN
aji-165	354	3	of	of	ADP
aji-165	354	4	fc	fc	PROPN
aji-165	354	5	and	and	CCONJ
aji-165	354	6	crp	crp	PROPN
aji-165	354	7	showed	show	VERB
aji-165	354	8	that	that	SCONJ
aji-165	354	9	median	median	PROPN
aji-165	354	10	fc	fc	PROPN
aji-165	354	11	levels	level	NOUN
aji-165	354	12	progressively	progressively	ADV
aji-165	354	13	increased	increase	VERB
aji-165	354	14	in	in	ADP
aji-165	354	15	patients	patient	NOUN
aji-165	354	16	who	who	PRON
aji-165	354	17	relapsed	relapse	VERB
aji-165	354	18	during	during	ADP
aji-165	354	19	the	the	DET
aji-165	354	20	follow	follow	NOUN
aji-165	354	21	-	-	PUNCT
aji-165	354	22	up	up	NOUN
aji-165	354	23	period	period	NOUN
aji-165	354	24	,	,	PUNCT
aji-165	354	25	rising	rise	VERB
aji-165	354	26	from	from	ADP
aji-165	354	27	26	26	NUM
aji-165	354	28	µg	µg	NOUN
aji-165	354	29	/	/	SYM
aji-165	354	30	g	g	NOUN
aji-165	354	31	at	at	ADP
aji-165	354	32	baseline	baseline	NOUN
aji-165	354	33	to	to	ADP
aji-165	354	34	105	105	NUM
aji-165	354	35	µg	µg	NOUN
aji-165	354	36	/	/	SYM
aji-165	354	37	g	g	NOUN
aji-165	354	38	at	at	ADP
aji-165	354	39	three	three	NUM
aji-165	354	40	months	month	NOUN
aji-165	354	41	,	,	PUNCT
aji-165	354	42	177	177	NUM
aji-165	354	43	µg	µg	NOUN
aji-165	354	44	/	/	SYM
aji-165	354	45	g	g	NOUN
aji-165	354	46	at	at	ADP
aji-165	354	47	six	six	NUM
aji-165	354	48	months	month	NOUN
aji-165	354	49	,	,	PUNCT
aji-165	354	50	and	and	CCONJ
aji-165	354	51	292	292	NUM
aji-165	354	52	µg	µg	NOUN
aji-165	354	53	/	/	SYM
aji-165	354	54	g	g	NOUN
aji-165	354	55	at	at	ADP
aji-165	354	56	the	the	DET
aji-165	354	57	time	time	NOUN
aji-165	354	58	of	of	ADP
aji-165	354	59	relapse	relapse	NOUN
aji-165	354	60	(	(	PUNCT
aji-165	354	61	p	p	X
aji-165	354	62	=	=	NOUN
aji-165	354	63	0.049	0.049	NUM
aji-165	354	64	between	between	ADP
aji-165	354	65	baseline	baseline	NOUN
aji-165	354	66	and	and	CCONJ
aji-165	354	67	relapse	relapse	NOUN
aji-165	354	68	)	)	PUNCT
aji-165	354	69	1	1	NUM
aji-165	354	70	.	.	X
aji-165	354	71	serum	serum	PROPN
aji-165	354	72	crp	crp	PROPN
aji-165	354	73	levels	level	NOUN
aji-165	354	74	fluctuated	fluctuate	VERB
aji-165	354	75	during	during	ADP
aji-165	354	76	follow	follow	NOUN
aji-165	354	77	-	-	PUNCT
aji-165	354	78	up	up	NOUN
aji-165	354	79	,	,	PUNCT
aji-165	354	80	but	but	CCONJ
aji-165	354	81	a	a	DET
aji-165	354	82	significant	significant	ADJ
aji-165	354	83	difference	difference	NOUN
aji-165	354	84	in	in	ADP
aji-165	354	85	median	median	PROPN
aji-165	354	86	crp	crp	PROPN
aji-165	354	87	levels	level	NOUN
aji-165	354	88	was	be	AUX
aji-165	354	89	observed	observe	VERB
aji-165	354	90	between	between	ADP
aji-165	354	91	baseline	baseline	NOUN
aji-165	354	92	and	and	CCONJ
aji-165	354	93	relapse	relapse	NOUN
aji-165	354	94	(	(	PUNCT
aji-165	354	95	1.5	1.5	NUM
aji-165	354	96	mg	mg	NOUN
aji-165	354	97	/	/	SYM
aji-165	354	98	l	l	NOUN
aji-165	354	99	vs.	vs.	ADP
aji-165	354	100	3.3	3.3	NUM
aji-165	354	101	mg	mg	PROPN
aji-165	354	102	/	/	SYM
aji-165	354	103	l	l	NOUN
aji-165	354	104	,	,	PUNCT
aji-165	354	105	respectively	respectively	ADV
aji-165	354	106	;	;	PUNCT
aji-165	354	107	p	p	X
aji-165	354	108	=	=	NOUN
aji-165	354	109	0.008	0.008	NUM
aji-165	354	110	)	)	PUNCT
aji-165	354	111	.	.	PUNCT
aji-165	355	1	however	however	ADV
aji-165	355	2	,	,	PUNCT
aji-165	355	3	median	median	PROPN
aji-165	355	4	crp	crp	PROPN
aji-165	355	5	levels	level	NOUN
aji-165	355	6	remained	remain	VERB
aji-165	355	7	normal	normal	ADJ
aji-165	355	8	below	below	ADP
aji-165	355	9	5	5	NUM
aji-165	355	10	mg	mg	PROPN
aji-165	355	11	/	/	SYM
aji-165	355	12	l	l	NOUN
aji-165	355	13	(	(	PUNCT
aji-165	355	14	li	li	PROPN
aji-165	355	15	et	et	PROPN
aji-165	355	16	al	al	PROPN
aji-165	355	17	.	.	PROPN
aji-165	355	18	,	,	PUNCT
aji-165	355	19	2023	2023	NUM
aji-165	355	20	)	)	PUNCT
aji-165	355	21	.	.	PUNCT
aji-165	356	1	a	a	DET
aji-165	356	2	study	study	NOUN
aji-165	356	3	involving	involve	VERB
aji-165	356	4	twenty	twenty	NUM
aji-165	356	5	-	-	PUNCT
aji-165	356	6	six	six	NUM
aji-165	356	7	patients	patient	NOUN
aji-165	356	8	with	with	ADP
aji-165	356	9	inflammatory	inflammatory	ADJ
aji-165	356	10	bowel	bowel	NOUN
aji-165	356	11	disease	disease	NOUN
aji-165	356	12	,	,	PUNCT
aji-165	356	13	including	include	VERB
aji-165	356	14	five	five	NUM
aji-165	356	15	with	with	ADP
aji-165	356	16	crohn	crohn	PROPN
aji-165	356	17	's	's	PART
aji-165	356	18	disease	disease	NOUN
aji-165	356	19	and	and	CCONJ
aji-165	356	20	twenty	twenty	NUM
aji-165	356	21	-	-	PUNCT
aji-165	356	22	one	one	NUM
aji-165	356	23	with	with	ADP
aji-165	356	24	ulcerative	ulcerative	ADJ
aji-165	356	25	colitis	colitis	NOUN
aji-165	356	26	,	,	PUNCT
aji-165	356	27	revealed	reveal	VERB
aji-165	356	28	no	no	DET
aji-165	356	29	significant	significant	ADJ
aji-165	356	30	correlation	correlation	NOUN
aji-165	356	31	between	between	ADP
aji-165	356	32	fc	fc	PROPN
aji-165	356	33	and	and	CCONJ
aji-165	356	34	crp	crp	PROPN
aji-165	356	35	(	(	PUNCT
aji-165	356	36	r	r	NOUN
aji-165	356	37	=	=	NOUN
aji-165	356	38	0.2	0.2	NUM
aji-165	356	39	)	)	PUNCT
aji-165	356	40	(	(	PUNCT
aji-165	356	41	sousa	sousa	NOUN
aji-165	356	42	et	et	PROPN
aji-165	356	43	al	al	PROPN
aji-165	356	44	.	.	PROPN
aji-165	356	45	,	,	PUNCT
aji-165	356	46	2017	2017	NUM
aji-165	356	47	)	)	PUNCT
aji-165	356	48	.	.	PUNCT
aji-165	357	1	in	in	ADP
aji-165	357	2	another	another	DET
aji-165	357	3	observational	observational	ADJ
aji-165	357	4	prospective	prospective	ADJ
aji-165	357	5	study	study	NOUN
aji-165	357	6	of	of	ADP
aji-165	357	7	fifty	fifty	NUM
aji-165	357	8	-	-	PUNCT
aji-165	357	9	nine	nine	NUM
aji-165	357	10	patients	patient	NOUN
aji-165	357	11	with	with	ADP
aji-165	357	12	ulcerative	ulcerative	ADJ
aji-165	357	13	colitis	colitis	NOUN
aji-165	357	14	,	,	PUNCT
aji-165	357	15	eighteen	eighteen	NUM
aji-165	357	16	patients	patient	NOUN
aji-165	357	17	(	(	PUNCT
aji-165	357	18	30.5	30.5	NUM
aji-165	357	19	%	%	NOUN
aji-165	357	20	)	)	PUNCT
aji-165	357	21	exhibited	exhibit	VERB
aji-165	357	22	signs	sign	NOUN
aji-165	357	23	of	of	ADP
aji-165	357	24	active	active	ADJ
aji-165	357	25	histological	histological	ADJ
aji-165	357	26	inflammation	inflammation	NOUN
aji-165	357	27	.	.	PUNCT
aji-165	358	1	these	these	DET
aji-165	358	2	patients	patient	NOUN
aji-165	358	3	had	have	VERB
aji-165	358	4	a	a	DET
aji-165	358	5	significantly	significantly	ADV
aji-165	358	6	higher	high	ADJ
aji-165	358	7	median	median	PROPN
aji-165	358	8	fc	fc	PROPN
aji-165	358	9	level	level	NOUN
aji-165	358	10	(	(	PUNCT
aji-165	358	11	278	278	NUM
aji-165	358	12	µg	µg	NOUN
aji-165	358	13	/	/	SYM
aji-165	358	14	g	g	NOUN
aji-165	358	15	)	)	PUNCT
aji-165	358	16	,	,	PUNCT
aji-165	358	17	while	while	SCONJ
aji-165	358	18	the	the	DET
aji-165	358	19	average	average	ADJ
aji-165	358	20	crp	crp	NOUN
aji-165	358	21	level	level	NOUN
aji-165	358	22	was	be	AUX
aji-165	358	23	16	16	NUM
aji-165	358	24	mg	mg	PROPN
aji-165	358	25	/	/	SYM
aji-165	358	26	l	l	NOUN
aji-165	358	27	(	(	PUNCT
aji-165	358	28	veyrard	veyrard	PROPN
aji-165	358	29	et	et	PROPN
aji-165	358	30	al	al	PROPN
aji-165	358	31	.	.	PROPN
aji-165	358	32	,	,	PUNCT
aji-165	358	33	2022	2022	NUM
aji-165	358	34	)	)	PUNCT
aji-165	358	35	.	.	PUNCT
aji-165	359	1	a	a	DET
aji-165	359	2	study	study	NOUN
aji-165	359	3	conducted	conduct	VERB
aji-165	359	4	on	on	ADP
aji-165	359	5	273	273	NUM
aji-165	359	6	patients	patient	NOUN
aji-165	359	7	with	with	ADP
aji-165	359	8	crohn	crohn	PROPN
aji-165	359	9	's	's	PART
aji-165	359	10	disease	disease	NOUN
aji-165	359	11	at	at	ADP
aji-165	359	12	the	the	DET
aji-165	359	13	gastroenterology	gastroenterology	NOUN
aji-165	359	14	division	division	NOUN
aji-165	359	15	of	of	ADP
aji-165	359	16	tongji	tongji	PROPN
aji-165	359	17	medical	medical	PROPN
aji-165	359	18	college	college	PROPN
aji-165	359	19	in	in	ADP
aji-165	359	20	wuhan	wuhan	PROPN
aji-165	359	21	,	,	PUNCT
aji-165	359	22	china	china	PROPN
aji-165	359	23	,	,	PUNCT
aji-165	359	24	found	find	VERB
aji-165	359	25	median	median	PROPN
aji-165	359	26	fc	fc	PROPN
aji-165	359	27	levels	level	NOUN
aji-165	359	28	in	in	ADP
aji-165	359	29	patients	patient	NOUN
aji-165	359	30	in	in	ADP
aji-165	359	31	endoscopic	endoscopic	ADJ
aji-165	359	32	remission	remission	NOUN
aji-165	359	33	,	,	PUNCT
aji-165	359	34	mildly	mildly	ADV
aji-165	359	35	active	active	ADJ
aji-165	359	36	,	,	PUNCT
aji-165	359	37	and	and	CCONJ
aji-165	359	38	moderately	moderately	ADV
aji-165	359	39	to	to	PART
aji-165	359	40	severely	severely	ADV
aji-165	359	41	active	active	ADJ
aji-165	359	42	stages	stage	NOUN
aji-165	359	43	to	to	PART
aji-165	359	44	be	be	AUX
aji-165	359	45	26.94	26.94	NUM
aji-165	359	46	,	,	PUNCT
aji-165	359	47	66.77	66.77	NUM
aji-165	359	48	,	,	PUNCT
aji-165	359	49	and	and	CCONJ
aji-165	359	50	327.22	327.22	NUM
aji-165	359	51	µg	µg	NOUN
aji-165	359	52	/	/	SYM
aji-165	359	53	g	g	NOUN
aji-165	359	54	respectively	respectively	ADV
aji-165	359	55	,	,	PUNCT
aji-165	359	56	with	with	ADP
aji-165	359	57	significant	significant	ADJ
aji-165	359	58	differences	difference	NOUN
aji-165	359	59	observed	observe	VERB
aji-165	359	60	(	(	PUNCT
aji-165	359	61	p	p	X
aji-165	359	62	<	<	X
aji-165	359	63	0.001	0.001	NUM
aji-165	359	64	)	)	PUNCT
aji-165	359	65	.	.	PUNCT
aji-165	360	1	median	median	PROPN
aji-165	360	2	crp	crp	PROPN
aji-165	360	3	levels	level	NOUN
aji-165	360	4	in	in	ADP
aji-165	360	5	clinically	clinically	ADV
aji-165	360	6	remission	remission	NOUN
aji-165	360	7	,	,	PUNCT
aji-165	360	8	mildly	mildly	ADV
aji-165	360	9	active	active	ADJ
aji-165	360	10	,	,	PUNCT
aji-165	360	11	and	and	CCONJ
aji-165	360	12	moderately	moderately	ADV
aji-165	360	13	to	to	PART
aji-165	360	14	severely	severely	ADV
aji-165	360	15	active	active	ADJ
aji-165	360	16	groups	group	NOUN
aji-165	360	17	were	be	AUX
aji-165	360	18	respectively	respectively	ADV
aji-165	360	19	3.30	3.30	NUM
aji-165	360	20	,	,	PUNCT
aji-165	360	21	6.30	6.30	NUM
aji-165	360	22	,	,	PUNCT
aji-165	360	23	and	and	CCONJ
aji-165	360	24	30.30	30.30	NUM
aji-165	360	25	mg	mg	PROPN
aji-165	360	26	/	/	SYM
aji-165	360	27	l	l	NOUN
aji-165	360	28	(	(	PUNCT
aji-165	360	29	gecse	gecse	PROPN
aji-165	360	30	et	et	PROPN
aji-165	360	31	al	al	PROPN
aji-165	360	32	.	.	PROPN
aji-165	360	33	,	,	PUNCT
aji-165	360	34	2015	2015	NUM
aji-165	360	35	)	)	PUNCT
aji-165	360	36	.	.	PUNCT
aji-165	361	1	in	in	ADP
aji-165	361	2	our	our	PRON
aji-165	361	3	study	study	NOUN
aji-165	361	4	,	,	PUNCT
aji-165	361	5	the	the	DET
aji-165	361	6	average	average	ADJ
aji-165	361	7	fc	fc	NOUN
aji-165	361	8	level	level	NOUN
aji-165	361	9	in	in	ADP
aji-165	361	10	patients	patient	NOUN
aji-165	361	11	with	with	ADP
aji-165	361	12	active	active	ADJ
aji-165	361	13	crohn	crohn	NOUN
aji-165	361	14	's	's	PART
aji-165	361	15	disease	disease	NOUN
aji-165	361	16	was	be	AUX
aji-165	361	17	250	250	NUM
aji-165	361	18	µg	µg	NOUN
aji-165	361	19	/	/	SYM
aji-165	361	20	g	g	NOUN
aji-165	361	21	,	,	PUNCT
aji-165	361	22	while	while	SCONJ
aji-165	361	23	it	it	PRON
aji-165	361	24	was	be	AUX
aji-165	361	25	258	258	NUM
aji-165	361	26	µg	µg	NOUN
aji-165	361	27	/	/	SYM
aji-165	361	28	g	g	NOUN
aji-165	361	29	in	in	ADP
aji-165	361	30	remission	remission	NOUN
aji-165	361	31	.	.	PUNCT
aji-165	362	1	average	average	ADJ
aji-165	362	2	crp	crp	PROPN
aji-165	362	3	levels	level	NOUN
aji-165	362	4	were	be	AUX
aji-165	362	5	19	19	NUM
aji-165	362	6	mg	mg	NUM
aji-165	362	7	/	/	SYM
aji-165	362	8	l	l	NOUN
aji-165	362	9	during	during	ADP
aji-165	362	10	flare	flare	NOUN
aji-165	362	11	-	-	PUNCT
aji-165	362	12	ups	up	NOUN
aji-165	362	13	and	and	CCONJ
aji-165	362	14	12	12	NUM
aji-165	362	15	mg	mg	PROPN
aji-165	362	16	/	/	SYM
aji-165	362	17	l	l	NOUN
aji-165	362	18	in	in	ADP
aji-165	362	19	remission	remission	NOUN
aji-165	362	20	.	.	PUNCT
aji-165	363	1	this	this	DET
aji-165	363	2	difference	difference	NOUN
aji-165	363	3	may	may	AUX
aji-165	363	4	be	be	AUX
aji-165	363	5	attributed	attribute	VERB
aji-165	363	6	to	to	ADP
aji-165	363	7	individual	individual	ADJ
aji-165	363	8	variability	variability	NOUN
aji-165	363	9	in	in	ADP
aji-165	363	10	inflammatory	inflammatory	ADJ
aji-165	363	11	response	response	NOUN
aji-165	363	12	or	or	CCONJ
aji-165	363	13	the	the	DET
aji-165	363	14	presence	presence	NOUN
aji-165	363	15	of	of	ADP
aji-165	363	16	confounding	confound	VERB
aji-165	363	17	factors	factor	NOUN
aji-165	363	18	such	such	ADJ
aji-165	363	19	as	as	ADP
aji-165	363	20	the	the	DET
aji-165	363	21	use	use	NOUN
aji-165	363	22	of	of	ADP
aji-165	363	23	immunosuppressive	immunosuppressive	ADJ
aji-165	363	24	medications	medication	NOUN
aji-165	363	25	.	.	PUNCT
aji-165	364	1	a	a	DET
aji-165	364	2	separate	separate	ADJ
aji-165	364	3	study	study	NOUN
aji-165	364	4	on	on	ADP
aji-165	364	5	fifty	fifty	NUM
aji-165	364	6	patients	patient	NOUN
aji-165	364	7	with	with	ADP
aji-165	364	8	ulcerative	ulcerative	ADJ
aji-165	364	9	colitis	colitis	NOUN
aji-165	364	10	aged	age	VERB
aji-165	364	11	between	between	ADP
aji-165	364	12	twelve	twelve	NUM
aji-165	364	13	and	and	CCONJ
aji-165	364	14	seventy	seventy	NUM
aji-165	364	15	-	-	PUNCT
aji-165	364	16	four	four	NUM
aji-165	364	17	years	year	NOUN
aji-165	364	18	measured	measure	VERB
aji-165	364	19	fc	fc	PROPN
aji-165	364	20	and	and	CCONJ
aji-165	364	21	crp	crp	PROPN
aji-165	364	22	levels	level	NOUN
aji-165	364	23	based	base	VERB
aji-165	364	24	on	on	ADP
aji-165	364	25	disease	disease	NOUN
aji-165	364	26	severity	severity	NOUN
aji-165	364	27	.	.	PUNCT
aji-165	365	1	patients	patient	NOUN
aji-165	365	2	with	with	ADP
aji-165	365	3	mild	mild	ADJ
aji-165	365	4	activity	activity	NOUN
aji-165	365	5	had	have	VERB
aji-165	365	6	an	an	DET
aji-165	365	7	average	average	ADJ
aji-165	365	8	fc	fc	NOUN
aji-165	365	9	level	level	NOUN
aji-165	365	10	of	of	ADP
aji-165	365	11	207.46	207.46	NUM
aji-165	365	12	g	g	NOUN
aji-165	365	13	/	/	SYM
aji-165	365	14	kg	kg	PROPN
aji-165	365	15	and	and	CCONJ
aji-165	365	16	an	an	DET
aji-165	365	17	average	average	ADJ
aji-165	365	18	crp	crp	NOUN
aji-165	365	19	level	level	NOUN
aji-165	365	20	of	of	ADP
aji-165	365	21	11.37	11.37	NUM
aji-165	365	22	mg	mg	PROPN
aji-165	365	23	/	/	SYM
aji-165	365	24	l	l	NOUN
aji-165	365	25	;	;	PUNCT
aji-165	365	26	those	those	PRON
aji-165	365	27	with	with	ADP
aji-165	365	28	moderate	moderate	ADJ
aji-165	365	29	to	to	ADP
aji-165	365	30	severe	severe	ADJ
aji-165	365	31	activity	activity	NOUN
aji-165	365	32	had	have	VERB
aji-165	365	33	an	an	DET
aji-165	365	34	average	average	ADJ
aji-165	365	35	fc	fc	NOUN
aji-165	365	36	level	level	NOUN
aji-165	365	37	of	of	ADP
aji-165	365	38	729.85	729.85	NUM
aji-165	365	39	g	g	NOUN
aji-165	365	40	/	/	SYM
aji-165	365	41	kg	kg	PROPN
aji-165	365	42	and	and	CCONJ
aji-165	365	43	an	an	DET
aji-165	365	44	average	average	ADJ
aji-165	365	45	crp	crp	NOUN
aji-165	365	46	level	level	NOUN
aji-165	365	47	of	of	ADP
aji-165	365	48	29.38	29.38	NUM
aji-165	365	49	mg	mg	PROPN
aji-165	365	50	/	/	SYM
aji-165	365	51	l.	l.	PROPN
aji-165	365	52	a	a	DET
aji-165	365	53	statistically	statistically	ADV
aji-165	365	54	significant	significant	ADJ
aji-165	365	55	difference	difference	NOUN
aji-165	365	56	was	be	AUX
aji-165	365	57	observed	observe	VERB
aji-165	365	58	between	between	ADP
aji-165	365	59	the	the	DET
aji-165	365	60	two	two	NUM
aji-165	365	61	groups	group	NOUN
aji-165	365	62	for	for	ADP
aji-165	365	63	both	both	DET
aji-165	365	64	fc	fc	PROPN
aji-165	366	1	(	(	PUNCT
aji-165	366	2	p	p	NOUN
aji-165	366	3	=	=	NOUN
aji-165	366	4	0.001	0.001	NUM
aji-165	366	5	)	)	PUNCT
aji-165	366	6	and	and	CCONJ
aji-165	366	7	crp	crp	PROPN
aji-165	366	8	(	(	PUNCT
aji-165	366	9	p=	p=	NOUN
aji-165	366	10	0.0001	0.0001	NUM
aji-165	366	11	)	)	PUNCT
aji-165	366	12	,	,	PUNCT
aji-165	366	13	indicating	indicate	VERB
aji-165	366	14	that	that	SCONJ
aji-165	366	15	both	both	DET
aji-165	366	16	markers	marker	NOUN
aji-165	366	17	increase	increase	VERB
aji-165	366	18	significantly	significantly	ADV
aji-165	366	19	with	with	ADP
aji-165	366	20	the	the	DET
aji-165	366	21	severity	severity	NOUN
aji-165	366	22	of	of	ADP
aji-165	366	23	ulcerative	ulcerative	ADJ
aji-165	366	24	colitis	colitis	NOUN
aji-165	366	25	(	(	PUNCT
aji-165	366	26	kyle	kyle	PROPN
aji-165	366	27	et	et	PROPN
aji-165	366	28	al	al	PROPN
aji-165	366	29	.	.	PROPN
aji-165	366	30	,	,	PUNCT
aji-165	366	31	2021	2021	NUM
aji-165	366	32	)	)	PUNCT
aji-165	366	33	.	.	PUNCT
aji-165	367	1	rodriguez	rodriguez	NOUN
aji-165	367	2	-	-	PUNCT
aji-165	367	3	moranta	moranta	PROPN
aji-165	367	4	and	and	CCONJ
aji-165	367	5	al	al	PROPN
aji-165	367	6	.	.	PROPN
aji-165	367	7	found	find	VERB
aji-165	367	8	that	that	SCONJ
aji-165	367	9	fc	fc	PROPN
aji-165	367	10	is	be	AUX
aji-165	367	11	better	well	ADV
aji-165	367	12	correlated	correlate	VERB
aji-165	367	13	with	with	ADP
aji-165	367	14	the	the	DET
aji-165	367	15	degree	degree	NOUN
aji-165	367	16	of	of	ADP
aji-165	367	17	inflammation	inflammation	NOUN
aji-165	367	18	than	than	ADP
aji-165	367	19	other	other	ADJ
aji-165	367	20	clinical	clinical	ADJ
aji-165	367	21	indicators	indicator	NOUN
aji-165	367	22	and	and	CCONJ
aji-165	367	23	serological	serological	ADJ
aji-165	367	24	nassar	nassar	PROPN
aji-165	367	25	et	et	PROPN
aji-165	367	26	al	al	PROPN
aji-165	367	27	.	.	PROPN
aji-165	367	28	;	;	PUNCT
aji-165	368	1	asian	asian	PROPN
aji-165	368	2	j.	j.	PROPN
aji-165	368	3	immunol	immunol	PROPN
aji-165	368	4	.	.	PROPN
aji-165	368	5	,	,	PUNCT
aji-165	368	6	vol	vol	NOUN
aji-165	368	7	.	.	PROPN
aji-165	368	8	8	8	NUM
aji-165	368	9	,	,	PUNCT
aji-165	368	10	no	no	INTJ
aji-165	368	11	.	.	NOUN
aji-165	368	12	1	1	NUM
aji-165	368	13	,	,	PUNCT
aji-165	368	14	pp	pp	ADJ
aji-165	368	15	.	.	PUNCT
aji-165	369	1	104	104	NUM
aji-165	369	2	-	-	SYM
aji-165	369	3	119	119	NUM
aji-165	369	4	,	,	PUNCT
aji-165	369	5	2025	2025	NUM
aji-165	369	6	;	;	PUNCT
aji-165	369	7	article	article	NOUN
aji-165	369	8	no.aji.135189	no.aji.135189	ADJ
aji-165	369	9	116	116	NUM
aji-165	369	10	markers	marker	NOUN
aji-165	369	11	(	(	PUNCT
aji-165	369	12	guardiola	guardiola	NOUN
aji-165	369	13	et	et	PROPN
aji-165	369	14	al	al	PROPN
aji-165	369	15	.	.	PROPN
aji-165	369	16	,	,	PUNCT
aji-165	369	17	2014	2014	NUM
aji-165	369	18	)	)	PUNCT
aji-165	369	19	.	.	PUNCT
aji-165	370	1	moreover	moreover	ADV
aji-165	370	2	,	,	PUNCT
aji-165	370	3	it	it	PRON
aji-165	370	4	could	could	AUX
aji-165	370	5	also	also	ADV
aji-165	370	6	be	be	AUX
aji-165	370	7	useful	useful	ADJ
aji-165	370	8	for	for	ADP
aji-165	370	9	predicting	predict	VERB
aji-165	370	10	mucosal	mucosal	NOUN
aji-165	370	11	healing	healing	NOUN
aji-165	370	12	and	and	CCONJ
aji-165	370	13	the	the	DET
aji-165	370	14	risk	risk	NOUN
aji-165	370	15	of	of	ADP
aji-165	370	16	relapse	relapse	NOUN
aji-165	370	17	.	.	PUNCT
aji-165	371	1	according	accord	VERB
aji-165	371	2	to	to	ADP
aji-165	371	3	a	a	DET
aji-165	371	4	study	study	NOUN
aji-165	371	5	by	by	ADP
aji-165	371	6	mohamed	mohamed	PROPN
aji-165	371	7	and	and	CCONJ
aji-165	371	8	al	al	PROPN
aji-165	371	9	.	.	PROPN
aji-165	371	10	,	,	PUNCT
aji-165	371	11	there	there	PRON
aji-165	371	12	was	be	VERB
aji-165	371	13	a	a	DET
aji-165	371	14	highly	highly	ADV
aji-165	371	15	significant	significant	ADJ
aji-165	371	16	increase	increase	NOUN
aji-165	371	17	in	in	ADP
aji-165	371	18	average	average	ADJ
aji-165	371	19	fc	fc	PROPN
aji-165	371	20	values	value	NOUN
aji-165	371	21	among	among	ADP
aji-165	371	22	active	active	ADJ
aji-165	371	23	ulcerative	ulcerative	ADJ
aji-165	371	24	colitis	colitis	NOUN
aji-165	371	25	patients	patient	NOUN
aji-165	371	26	compared	compare	VERB
aji-165	371	27	to	to	ADP
aji-165	371	28	inactive	inactive	ADJ
aji-165	371	29	ones	one	NOUN
aji-165	371	30	;	;	PUNCT
aji-165	371	31	similarly	similarly	ADV
aji-165	371	32	,	,	PUNCT
aji-165	371	33	there	there	PRON
aji-165	371	34	was	be	VERB
aji-165	371	35	a	a	DET
aji-165	371	36	significant	significant	ADJ
aji-165	371	37	increase	increase	NOUN
aji-165	371	38	in	in	ADP
aji-165	371	39	average	average	ADJ
aji-165	371	40	fc	fc	PROPN
aji-165	371	41	values	value	NOUN
aji-165	371	42	among	among	ADP
aji-165	371	43	inactive	inactive	ADJ
aji-165	371	44	ulcerative	ulcerative	ADJ
aji-165	371	45	colitis	colitis	NOUN
aji-165	371	46	patients	patient	NOUN
aji-165	371	47	compared	compare	VERB
aji-165	371	48	to	to	ADP
aji-165	371	49	controls	control	NOUN
aji-165	371	50	(	(	PUNCT
aji-165	371	51	ahmed	ahmed	PROPN
aji-165	371	52	et	et	PROPN
aji-165	371	53	al	al	PROPN
aji-165	371	54	.	.	PROPN
aji-165	371	55	,	,	PUNCT
aji-165	371	56	2017	2017	NUM
aji-165	371	57	)	)	PUNCT
aji-165	371	58	.	.	PUNCT
aji-165	372	1	in	in	ADP
aji-165	372	2	our	our	PRON
aji-165	372	3	study	study	NOUN
aji-165	372	4	,	,	PUNCT
aji-165	372	5	the	the	DET
aji-165	372	6	average	average	ADJ
aji-165	372	7	fc	fc	NOUN
aji-165	372	8	level	level	NOUN
aji-165	372	9	among	among	ADP
aji-165	372	10	patients	patient	NOUN
aji-165	372	11	with	with	ADP
aji-165	372	12	active	active	ADJ
aji-165	372	13	ulcerative	ulcerative	ADJ
aji-165	372	14	colitis	colitis	NOUN
aji-165	372	15	was	be	AUX
aji-165	372	16	found	find	VERB
aji-165	372	17	to	to	PART
aji-165	372	18	be	be	AUX
aji-165	372	19	531	531	NUM
aji-165	372	20	µg	µg	ADJ
aji-165	372	21	/	/	SYM
aji-165	372	22	g	g	NOUN
aji-165	372	23	while	while	SCONJ
aji-165	372	24	it	it	PRON
aji-165	372	25	was	be	AUX
aji-165	372	26	412.6	412.6	NUM
aji-165	372	27	µg	µg	NOUN
aji-165	372	28	/	/	SYM
aji-165	372	29	g	g	NOUN
aji-165	372	30	in	in	ADP
aji-165	372	31	remission	remission	NOUN
aji-165	372	32	.	.	PUNCT
aji-165	373	1	the	the	DET
aji-165	373	2	student	student	NOUN
aji-165	373	3	's	's	PART
aji-165	373	4	t	t	PROPN
aji-165	373	5	-	-	PUNCT
aji-165	373	6	test	test	NOUN
aji-165	373	7	yielded	yield	VERB
aji-165	373	8	a	a	DET
aji-165	373	9	non	non	ADJ
aji-165	373	10	-	-	ADJ
aji-165	373	11	significant	significant	ADJ
aji-165	373	12	pvalue	pvalue	NOUN
aji-165	373	13	of	of	ADP
aji-165	373	14	0.73	0.73	NUM
aji-165	373	15	for	for	ADP
aji-165	373	16	comparing	compare	VERB
aji-165	373	17	these	these	DET
aji-165	373	18	two	two	NUM
aji-165	373	19	groups	group	NOUN
aji-165	373	20	regarding	regard	VERB
aji-165	373	21	fc	fc	PROPN
aji-165	373	22	levels	level	NOUN
aji-165	373	23	.	.	PUNCT
aji-165	374	1	average	average	ADJ
aji-165	374	2	crp	crp	PROPN
aji-165	374	3	levels	level	NOUN
aji-165	374	4	were	be	AUX
aji-165	374	5	found	find	VERB
aji-165	374	6	to	to	PART
aji-165	374	7	be	be	AUX
aji-165	374	8	17.73	17.73	NUM
aji-165	374	9	mg	mg	NUM
aji-165	374	10	/	/	SYM
aji-165	374	11	l	l	NOUN
aji-165	374	12	during	during	ADP
aji-165	374	13	flare	flare	NOUN
aji-165	374	14	-	-	PUNCT
aji-165	374	15	ups	up	NOUN
aji-165	374	16	and	and	CCONJ
aji-165	374	17	6.84	6.84	NUM
aji-165	374	18	mg	mg	PROPN
aji-165	374	19	/	/	SYM
aji-165	374	20	l	l	NOUN
aji-165	374	21	in	in	ADP
aji-165	374	22	remission	remission	NOUN
aji-165	374	23	;	;	PUNCT
aji-165	374	24	the	the	DET
aji-165	374	25	student	student	NOUN
aji-165	374	26	's	's	PART
aji-165	374	27	t	t	PROPN
aji-165	374	28	-	-	PUNCT
aji-165	374	29	test	test	NOUN
aji-165	374	30	yielded	yield	VERB
aji-165	374	31	a	a	DET
aji-165	374	32	significant	significant	ADJ
aji-165	374	33	p	p	NOUN
aji-165	374	34	-	-	PUNCT
aji-165	374	35	value	value	NOUN
aji-165	374	36	of	of	ADP
aji-165	374	37	0.03	0.03	NUM
aji-165	374	38	when	when	SCONJ
aji-165	374	39	comparing	compare	VERB
aji-165	374	40	the	the	DET
aji-165	374	41	two	two	NUM
aji-165	374	42	groups	group	NOUN
aji-165	374	43	for	for	ADP
aji-165	374	44	crp	crp	PROPN
aji-165	374	45	.	.	PUNCT
aji-165	375	1	a	a	DET
aji-165	375	2	retrospective	retrospective	ADJ
aji-165	375	3	analysis	analysis	NOUN
aji-165	375	4	of	of	ADP
aji-165	375	5	records	record	NOUN
aji-165	375	6	from	from	ADP
aji-165	375	7	inflammatory	inflammatory	ADJ
aji-165	375	8	bowel	bowel	NOUN
aji-165	375	9	disease	disease	NOUN
aji-165	375	10	patients	patient	NOUN
aji-165	375	11	followed	follow	VERB
aji-165	375	12	between	between	ADP
aji-165	375	13	january	january	PROPN
aji-165	375	14	2012	2012	NUM
aji-165	375	15	and	and	CCONJ
aji-165	375	16	october	october	PROPN
aji-165	375	17	2014	2014	NUM
aji-165	375	18	at	at	ADP
aji-165	375	19	a	a	DET
aji-165	375	20	gastroenterology	gastroenterology	NOUN
aji-165	375	21	care	care	NOUN
aji-165	375	22	center	center	NOUN
aji-165	375	23	in	in	ADP
aji-165	375	24	mumbai	mumbai	PROPN
aji-165	375	25	included	include	VERB
aji-165	375	26	sixty	sixty	NUM
aji-165	375	27	-	-	PUNCT
aji-165	375	28	three	three	NUM
aji-165	375	29	patients	patient	NOUN
aji-165	375	30	(	(	PUNCT
aji-165	375	31	32	32	NUM
aji-165	375	32	with	with	ADP
aji-165	375	33	ulcerative	ulcerative	ADJ
aji-165	375	34	colitis	colitis	NOUN
aji-165	375	35	and	and	CCONJ
aji-165	375	36	31	31	NUM
aji-165	375	37	with	with	ADP
aji-165	375	38	crohn	crohn	PROPN
aji-165	375	39	's	's	PART
aji-165	375	40	disease	disease	NOUN
aji-165	375	41	)	)	PUNCT
aji-165	375	42	.	.	PUNCT
aji-165	376	1	erythrocyte	erythrocyte	PROPN
aji-165	376	2	sedimentation	sedimentation	NOUN
aji-165	376	3	rate	rate	NOUN
aji-165	376	4	(	(	PUNCT
aji-165	376	5	esr	esr	PROPN
aji-165	376	6	)	)	PUNCT
aji-165	376	7	,	,	PUNCT
aji-165	376	8	crp	crp	PROPN
aji-165	376	9	,	,	PUNCT
aji-165	376	10	and	and	CCONJ
aji-165	376	11	fc	fc	PROPN
aji-165	376	12	were	be	AUX
aji-165	376	13	compared	compare	VERB
aji-165	376	14	against	against	ADP
aji-165	376	15	endoscopic	endoscopic	ADJ
aji-165	376	16	results	result	NOUN
aji-165	376	17	to	to	PART
aji-165	376	18	evaluate	evaluate	VERB
aji-165	376	19	inflammation	inflammation	NOUN
aji-165	376	20	.	.	PUNCT
aji-165	377	1	patients	patient	NOUN
aji-165	377	2	with	with	ADP
aji-165	377	3	ulcerative	ulcerative	ADJ
aji-165	377	4	colitis	colitis	NOUN
aji-165	377	5	exhibited	exhibit	VERB
aji-165	377	6	higher	high	ADJ
aji-165	377	7	fc	fc	PROPN
aji-165	377	8	levels	level	NOUN
aji-165	377	9	than	than	ADP
aji-165	377	10	those	those	PRON
aji-165	377	11	with	with	ADP
aji-165	377	12	ileocolic	ileocolic	PROPN
aji-165	377	13	crohn	crohn	PROPN
aji-165	377	14	's	's	PART
aji-165	377	15	disease	disease	NOUN
aji-165	377	16	(	(	PUNCT
aji-165	377	17	median	median	PROPN
aji-165	377	18	fc	fc	PROPN
aji-165	377	19	:	:	PUNCT
aji-165	377	20	1800	1800	NUM
aji-165	377	21	mg	mg	NUM
aji-165	377	22	/	/	SYM
aji-165	377	23	g	g	NOUN
aji-165	377	24	vs.	vs.	ADP
aji-165	377	25	619	619	NUM
aji-165	377	26	mg	mg	PROPN
aji-165	377	27	/	/	SYM
aji-165	377	28	g	g	NOUN
aji-165	377	29	;	;	PUNCT
aji-165	377	30	p	p	X
aji-165	377	31	=	=	NOUN
aji-165	377	32	0.04	0.04	NUM
aji-165	377	33	)	)	PUNCT
aji-165	377	34	.	.	PUNCT
aji-165	378	1	additionally	additionally	ADV
aji-165	378	2	,	,	PUNCT
aji-165	378	3	fc	fc	PROPN
aji-165	378	4	levels	level	NOUN
aji-165	378	5	were	be	AUX
aji-165	378	6	correlated	correlate	VERB
aji-165	378	7	with	with	ADP
aji-165	378	8	crp	crp	PROPN
aji-165	378	9	(	(	PUNCT
aji-165	378	10	r	r	NOUN
aji-165	378	11	=	=	SYM
aji-165	378	12	0.4	0.4	NUM
aji-165	378	13	;	;	PUNCT
aji-165	378	14	p	p	X
aji-165	378	15	<	<	X
aji-165	378	16	0.001	0.001	NUM
aji-165	378	17	)	)	PUNCT
aji-165	378	18	.	.	PUNCT
aji-165	379	1	among	among	ADP
aji-165	379	2	the	the	DET
aji-165	379	3	sixtythree	sixtythree	PROPN
aji-165	379	4	patients	patient	NOUN
aji-165	379	5	showing	show	VERB
aji-165	379	6	signs	sign	NOUN
aji-165	379	7	of	of	ADP
aji-165	379	8	inflammation	inflammation	NOUN
aji-165	379	9	upon	upon	SCONJ
aji-165	379	10	endoscopic	endoscopic	ADJ
aji-165	379	11	examination	examination	NOUN
aji-165	379	12	,	,	PUNCT
aji-165	379	13	a	a	DET
aji-165	379	14	higher	high	ADJ
aji-165	379	15	proportion	proportion	NOUN
aji-165	379	16	(	(	PUNCT
aji-165	379	17	86.9	86.9	NUM
aji-165	379	18	%	%	NOUN
aji-165	379	19	)	)	PUNCT
aji-165	379	20	had	have	VERB
aji-165	379	21	positive	positive	ADJ
aji-165	379	22	fc	fc	NOUN
aji-165	379	23	concentrations	concentration	NOUN
aji-165	379	24	compared	compare	VERB
aji-165	379	25	to	to	ADP
aji-165	379	26	those	those	PRON
aji-165	379	27	showing	show	VERB
aji-165	379	28	positive	positive	ADJ
aji-165	379	29	crp	crp	NOUN
aji-165	379	30	results	result	NOUN
aji-165	379	31	(	(	PUNCT
aji-165	379	32	65.6	65.6	NUM
aji-165	379	33	%	%	NOUN
aji-165	379	34	;	;	PUNCT
aji-165	379	35	p	p	X
aji-165	379	36	<	<	X
aji-165	379	37	0.01	0.01	NUM
aji-165	379	38	)	)	PUNCT
aji-165	379	39	(	(	PUNCT
aji-165	379	40	rodríguez	rodríguez	NOUN
aji-165	379	41	-	-	PUNCT
aji-165	379	42	moranta	moranta	NOUN
aji-165	379	43	et	et	PROPN
aji-165	379	44	al	al	PROPN
aji-165	379	45	.	.	PROPN
aji-165	379	46	,	,	PUNCT
aji-165	379	47	2013	2013	NUM
aji-165	379	48	)	)	PUNCT
aji-165	379	49	.	.	PUNCT
aji-165	380	1	in	in	ADP
aji-165	380	2	our	our	PRON
aji-165	380	3	study	study	NOUN
aji-165	380	4	,	,	PUNCT
aji-165	380	5	average	average	ADJ
aji-165	380	6	fc	fc	PROPN
aji-165	380	7	levels	level	NOUN
aji-165	380	8	were	be	AUX
aji-165	380	9	higher	high	ADJ
aji-165	380	10	in	in	ADP
aji-165	380	11	ulcerative	ulcerative	ADJ
aji-165	380	12	colitis	colitis	NOUN
aji-165	380	13	than	than	ADP
aji-165	380	14	in	in	ADP
aji-165	380	15	crohn	crohn	PROPN
aji-165	380	16	's	's	PART
aji-165	380	17	disease	disease	NOUN
aji-165	380	18	;	;	PUNCT
aji-165	380	19	however	however	ADV
aji-165	380	20	,	,	PUNCT
aji-165	380	21	these	these	DET
aji-165	380	22	results	result	NOUN
aji-165	380	23	did	do	AUX
aji-165	380	24	not	not	PART
aji-165	380	25	significantly	significantly	ADV
aji-165	380	26	distinguish	distinguish	VERB
aji-165	380	27	between	between	ADP
aji-165	380	28	ulcerative	ulcerative	ADJ
aji-165	380	29	colitis	colitis	NOUN
aji-165	380	30	and	and	CCONJ
aji-165	380	31	crohn	crohn	NOUN
aji-165	380	32	's	's	PART
aji-165	380	33	disease	disease	NOUN
aji-165	380	34	concerning	concern	VERB
aji-165	380	35	fc	fc	PROPN
aji-165	380	36	levels	level	NOUN
aji-165	380	37	.	.	PUNCT
aji-165	381	1	the	the	DET
aji-165	381	2	student	student	NOUN
aji-165	381	3	's	's	PART
aji-165	381	4	ttest	ttest	NOUN
aji-165	381	5	applied	apply	VERB
aji-165	381	6	to	to	ADP
aji-165	381	7	average	average	ADJ
aji-165	381	8	crp	crp	PROPN
aji-165	381	9	levels	level	NOUN
aji-165	381	10	yielded	yield	VERB
aji-165	381	11	a	a	DET
aji-165	381	12	pvalue	pvalue	NOUN
aji-165	381	13	of	of	ADP
aji-165	381	14	0.88	0.88	NUM
aji-165	381	15	,	,	PUNCT
aji-165	381	16	indicating	indicate	VERB
aji-165	381	17	no	no	DET
aji-165	381	18	statistically	statistically	ADV
aji-165	381	19	significant	significant	ADJ
aji-165	381	20	difference	difference	NOUN
aji-165	381	21	between	between	ADP
aji-165	381	22	the	the	DET
aji-165	381	23	average	average	ADJ
aji-165	381	24	crp	crp	PROPN
aji-165	381	25	levels	level	NOUN
aji-165	381	26	of	of	ADP
aji-165	381	27	both	both	DET
aji-165	381	28	groups	group	NOUN
aji-165	381	29	.	.	PUNCT
aji-165	382	1	finally	finally	ADV
aji-165	382	2	,	,	PUNCT
aji-165	382	3	the	the	DET
aji-165	382	4	correlation	correlation	NOUN
aji-165	382	5	between	between	ADP
aji-165	382	6	crp	crp	PROPN
aji-165	382	7	and	and	CCONJ
aji-165	382	8	fc	fc	PROPN
aji-165	382	9	was	be	AUX
aji-165	382	10	weakly	weakly	ADV
aji-165	382	11	positive	positive	ADJ
aji-165	382	12	(	(	PUNCT
aji-165	382	13	r	r	NOUN
aji-165	382	14	=	=	SYM
aji-165	382	15	0.12	0.12	NUM
aji-165	382	16	;	;	PUNCT
aji-165	382	17	p	p	X
aji-165	382	18	=	=	NOUN
aji-165	382	19	0.48	0.48	NUM
aji-165	382	20	)	)	PUNCT
aji-165	382	21	.	.	PUNCT
aji-165	383	1	previous	previous	ADJ
aji-165	383	2	studies	study	NOUN
aji-165	383	3	have	have	AUX
aji-165	383	4	shown	show	VERB
aji-165	383	5	that	that	SCONJ
aji-165	383	6	both	both	CCONJ
aji-165	383	7	fc	fc	PROPN
aji-165	383	8	and	and	CCONJ
aji-165	383	9	crp	crp	PROPN
aji-165	383	10	significantly	significantly	ADV
aji-165	383	11	increase	increase	VERB
aji-165	383	12	in	in	ADP
aji-165	383	13	correlation	correlation	NOUN
aji-165	383	14	with	with	ADP
aji-165	383	15	inflammation	inflammation	ADJ
aji-165	383	16	severity	severity	NOUN
aji-165	383	17	;	;	PUNCT
aji-165	383	18	however	however	ADV
aji-165	383	19	,	,	PUNCT
aji-165	383	20	our	our	PRON
aji-165	383	21	analysis	analysis	NOUN
aji-165	383	22	reveals	reveal	VERB
aji-165	383	23	a	a	DET
aji-165	383	24	weak	weak	ADJ
aji-165	383	25	and	and	CCONJ
aji-165	383	26	non	non	ADJ
aji-165	383	27	-	-	ADJ
aji-165	383	28	significant	significant	ADJ
aji-165	383	29	correlation	correlation	NOUN
aji-165	383	30	within	within	ADP
aji-165	383	31	our	our	PRON
aji-165	383	32	cohort	cohort	NOUN
aji-165	383	33	(	(	PUNCT
aji-165	383	34	r	r	NOUN
aji-165	383	35	=	=	NOUN
aji-165	383	36	0.12	0.12	NUM
aji-165	383	37	;	;	PUNCT
aji-165	383	38	p	p	X
aji-165	383	39	=	=	NOUN
aji-165	383	40	0.48	0.48	NUM
aji-165	383	41	)	)	PUNCT
aji-165	383	42	.	.	PUNCT
aji-165	384	1	this	this	PRON
aji-165	384	2	suggests	suggest	VERB
aji-165	384	3	that	that	SCONJ
aji-165	384	4	within	within	ADP
aji-165	384	5	our	our	PRON
aji-165	384	6	cohort	cohort	NOUN
aji-165	384	7	,	,	PUNCT
aji-165	384	8	crp	crp	PROPN
aji-165	384	9	and	and	CCONJ
aji-165	384	10	fc	fc	PROPN
aji-165	384	11	do	do	AUX
aji-165	384	12	not	not	PART
aji-165	384	13	act	act	VERB
aji-165	384	14	together	together	ADV
aji-165	384	15	to	to	PART
aji-165	384	16	reflect	reflect	VERB
aji-165	384	17	inflammation	inflammation	NOUN
aji-165	384	18	effectively	effectively	ADV
aji-165	384	19	(	(	PUNCT
aji-165	384	20	badawy	badawy	PROPN
aji-165	384	21	et	et	PROPN
aji-165	384	22	al	al	PROPN
aji-165	384	23	.	.	PROPN
aji-165	384	24	,	,	PUNCT
aji-165	384	25	2014;samant	2014;samant	PROPN
aji-165	384	26	et	et	NOUN
aji-165	384	27	al	al	PROPN
aji-165	384	28	.	.	PROPN
aji-165	384	29	,	,	PUNCT
aji-165	384	30	2015	2015	NUM
aji-165	384	31	)	)	PUNCT
aji-165	384	32	.	.	PUNCT
aji-165	385	1	5	5	X
aji-165	385	2	.	.	X
aji-165	385	3	conclusion	conclusion	NOUN
aji-165	385	4	and	and	CCONJ
aji-165	385	5	perspectives	perspective	NOUN
aji-165	385	6	our	our	PRON
aji-165	385	7	study	study	NOUN
aji-165	385	8	has	have	AUX
aji-165	385	9	provided	provide	VERB
aji-165	385	10	a	a	DET
aji-165	385	11	clearer	clear	ADJ
aji-165	385	12	definition	definition	NOUN
aji-165	385	13	of	of	ADP
aji-165	385	14	the	the	DET
aji-165	385	15	clinical	clinical	ADJ
aji-165	385	16	and	and	CCONJ
aji-165	385	17	epidemiological	epidemiological	ADJ
aji-165	385	18	profile	profile	NOUN
aji-165	385	19	of	of	ADP
aji-165	385	20	inflammatory	inflammatory	ADJ
aji-165	385	21	bowel	bowel	NOUN
aji-165	385	22	diseases	disease	NOUN
aji-165	385	23	(	(	PUNCT
aji-165	385	24	ibd	ibd	NOUN
aji-165	385	25	)	)	PUNCT
aji-165	385	26	in	in	ADP
aji-165	385	27	adults	adult	NOUN
aji-165	385	28	,	,	PUNCT
aji-165	385	29	highlighting	highlight	VERB
aji-165	385	30	the	the	DET
aji-165	385	31	distinctive	distinctive	ADJ
aji-165	385	32	characteristics	characteristic	NOUN
aji-165	385	33	of	of	ADP
aji-165	385	34	crohn	crohn	PROPN
aji-165	385	35	's	's	PART
aji-165	385	36	disease	disease	NOUN
aji-165	385	37	(	(	PUNCT
aji-165	385	38	cd	cd	PROPN
aji-165	385	39	)	)	PUNCT
aji-165	385	40	and	and	CCONJ
aji-165	385	41	ulcerative	ulcerative	ADJ
aji-165	385	42	colitis	colitis	NOUN
aji-165	385	43	(	(	PUNCT
aji-165	385	44	uc	uc	PROPN
aji-165	385	45	)	)	PUNCT
aji-165	385	46	.	.	PUNCT
aji-165	386	1	the	the	DET
aji-165	386	2	results	result	NOUN
aji-165	386	3	indicate	indicate	VERB
aji-165	386	4	a	a	DET
aji-165	386	5	higher	high	ADJ
aji-165	386	6	prevalence	prevalence	NOUN
aji-165	386	7	of	of	ADP
aji-165	386	8	ibd	ibd	NOUN
aji-165	386	9	among	among	ADP
aji-165	386	10	adult	adult	NOUN
aji-165	386	11	women	woman	NOUN
aji-165	386	12	.	.	PUNCT
aji-165	387	1	in	in	ADP
aji-165	387	2	terms	term	NOUN
aji-165	387	3	of	of	ADP
aji-165	387	4	biomarkers	biomarker	NOUN
aji-165	387	5	,	,	PUNCT
aji-165	387	6	creactive	creactive	ADJ
aji-165	387	7	protein	protein	NOUN
aji-165	387	8	(	(	PUNCT
aji-165	387	9	crp	crp	NOUN
aji-165	387	10	)	)	PUNCT
aji-165	387	11	and	and	CCONJ
aji-165	387	12	final	final	ADJ
aji-165	387	13	concentration	concentration	NOUN
aji-165	387	14	(	(	PUNCT
aji-165	387	15	fc	fc	INTJ
aji-165	387	16	)	)	PUNCT
aji-165	387	17	have	have	AUX
aji-165	387	18	proven	prove	VERB
aji-165	387	19	relevant	relevant	ADJ
aji-165	387	20	for	for	ADP
aji-165	387	21	monitoring	monitor	VERB
aji-165	387	22	intestinal	intestinal	ADJ
aji-165	387	23	inflammation	inflammation	NOUN
aji-165	387	24	,	,	PUNCT
aji-165	387	25	with	with	ADP
aji-165	387	26	significantly	significantly	ADV
aji-165	387	27	elevated	elevate	VERB
aji-165	387	28	levels	level	NOUN
aji-165	387	29	of	of	ADP
aji-165	387	30	fc	fc	PROPN
aji-165	387	31	during	during	ADP
aji-165	387	32	flare	flare	NOUN
aji-165	387	33	-	-	PUNCT
aji-165	387	34	ups	up	NOUN
aji-165	387	35	,	,	PUNCT
aji-165	387	36	confirming	confirm	VERB
aji-165	387	37	its	its	PRON
aji-165	387	38	utility	utility	NOUN
aji-165	387	39	as	as	ADP
aji-165	387	40	an	an	DET
aji-165	387	41	inflammation	inflammation	ADJ
aji-165	387	42	indicator	indicator	NOUN
aji-165	387	43	.	.	PUNCT
aji-165	388	1	however	however	ADV
aji-165	388	2	,	,	PUNCT
aji-165	388	3	the	the	DET
aji-165	388	4	absence	absence	NOUN
aji-165	388	5	of	of	ADP
aji-165	388	6	a	a	DET
aji-165	388	7	significant	significant	ADJ
aji-165	388	8	correlation	correlation	NOUN
aji-165	388	9	between	between	ADP
aji-165	388	10	fc	fc	PROPN
aji-165	388	11	and	and	CCONJ
aji-165	388	12	crp	crp	PROPN
aji-165	388	13	during	during	ADP
aji-165	388	14	flare	flare	NOUN
aji-165	388	15	-	-	PUNCT
aji-165	388	16	ups	up	NOUN
aji-165	388	17	suggests	suggest	VERB
aji-165	388	18	that	that	SCONJ
aji-165	388	19	these	these	DET
aji-165	388	20	biomarkers	biomarker	NOUN
aji-165	388	21	reflect	reflect	VERB
aji-165	388	22	distinct	distinct	ADJ
aji-165	388	23	aspects	aspect	NOUN
aji-165	388	24	of	of	ADP
aji-165	388	25	inflammation	inflammation	NOUN
aji-165	388	26	.	.	PUNCT
aji-165	389	1	an	an	DET
aji-165	389	2	integrated	integrated	ADJ
aji-165	389	3	assessment	assessment	NOUN
aji-165	389	4	,	,	PUNCT
aji-165	389	5	combining	combine	VERB
aji-165	389	6	these	these	DET
aji-165	389	7	biomarkers	biomarker	NOUN
aji-165	389	8	with	with	ADP
aji-165	389	9	clinical	clinical	ADJ
aji-165	389	10	scores	score	NOUN
aji-165	389	11	and	and	CCONJ
aji-165	389	12	imaging	imaging	NOUN
aji-165	389	13	,	,	PUNCT
aji-165	389	14	remains	remain	VERB
aji-165	389	15	essential	essential	ADJ
aji-165	389	16	for	for	ADP
aji-165	389	17	optimal	optimal	ADJ
aji-165	389	18	monitoring	monitoring	NOUN
aji-165	389	19	.	.	PUNCT
aji-165	390	1	in	in	ADP
aji-165	390	2	conclusion	conclusion	NOUN
aji-165	390	3	,	,	PUNCT
aji-165	390	4	this	this	DET
aji-165	390	5	study	study	NOUN
aji-165	390	6	highlights	highlight	VERB
aji-165	390	7	clinical	clinical	ADJ
aji-165	390	8	and	and	CCONJ
aji-165	390	9	biological	biological	ADJ
aji-165	390	10	differences	difference	NOUN
aji-165	390	11	based	base	VERB
aji-165	390	12	on	on	ADP
aji-165	390	13	the	the	DET
aji-165	390	14	type	type	NOUN
aji-165	390	15	of	of	ADP
aji-165	390	16	ibd	ibd	NOUN
aji-165	390	17	,	,	PUNCT
aji-165	390	18	the	the	DET
aji-165	390	19	location	location	NOUN
aji-165	390	20	of	of	ADP
aji-165	390	21	lesions	lesion	NOUN
aji-165	390	22	(	(	PUNCT
aji-165	390	23	ileal	ileal	NOUN
aji-165	390	24	,	,	PUNCT
aji-165	390	25	ileocolic	ileocolic	ADJ
aji-165	390	26	,	,	PUNCT
aji-165	390	27	or	or	CCONJ
aji-165	390	28	colonic	colonic	NOUN
aji-165	390	29	)	)	PUNCT
aji-165	390	30	,	,	PUNCT
aji-165	390	31	and	and	CCONJ
aji-165	390	32	the	the	DET
aji-165	390	33	nature	nature	NOUN
aji-165	390	34	of	of	ADP
aji-165	390	35	complications	complication	NOUN
aji-165	390	36	,	,	PUNCT
aji-165	390	37	emphasizing	emphasize	VERB
aji-165	390	38	the	the	DET
aji-165	390	39	importance	importance	NOUN
aji-165	390	40	of	of	ADP
aji-165	390	41	a	a	DET
aji-165	390	42	personalized	personalized	ADJ
aji-165	390	43	approach	approach	NOUN
aji-165	390	44	to	to	ADP
aji-165	390	45	managing	manage	VERB
aji-165	390	46	ibd	ibd	NOUN
aji-165	390	47	that	that	PRON
aji-165	390	48	incorporates	incorporate	VERB
aji-165	390	49	specific	specific	ADJ
aji-165	390	50	biomarkers	biomarker	NOUN
aji-165	390	51	(	(	PUNCT
aji-165	390	52	crp	crp	PROPN
aji-165	390	53	,	,	PUNCT
aji-165	390	54	fc	fc	PROPN
aji-165	390	55	)	)	PUNCT
aji-165	390	56	and	and	CCONJ
aji-165	390	57	patient	patient	ADJ
aji-165	390	58	profiles	profile	NOUN
aji-165	390	59	.	.	PUNCT
aji-165	391	1	larger	large	ADJ
aji-165	391	2	comparative	comparative	ADJ
aji-165	391	3	studies	study	NOUN
aji-165	391	4	exploring	explore	VERB
aji-165	391	5	genetic	genetic	ADJ
aji-165	391	6	and	and	CCONJ
aji-165	391	7	environmental	environmental	ADJ
aji-165	391	8	factors	factor	NOUN
aji-165	391	9	are	be	AUX
aji-165	391	10	necessary	necessary	ADJ
aji-165	391	11	to	to	PART
aji-165	391	12	refine	refine	VERB
aji-165	391	13	diagnostic	diagnostic	ADJ
aji-165	391	14	tools	tool	NOUN
aji-165	391	15	and	and	CCONJ
aji-165	391	16	further	further	ADJ
aji-165	391	17	tailor	tailor	NOUN
aji-165	391	18	treatments	treatment	NOUN
aji-165	391	19	.	.	PUNCT
aji-165	392	1	additional	additional	ADJ
aji-165	392	2	research	research	NOUN
aji-165	392	3	will	will	AUX
aji-165	392	4	help	help	VERB
aji-165	392	5	validate	validate	VERB
aji-165	392	6	these	these	DET
aji-165	392	7	findings	finding	NOUN
aji-165	392	8	and	and	CCONJ
aji-165	392	9	optimize	optimize	VERB
aji-165	392	10	clinical	clinical	ADJ
aji-165	392	11	follow	follow	NOUN
aji-165	392	12	-	-	PUNCT
aji-165	392	13	up	up	ADP
aji-165	392	14	protocols	protocol	NOUN
aji-165	392	15	for	for	ADP
aji-165	392	16	more	more	ADV
aji-165	392	17	precise	precise	ADJ
aji-165	392	18	and	and	CCONJ
aji-165	392	19	tailored	tailored	ADJ
aji-165	392	20	care	care	NOUN
aji-165	392	21	.	.	PUNCT
aji-165	393	1	disclaimer	disclaimer	NOUN
aji-165	393	2	(	(	PUNCT
aji-165	393	3	artificial	artificial	ADJ
aji-165	393	4	intelligence	intelligence	NOUN
aji-165	393	5	)	)	PUNCT
aji-165	393	6	author(s	author(s	NOUN
aji-165	393	7	)	)	PUNCT
aji-165	393	8	hereby	hereby	ADV
aji-165	393	9	declare	declare	VERB
aji-165	393	10	that	that	SCONJ
aji-165	393	11	no	no	DET
aji-165	393	12	generative	generative	NOUN
aji-165	393	13	ai	ai	VERB
aji-165	393	14	technologies	technology	NOUN
aji-165	393	15	such	such	ADJ
aji-165	393	16	as	as	ADP
aji-165	393	17	large	large	ADJ
aji-165	393	18	language	language	NOUN
aji-165	393	19	models	model	NOUN
aji-165	393	20	(	(	PUNCT
aji-165	393	21	chatgpt	chatgpt	NOUN
aji-165	393	22	,	,	PUNCT
aji-165	393	23	copilot	copilot	NOUN
aji-165	393	24	,	,	PUNCT
aji-165	393	25	etc	etc	X
aji-165	393	26	)	)	PUNCT
aji-165	393	27	and	and	CCONJ
aji-165	393	28	text	text	NOUN
aji-165	393	29	-	-	PUNCT
aji-165	393	30	to	to	ADP
aji-165	393	31	-	-	PUNCT
aji-165	393	32	image	image	NOUN
aji-165	393	33	generators	generator	NOUN
aji-165	393	34	have	have	AUX
aji-165	393	35	been	be	AUX
aji-165	393	36	used	use	VERB
aji-165	393	37	during	during	ADP
aji-165	393	38	writing	writing	NOUN
aji-165	393	39	or	or	CCONJ
aji-165	393	40	editing	editing	NOUN
aji-165	393	41	of	of	ADP
aji-165	393	42	this	this	DET
aji-165	393	43	manuscript	manuscript	NOUN
aji-165	393	44	.	.	PUNCT
aji-165	394	1	consent	consent	NOUN
aji-165	394	2	and	and	CCONJ
aji-165	394	3	ethical	ethical	ADJ
aji-165	394	4	approval	approval	NOUN
aji-165	394	5	informed	inform	VERB
aji-165	394	6	consent	consent	NOUN
aji-165	394	7	was	be	AUX
aji-165	394	8	obtained	obtain	VERB
aji-165	394	9	from	from	ADP
aji-165	394	10	all	all	DET
aji-165	394	11	participants	participant	NOUN
aji-165	394	12	after	after	SCONJ
aji-165	394	13	they	they	PRON
aji-165	394	14	were	be	AUX
aji-165	394	15	fully	fully	ADV
aji-165	394	16	informed	inform	VERB
aji-165	394	17	about	about	ADP
aji-165	394	18	nassar	nassar	PROPN
aji-165	394	19	et	et	PROPN
aji-165	394	20	al	al	PROPN
aji-165	394	21	.	.	PROPN
aji-165	394	22	;	;	PUNCT
aji-165	395	1	asian	asian	PROPN
aji-165	395	2	j.	j.	PROPN
aji-165	395	3	immunol	immunol	PROPN
aji-165	395	4	.	.	PROPN
aji-165	395	5	,	,	PUNCT
aji-165	395	6	vol	vol	NOUN
aji-165	395	7	.	.	PROPN
aji-165	395	8	8	8	NUM
aji-165	395	9	,	,	PUNCT
aji-165	395	10	no	no	INTJ
aji-165	395	11	.	.	NOUN
aji-165	395	12	1	1	NUM
aji-165	395	13	,	,	PUNCT
aji-165	395	14	pp	pp	ADJ
aji-165	395	15	.	.	PUNCT
aji-165	396	1	104	104	NUM
aji-165	396	2	-	-	SYM
aji-165	396	3	119	119	NUM
aji-165	396	4	,	,	PUNCT
aji-165	396	5	2025	2025	NUM
aji-165	396	6	;	;	PUNCT
aji-165	396	7	article	article	NOUN
aji-165	396	8	no.aji.135189	no.aji.135189	VERB
aji-165	396	9	117	117	NUM
aji-165	397	1	the	the	DET
aji-165	397	2	study	study	NOUN
aji-165	397	3	’s	’s	PART
aji-165	397	4	objectives	objective	NOUN
aji-165	397	5	,	,	PUNCT
aji-165	397	6	procedures	procedure	NOUN
aji-165	397	7	,	,	PUNCT
aji-165	397	8	and	and	CCONJ
aji-165	397	9	measures	measure	NOUN
aji-165	397	10	to	to	PART
aji-165	397	11	ensure	ensure	VERB
aji-165	397	12	confidentiality	confidentiality	NOUN
aji-165	397	13	and	and	CCONJ
aji-165	397	14	data	datum	NOUN
aji-165	397	15	protection	protection	NOUN
aji-165	397	16	.	.	PUNCT
aji-165	398	1	the	the	DET
aji-165	398	2	study	study	NOUN
aji-165	398	3	protocol	protocol	NOUN
aji-165	398	4	was	be	AUX
aji-165	398	5	conducted	conduct	VERB
aji-165	398	6	in	in	ADP
aji-165	398	7	accordance	accordance	NOUN
aji-165	398	8	with	with	ADP
aji-165	398	9	ethical	ethical	ADJ
aji-165	398	10	standards	standard	NOUN
aji-165	398	11	.	.	PUNCT
aji-165	399	1	acknowledgements	acknowledgement	NOUN
aji-165	399	2	the	the	DET
aji-165	399	3	authors	author	NOUN
aji-165	399	4	are	be	AUX
aji-165	399	5	grateful	grateful	ADJ
aji-165	399	6	to	to	ADP
aji-165	399	7	all	all	DET
aji-165	399	8	the	the	DET
aji-165	399	9	subjects	subject	NOUN
aji-165	399	10	who	who	PRON
aji-165	399	11	helped	help	VERB
aji-165	399	12	finalize	finalize	VERB
aji-165	399	13	the	the	DET
aji-165	399	14	study	study	NOUN
aji-165	399	15	.	.	PUNCT
aji-165	400	1	competing	compete	VERB
aji-165	400	2	interests	interest	NOUN
aji-165	400	3	authors	author	NOUN
aji-165	400	4	have	have	AUX
aji-165	400	5	declared	declare	VERB
aji-165	400	6	that	that	SCONJ
aji-165	400	7	no	no	DET
aji-165	400	8	competing	compete	VERB
aji-165	400	9	interests	interest	NOUN
aji-165	400	10	exist	exist	VERB
aji-165	400	11	.	.	PUNCT
aji-165	401	1	references	reference	NOUN
aji-165	401	2	ahmed	ahmed	PROPN
aji-165	401	3	,	,	PUNCT
aji-165	401	4	r.	r.	PROPN
aji-165	401	5	,	,	PUNCT
aji-165	401	6	el	el	PROPN
aji-165	401	7	-	-	PUNCT
aji-165	401	8	atreb	atreb	PROPN
aji-165	401	9	,	,	PUNCT
aji-165	401	10	k.	k.	PROPN
aji-165	401	11	a.	a.	PROPN
aji-165	401	12	,	,	PUNCT
aji-165	401	13	hassan	hassan	PROPN
aji-165	401	14	,	,	PUNCT
aji-165	401	15	a.	a.	NOUN
aji-165	401	16	,	,	PUNCT
aji-165	401	17	haydara	haydara	NOUN
aji-165	401	18	,	,	PUNCT
aji-165	401	19	t.	t.	NOUN
aji-165	401	20	,	,	PUNCT
aji-165	401	21	abo	abo	NOUN
aji-165	401	22	-	-	PUNCT
aji-165	401	23	amer	amer	NOUN
aji-165	401	24	,	,	PUNCT
aji-165	401	25	y.	y.	PROPN
aji-165	401	26	,	,	PUNCT
aji-165	401	27	&	&	CCONJ
aji-165	401	28	abd	abd	PROPN
aji-165	401	29	-	-	PROPN
aji-165	401	30	elsalam	elsalam	PROPN
aji-165	401	31	,	,	PUNCT
aji-165	401	32	s.	s.	PROPN
aji-165	401	33	(	(	PUNCT
aji-165	401	34	2017	2017	NUM
aji-165	401	35	)	)	PUNCT
aji-165	401	36	.	.	PUNCT
aji-165	402	1	fecal	fecal	ADJ
aji-165	402	2	calprotectin	calprotectin	NOUN
aji-165	402	3	and	and	CCONJ
aji-165	402	4	crp	crp	NOUN
aji-165	402	5	as	as	ADP
aji-165	402	6	biochemical	biochemical	ADJ
aji-165	402	7	markers	marker	NOUN
aji-165	402	8	in	in	ADP
aji-165	402	9	predicting	predict	VERB
aji-165	402	10	inflammatory	inflammatory	ADJ
aji-165	402	11	bowel	bowel	NOUN
aji-165	402	12	disease	disease	NOUN
aji-165	402	13	activity	activity	NOUN
aji-165	402	14	in	in	ADP
aji-165	402	15	patients	patient	NOUN
aji-165	402	16	with	with	ADP
aji-165	402	17	ulcerative	ulcerative	ADJ
aji-165	402	18	colitis	colitis	NOUN
aji-165	402	19	.	.	PUNCT
aji-165	403	1	int	int	PROPN
aji-165	403	2	j	j	PROPN
aji-165	403	3	med	med	PROPN
aji-165	403	4	res	re	NOUN
aji-165	403	5	,	,	PUNCT
aji-165	403	6	38(1	38(1	NUM
aji-165	403	7	)	)	PUNCT
aji-165	403	8	,	,	PUNCT
aji-165	403	9	10	10	NUM
aji-165	403	10	-	-	SYM
aji-165	403	11	5	5	NUM
aji-165	403	12	.	.	PUNCT
aji-165	403	13	amati	amati	PROPN
aji-165	403	14	,	,	PUNCT
aji-165	403	15	l.	l.	PROPN
aji-165	403	16	,	,	PUNCT
aji-165	403	17	passeri	passeri	PROPN
aji-165	403	18	,	,	PUNCT
aji-165	403	19	m.	m.	PROPN
aji-165	403	20	e.	e.	PROPN
aji-165	403	21	,	,	PUNCT
aji-165	403	22	selicato	selicato	PROPN
aji-165	403	23	,	,	PUNCT
aji-165	403	24	f.	f.	PROPN
aji-165	403	25	,	,	PUNCT
aji-165	403	26	mastronardi	mastronardi	PROPN
aji-165	403	27	,	,	PUNCT
aji-165	403	28	m.	m.	NOUN
aji-165	403	29	l.	l.	PROPN
aji-165	403	30	,	,	PUNCT
aji-165	403	31	penna	penna	PROPN
aji-165	403	32	,	,	PUNCT
aji-165	403	33	a.	a.	PROPN
aji-165	403	34	,	,	PUNCT
aji-165	403	35	jirillo	jirillo	PROPN
aji-165	403	36	,	,	PUNCT
aji-165	403	37	e.	e.	PROPN
aji-165	403	38	,	,	PUNCT
aji-165	403	39	&	&	CCONJ
aji-165	403	40	covelli	covelli	PROPN
aji-165	403	41	,	,	PUNCT
aji-165	403	42	v.	v.	PROPN
aji-165	403	43	(	(	PUNCT
aji-165	403	44	2006	2006	NUM
aji-165	403	45	)	)	PUNCT
aji-165	403	46	.	.	PUNCT
aji-165	404	1	new	new	ADJ
aji-165	404	2	insights	insight	NOUN
aji-165	404	3	into	into	ADP
aji-165	404	4	the	the	DET
aji-165	404	5	biological	biological	ADJ
aji-165	404	6	and	and	CCONJ
aji-165	404	7	clinical	clinical	ADJ
aji-165	404	8	significance	significance	NOUN
aji-165	404	9	of	of	ADP
aji-165	404	10	fecal	fecal	ADJ
aji-165	404	11	calprotectin	calprotectin	NOUN
aji-165	404	12	in	in	ADP
aji-165	404	13	inflammatory	inflammatory	ADJ
aji-165	404	14	bowel	bowel	NOUN
aji-165	404	15	disease	disease	NOUN
aji-165	404	16	.	.	PUNCT
aji-165	405	1	immunopharmacology	immunopharmacology	NOUN
aji-165	405	2	and	and	CCONJ
aji-165	405	3	immunotoxicology	immunotoxicology	NOUN
aji-165	405	4	,	,	PUNCT
aji-165	405	5	28(4	28(4	NUM
aji-165	405	6	)	)	PUNCT
aji-165	405	7	,	,	PUNCT
aji-165	405	8	665	665	NUM
aji-165	405	9	-	-	SYM
aji-165	405	10	681	681	NUM
aji-165	405	11	.	.	PUNCT
aji-165	406	1	available	available	ADJ
aji-165	406	2	:	:	PUNCT
aji-165	406	3	https://www.tandfonline.com	https://www.tandfonline.com	X
aji-165	406	4	/	/	SYM
aji-165	406	5	doi/	doi/	PROPN
aji-165	406	6	abs/10.1080/08923970601067326	abs/10.1080/08923970601067326	PROPN
aji-165	406	7	anindita	anindita	PROPN
aji-165	406	8	,	,	PUNCT
aji-165	406	9	b.	b.	PROPN
aji-165	406	10	,	,	PUNCT
aji-165	406	11	sugihartono	sugihartono	PROPN
aji-165	406	12	,	,	PUNCT
aji-165	406	13	t.	t.	PROPN
aji-165	406	14	,	,	PUNCT
aji-165	406	15	miftahussurur	miftahussurur	PROPN
aji-165	406	16	,	,	PUNCT
aji-165	406	17	m.	m.	NOUN
aji-165	406	18	,	,	PUNCT
aji-165	406	19	maimunah	maimunah	PROPN
aji-165	406	20	,	,	PUNCT
aji-165	406	21	u.	u.	PROPN
aji-165	406	22	,	,	PUNCT
aji-165	406	23	nusi	nusi	PROPN
aji-165	406	24	,	,	PUNCT
aji-165	406	25	i.	i.	PROPN
aji-165	406	26	a.	a.	PROPN
aji-165	406	27	,	,	PUNCT
aji-165	406	28	setiawan	setiawan	PROPN
aji-165	406	29	,	,	PUNCT
aji-165	406	30	p.	p.	PROPN
aji-165	406	31	b.	b.	PROPN
aji-165	406	32	,	,	PUNCT
aji-165	406	33	et	et	PROPN
aji-165	406	34	al	al	PROPN
aji-165	406	35	.	.	PROPN
aji-165	407	1	(	(	PUNCT
aji-165	407	2	2023	2023	NUM
aji-165	407	3	)	)	PUNCT
aji-165	407	4	.	.	PUNCT
aji-165	408	1	high	high	ADJ
aji-165	408	2	levels	level	NOUN
aji-165	408	3	of	of	ADP
aji-165	408	4	fecal	fecal	ADJ
aji-165	408	5	calprotectin	calprotectin	NOUN
aji-165	408	6	and	and	CCONJ
aji-165	408	7	c	c	NOUN
aji-165	408	8	-	-	PUNCT
aji-165	408	9	reactive	reactive	ADJ
aji-165	408	10	protein	protein	NOUN
aji-165	408	11	in	in	ADP
aji-165	408	12	patients	patient	NOUN
aji-165	408	13	with	with	ADP
aji-165	408	14	colitis	colitis	NOUN
aji-165	408	15	.	.	PUNCT
aji-165	409	1	j	j	PROPN
aji-165	409	2	med	med	PROPN
aji-165	409	3	life	life	NOUN
aji-165	409	4	,	,	PUNCT
aji-165	409	5	16(1	16(1	NUM
aji-165	409	6	)	)	PUNCT
aji-165	409	7	,	,	PUNCT
aji-165	409	8	48	48	NUM
aji-165	409	9	–	–	SYM
aji-165	409	10	51	51	NUM
aji-165	409	11	.	.	PUNCT
aji-165	409	12	badawy	badawy	PROPN
aji-165	409	13	,	,	PUNCT
aji-165	409	14	a.	a.	NOUN
aji-165	409	15	m.	m.	NOUN
aji-165	409	16	,	,	PUNCT
aji-165	409	17	nouh	nouh	NOUN
aji-165	409	18	,	,	PUNCT
aji-165	409	19	m.	m.	NOUN
aji-165	409	20	a.	a.	PROPN
aji-165	409	21	,	,	PUNCT
aji-165	409	22	ali	ali	PROPN
aji-165	409	23	,	,	PUNCT
aji-165	409	24	a.	a.	PROPN
aji-165	409	25	e.	e.	PROPN
aji-165	409	26	,	,	PUNCT
aji-165	409	27	el	el	PROPN
aji-165	409	28	halim	halim	PROPN
aji-165	409	29	,	,	PUNCT
aji-165	409	30	e.	e.	PROPN
aji-165	409	31	m.	m.	PROPN
aji-165	409	32	,	,	PUNCT
aji-165	409	33	mohamed	mohamed	PROPN
aji-165	409	34	,	,	PUNCT
aji-165	409	35	h.	h.	PROPN
aji-165	409	36	i.	i.	PROPN
aji-165	409	37	,	,	PUNCT
aji-165	409	38	&	&	CCONJ
aji-165	409	39	el	el	PROPN
aji-165	409	40	ghany	ghany	PROPN
aji-165	409	41	,	,	PUNCT
aji-165	409	42	a.	a.	NOUN
aji-165	409	43	m.	m.	NOUN
aji-165	409	44	(	(	PUNCT
aji-165	409	45	2014	2014	NUM
aji-165	409	46	)	)	PUNCT
aji-165	409	47	.	.	PUNCT
aji-165	410	1	calprotectin	calprotectin	NOUN
aji-165	410	2	as	as	ADP
aji-165	410	3	a	a	DET
aji-165	410	4	fecal	fecal	ADJ
aji-165	410	5	marker	marker	NOUN
aji-165	410	6	for	for	ADP
aji-165	410	7	diagnosis	diagnosis	NOUN
aji-165	410	8	and	and	CCONJ
aji-165	410	9	follow	follow	VERB
aji-165	410	10	-	-	PUNCT
aji-165	410	11	up	up	NOUN
aji-165	410	12	in	in	ADP
aji-165	410	13	patients	patient	NOUN
aji-165	410	14	with	with	ADP
aji-165	410	15	ulcerative	ulcerative	ADJ
aji-165	410	16	colitis	colitis	NOUN
aji-165	410	17	.	.	PUNCT
aji-165	411	1	menoufia	menoufia	PROPN
aji-165	411	2	med	med	PROPN
aji-165	411	3	j	j	PROPN
aji-165	411	4	,	,	PUNCT
aji-165	411	5	27(1	27(1	NUM
aji-165	411	6	)	)	PUNCT
aji-165	411	7	,	,	PUNCT
aji-165	411	8	35	35	NUM
aji-165	411	9	.	.	PUNCT
aji-165	412	1	benchimol	benchimol	PROPN
aji-165	412	2	,	,	PUNCT
aji-165	412	3	e.	e.	PROPN
aji-165	412	4	i.	i.	PROPN
aji-165	412	5	,	,	PUNCT
aji-165	412	6	kaplan	kaplan	PROPN
aji-165	412	7	,	,	PUNCT
aji-165	412	8	g.	g.	PROPN
aji-165	412	9	g.	g.	PROPN
aji-165	412	10	,	,	PUNCT
aji-165	412	11	otley	otley	PROPN
aji-165	412	12	,	,	PUNCT
aji-165	412	13	a.	a.	PROPN
aji-165	412	14	r.	r.	PROPN
aji-165	412	15	,	,	PUNCT
aji-165	412	16	nguyen	nguyen	PROPN
aji-165	412	17	,	,	PUNCT
aji-165	412	18	g.	g.	PROPN
aji-165	412	19	c.	c.	PROPN
aji-165	412	20	,	,	PUNCT
aji-165	412	21	underwood	underwood	PROPN
aji-165	412	22	,	,	PUNCT
aji-165	412	23	f.	f.	PROPN
aji-165	412	24	e.	e.	PROPN
aji-165	412	25	,	,	PUNCT
aji-165	412	26	guttmann	guttmann	PROPN
aji-165	412	27	,	,	PUNCT
aji-165	412	28	a.	a.	PROPN
aji-165	412	29	,	,	PUNCT
aji-165	412	30	et	et	PROPN
aji-165	412	31	al	al	PROPN
aji-165	412	32	.	.	PUNCT
aji-165	413	1	(	(	PUNCT
aji-165	413	2	2017	2017	NUM
aji-165	413	3	)	)	PUNCT
aji-165	413	4	.	.	PUNCT
aji-165	414	1	rural	rural	ADJ
aji-165	414	2	and	and	CCONJ
aji-165	414	3	urban	urban	ADJ
aji-165	414	4	residence	residence	NOUN
aji-165	414	5	during	during	ADP
aji-165	414	6	early	early	ADJ
aji-165	414	7	life	life	NOUN
aji-165	414	8	is	be	AUX
aji-165	414	9	associated	associate	VERB
aji-165	414	10	with	with	ADP
aji-165	414	11	risk	risk	NOUN
aji-165	414	12	of	of	ADP
aji-165	414	13	inflammatory	inflammatory	ADJ
aji-165	414	14	bowel	bowel	NOUN
aji-165	414	15	disease	disease	NOUN
aji-165	414	16	:	:	PUNCT
aji-165	414	17	a	a	DET
aji-165	414	18	population	population	NOUN
aji-165	414	19	-	-	PUNCT
aji-165	414	20	based	base	VERB
aji-165	414	21	inception	inception	NOUN
aji-165	414	22	and	and	CCONJ
aji-165	414	23	birth	birth	NOUN
aji-165	414	24	cohort	cohort	NOUN
aji-165	414	25	study	study	NOUN
aji-165	414	26	.	.	PUNCT
aji-165	415	1	am	be	AUX
aji-165	415	2	j	j	PROPN
aji-165	415	3	gastroenterol	gastroenterol	NOUN
aji-165	415	4	,	,	PUNCT
aji-165	415	5	112(9	112(9	NUM
aji-165	415	6	)	)	PUNCT
aji-165	415	7	,	,	PUNCT
aji-165	415	8	1412–1422	1412–1422	NUM
aji-165	415	9	.	.	PUNCT
aji-165	416	1	cosnes	cosnes	PROPN
aji-165	416	2	,	,	PUNCT
aji-165	416	3	j.	j.	PROPN
aji-165	416	4	,	,	PUNCT
aji-165	416	5	gower	gower	PROPN
aji-165	416	6	-	-	PUNCT
aji-165	416	7	rousseau	rousseau	PROPN
aji-165	416	8	,	,	PUNCT
aji-165	416	9	c.	c.	PROPN
aji-165	416	10	,	,	PUNCT
aji-165	416	11	seksik	seksik	NOUN
aji-165	416	12	,	,	PUNCT
aji-165	416	13	p.	p.	PROPN
aji-165	416	14	,	,	PUNCT
aji-165	416	15	&	&	CCONJ
aji-165	416	16	cortot	cortot	PROPN
aji-165	416	17	,	,	PUNCT
aji-165	416	18	a.	a.	NOUN
aji-165	416	19	(	(	PUNCT
aji-165	416	20	2011	2011	NUM
aji-165	416	21	)	)	PUNCT
aji-165	416	22	.	.	PUNCT
aji-165	417	1	epidemiology	epidemiology	NOUN
aji-165	417	2	and	and	CCONJ
aji-165	417	3	natural	natural	ADJ
aji-165	417	4	history	history	NOUN
aji-165	417	5	of	of	ADP
aji-165	417	6	inflammatory	inflammatory	ADJ
aji-165	417	7	bowel	bowel	NOUN
aji-165	417	8	diseases	disease	NOUN
aji-165	417	9	.	.	PUNCT
aji-165	418	1	gastroenterology	gastroenterology	NOUN
aji-165	418	2	,	,	PUNCT
aji-165	418	3	140(6	140(6	NUM
aji-165	418	4	)	)	PUNCT
aji-165	418	5	,	,	PUNCT
aji-165	418	6	1785	1785	NUM
aji-165	418	7	–	–	PUNCT
aji-165	418	8	1794	1794	NUM
aji-165	418	9	.	.	PUNCT
aji-165	419	1	d’amico	d’amico	PROPN
aji-165	419	2	,	,	PUNCT
aji-165	419	3	f.	f.	PROPN
aji-165	419	4	,	,	PUNCT
aji-165	419	5	rubin	rubin	PROPN
aji-165	419	6	,	,	PUNCT
aji-165	419	7	d.	d.	PROPN
aji-165	419	8	t.	t.	PROPN
aji-165	419	9	,	,	PUNCT
aji-165	419	10	kotze	kotze	PROPN
aji-165	419	11	,	,	PUNCT
aji-165	419	12	p.	p.	NOUN
aji-165	419	13	g.	g.	PROPN
aji-165	419	14	,	,	PUNCT
aji-165	419	15	magro	magro	PROPN
aji-165	419	16	,	,	PUNCT
aji-165	419	17	f.	f.	PROPN
aji-165	419	18	,	,	PUNCT
aji-165	419	19	siegmund	siegmund	PROPN
aji-165	419	20	,	,	PUNCT
aji-165	419	21	b.	b.	PROPN
aji-165	419	22	,	,	PUNCT
aji-165	419	23	kobayashi	kobayashi	PROPN
aji-165	419	24	,	,	PUNCT
aji-165	419	25	t.	t.	PROPN
aji-165	419	26	,	,	PUNCT
aji-165	419	27	et	et	PROPN
aji-165	419	28	al	al	PROPN
aji-165	419	29	.	.	PROPN
aji-165	419	30	(	(	PUNCT
aji-165	419	31	2021	2021	NUM
aji-165	419	32	,	,	PUNCT
aji-165	419	33	may	may	AUX
aji-165	419	34	)	)	PUNCT
aji-165	419	35	.	.	PUNCT
aji-165	420	1	international	international	ADJ
aji-165	420	2	consensus	consensus	NOUN
aji-165	420	3	on	on	ADP
aji-165	420	4	methodological	methodological	ADJ
aji-165	420	5	issues	issue	NOUN
aji-165	420	6	in	in	ADP
aji-165	420	7	standardization	standardization	NOUN
aji-165	420	8	of	of	ADP
aji-165	420	9	fecal	fecal	ADJ
aji-165	420	10	calprotectin	calprotectin	NOUN
aji-165	420	11	measurement	measurement	NOUN
aji-165	420	12	in	in	ADP
aji-165	420	13	inflammatory	inflammatory	ADJ
aji-165	420	14	bowel	bowel	NOUN
aji-165	420	15	diseases	disease	NOUN
aji-165	420	16	.	.	PUNCT
aji-165	421	1	united	united	PROPN
aji-165	421	2	european	european	PROPN
aji-165	421	3	gastroenterol	gastroenterol	PROPN
aji-165	421	4	j	j	PROPN
aji-165	421	5	,	,	PUNCT
aji-165	421	6	9(4	9(4	PROPN
aji-165	421	7	)	)	PUNCT
aji-165	421	8	,	,	PUNCT
aji-165	421	9	451–460	451–460	NUM
aji-165	421	10	.	.	PUNCT
aji-165	422	1	gao	gao	PROPN
aji-165	422	2	,	,	PUNCT
aji-165	422	3	y.	y.	PROPN
aji-165	422	4	,	,	PUNCT
aji-165	422	5	khan	khan	PROPN
aji-165	422	6	,	,	PUNCT
aji-165	422	7	s.	s.	PROPN
aji-165	422	8	,	,	PUNCT
aji-165	422	9	akerman	akerman	NOUN
aji-165	422	10	,	,	PUNCT
aji-165	422	11	m.	m.	NOUN
aji-165	422	12	,	,	PUNCT
aji-165	422	13	&	&	CCONJ
aji-165	422	14	sultan	sultan	PROPN
aji-165	422	15	,	,	PUNCT
aji-165	422	16	k.	k.	PROPN
aji-165	422	17	(	(	PUNCT
aji-165	422	18	2017	2017	NUM
aji-165	422	19	)	)	PUNCT
aji-165	422	20	.	.	PUNCT
aji-165	423	1	analysis	analysis	NOUN
aji-165	423	2	of	of	ADP
aji-165	423	3	the	the	DET
aji-165	423	4	clinical	clinical	ADJ
aji-165	423	5	indications	indication	NOUN
aji-165	423	6	for	for	ADP
aji-165	423	7	opiate	opiate	ADJ
aji-165	423	8	use	use	NOUN
aji-165	423	9	in	in	ADP
aji-165	423	10	inflammatory	inflammatory	ADJ
aji-165	423	11	bowel	bowel	NOUN
aji-165	423	12	disease	disease	NOUN
aji-165	423	13	.	.	PUNCT
aji-165	424	1	intestinal	intestinal	ADJ
aji-165	424	2	research	research	NOUN
aji-165	424	3	,	,	PUNCT
aji-165	424	4	15(1	15(1	NUM
aji-165	424	5	)	)	PUNCT
aji-165	424	6	,	,	PUNCT
aji-165	424	7	83	83	NUM
aji-165	424	8	-	-	SYM
aji-165	424	9	89	89	NUM
aji-165	424	10	.	.	PUNCT
aji-165	425	1	available	available	ADJ
aji-165	425	2	:	:	PUNCT
aji-165	425	3	https://pmc.ncbi.nlm.nih.gov	https://pmc.ncbi.nlm.nih.gov	ADJ
aji-165	425	4	/	/	SYM
aji-165	425	5	articl	articl	NOUN
aji-165	425	6	es	es	PROPN
aji-165	425	7	/	/	SYM
aji-165	425	8	pmc5323312/	pmc5323312/	NOUN
aji-165	425	9	gecse	gecse	PROPN
aji-165	425	10	,	,	PUNCT
aji-165	425	11	k.	k.	PROPN
aji-165	425	12	b.	b.	PROPN
aji-165	425	13	,	,	PUNCT
aji-165	425	14	brandse	brandse	PROPN
aji-165	425	15	,	,	PUNCT
aji-165	425	16	j.	j.	PROPN
aji-165	425	17	f.	f.	PROPN
aji-165	425	18	,	,	PUNCT
aji-165	425	19	van	van	PROPN
aji-165	425	20	wilpe	wilpe	PROPN
aji-165	425	21	,	,	PUNCT
aji-165	425	22	s.	s.	PROPN
aji-165	425	23	,	,	PUNCT
aji-165	425	24	löwenberg	löwenberg	PROPN
aji-165	425	25	,	,	PUNCT
aji-165	425	26	m.	m.	NOUN
aji-165	425	27	,	,	PUNCT
aji-165	425	28	ponsioen	ponsioen	PROPN
aji-165	425	29	,	,	PUNCT
aji-165	425	30	c.	c.	PROPN
aji-165	425	31	,	,	PUNCT
aji-165	425	32	van	van	PROPN
aji-165	425	33	den	den	PROPN
aji-165	425	34	brink	brink	PROPN
aji-165	425	35	,	,	PUNCT
aji-165	425	36	g.	g.	PROPN
aji-165	425	37	,	,	PUNCT
aji-165	425	38	et	et	PROPN
aji-165	425	39	al	al	PROPN
aji-165	425	40	.	.	PUNCT
aji-165	425	41	(	(	PUNCT
aji-165	425	42	2015	2015	NUM
aji-165	425	43	)	)	PUNCT
aji-165	425	44	.	.	PUNCT
aji-165	426	1	impact	impact	NOUN
aji-165	426	2	of	of	ADP
aji-165	426	3	disease	disease	NOUN
aji-165	426	4	location	location	NOUN
aji-165	426	5	on	on	ADP
aji-165	426	6	fecal	fecal	ADJ
aji-165	426	7	calprotectin	calprotectin	NOUN
aji-165	426	8	levels	level	NOUN
aji-165	426	9	in	in	ADP
aji-165	426	10	crohn	crohn	PROPN
aji-165	426	11	’s	’s	PART
aji-165	426	12	disease	disease	NOUN
aji-165	426	13	.	.	PUNCT
aji-165	427	1	scand	scand	PROPN
aji-165	427	2	j	j	PROPN
aji-165	427	3	gastroenterol	gastroenterol	PROPN
aji-165	427	4	,	,	PUNCT
aji-165	427	5	50(7	50(7	NUM
aji-165	427	6	)	)	PUNCT
aji-165	427	7	,	,	PUNCT
aji-165	427	8	841–847	841–847	PROPN
aji-165	427	9	.	.	PUNCT
aji-165	428	1	guardiola	guardiola	PROPN
aji-165	428	2	,	,	PUNCT
aji-165	428	3	j.	j.	PROPN
aji-165	428	4	,	,	PUNCT
aji-165	428	5	lobatón	lobatón	PROPN
aji-165	428	6	,	,	PUNCT
aji-165	428	7	t.	t.	PROPN
aji-165	428	8	,	,	PUNCT
aji-165	428	9	rodríguez	rodríguez	NOUN
aji-165	428	10	-	-	PUNCT
aji-165	428	11	alonso	alonso	PROPN
aji-165	428	12	,	,	PUNCT
aji-165	428	13	l.	l.	PROPN
aji-165	428	14	,	,	PUNCT
aji-165	428	15	ruiz	ruiz	NOUN
aji-165	428	16	-	-	PUNCT
aji-165	428	17	cerulla	cerulla	NOUN
aji-165	428	18	,	,	PUNCT
aji-165	428	19	a.	a.	NOUN
aji-165	428	20	,	,	PUNCT
aji-165	428	21	arajol	arajol	NOUN
aji-165	428	22	,	,	PUNCT
aji-165	428	23	c.	c.	NOUN
aji-165	428	24	,	,	PUNCT
aji-165	428	25	loayza	loayza	NOUN
aji-165	428	26	,	,	PUNCT
aji-165	428	27	c.	c.	PROPN
aji-165	428	28	,	,	PUNCT
aji-165	428	29	et	et	PROPN
aji-165	428	30	al	al	PROPN
aji-165	428	31	.	.	PUNCT
aji-165	428	32	(	(	PUNCT
aji-165	428	33	2014	2014	NUM
aji-165	428	34	)	)	PUNCT
aji-165	428	35	.	.	PUNCT
aji-165	429	1	fecal	fecal	ADJ
aji-165	429	2	level	level	NOUN
aji-165	429	3	of	of	ADP
aji-165	429	4	calprotectin	calprotectin	NOUN
aji-165	429	5	identifies	identify	VERB
aji-165	429	6	histologic	histologic	ADJ
aji-165	429	7	inflammation	inflammation	NOUN
aji-165	429	8	in	in	ADP
aji-165	429	9	patients	patient	NOUN
aji-165	429	10	with	with	ADP
aji-165	429	11	ulcerative	ulcerative	ADJ
aji-165	429	12	colitis	colitis	NOUN
aji-165	429	13	in	in	ADP
aji-165	429	14	clinical	clinical	ADJ
aji-165	429	15	and	and	CCONJ
aji-165	429	16	endoscopic	endoscopic	ADJ
aji-165	429	17	remission	remission	NOUN
aji-165	429	18	.	.	PUNCT
aji-165	430	1	clin	clin	PROPN
aji-165	430	2	gastroenterol	gastroenterol	PROPN
aji-165	430	3	hepatol	hepatol	ADJ
aji-165	430	4	,	,	PUNCT
aji-165	430	5	12(11	12(11	NUM
aji-165	430	6	)	)	PUNCT
aji-165	430	7	,	,	PUNCT
aji-165	430	8	1865–1870	1865–1870	NUM
aji-165	430	9	.	.	PUNCT
aji-165	431	1	immunoclinical	immunoclinical	ADJ
aji-165	431	2	profile	profile	NOUN
aji-165	431	3	of	of	ADP
aji-165	431	4	inflammatory	inflammatory	ADJ
aji-165	431	5	bowel	bowel	NOUN
aji-165	431	6	diseases	disease	NOUN
aji-165	431	7	(	(	PUNCT
aji-165	431	8	ibd	ibd	PROPN
aji-165	431	9	)	)	PUNCT
aji-165	431	10	.	.	PUNCT
aji-165	432	1	jm	jm	PROPN
aji-165	432	2	,	,	PUNCT
aji-165	432	3	h.	h.	PROPN
aji-165	432	4	,	,	PUNCT
aji-165	432	5	m	m	VERB
aji-165	432	6	i	i	PRON
aji-165	432	7	,	,	PUNCT
aji-165	432	8	mm	mm	PROPN
aji-165	432	9	,	,	PUNCT
aji-165	432	10	b.	b.	PROPN
aji-165	432	11	w.	w.	PROPN
aji-165	432	12	,	,	PUNCT
aji-165	432	13	n	n	CCONJ
aji-165	432	14	,	,	PUNCT
aji-165	432	15	m.	m.	NOUN
aji-165	432	16	,	,	PUNCT
aji-165	432	17	r	r	NOUN
aji-165	432	18	,	,	PUNCT
aji-165	432	19	g.	g.	PROPN
aji-165	432	20	,	,	PUNCT
aji-165	432	21	x	x	PROPN
aji-165	432	22	,	,	PUNCT
aji-165	432	23	c.	c.	PROPN
aji-165	432	24	,	,	PUNCT
aji-165	432	25	et	et	PROPN
aji-165	432	26	al	al	PROPN
aji-165	432	27	.	.	PUNCT
aji-165	432	28	(	(	PUNCT
aji-165	432	29	2018	2018	NUM
aji-165	432	30	)	)	PUNCT
aji-165	432	31	.	.	PUNCT
aji-165	433	1	inflammatory	inflammatory	ADJ
aji-165	433	2	bowel	bowel	NOUN
aji-165	433	3	disease	disease	NOUN
aji-165	433	4	in	in	ADP
aji-165	433	5	patients	patient	NOUN
aji-165	433	6	over	over	ADP
aji-165	433	7	the	the	DET
aji-165	433	8	age	age	NOUN
aji-165	433	9	of	of	ADP
aji-165	433	10	70	70	NUM
aji-165	433	11	years	year	NOUN
aji-165	433	12	:	:	PUNCT
aji-165	433	13	does	do	AUX
aji-165	433	14	the	the	DET
aji-165	433	15	disease	disease	NOUN
aji-165	433	16	duration	duration	NOUN
aji-165	433	17	influence	influence	NOUN
aji-165	433	18	its	its	PRON
aji-165	433	19	behavior	behavior	NOUN
aji-165	433	20	?	?	PUNCT
aji-165	434	1	scand	scand	PROPN
aji-165	434	2	j	j	PROPN
aji-165	434	3	gastroenterol	gastroenterol	PROPN
aji-165	434	4	,	,	PUNCT
aji-165	434	5	53(9	53(9	NOUN
aji-165	434	6	)	)	PUNCT
aji-165	434	7	.	.	PUNCT
aji-165	435	1	available	available	ADJ
aji-165	435	2	:	:	PUNCT
aji-165	435	3	https://pubmed.ncbi.nlm.nih.gov/	https://pubmed.ncbi.nlm.nih.gov/	PROPN
aji-165	435	4	30189153/	30189153/	NUM
aji-165	435	5	kostev	kostev	NOUN
aji-165	435	6	,	,	PUNCT
aji-165	435	7	k.	k.	PROPN
aji-165	435	8	,	,	PUNCT
aji-165	435	9	konrad	konrad	PROPN
aji-165	435	10	,	,	PUNCT
aji-165	435	11	m.	m.	NOUN
aji-165	435	12	,	,	PUNCT
aji-165	435	13	&	&	CCONJ
aji-165	435	14	jacob	jacob	PROPN
aji-165	435	15	,	,	PUNCT
aji-165	435	16	l.	l.	PROPN
aji-165	435	17	(	(	PUNCT
aji-165	435	18	2018	2018	NUM
aji-165	435	19	)	)	PUNCT
aji-165	435	20	.	.	PUNCT
aji-165	436	1	time	time	NOUN
aji-165	436	2	between	between	ADP
aji-165	436	3	suspected	suspect	VERB
aji-165	436	4	and	and	CCONJ
aji-165	436	5	confirmed	confirm	VERB
aji-165	436	6	diagnoses	diagnosis	NOUN
aji-165	436	7	of	of	ADP
aji-165	436	8	crohn	crohn	PROPN
aji-165	436	9	’s	’s	PART
aji-165	436	10	disease	disease	NOUN
aji-165	436	11	and	and	CCONJ
aji-165	436	12	ulcerative	ulcerative	ADJ
aji-165	436	13	colitis	colitis	NOUN
aji-165	436	14	in	in	ADP
aji-165	436	15	patients	patient	NOUN
aji-165	436	16	followed	follow	VERB
aji-165	436	17	in	in	ADP
aji-165	436	18	gastroenterological	gastroenterological	ADJ
aji-165	436	19	practices	practice	NOUN
aji-165	436	20	in	in	ADP
aji-165	436	21	germany	germany	PROPN
aji-165	436	22	.	.	PUNCT
aji-165	437	1	int	int	PROPN
aji-165	437	2	j	j	PROPN
aji-165	437	3	colorectal	colorectal	PROPN
aji-165	437	4	dis	dis	PROPN
aji-165	437	5	,	,	PUNCT
aji-165	437	6	33(7	33(7	NUM
aji-165	437	7	)	)	PUNCT
aji-165	437	8	,	,	PUNCT
aji-165	437	9	967–971	967–971	NUM
aji-165	437	10	.	.	PUNCT
aji-165	438	1	kyle	kyle	PROPN
aji-165	438	2	,	,	PUNCT
aji-165	438	3	b.	b.	PROPN
aji-165	438	4	d.	d.	PROPN
aji-165	438	5	,	,	PUNCT
aji-165	438	6	agbor	agbor	PROPN
aji-165	438	7	,	,	PUNCT
aji-165	438	8	t.	t.	PROPN
aji-165	438	9	a.	a.	PROPN
aji-165	438	10	,	,	PUNCT
aji-165	438	11	sharif	sharif	PROPN
aji-165	438	12	,	,	PUNCT
aji-165	438	13	s.	s.	PROPN
aji-165	438	14	,	,	PUNCT
aji-165	438	15	chauhan	chauhan	PROPN
aji-165	438	16	,	,	PUNCT
aji-165	438	17	u.	u.	PROPN
aji-165	438	18	,	,	PUNCT
aji-165	438	19	marshall	marshall	PROPN
aji-165	438	20	,	,	PUNCT
aji-165	438	21	j.	j.	PROPN
aji-165	438	22	,	,	PUNCT
aji-165	438	23	halder	halder	PROPN
aji-165	438	24	,	,	PUNCT
aji-165	438	25	s.	s.	PROPN
aji-165	438	26	l.	l.	PROPN
aji-165	438	27	s.	s.	PROPN
aji-165	438	28	,	,	PUNCT
aji-165	438	29	et	et	PROPN
aji-165	438	30	al	al	PROPN
aji-165	438	31	.	.	PUNCT
aji-165	438	32	(	(	PUNCT
aji-165	438	33	2021	2021	NUM
aji-165	438	34	)	)	PUNCT
aji-165	438	35	.	.	PUNCT
aji-165	439	1	fecal	fecal	ADJ
aji-165	439	2	calprotectin	calprotectin	NOUN
aji-165	439	3	,	,	PUNCT
aji-165	439	4	crp	crp	PROPN
aji-165	439	5	,	,	PUNCT
aji-165	439	6	and	and	CCONJ
aji-165	439	7	leukocytes	leukocyte	NOUN
aji-165	439	8	in	in	ADP
aji-165	439	9	ibd	ibd	NOUN
aji-165	439	10	patients	patient	NOUN
aji-165	439	11	:	:	PUNCT
aji-165	439	12	comparison	comparison	NOUN
aji-165	439	13	of	of	ADP
aji-165	439	14	biomarkers	biomarker	NOUN
aji-165	439	15	with	with	ADP
aji-165	439	16	biopsy	biopsy	NOUN
aji-165	439	17	results	result	NOUN
aji-165	439	18	.	.	PUNCT
aji-165	440	1	j	j	PROPN
aji-165	440	2	can	can	AUX
aji-165	440	3	assoc	assoc	PROPN
aji-165	440	4	gastroenterol	gastroenterol	PROPN
aji-165	440	5	,	,	PUNCT
aji-165	440	6	4(2	4(2	NUM
aji-165	440	7	)	)	PUNCT
aji-165	440	8	,	,	PUNCT
aji-165	440	9	84–90	84–90	NUM
aji-165	440	10	.	.	PUNCT
aji-165	441	1	li	li	PROPN
aji-165	441	2	,	,	PUNCT
aji-165	441	3	j.	j.	PROPN
aji-165	441	4	,	,	PUNCT
aji-165	441	5	xu	xu	PROPN
aji-165	441	6	,	,	PUNCT
aji-165	441	7	m.	m.	NOUN
aji-165	441	8	,	,	PUNCT
aji-165	441	9	qian	qian	PROPN
aji-165	441	10	,	,	PUNCT
aji-165	441	11	w.	w.	PROPN
aji-165	441	12	,	,	PUNCT
aji-165	441	13	ling	ling	PROPN
aji-165	441	14	,	,	PUNCT
aji-165	441	15	f.	f.	PROPN
aji-165	441	16	,	,	PUNCT
aji-165	441	17	chen	chen	PROPN
aji-165	441	18	,	,	PUNCT
aji-165	441	19	y.	y.	PROPN
aji-165	441	20	,	,	PUNCT
aji-165	441	21	li	li	PROPN
aji-165	441	22	,	,	PUNCT
aji-165	441	23	s.	s.	PROPN
aji-165	441	24	,	,	PUNCT
aji-165	441	25	...	...	PUNCT
aji-165	441	26	&	&	CCONJ
aji-165	441	27	zhu	zhu	PROPN
aji-165	441	28	,	,	PUNCT
aji-165	441	29	l.	l.	PROPN
aji-165	441	30	(	(	PUNCT
aji-165	441	31	2023	2023	NUM
aji-165	441	32	)	)	PUNCT
aji-165	441	33	.	.	PUNCT
aji-165	442	1	clinical	clinical	ADJ
aji-165	442	2	value	value	NOUN
aji-165	442	3	of	of	ADP
aji-165	442	4	fecal	fecal	ADJ
aji-165	442	5	calprotectin	calprotectin	NOUN
aji-165	442	6	for	for	ADP
aji-165	442	7	evaluating	evaluate	VERB
aji-165	442	8	disease	disease	NOUN
aji-165	442	9	activity	activity	NOUN
aji-165	442	10	in	in	ADP
aji-165	442	11	patients	patient	NOUN
aji-165	442	12	with	with	ADP
aji-165	442	13	crohn	crohn	PROPN
aji-165	442	14	’s	’s	PART
aji-165	442	15	disease	disease	NOUN
aji-165	442	16	.	.	PUNCT
aji-165	443	1	frontiers	frontier	NOUN
aji-165	443	2	in	in	ADP
aji-165	443	3	physiology	physiology	NOUN
aji-165	443	4	,	,	PUNCT
aji-165	443	5	14	14	NUM
aji-165	443	6	,	,	PUNCT
aji-165	443	7	1186665	1186665	NUM
aji-165	443	8	.	.	PUNCT
aji-165	444	1	lm	lm	INTJ
aji-165	444	2	,	,	PUNCT
aji-165	444	3	a.	a.	PROPN
aji-165	444	4	,	,	PUNCT
aji-165	444	5	ra	ra	PROPN
aji-165	444	6	,	,	PUNCT
aji-165	444	7	v.	v.	PROPN
aji-165	444	8	,	,	PUNCT
aji-165	444	9	&	&	CCONJ
aji-165	444	10	mdp	mdp	PROPN
aji-165	444	11	,	,	PUNCT
aji-165	444	12	z.	z.	PROPN
aji-165	444	13	g.	g.	PROPN
aji-165	444	14	(	(	PUNCT
aji-165	444	15	2018	2018	NUM
aji-165	444	16	)	)	PUNCT
aji-165	444	17	.	.	PUNCT
aji-165	445	1	the	the	DET
aji-165	445	2	prevalence	prevalence	NOUN
aji-165	445	3	and	and	CCONJ
aji-165	445	4	phenotype	phenotype	NOUN
aji-165	445	5	in	in	ADP
aji-165	445	6	brazilian	brazilian	ADJ
aji-165	445	7	https://www.tandfonline.com/doi/abs/10.1080/08923970601067326	https://www.tandfonline.com/doi/abs/10.1080/08923970601067326	PROPN
aji-165	445	8	https://www.tandfonline.com/doi/abs/10.1080/08923970601067326	https://www.tandfonline.com/doi/abs/10.1080/08923970601067326	PROPN
aji-165	445	9	https://pmc.ncbi.nlm.nih.gov/articles/pmc5323312/	https://pmc.ncbi.nlm.nih.gov/articles/pmc5323312/	NOUN
aji-165	446	1	https://pmc.ncbi.nlm.nih.gov/articles/pmc5323312/	https://pmc.ncbi.nlm.nih.gov/articles/pmc5323312/	PROPN
aji-165	447	1	https://pubmed.ncbi.nlm.nih.gov/30189153/	https://pubmed.ncbi.nlm.nih.gov/30189153/	PROPN
aji-165	447	2	https://pubmed.ncbi.nlm.nih.gov/30189153/	https://pubmed.ncbi.nlm.nih.gov/30189153/	PROPN
aji-165	447	3	nassar	nassar	PROPN
aji-165	447	4	et	et	PROPN
aji-165	447	5	al	al	PROPN
aji-165	447	6	.	.	PROPN
aji-165	447	7	;	;	PUNCT
aji-165	447	8	asian	asian	PROPN
aji-165	447	9	j.	j.	PROPN
aji-165	447	10	immunol	immunol	PROPN
aji-165	447	11	.	.	PROPN
aji-165	447	12	,	,	PUNCT
aji-165	447	13	vol	vol	NOUN
aji-165	447	14	.	.	PROPN
aji-165	447	15	8	8	NUM
aji-165	447	16	,	,	PUNCT
aji-165	447	17	no	no	INTJ
aji-165	447	18	.	.	NOUN
aji-165	447	19	1	1	NUM
aji-165	447	20	,	,	PUNCT
aji-165	447	21	pp	pp	ADJ
aji-165	447	22	.	.	PUNCT
aji-165	448	1	104	104	NUM
aji-165	448	2	-	-	SYM
aji-165	448	3	119	119	NUM
aji-165	448	4	,	,	PUNCT
aji-165	448	5	2025	2025	NUM
aji-165	448	6	;	;	PUNCT
aji-165	448	7	article	article	NOUN
aji-165	448	8	no.aji.135189	no.aji.135189	VERB
aji-165	448	9	118	118	NUM
aji-165	448	10	patients	patient	NOUN
aji-165	448	11	with	with	ADP
aji-165	448	12	inflammatory	inflammatory	ADJ
aji-165	448	13	bowel	bowel	NOUN
aji-165	448	14	disease	disease	NOUN
aji-165	448	15	.	.	PUNCT
aji-165	449	1	bmc	bmc	ADJ
aji-165	449	2	gastroenterology	gastroenterology	NOUN
aji-165	449	3	,	,	PUNCT
aji-165	449	4	18(1	18(1	NUM
aji-165	449	5	)	)	PUNCT
aji-165	449	6	.	.	PUNCT
aji-165	450	1	available	available	ADJ
aji-165	450	2	:	:	PUNCT
aji-165	450	3	https://pubmed.ncbi.nlm.nih.gov/	https://pubmed.ncbi.nlm.nih.gov/	PROPN
aji-165	450	4	29914399/	29914399/	NUM
aji-165	450	5	lm	lm	PROPN
aji-165	450	6	,	,	PUNCT
aji-165	450	7	d.	d.	PROPN
aji-165	450	8	,	,	PUNCT
aji-165	450	9	mo	mo	PROPN
aji-165	450	10	,	,	PUNCT
aji-165	450	11	n.	n.	NOUN
aji-165	450	12	,	,	PUNCT
aji-165	450	13	ar	ar	PROPN
aji-165	450	14	,	,	PUNCT
aji-165	450	15	a.	a.	NOUN
aji-165	450	16	,	,	PUNCT
aji-165	450	17	mm	mm	PROPN
aji-165	450	18	,	,	PUNCT
aji-165	450	19	o.	o.	PROPN
aji-165	450	20	,	,	PUNCT
aji-165	450	21	le	le	X
aji-165	450	22	,	,	PUNCT
aji-165	450	23	c.	c.	PROPN
aji-165	450	24	,	,	PUNCT
aji-165	450	25	&	&	CCONJ
aji-165	450	26	jd	jd	PROPN
aji-165	450	27	,	,	PUNCT
aji-165	450	28	t.	t.	PROPN
aji-165	450	29	n.	n.	PROPN
aji-165	450	30	(	(	PUNCT
aji-165	450	31	2015	2015	NUM
aji-165	450	32	)	)	PUNCT
aji-165	450	33	.	.	PUNCT
aji-165	451	1	clinical	clinical	ADJ
aji-165	451	2	and	and	CCONJ
aji-165	451	3	sociodemographic	sociodemographic	ADJ
aji-165	451	4	aspects	aspect	NOUN
aji-165	451	5	of	of	ADP
aji-165	451	6	inflammatory	inflammatory	ADJ
aji-165	451	7	bowel	bowel	NOUN
aji-165	451	8	disease	disease	NOUN
aji-165	451	9	patients	patient	NOUN
aji-165	451	10	.	.	PUNCT
aji-165	452	1	gastroenterology	gastroenterology	NOUN
aji-165	452	2	research	research	NOUN
aji-165	452	3	,	,	PUNCT
aji-165	452	4	8(3	8(3	NUM
aji-165	452	5	–	–	PUNCT
aji-165	452	6	4	4	NUM
aji-165	452	7	)	)	PUNCT
aji-165	452	8	.	.	PUNCT
aji-165	453	1	available	available	ADJ
aji-165	453	2	:	:	PUNCT
aji-165	453	3	https://pubmed.ncbi.nlm.nih.gov/	https://pubmed.ncbi.nlm.nih.gov/	PROPN
aji-165	453	4	27785298/	27785298/	NUM
aji-165	453	5	ma	ma	PROPN
aji-165	453	6	,	,	PUNCT
aji-165	453	7	c.	c.	PROPN
aji-165	453	8	,	,	PUNCT
aji-165	453	9	battat	battat	PROPN
aji-165	453	10	,	,	PUNCT
aji-165	453	11	r.	r.	PROPN
aji-165	453	12	,	,	PUNCT
aji-165	453	13	khanna	khanna	PROPN
aji-165	453	14	,	,	PUNCT
aji-165	453	15	r.	r.	PROPN
aji-165	453	16	,	,	PUNCT
aji-165	453	17	parker	parker	PROPN
aji-165	453	18	,	,	PUNCT
aji-165	453	19	c.	c.	PROPN
aji-165	453	20	e.	e.	PROPN
aji-165	453	21	,	,	PUNCT
aji-165	453	22	feagan	feagan	PROPN
aji-165	453	23	,	,	PUNCT
aji-165	453	24	b.	b.	PROPN
aji-165	453	25	g.	g.	PROPN
aji-165	453	26	,	,	PUNCT
aji-165	453	27	&	&	CCONJ
aji-165	453	28	jairath	jairath	PROPN
aji-165	453	29	,	,	PUNCT
aji-165	453	30	v.	v.	PROPN
aji-165	453	31	(	(	PUNCT
aji-165	453	32	2019	2019	NUM
aji-165	453	33	)	)	PUNCT
aji-165	453	34	.	.	PUNCT
aji-165	454	1	what	what	PRON
aji-165	454	2	is	be	AUX
aji-165	454	3	the	the	DET
aji-165	454	4	role	role	NOUN
aji-165	454	5	of	of	ADP
aji-165	454	6	c	c	NOUN
aji-165	454	7	-	-	PUNCT
aji-165	454	8	reactive	reactive	ADJ
aji-165	454	9	protein	protein	NOUN
aji-165	454	10	and	and	CCONJ
aji-165	454	11	fecal	fecal	ADJ
aji-165	454	12	calprotectin	calprotectin	NOUN
aji-165	454	13	in	in	ADP
aji-165	454	14	evaluating	evaluate	VERB
aji-165	454	15	crohn	crohn	PROPN
aji-165	454	16	’s	’s	PART
aji-165	454	17	disease	disease	NOUN
aji-165	454	18	activity	activity	NOUN
aji-165	454	19	?	?	PUNCT
aji-165	455	1	best	good	ADJ
aji-165	455	2	pract	pract	PROPN
aji-165	455	3	res	res	PROPN
aji-165	455	4	clin	clin	PROPN
aji-165	455	5	gastroenterol	gastroenterol	PROPN
aji-165	455	6	,	,	PUNCT
aji-165	455	7	38–39	38–39	NUM
aji-165	455	8	,	,	PUNCT
aji-165	455	9	101602	101602	NUM
aji-165	455	10	.	.	PUNCT
aji-165	456	1	management	management	NOUN
aji-165	456	2	of	of	ADP
aji-165	456	3	acute	acute	ADJ
aji-165	456	4	ano	ano	ADJ
aji-165	456	5	-	-	ADJ
aji-165	456	6	perineal	perineal	ADJ
aji-165	456	7	crohn	crohn	NOUN
aji-165	456	8	’s	’s	PART
aji-165	456	9	disease	disease	NOUN
aji-165	456	10	localization	localization	NOUN
aji-165	456	11	(	(	PUNCT
aji-165	456	12	apl	apl	PROPN
aji-165	456	13	)	)	PUNCT
aji-165	456	14	–	–	PUNCT
aji-165	456	15	fmc	fmc	PROPN
aji-165	456	16	-	-	PUNCT
aji-165	456	17	hge	hge	NOUN
aji-165	456	18	.	.	PUNCT
aji-165	457	1	(	(	PUNCT
aji-165	457	2	2024	2024	NUM
aji-165	457	3	)	)	PUNCT
aji-165	457	4	.	.	PUNCT
aji-165	458	1	available	available	ADJ
aji-165	458	2	:	:	PUNCT
aji-165	458	3	https://www.fmcgastro.org	https://www.fmcgastro.org	NUM
aji-165	458	4	/	/	SYM
aji-165	458	5	postumain	postumain	NOUN
aji-165	458	6	/	/	SYM
aji-165	458	7	archives	archive	NOUN
aji-165	458	8	/	/	SYM
aji-165	458	9	postu-2010	postu-2010	NOUN
aji-165	458	10	-	-	PUNCT
aji-165	458	11	paris	paris	NOUN
aji-165	458	12	/	/	SYM
aji-165	458	13	prise	prise	NOUN
aji-165	458	14	-	-	PUNCT
aji-165	458	15	encharge	encharge	NOUN
aji-165	458	16	-	-	PUNCT
aji-165	458	17	dune	dune	NOUN
aji-165	458	18	-	-	PUNCT
aji-165	458	19	localisation	localisation	NOUN
aji-165	458	20	-	-	PUNCT
aji-165	458	21	ano	ano	NOUN
aji-165	458	22	-	-	ADJ
aji-165	458	23	perinealelap	perinealelap	ADJ
aji-165	458	24	-	-	PUNCT
aji-165	458	25	de	de	NOUN
aji-165	458	26	-	-	NOUN
aji-165	458	27	crohn	crohn	NOUN
aji-165	458	28	-	-	PUNCT
aji-165	458	29	a	a	DET
aji-165	458	30	-	-	PUNCT
aji-165	458	31	sa	sa	NOUN
aji-165	458	32	-	-	PUNCT
aji-165	458	33	phase	phase	NOUN
aji-165	458	34	-	-	PUNCT
aji-165	458	35	aigue-2/	aigue-2/	VERB
aji-165	458	36	masson	masson	PROPN
aji-165	458	37	,	,	PUNCT
aji-165	458	38	e.	e.	PROPN
aji-165	458	39	(	(	PUNCT
aji-165	458	40	2024	2024	NUM
aji-165	458	41	)	)	PUNCT
aji-165	458	42	.	.	PUNCT
aji-165	459	1	epidemiological	epidemiological	ADJ
aji-165	459	2	aspects	aspect	NOUN
aji-165	459	3	of	of	ADP
aji-165	459	4	crohn	crohn	PROPN
aji-165	459	5	’s	’s	PART
aji-165	459	6	disease	disease	NOUN
aji-165	459	7	in	in	ADP
aji-165	459	8	the	the	DET
aji-165	459	9	oran	oran	ADJ
aji-165	459	10	region	region	NOUN
aji-165	459	11	,	,	PUNCT
aji-165	459	12	algeria	algeria	PROPN
aji-165	459	13	.	.	PUNCT
aji-165	460	1	em	em	PROPN
aji-165	460	2	-	-	PUNCT
aji-165	460	3	consulte	consulte	PROPN
aji-165	460	4	.	.	PUNCT
aji-165	461	1	available	available	ADJ
aji-165	461	2	:	:	PUNCT
aji-165	461	3	https://www.emconsulte.com	https://www.emconsulte.com	X
aji-165	461	4	/	/	SYM
aji-165	461	5	article/1075150	article/1075150	PROPN
aji-165	461	6	/	/	SYM
aji-165	461	7	aspectsepidemiologiques	aspectsepidemiologique	NOUN
aji-165	461	8	-	-	PUNCT
aji-165	461	9	de	de	X
aji-165	461	10	-	-	ADJ
aji-165	461	11	la	la	ADJ
aji-165	461	12	-	-	PUNCT
aji-165	461	13	maladie	maladie	NOUN
aji-165	461	14	-	-	PUNCT
aji-165	461	15	de	de	NOUN
aji-165	461	16	-	-	NOUN
aji-165	461	17	crohnda	crohnda	NOUN
aji-165	461	18	nahon	nahon	PROPN
aji-165	461	19	,	,	PUNCT
aji-165	461	20	s.	s.	PROPN
aji-165	461	21	,	,	PUNCT
aji-165	461	22	ramtohul	ramtohul	PROPN
aji-165	461	23	,	,	PUNCT
aji-165	461	24	t.	t.	PROPN
aji-165	461	25	,	,	PUNCT
aji-165	461	26	paupard	paupard	ADJ
aji-165	461	27	,	,	PUNCT
aji-165	461	28	t.	t.	NOUN
aji-165	461	29	,	,	PUNCT
aji-165	461	30	belhassan	belhassan	ADJ
aji-165	461	31	,	,	PUNCT
aji-165	461	32	m.	m.	NOUN
aji-165	461	33	,	,	PUNCT
aji-165	461	34	clair	clair	PROPN
aji-165	461	35	,	,	PUNCT
aji-165	461	36	e.	e.	PROPN
aji-165	461	37	,	,	PUNCT
aji-165	461	38	&	&	CCONJ
aji-165	461	39	abitbol	abitbol	PROPN
aji-165	461	40	,	,	PUNCT
aji-165	461	41	v.	v.	PROPN
aji-165	461	42	(	(	PUNCT
aji-165	461	43	2018	2018	NUM
aji-165	461	44	)	)	PUNCT
aji-165	461	45	.	.	PUNCT
aji-165	462	1	evolution	evolution	NOUN
aji-165	462	2	in	in	ADP
aji-165	462	3	clinical	clinical	ADJ
aji-165	462	4	presentation	presentation	NOUN
aji-165	462	5	of	of	ADP
aji-165	462	6	inflammatory	inflammatory	ADJ
aji-165	462	7	bowel	bowel	NOUN
aji-165	462	8	disease	disease	NOUN
aji-165	462	9	over	over	ADP
aji-165	462	10	time	time	NOUN
aji-165	462	11	at	at	ADP
aji-165	462	12	diagnosis	diagnosis	NOUN
aji-165	462	13	:	:	PUNCT
aji-165	462	14	a	a	DET
aji-165	462	15	multicenter	multicenter	ADJ
aji-165	462	16	cohort	cohort	NOUN
aji-165	462	17	study	study	NOUN
aji-165	462	18	.	.	PUNCT
aji-165	463	1	eur	eur	PROPN
aji-165	463	2	j	j	PROPN
aji-165	463	3	gastroenterol	gastroenterol	NOUN
aji-165	463	4	hepatol	hepatol	ADJ
aji-165	463	5	,	,	PUNCT
aji-165	463	6	30(10	30(10	NUM
aji-165	463	7	)	)	PUNCT
aji-165	463	8	,	,	PUNCT
aji-165	463	9	1125	1125	NUM
aji-165	463	10	–	–	PUNCT
aji-165	463	11	1129	1129	NUM
aji-165	463	12	.	.	PUNCT
aji-165	464	1	rodríguez	rodríguez	NOUN
aji-165	464	2	-	-	PUNCT
aji-165	464	3	moranta	moranta	PROPN
aji-165	464	4	,	,	PUNCT
aji-165	464	5	f.	f.	PROPN
aji-165	464	6	,	,	PUNCT
aji-165	464	7	lobatón	lobatón	PROPN
aji-165	464	8	,	,	PUNCT
aji-165	464	9	t.	t.	PROPN
aji-165	464	10	,	,	PUNCT
aji-165	464	11	rodríguezalonso	rodríguezalonso	NOUN
aji-165	464	12	,	,	PUNCT
aji-165	464	13	l.	l.	PROPN
aji-165	464	14	,	,	PUNCT
aji-165	464	15	&	&	CCONJ
aji-165	464	16	guardiola	guardiola	PROPN
aji-165	464	17	,	,	PUNCT
aji-165	464	18	j.	j.	PROPN
aji-165	464	19	(	(	PUNCT
aji-165	464	20	2013	2013	NUM
aji-165	464	21	)	)	PUNCT
aji-165	464	22	.	.	PUNCT
aji-165	465	1	fecal	fecal	ADJ
aji-165	465	2	calprotectin	calprotectin	NOUN
aji-165	465	3	in	in	ADP
aji-165	465	4	the	the	DET
aji-165	465	5	diagnosis	diagnosis	NOUN
aji-165	465	6	of	of	ADP
aji-165	465	7	inflammatory	inflammatory	ADJ
aji-165	465	8	bowel	bowel	NOUN
aji-165	465	9	diseases	disease	NOUN
aji-165	465	10	.	.	PUNCT
aji-165	466	1	gastroenterol	gastroenterol	NOUN
aji-165	466	2	hepatol	hepatol	ADJ
aji-165	466	3	,	,	PUNCT
aji-165	466	4	36(6	36(6	NUM
aji-165	466	5	)	)	PUNCT
aji-165	466	6	,	,	PUNCT
aji-165	466	7	400–406	400–406	NUM
aji-165	466	8	.	.	PUNCT
aji-165	466	9	samant	samant	NOUN
aji-165	466	10	,	,	PUNCT
aji-165	466	11	h.	h.	PROPN
aji-165	466	12	,	,	PUNCT
aji-165	466	13	desai	desai	PROPN
aji-165	466	14	,	,	PUNCT
aji-165	466	15	d.	d.	PROPN
aji-165	466	16	,	,	PUNCT
aji-165	466	17	abraham	abraham	PROPN
aji-165	466	18	,	,	PUNCT
aji-165	466	19	p.	p.	PROPN
aji-165	466	20	,	,	PUNCT
aji-165	466	21	joshi	joshi	PROPN
aji-165	466	22	,	,	PUNCT
aji-165	466	23	a.	a.	PROPN
aji-165	466	24	,	,	PUNCT
aji-165	466	25	gupta	gupta	PROPN
aji-165	466	26	,	,	PUNCT
aji-165	466	27	t.	t.	PROPN
aji-165	466	28	,	,	PUNCT
aji-165	466	29	dherai	dherai	PROPN
aji-165	466	30	,	,	PUNCT
aji-165	466	31	a.	a.	NOUN
aji-165	466	32	,	,	PUNCT
aji-165	466	33	et	et	PROPN
aji-165	466	34	al	al	PROPN
aji-165	466	35	.	.	PUNCT
aji-165	467	1	(	(	PUNCT
aji-165	467	2	2015	2015	NUM
aji-165	467	3	)	)	PUNCT
aji-165	467	4	.	.	PUNCT
aji-165	468	1	fecal	fecal	ADJ
aji-165	468	2	calprotectin	calprotectin	NOUN
aji-165	468	3	and	and	CCONJ
aji-165	468	4	its	its	PRON
aji-165	468	5	correlation	correlation	NOUN
aji-165	468	6	with	with	ADP
aji-165	468	7	inflammatory	inflammatory	ADJ
aji-165	468	8	markers	marker	NOUN
aji-165	468	9	and	and	CCONJ
aji-165	468	10	endoscopy	endoscopy	VERB
aji-165	468	11	in	in	ADP
aji-165	468	12	patients	patient	NOUN
aji-165	468	13	from	from	ADP
aji-165	468	14	india	india	PROPN
aji-165	468	15	with	with	ADP
aji-165	468	16	inflammatory	inflammatory	ADJ
aji-165	468	17	bowel	bowel	NOUN
aji-165	468	18	disease	disease	NOUN
aji-165	468	19	.	.	PUNCT
aji-165	469	1	indian	indian	PROPN
aji-165	469	2	j	j	PROPN
aji-165	469	3	gastroenterol	gastroenterol	PROPN
aji-165	469	4	,	,	PUNCT
aji-165	469	5	34(6	34(6	NOUN
aji-165	469	6	)	)	PUNCT
aji-165	469	7	,	,	PUNCT
aji-165	469	8	431–435	431–435	NUM
aji-165	469	9	.	.	PUNCT
aji-165	470	1	sands	sand	NOUN
aji-165	470	2	,	,	PUNCT
aji-165	470	3	b.	b.	PROPN
aji-165	470	4	e.	e.	PROPN
aji-165	470	5	(	(	PUNCT
aji-165	470	6	2015	2015	NUM
aji-165	470	7	)	)	PUNCT
aji-165	470	8	.	.	PUNCT
aji-165	471	1	biomarkers	biomarker	NOUN
aji-165	471	2	of	of	ADP
aji-165	471	3	inflammation	inflammation	NOUN
aji-165	471	4	in	in	ADP
aji-165	471	5	inflammatory	inflammatory	ADJ
aji-165	471	6	bowel	bowel	NOUN
aji-165	471	7	disease	disease	NOUN
aji-165	471	8	.	.	PUNCT
aji-165	472	1	gastroenterology	gastroenterology	NOUN
aji-165	472	2	,	,	PUNCT
aji-165	472	3	149(5	149(5	NUM
aji-165	472	4	)	)	PUNCT
aji-165	472	5	,	,	PUNCT
aji-165	472	6	1275	1275	NUM
aji-165	472	7	-	-	SYM
aji-165	472	8	1285.e2	1285.e2	PROPN
aji-165	472	9	.	.	PUNCT
aji-165	473	1	satsangi	satsangi	PROPN
aji-165	473	2	,	,	PUNCT
aji-165	473	3	j.	j.	PROPN
aji-165	473	4	,	,	PUNCT
aji-165	473	5	silverberg	silverberg	PROPN
aji-165	473	6	,	,	PUNCT
aji-165	473	7	m.	m.	NOUN
aji-165	473	8	s.	s.	PROPN
aji-165	473	9	,	,	PUNCT
aji-165	473	10	vermeire	vermeire	NOUN
aji-165	473	11	,	,	PUNCT
aji-165	473	12	s.	s.	PROPN
aji-165	473	13	,	,	PUNCT
aji-165	473	14	&	&	CCONJ
aji-165	473	15	colombel	colombel	PROPN
aji-165	473	16	,	,	PUNCT
aji-165	473	17	j.	j.	PROPN
aji-165	473	18	f.	f.	PROPN
aji-165	473	19	(	(	PUNCT
aji-165	473	20	2006	2006	NUM
aji-165	473	21	)	)	PUNCT
aji-165	473	22	.	.	PUNCT
aji-165	474	1	the	the	DET
aji-165	474	2	montreal	montreal	PROPN
aji-165	474	3	classification	classification	NOUN
aji-165	474	4	of	of	ADP
aji-165	474	5	inflammatory	inflammatory	ADJ
aji-165	474	6	bowel	bowel	NOUN
aji-165	474	7	disease	disease	NOUN
aji-165	474	8	:	:	PUNCT
aji-165	474	9	controversies	controversy	NOUN
aji-165	474	10	,	,	PUNCT
aji-165	474	11	consensus	consensus	NOUN
aji-165	474	12	,	,	PUNCT
aji-165	474	13	and	and	CCONJ
aji-165	474	14	implications	implication	NOUN
aji-165	474	15	.	.	PUNCT
aji-165	475	1	gut	gut	VERB
aji-165	475	2	,	,	PUNCT
aji-165	475	3	55(6	55(6	NUM
aji-165	475	4	)	)	PUNCT
aji-165	475	5	,	,	PUNCT
aji-165	475	6	749–753	749–753	NUM
aji-165	475	7	.	.	PUNCT
aji-165	476	1	schoepfer	schoepfer	NOUN
aji-165	476	2	,	,	PUNCT
aji-165	476	3	a.	a.	NOUN
aji-165	476	4	m.	m.	NOUN
aji-165	476	5	,	,	PUNCT
aji-165	476	6	beglinger	beglinger	NOUN
aji-165	476	7	,	,	PUNCT
aji-165	476	8	c.	c.	PROPN
aji-165	476	9	,	,	PUNCT
aji-165	476	10	straumann	straumann	PROPN
aji-165	476	11	,	,	PUNCT
aji-165	476	12	a.	a.	NOUN
aji-165	476	13	,	,	PUNCT
aji-165	476	14	safroneeva	safroneeva	PROPN
aji-165	476	15	,	,	PUNCT
aji-165	476	16	e.	e.	PROPN
aji-165	476	17	,	,	PUNCT
aji-165	476	18	romero	romero	PROPN
aji-165	476	19	,	,	PUNCT
aji-165	476	20	y.	y.	PROPN
aji-165	476	21	,	,	PUNCT
aji-165	476	22	armstrong	armstrong	PROPN
aji-165	476	23	,	,	PUNCT
aji-165	476	24	d.	d.	PROPN
aji-165	476	25	,	,	PUNCT
aji-165	476	26	schmidt	schmidt	PROPN
aji-165	476	27	,	,	PUNCT
aji-165	476	28	c.	c.	PROPN
aji-165	476	29	,	,	PUNCT
aji-165	476	30	trummler	trummler	NOUN
aji-165	476	31	,	,	PUNCT
aji-165	476	32	m.	m.	NOUN
aji-165	476	33	,	,	PUNCT
aji-165	476	34	pittet	pittet	NOUN
aji-165	476	35	,	,	PUNCT
aji-165	476	36	v.	v.	ADV
aji-165	476	37	,	,	PUNCT
aji-165	476	38	&	&	CCONJ
aji-165	476	39	vavricka	vavricka	PROPN
aji-165	476	40	,	,	PUNCT
aji-165	476	41	s.	s.	PROPN
aji-165	476	42	r.	r.	PROPN
aji-165	476	43	(	(	PUNCT
aji-165	476	44	2024	2024	NUM
aji-165	476	45	)	)	PUNCT
aji-165	476	46	fecal	fecal	ADJ
aji-165	476	47	calprotectin	calprotectin	NOUN
aji-165	476	48	more	more	ADV
aji-165	476	49	accurately	accurately	ADV
aji-165	476	50	reflects	reflect	VERB
aji-165	476	51	endoscopic	endoscopic	ADJ
aji-165	476	52	activity	activity	NOUN
aji-165	476	53	of	of	ADP
aji-165	476	54	ulcerative	ulcerative	ADJ
aji-165	476	55	colitis	colitis	NOUN
aji-165	476	56	than	than	ADP
aji-165	476	57	the	the	DET
aji-165	476	58	lichtiger	lichtiger	NOUN
aji-165	476	59	index	index	NOUN
aji-165	476	60	,	,	PUNCT
aji-165	476	61	c	c	NOUN
aji-165	476	62	-	-	PUNCT
aji-165	476	63	reactive	reactive	ADJ
aji-165	476	64	protein	protein	NOUN
aji-165	476	65	,	,	PUNCT
aji-165	476	66	platelets	platelet	NOUN
aji-165	476	67	,	,	PUNCT
aji-165	476	68	hemoglobin	hemoglobin	NOUN
aji-165	476	69	,	,	PUNCT
aji-165	476	70	and	and	CCONJ
aji-165	476	71	blood	blood	NOUN
aji-165	476	72	leukocytes	leukocyte	NOUN
aji-165	476	73	–	–	PUNCT
aji-165	476	74	pubmed	pubmed	PROPN
aji-165	476	75	.	.	PUNCT
aji-165	477	1	available	available	ADJ
aji-165	477	2	from	from	ADP
aji-165	477	3	:	:	PUNCT
aji-165	477	4	https://pubmed.ncbi.nlm.nih.gov/23328771	https://pubmed.ncbi.nlm.nih.gov/23328771	ADJ
aji-165	477	5	/	/	SYM
aji-165	477	6	słowińska	słowińska	NOUN
aji-165	477	7	-	-	PUNCT
aji-165	477	8	solnica	solnica	PROPN
aji-165	477	9	,	,	PUNCT
aji-165	477	10	k.	k.	PROPN
aji-165	477	11	,	,	PUNCT
aji-165	477	12	pawlica	pawlica	PROPN
aji-165	477	13	-	-	PUNCT
aji-165	477	14	gosiewska	gosiewska	PROPN
aji-165	477	15	,	,	PUNCT
aji-165	477	16	d.	d.	PROPN
aji-165	477	17	,	,	PUNCT
aji-165	477	18	gawlik	gawlik	PROPN
aji-165	477	19	,	,	PUNCT
aji-165	477	20	k.	k.	PROPN
aji-165	477	21	,	,	PUNCT
aji-165	477	22	owczarek	owczarek	PROPN
aji-165	477	23	,	,	PUNCT
aji-165	477	24	d.	d.	PROPN
aji-165	477	25	,	,	PUNCT
aji-165	477	26	cibor	cibor	PROPN
aji-165	477	27	,	,	PUNCT
aji-165	477	28	d.	d.	PROPN
aji-165	477	29	,	,	PUNCT
aji-165	477	30	pocztar	pocztar	NOUN
aji-165	477	31	,	,	PUNCT
aji-165	477	32	h.	h.	PROPN
aji-165	477	33	,	,	PUNCT
aji-165	477	34	...	...	PUNCT
aji-165	477	35	&	&	CCONJ
aji-165	477	36	solnica	solnica	PROPN
aji-165	477	37	,	,	PUNCT
aji-165	477	38	b.	b.	PROPN
aji-165	477	39	(	(	PUNCT
aji-165	477	40	2021	2021	NUM
aji-165	477	41	)	)	PUNCT
aji-165	477	42	.	.	PUNCT
aji-165	478	1	serum	serum	VERB
aji-165	478	2	inflammatory	inflammatory	ADJ
aji-165	478	3	markers	marker	NOUN
aji-165	478	4	in	in	ADP
aji-165	478	5	the	the	DET
aji-165	478	6	diagnosis	diagnosis	NOUN
aji-165	478	7	and	and	CCONJ
aji-165	478	8	assessment	assessment	NOUN
aji-165	478	9	of	of	ADP
aji-165	478	10	crohn	crohn	PROPN
aji-165	478	11	’s	’s	PART
aji-165	478	12	disease	disease	NOUN
aji-165	478	13	activity	activity	NOUN
aji-165	478	14	.	.	PUNCT
aji-165	479	1	archives	archive	NOUN
aji-165	479	2	of	of	ADP
aji-165	479	3	medical	medical	ADJ
aji-165	479	4	science	science	NOUN
aji-165	479	5	:	:	PUNCT
aji-165	479	6	ams	am	NOUN
aji-165	479	7	,	,	PUNCT
aji-165	479	8	17(1	17(1	NUM
aji-165	479	9	)	)	PUNCT
aji-165	479	10	,	,	PUNCT
aji-165	479	11	252	252	NUM
aji-165	479	12	.	.	PUNCT
aji-165	479	13	available	available	ADJ
aji-165	479	14	:	:	PUNCT
aji-165	479	15	https://pmc.ncbi.nlm.nih.gov	https://pmc.ncbi.nlm.nih.gov	ADJ
aji-165	479	16	/	/	SYM
aji-165	479	17	artic	artic	PROPN
aji-165	479	18	les	les	PROPN
aji-165	479	19	/	/	SYM
aji-165	479	20	pmc7811324/	pmc7811324/	PROPN
aji-165	479	21	smids	smid	NOUN
aji-165	479	22	,	,	PUNCT
aji-165	479	23	c.	c.	PROPN
aji-165	479	24	,	,	PUNCT
aji-165	479	25	horjus	horju	VERB
aji-165	479	26	talabur	talabur	NOUN
aji-165	479	27	horje	horje	NOUN
aji-165	479	28	,	,	PUNCT
aji-165	479	29	c.	c.	PROPN
aji-165	479	30	s.	s.	PROPN
aji-165	479	31	,	,	PUNCT
aji-165	479	32	groenen	groenen	NOUN
aji-165	479	33	,	,	PUNCT
aji-165	479	34	m.	m.	NOUN
aji-165	479	35	j.	j.	PROPN
aji-165	479	36	m.	m.	PROPN
aji-165	479	37	,	,	PUNCT
aji-165	479	38	van	van	PROPN
aji-165	479	39	koolwijk	koolwijk	PROPN
aji-165	479	40	,	,	PUNCT
aji-165	479	41	e.	e.	PROPN
aji-165	479	42	h.	h.	PROPN
aji-165	479	43	m.	m.	PROPN
aji-165	479	44	,	,	PUNCT
aji-165	479	45	wahab	wahab	PROPN
aji-165	479	46	,	,	PUNCT
aji-165	479	47	p.	p.	PROPN
aji-165	479	48	j.	j.	PROPN
aji-165	479	49	,	,	PUNCT
aji-165	479	50	van	van	PROPN
aji-165	479	51	lochem	lochem	PROPN
aji-165	479	52	,	,	PUNCT
aji-165	479	53	e.	e.	PROPN
aji-165	479	54	g.	g.	PROPN
aji-165	479	55	(	(	PUNCT
aji-165	479	56	2017	2017	NUM
aji-165	479	57	)	)	PUNCT
aji-165	479	58	.	.	PUNCT
aji-165	480	1	the	the	DET
aji-165	480	2	value	value	NOUN
aji-165	480	3	of	of	ADP
aji-165	480	4	serum	serum	NOUN
aji-165	480	5	antibodies	antibody	NOUN
aji-165	480	6	in	in	ADP
aji-165	480	7	differentiating	differentiate	VERB
aji-165	480	8	inflammatory	inflammatory	ADJ
aji-165	480	9	bowel	bowel	NOUN
aji-165	480	10	disease	disease	NOUN
aji-165	480	11	,	,	PUNCT
aji-165	480	12	predicting	predict	VERB
aji-165	480	13	disease	disease	NOUN
aji-165	480	14	activity	activity	NOUN
aji-165	480	15	,	,	PUNCT
aji-165	480	16	and	and	CCONJ
aji-165	480	17	disease	disease	NOUN
aji-165	480	18	course	course	NOUN
aji-165	480	19	in	in	ADP
aji-165	480	20	the	the	DET
aji-165	480	21	newly	newly	ADV
aji-165	480	22	diagnosed	diagnose	VERB
aji-165	480	23	patient	patient	NOUN
aji-165	480	24	.	.	PUNCT
aji-165	481	1	scand	scand	PROPN
aji-165	481	2	j	j	PROPN
aji-165	481	3	gastroenterol	gastroenterol	PROPN
aji-165	481	4	,	,	PUNCT
aji-165	481	5	52(10	52(10	PROPN
aji-165	481	6	)	)	PUNCT
aji-165	481	7	,	,	PUNCT
aji-165	481	8	1104–1112	1104–1112	NUM
aji-165	481	9	.	.	PUNCT
aji-165	482	1	sousa	sousa	PROPN
aji-165	482	2	,	,	PUNCT
aji-165	482	3	p.	p.	PROPN
aji-165	482	4	,	,	PUNCT
aji-165	482	5	martins	martin	NOUN
aji-165	482	6	,	,	PUNCT
aji-165	482	7	d.	d.	PROPN
aji-165	482	8	,	,	PUNCT
aji-165	482	9	pinho	pinho	NOUN
aji-165	482	10	,	,	PUNCT
aji-165	482	11	j.	j.	PROPN
aji-165	482	12	,	,	PUNCT
aji-165	482	13	cancela	cancela	PROPN
aji-165	482	14	,	,	PUNCT
aji-165	482	15	e.	e.	PROPN
aji-165	482	16	,	,	PUNCT
aji-165	482	17	cardoso	cardoso	PROPN
aji-165	482	18	,	,	PUNCT
aji-165	482	19	r.	r.	PROPN
aji-165	482	20	,	,	PUNCT
aji-165	482	21	araujo	araujo	PROPN
aji-165	482	22	,	,	PUNCT
aji-165	482	23	r.	r.	PROPN
aji-165	482	24	,	,	PUNCT
aji-165	482	25	...	...	PUNCT
aji-165	482	26	&	&	CCONJ
aji-165	482	27	ministro	ministro	PROPN
aji-165	482	28	,	,	PUNCT
aji-165	482	29	p.	p.	NOUN
aji-165	482	30	(	(	PUNCT
aji-165	482	31	2017	2017	NUM
aji-165	482	32	)	)	PUNCT
aji-165	482	33	.	.	PUNCT
aji-165	483	1	p255	p255	PROPN
aji-165	483	2	predictors	predictor	NOUN
aji-165	483	3	of	of	ADP
aji-165	483	4	negative	negative	ADJ
aji-165	483	5	creactive	creactive	ADJ
aji-165	483	6	protein	protein	NOUN
aji-165	483	7	in	in	ADP
aji-165	483	8	active	active	ADJ
aji-165	483	9	crohn	crohn	NOUN
aji-165	483	10	's	's	PART
aji-165	483	11	disease	disease	NOUN
aji-165	483	12	.	.	PUNCT
aji-165	484	1	journal	journal	PROPN
aji-165	484	2	of	of	ADP
aji-165	484	3	crohn	crohn	PROPN
aji-165	484	4	’s	’s	PART
aji-165	484	5	and	and	CCONJ
aji-165	484	6	colitis	colitis	NOUN
aji-165	484	7	(	(	PUNCT
aji-165	484	8	ecco	ecco	PROPN
aji-165	484	9	-	-	PUNCT
aji-165	484	10	jcc	jcc	PROPN
aji-165	484	11	)	)	PUNCT
aji-165	484	12	,	,	PUNCT
aji-165	484	13	11(suppl_1	11(suppl_1	NUM
aji-165	484	14	)	)	PUNCT
aji-165	484	15	,	,	PUNCT
aji-165	484	16	s207	s207	PROPN
aji-165	484	17	-	-	PUNCT
aji-165	484	18	s208	s208	PROPN
aji-165	484	19	.	.	PUNCT
aji-165	485	1	available	available	ADJ
aji-165	485	2	:	:	PUNCT
aji-165	485	3	https://www.researchgate.net	https://www.researchgate.net	PROPN
aji-165	485	4	/	/	SYM
aji-165	485	5	pu	pu	PROPN
aji-165	485	6	blication/313463358_p255_predictors_of	blication/313463358_p255_predictors_of	PROPN
aji-165	485	7	_	_	PRON
aji-165	485	8	negative_creactive_protein_in_active_crohn's_diseas	negative_creactive_protein_in_active_crohn's_diseas	NUM
aji-165	486	1	e	e	VERB
aji-165	486	2	stawczyk	stawczyk	NOUN
aji-165	486	3	-	-	PUNCT
aji-165	486	4	eder	eder	NOUN
aji-165	486	5	,	,	PUNCT
aji-165	486	6	k.	k.	NOUN
aji-165	486	7	,	,	PUNCT
aji-165	486	8	eder	eder	NOUN
aji-165	486	9	,	,	PUNCT
aji-165	486	10	p.	p.	NOUN
aji-165	486	11	,	,	PUNCT
aji-165	486	12	lykowska	lykowska	NOUN
aji-165	486	13	-	-	PUNCT
aji-165	486	14	szuber	szuber	NOUN
aji-165	486	15	,	,	PUNCT
aji-165	486	16	l.	l.	PROPN
aji-165	486	17	,	,	PUNCT
aji-165	486	18	krela	krela	NOUN
aji-165	486	19	-	-	PUNCT
aji-165	486	20	kazmierczak	kazmierczak	PROPN
aji-165	486	21	,	,	PUNCT
aji-165	486	22	i.	i.	PROPN
aji-165	486	23	,	,	PUNCT
aji-165	486	24	klimczak	klimczak	PROPN
aji-165	486	25	,	,	PUNCT
aji-165	486	26	k.	k.	PROPN
aji-165	486	27	,	,	PUNCT
aji-165	486	28	szymczak	szymczak	PROPN
aji-165	486	29	,	,	PUNCT
aji-165	486	30	a.	a.	NOUN
aji-165	486	31	,	,	PUNCT
aji-165	486	32	et	et	PROPN
aji-165	486	33	al	al	PROPN
aji-165	486	34	.	.	PUNCT
aji-165	486	35	(	(	PUNCT
aji-165	486	36	2015	2015	NUM
aji-165	486	37	)	)	PUNCT
aji-165	486	38	.	.	PUNCT
aji-165	487	1	is	be	AUX
aji-165	487	2	fecal	fecal	ADJ
aji-165	487	3	calprotectin	calprotectin	NOUN
aji-165	487	4	equally	equally	ADV
aji-165	487	5	useful	useful	ADJ
aji-165	487	6	in	in	ADP
aji-165	487	7	all	all	DET
aji-165	487	8	crohn	crohn	PROPN
aji-165	487	9	’s	’s	PART
aji-165	487	10	disease	disease	NOUN
aji-165	487	11	locations	location	NOUN
aji-165	487	12	?	?	PUNCT
aji-165	488	1	a	a	DET
aji-165	488	2	prospective	prospective	ADJ
aji-165	488	3	,	,	PUNCT
aji-165	488	4	comparative	comparative	ADJ
aji-165	488	5	study	study	NOUN
aji-165	488	6	.	.	PUNCT
aji-165	489	1	arch	arch	PROPN
aji-165	489	2	med	med	PROPN
aji-165	489	3	sci	sci	PROPN
aji-165	489	4	,	,	PUNCT
aji-165	489	5	11(2	11(2	NOUN
aji-165	489	6	)	)	PUNCT
aji-165	489	7	,	,	PUNCT
aji-165	489	8	353–361	353–361	NUM
aji-165	489	9	.	.	PUNCT
aji-165	490	1	swaminathan	swaminathan	PROPN
aji-165	490	2	,	,	PUNCT
aji-165	490	3	a.	a.	NOUN
aji-165	490	4	,	,	PUNCT
aji-165	490	5	&	&	CCONJ
aji-165	490	6	day	day	PROPN
aji-165	490	7	,	,	PUNCT
aji-165	490	8	a.	a.	PROPN
aji-165	490	9	s.	s.	PROPN
aji-165	490	10	(	(	PUNCT
aji-165	490	11	2024	2024	NUM
aji-165	490	12	,	,	PUNCT
aji-165	490	13	august	august	PROPN
aji-165	490	14	)	)	PUNCT
aji-165	490	15	.	.	PUNCT
aji-165	491	1	measures	measure	NOUN
aji-165	491	2	of	of	ADP
aji-165	491	3	gut	gut	NOUN
aji-165	491	4	inflammation	inflammation	NOUN
aji-165	491	5	in	in	ADP
aji-165	491	6	patients	patient	NOUN
aji-165	491	7	with	with	ADP
aji-165	491	8	inflammatory	inflammatory	ADJ
aji-165	491	9	bowel	bowel	NOUN
aji-165	491	10	disease	disease	NOUN
aji-165	491	11	:	:	PUNCT
aji-165	491	12	are	be	AUX
aji-165	491	13	blood	blood	NOUN
aji-165	491	14	-	-	PUNCT
aji-165	491	15	based	base	VERB
aji-165	491	16	biomarkers	biomarker	NOUN
aji-165	491	17	sufficient	sufficient	ADJ
aji-165	491	18	?	?	PUNCT
aji-165	492	1	dig	dig	VERB
aji-165	492	2	dis	dis	PROPN
aji-165	492	3	sci	sci	PROPN
aji-165	492	4	,	,	PUNCT
aji-165	492	5	69(8	69(8	NOUN
aji-165	492	6	)	)	PUNCT
aji-165	492	7	,	,	PUNCT
aji-165	492	8	2723–2724	2723–2724	NUM
aji-165	492	9	.	.	PUNCT
aji-165	493	1	torres	torre	NOUN
aji-165	493	2	,	,	PUNCT
aji-165	493	3	j.	j.	PROPN
aji-165	493	4	,	,	PUNCT
aji-165	493	5	mehandru	mehandru	PROPN
aji-165	493	6	,	,	PUNCT
aji-165	493	7	s.	s.	PROPN
aji-165	493	8	,	,	PUNCT
aji-165	493	9	colombel	colombel	NOUN
aji-165	493	10	,	,	PUNCT
aji-165	493	11	j.	j.	PROPN
aji-165	493	12	f.	f.	PROPN
aji-165	493	13	,	,	PUNCT
aji-165	493	14	&	&	CCONJ
aji-165	493	15	peyrin	peyrin	NOUN
aji-165	493	16	-	-	PUNCT
aji-165	493	17	biroulet	biroulet	NOUN
aji-165	493	18	,	,	PUNCT
aji-165	493	19	l.	l.	PROPN
aji-165	493	20	(	(	PUNCT
aji-165	493	21	2017	2017	NUM
aji-165	493	22	)	)	PUNCT
aji-165	493	23	.	.	PUNCT
aji-165	494	1	crohn	crohn	PROPN
aji-165	494	2	’s	’s	PART
aji-165	494	3	disease	disease	NOUN
aji-165	494	4	.	.	PUNCT
aji-165	495	1	lancet	lancet	NOUN
aji-165	495	2	,	,	PUNCT
aji-165	495	3	389(10080	389(10080	NUM
aji-165	495	4	)	)	PUNCT
aji-165	495	5	,	,	PUNCT
aji-165	495	6	1741–1755	1741–1755	NUM
aji-165	495	7	.	.	PUNCT
aji-165	496	1	https://pubmed.ncbi.nlm.nih.gov/29914399/	https://pubmed.ncbi.nlm.nih.gov/29914399/	PROPN
aji-165	496	2	https://pubmed.ncbi.nlm.nih.gov/29914399/	https://pubmed.ncbi.nlm.nih.gov/29914399/	PROPN
aji-165	496	3	https://pubmed.ncbi.nlm.nih.gov/27785298/	https://pubmed.ncbi.nlm.nih.gov/27785298/	PROPN
aji-165	496	4	https://pubmed.ncbi.nlm.nih.gov/27785298/	https://pubmed.ncbi.nlm.nih.gov/27785298/	PROPN
aji-165	496	5	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	VERB
aji-165	496	6	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	VERB
aji-165	496	7	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	VERB
aji-165	496	8	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	https://www.fmcgastro.org/postu-main/archives/postu-2010-paris/prise-en-charge-dune-localisation-ano-perineale-lap-de-crohn-a-sa-phase-aigue-2/	VERB
aji-165	496	9	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	PROPN
aji-165	496	10	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	PROPN
aji-165	496	11	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	PROPN
aji-165	497	1	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	https://www.em-consulte.com/article/1075150/aspects-epidemiologiques-de-la-maladie-de-crohn-da	PROPN
aji-165	497	2	https://pubmed.ncbi.nlm.nih.gov/23328771/	https://pubmed.ncbi.nlm.nih.gov/23328771/	PROPN
aji-165	497	3	https://pubmed.ncbi.nlm.nih.gov/23328771/	https://pubmed.ncbi.nlm.nih.gov/23328771/	PROPN
aji-165	497	4	https://pmc.ncbi.nlm.nih.gov/articles/pmc7811324/	https://pmc.ncbi.nlm.nih.gov/articles/pmc7811324/	PROPN
aji-165	497	5	https://pmc.ncbi.nlm.nih.gov/articles/pmc7811324/	https://pmc.ncbi.nlm.nih.gov/articles/pmc7811324/	PROPN
aji-165	497	6	nassar	nassar	PROPN
aji-165	497	7	et	et	PROPN
aji-165	497	8	al	al	PROPN
aji-165	497	9	.	.	PROPN
aji-165	497	10	;	;	PUNCT
aji-165	497	11	asian	asian	PROPN
aji-165	497	12	j.	j.	PROPN
aji-165	497	13	immunol	immunol	PROPN
aji-165	497	14	.	.	PROPN
aji-165	497	15	,	,	PUNCT
aji-165	497	16	vol	vol	NOUN
aji-165	497	17	.	.	PROPN
aji-165	497	18	8	8	NUM
aji-165	497	19	,	,	PUNCT
aji-165	497	20	no	no	INTJ
aji-165	497	21	.	.	NOUN
aji-165	497	22	1	1	NUM
aji-165	497	23	,	,	PUNCT
aji-165	497	24	pp	pp	ADJ
aji-165	497	25	.	.	PUNCT
aji-165	498	1	104	104	NUM
aji-165	498	2	-	-	SYM
aji-165	498	3	119	119	NUM
aji-165	498	4	,	,	PUNCT
aji-165	498	5	2025	2025	NUM
aji-165	498	6	;	;	PUNCT
aji-165	498	7	article	article	NOUN
aji-165	498	8	no.aji.135189	no.aji.135189	VERB
aji-165	498	9	119	119	NUM
aji-165	498	10	ulcerative	ulcerative	ADJ
aji-165	498	11	colitis	colitis	NOUN
aji-165	498	12	pubmed	pubmed	PROPN
aji-165	498	13	.	.	PUNCT
aji-165	499	1	(	(	PUNCT
aji-165	499	2	2024	2024	NUM
aji-165	499	3	,	,	PUNCT
aji-165	499	4	december	december	PROPN
aji-165	499	5	28	28	NUM
aji-165	499	6	)	)	PUNCT
aji-165	499	7	.	.	PUNCT
aji-165	500	1	available	available	ADJ
aji-165	500	2	:	:	PUNCT
aji-165	500	3	https://pubmed.ncbi.nlm.nih.gov/	https://pubmed.ncbi.nlm.nih.gov/	PROPN
aji-165	500	4	27914657/	27914657/	NUM
aji-165	500	5	veyrard	veyrard	ADV
aji-165	500	6	,	,	PUNCT
aji-165	500	7	p.	p.	PROPN
aji-165	500	8	,	,	PUNCT
aji-165	500	9	roblin	roblin	PROPN
aji-165	500	10	,	,	PUNCT
aji-165	500	11	x.	x.	NOUN
aji-165	500	12	,	,	PUNCT
aji-165	500	13	pansart	pansart	PROPN
aji-165	500	14	,	,	PUNCT
aji-165	500	15	c.	c.	PROPN
aji-165	500	16	,	,	PUNCT
aji-165	500	17	mao	mao	PROPN
aji-165	500	18	,	,	PUNCT
aji-165	500	19	r.	r.	PROPN
aji-165	500	20	,	,	PUNCT
aji-165	500	21	nancey	nancey	PROPN
aji-165	500	22	,	,	PUNCT
aji-165	500	23	s.	s.	PROPN
aji-165	500	24	,	,	PUNCT
aji-165	500	25	killian	killian	PROPN
aji-165	500	26	,	,	PUNCT
aji-165	500	27	m.	m.	NOUN
aji-165	500	28	,	,	PUNCT
aji-165	500	29	...	...	PUNCT
aji-165	500	30	&	&	CCONJ
aji-165	500	31	paul	paul	PROPN
aji-165	500	32	,	,	PUNCT
aji-165	500	33	s.	s.	PROPN
aji-165	500	34	(	(	PUNCT
aji-165	500	35	2022	2022	NUM
aji-165	500	36	)	)	PUNCT
aji-165	500	37	.	.	PUNCT
aji-165	501	1	serum	serum	NOUN
aji-165	501	2	calprotectin	calprotectin	PROPN
aji-165	501	3	is	be	AUX
aji-165	501	4	useful	useful	ADJ
aji-165	501	5	to	to	PART
aji-165	501	6	confirm	confirm	VERB
aji-165	501	7	inflammatory	inflammatory	ADJ
aji-165	501	8	bowel	bowel	NOUN
aji-165	501	9	disease	disease	NOUN
aji-165	501	10	activity	activity	NOUN
aji-165	501	11	but	but	CCONJ
aji-165	501	12	not	not	PART
aji-165	501	13	to	to	PART
aji-165	501	14	predict	predict	VERB
aji-165	501	15	relapse	relapse	NOUN
aji-165	501	16	.	.	PUNCT
aji-165	502	1	clinical	clinical	ADJ
aji-165	502	2	immunology	immunology	NOUN
aji-165	502	3	communications	communication	NOUN
aji-165	502	4	,	,	PUNCT
aji-165	502	5	2	2	NUM
aji-165	502	6	,	,	PUNCT
aji-165	502	7	33	33	NUM
aji-165	502	8	-	-	SYM
aji-165	502	9	38	38	NUM
aji-165	502	10	.	.	PUNCT
aji-165	503	1	wang	wang	PROPN
aji-165	503	2	,	,	PUNCT
aji-165	503	3	x.	x.	PROPN
aji-165	503	4	q.	q.	PROPN
aji-165	503	5	,	,	PUNCT
aji-165	503	6	zhang	zhang	PROPN
aji-165	503	7	,	,	PUNCT
aji-165	503	8	y.	y.	PROPN
aji-165	503	9	,	,	PUNCT
aji-165	503	10	xu	xu	PROPN
aji-165	503	11	,	,	PUNCT
aji-165	503	12	c.	c.	PROPN
aji-165	503	13	d.	d.	PROPN
aji-165	503	14	,	,	PUNCT
aji-165	503	15	jiang	jiang	PROPN
aji-165	503	16	,	,	PUNCT
aji-165	503	17	l.	l.	PROPN
aji-165	503	18	r.	r.	PROPN
aji-165	503	19	,	,	PUNCT
aji-165	503	20	huang	huang	PROPN
aji-165	503	21	,	,	PUNCT
aji-165	503	22	y.	y.	PROPN
aji-165	503	23	,	,	PUNCT
aji-165	503	24	du	du	PROPN
aji-165	503	25	,	,	PUNCT
aji-165	503	26	h.	h.	PROPN
aji-165	503	27	m.	m.	PROPN
aji-165	503	28	,	,	PUNCT
aji-165	503	29	et	et	PROPN
aji-165	503	30	al	al	PROPN
aji-165	503	31	.	.	PROPN
aji-165	503	32	(	(	PUNCT
aji-165	503	33	2013	2013	NUM
aji-165	503	34	)	)	PUNCT
aji-165	503	35	.	.	PUNCT
aji-165	504	1	inflammatory	inflammatory	ADJ
aji-165	504	2	bowel	bowel	NOUN
aji-165	504	3	disease	disease	NOUN
aji-165	504	4	in	in	ADP
aji-165	504	5	chinese	chinese	ADJ
aji-165	504	6	children	child	NOUN
aji-165	504	7	:	:	PUNCT
aji-165	504	8	a	a	DET
aji-165	504	9	multicenter	multicenter	ADJ
aji-165	504	10	analysis	analysis	NOUN
aji-165	504	11	over	over	ADP
aji-165	504	12	a	a	DET
aji-165	504	13	decade	decade	NOUN
aji-165	504	14	from	from	ADP
aji-165	504	15	shanghai	shanghai	PROPN
aji-165	504	16	.	.	PUNCT
aji-165	505	1	inflamm	inflamm	PROPN
aji-165	505	2	bowel	bowel	PROPN
aji-165	505	3	dis	dis	PROPN
aji-165	505	4	,	,	PUNCT
aji-165	505	5	19(2	19(2	NUM
aji-165	505	6	)	)	PUNCT
aji-165	505	7	,	,	PUNCT
aji-165	505	8	423–428	423–428	NUM
aji-165	505	9	.	.	PUNCT
aji-165	506	1	disclaimer	disclaimer	ADJ
aji-165	506	2	/	/	SYM
aji-165	506	3	publisher	publisher	NOUN
aji-165	506	4	’s	’s	PART
aji-165	506	5	note	note	NOUN
aji-165	506	6	:	:	PUNCT
aji-165	506	7	the	the	DET
aji-165	506	8	statements	statement	NOUN
aji-165	506	9	,	,	PUNCT
aji-165	506	10	opinions	opinion	NOUN
aji-165	506	11	and	and	CCONJ
aji-165	506	12	data	datum	NOUN
aji-165	506	13	contained	contain	VERB
aji-165	506	14	in	in	ADP
aji-165	506	15	all	all	DET
aji-165	506	16	publications	publication	NOUN
aji-165	506	17	are	be	AUX
aji-165	506	18	solely	solely	ADV
aji-165	506	19	those	those	PRON
aji-165	506	20	of	of	ADP
aji-165	506	21	the	the	DET
aji-165	506	22	individual	individual	ADJ
aji-165	506	23	author(s	author(s	PROPN
aji-165	506	24	)	)	PUNCT
aji-165	506	25	and	and	CCONJ
aji-165	506	26	contributor(s	contributor(s	NOUN
aji-165	506	27	)	)	PUNCT
aji-165	506	28	and	and	CCONJ
aji-165	506	29	not	not	PART
aji-165	506	30	of	of	ADP
aji-165	506	31	the	the	DET
aji-165	506	32	publisher	publisher	NOUN
aji-165	506	33	and/or	and/or	CCONJ
aji-165	506	34	the	the	DET
aji-165	506	35	editor(s	editor(s	NOUN
aji-165	506	36	)	)	PUNCT
aji-165	506	37	.	.	PUNCT
aji-165	507	1	this	this	DET
aji-165	507	2	publisher	publisher	NOUN
aji-165	507	3	and/or	and/or	CCONJ
aji-165	507	4	the	the	DET
aji-165	507	5	editor(s	editor(s	NOUN
aji-165	507	6	)	)	PUNCT
aji-165	507	7	disclaim	disclaim	VERB
aji-165	507	8	responsibility	responsibility	NOUN
aji-165	507	9	for	for	ADP
aji-165	507	10	any	any	DET
aji-165	507	11	injury	injury	NOUN
aji-165	507	12	to	to	ADP
aji-165	507	13	people	people	NOUN
aji-165	507	14	or	or	CCONJ
aji-165	507	15	property	property	NOUN
aji-165	507	16	resulting	result	VERB
aji-165	507	17	from	from	ADP
aji-165	507	18	any	any	DET
aji-165	507	19	ideas	idea	NOUN
aji-165	507	20	,	,	PUNCT
aji-165	507	21	methods	method	NOUN
aji-165	507	22	,	,	PUNCT
aji-165	507	23	instructions	instruction	NOUN
aji-165	507	24	or	or	CCONJ
aji-165	507	25	products	product	NOUN
aji-165	507	26	referred	refer	VERB
aji-165	507	27	to	to	ADP
aji-165	507	28	in	in	ADP
aji-165	507	29	the	the	DET
aji-165	507	30	content	content	NOUN
aji-165	507	31	.	.	PUNCT
aji-165	508	1	_	_	PUNCT
aji-165	509	1	_	_	PUNCT
aji-165	510	1	_	_	PUNCT
aji-165	511	1	_	_	PUNCT
aji-165	512	1	_	_	PUNCT
aji-165	513	1	_	_	PUNCT
aji-165	514	1	_	_	PUNCT
aji-165	515	1	_	_	PUNCT
aji-165	516	1	_	_	PUNCT
aji-165	517	1	_	_	PUNCT
aji-165	518	1	_	_	PUNCT
aji-165	519	1	_	_	PUNCT
aji-165	520	1	_	_	PUNCT
aji-165	521	1	_	_	PUNCT
aji-165	522	1	_	_	PUNCT
aji-165	523	1	_	_	PUNCT
aji-165	524	1	_	_	PUNCT
aji-165	525	1	_	_	PUNCT
aji-165	526	1	_	_	PUNCT
aji-165	527	1	_	_	PUNCT
aji-165	528	1	_	_	PUNCT
aji-165	529	1	_	_	PUNCT
aji-165	530	1	_	_	PUNCT
aji-165	531	1	_	_	PUNCT
aji-165	532	1	_	_	PUNCT
aji-165	533	1	_	_	PUNCT
aji-165	534	1	_	_	PUNCT
aji-165	535	1	_	_	PUNCT
aji-165	536	1	_	_	PUNCT
aji-165	537	1	_	_	PUNCT
aji-165	538	1	_	_	PUNCT
aji-165	539	1	_	_	PUNCT
aji-165	540	1	_	_	PUNCT
aji-165	541	1	_	_	PUNCT
aji-165	542	1	_	_	PUNCT
aji-165	543	1	_	_	PUNCT
aji-165	544	1	_	_	PUNCT
aji-165	545	1	_	_	PUNCT
aji-165	546	1	_	_	PUNCT
aji-165	547	1	_	_	PUNCT
aji-165	548	1	_	_	PUNCT
aji-165	549	1	_	_	PUNCT
aji-165	550	1	_	_	PUNCT
aji-165	551	1	_	_	PUNCT
aji-165	552	1	_	_	PUNCT
aji-165	553	1	_	_	PUNCT
aji-165	554	1	_	_	PUNCT
aji-165	555	1	_	_	PUNCT
aji-165	556	1	_	_	PUNCT
aji-165	557	1	_	_	PUNCT
aji-165	558	1	_	_	PUNCT
aji-165	559	1	_	_	PUNCT
aji-165	560	1	_	_	PUNCT
aji-165	561	1	_	_	PUNCT
aji-165	562	1	_	_	PUNCT
aji-165	563	1	_	_	PUNCT
aji-165	564	1	_	_	PUNCT
aji-165	565	1	_	_	PUNCT
aji-165	566	1	_	_	PUNCT
aji-165	567	1	_	_	PUNCT
aji-165	568	1	_	_	PUNCT
aji-165	569	1	_	_	PUNCT
aji-165	570	1	_	_	PUNCT
aji-165	571	1	_	_	PUNCT
aji-165	572	1	_	_	PUNCT
aji-165	573	1	_	_	PUNCT
aji-165	574	1	_	_	PUNCT
aji-165	575	1	_	_	PUNCT
aji-165	576	1	_	_	PUNCT
aji-165	577	1	_	_	PUNCT
aji-165	578	1	_	_	PUNCT
aji-165	579	1	_	_	PUNCT
aji-165	580	1	_	_	PUNCT
aji-165	581	1	_	_	PUNCT
aji-165	582	1	_	_	PUNCT
aji-165	583	1	_	_	PUNCT
aji-165	584	1	_	_	PUNCT
aji-165	585	1	_	_	PUNCT
aji-165	586	1	_	_	PUNCT
aji-165	587	1	_	_	PUNCT
aji-165	588	1	_	_	PUNCT
aji-165	589	1	©	©	PRON
aji-165	589	2	copyright	copyright	NOUN
aji-165	589	3	(	(	PUNCT
aji-165	589	4	2025	2025	NUM
aji-165	589	5	):	):	PUNCT
aji-165	589	6	author(s	author(s	NOUN
aji-165	589	7	)	)	PUNCT
aji-165	589	8	.	.	PUNCT
aji-165	590	1	the	the	DET
aji-165	590	2	licensee	licensee	NOUN
aji-165	590	3	is	be	AUX
aji-165	590	4	the	the	DET
aji-165	590	5	journal	journal	PROPN
aji-165	590	6	publisher	publisher	NOUN
aji-165	590	7	.	.	PUNCT
aji-165	591	1	this	this	PRON
aji-165	591	2	is	be	AUX
aji-165	591	3	an	an	DET
aji-165	591	4	open	open	ADJ
aji-165	591	5	access	access	NOUN
aji-165	591	6	article	article	NOUN
aji-165	591	7	distributed	distribute	VERB
aji-165	591	8	under	under	ADP
aji-165	591	9	the	the	DET
aji-165	591	10	terms	term	NOUN
aji-165	591	11	of	of	ADP
aji-165	591	12	the	the	DET
aji-165	591	13	creative	creative	ADJ
aji-165	591	14	commons	common	NOUN
aji-165	591	15	attribution	attribution	NOUN
aji-165	591	16	license	license	NOUN
aji-165	591	17	(	(	PUNCT
aji-165	591	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-165	591	19	)	)	PUNCT
aji-165	591	20	,	,	PUNCT
aji-165	591	21	which	which	PRON
aji-165	591	22	permits	permit	VERB
aji-165	591	23	unrestricted	unrestricted	ADJ
aji-165	591	24	use	use	NOUN
aji-165	591	25	,	,	PUNCT
aji-165	591	26	distribution	distribution	NOUN
aji-165	591	27	,	,	PUNCT
aji-165	591	28	and	and	CCONJ
aji-165	591	29	reproduction	reproduction	NOUN
aji-165	591	30	in	in	ADP
aji-165	591	31	any	any	DET
aji-165	591	32	medium	medium	NOUN
aji-165	591	33	,	,	PUNCT
aji-165	591	34	provided	provide	VERB
aji-165	591	35	the	the	DET
aji-165	591	36	original	original	ADJ
aji-165	591	37	work	work	NOUN
aji-165	591	38	is	be	AUX
aji-165	591	39	properly	properly	ADV
aji-165	591	40	cited	cite	VERB
aji-165	591	41	.	.	PUNCT
aji-165	592	1	peer	peer	NOUN
aji-165	592	2	-	-	PUNCT
aji-165	592	3	review	review	NOUN
aji-165	592	4	history	history	NOUN
aji-165	592	5	:	:	PUNCT
aji-165	592	6	the	the	DET
aji-165	592	7	peer	peer	NOUN
aji-165	592	8	review	review	NOUN
aji-165	592	9	history	history	NOUN
aji-165	592	10	for	for	ADP
aji-165	592	11	this	this	DET
aji-165	592	12	paper	paper	NOUN
aji-165	592	13	can	can	AUX
aji-165	592	14	be	be	AUX
aji-165	592	15	accessed	access	VERB
aji-165	592	16	here	here	ADV
aji-165	592	17	:	:	PUNCT
aji-165	593	1	https://pr.sdiarticle5.com/review-history/135189	https://pr.sdiarticle5.com/review-history/135189	PROPN
aji-165	593	2	https://pubmed.ncbi.nlm.nih.gov/27914657/	https://pubmed.ncbi.nlm.nih.gov/27914657/	PROPN
aji-165	593	3	https://pubmed.ncbi.nlm.nih.gov/27914657/	https://pubmed.ncbi.nlm.nih.gov/27914657/	PROPN
aji-165	593	4	https://pr.sdiarticle5.com/review-history/135189	https://pr.sdiarticle5.com/review-history/135189	VERB